,entities,start_tokens,end_tokens,start_chars,end_chars,text,pmid,lf_chemical_distsv,lf_disease_distsv,label,orig_index,olabel
44,methylprednisolone,9,10,67,85,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,0,-1,0,44,0
47,methylprednisolone,16,17,105,123,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,0,-1,0,47,0
60,methylprednisolone,16,17,100,118,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,0,-1,0,60,0
80,selegiline,32,33,180,190,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,0,-1,0,80,0
81,selegiline,7,8,37,47,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,0,-1,0,81,0
84,selegiline,23,24,159,169,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,0,-1,0,84,0
89,selegiline,29,30,174,184,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,0,-1,0,89,0
93,selegiline,17,18,116,126,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,0,-1,0,93,0
96,selegiline,18,19,107,117,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,0,-1,0,96,0
100,selegiline,9,10,67,77,Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.,10091617_8,0,-1,0,100,0
101,selegiline,1,2,9,19,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,0,-1,0,101,0
105,selegiline,9,10,58,68,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,0,-1,0,105,0
133,acetylsalicylic acid,36,38,153,173,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,0,-1,0,133,0
177,lignocaine,10,11,66,76,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,0,-1,0,177,0
185,lignocaine,10,11,64,74,All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.,10225068_1,0,-1,0,185,0
190,lignocaine,6,7,26,36,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,0,-1,0,190,0
193,lignocaine,15,16,84,94,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,0,-1,0,193,0
198,lignocaine,4,5,29,39,We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg.,10225068_7,0,-1,0,198,0
200,sirolimus,5,6,46,55,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,0,-1,0,200,0
201,rapamycin,8,9,66,75,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,0,-1,0,201,0
204,Sirolimus,2,3,12,21,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0,-1,0,204,0
205,rapamycin,5,6,32,41,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0,-1,0,205,0
209,sirolimus,14,15,101,110,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,0,-1,0,209,0
219,sirolimus,28,29,194,203,"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.",10328196_4,0,-1,0,219,0
221,sirolimus,6,7,39,48,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,0,-1,0,221,0
359,propofol,4,5,28,36,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0,-1,0,359,0
363,propofol,25,26,165,173,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0,-1,0,363,0
364,propofol,13,14,82,90,We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.,10520387_1,0,-1,0,364,0
366,propofol,17,18,77,85,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,0,-1,0,366,0
369,propofol,5,6,29,37,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0,-1,0,369,0
370,propofol,18,19,113,121,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0,-1,0,370,0
372,propofol,13,14,85,93,"However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.",10520387_4,0,-1,0,372,0
382,lead acetate,12,14,79,91,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,0,-1,0,382,0
388,malondialdehyde,9,10,51,66,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,0,-1,0,388,0
443,Gemcitabine,0,1,0,11,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0,-1,0,443,0
444,vinorelbine,2,3,17,28,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0,-1,0,444,0
446,cisplatin,20,21,123,132,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0,-1,0,446,0
450,vinorelbine,8,9,55,66,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0,-1,0,450,0
452,gemcitabine,13,14,76,87,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0,-1,0,452,0
457,cisplatin,28,29,170,179,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,0,-1,0,457,0
459,cisplatin,33,34,171,180,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,0,-1,0,459,0
505,creatinine,10,11,56,66,Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.,10539815_5,0,-1,0,505,0
509,creatinine,21,22,146,156,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,0,-1,0,509,0
552,olanzapine,4,5,35,45,Hypomania-like syndrome induced by olanzapine.,10565806_0,0,-1,0,552,0
556,olanzapine,26,27,159,169,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,0,-1,0,556,0
559,5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide,2,22,9,114,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,0,-1,0,559,0
776,bromocriptine,5,6,29,42,"In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.",10721819_4,0,-1,0,776,0
794,bromocriptine,13,14,72,85,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,0,-1,0,794,0
823,oral contraceptives,4,6,23,42,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,0,-1,0,823,0
829,oral contraceptives,16,18,105,124,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,0,-1,0,829,0
872,cyclosporine,8,9,65,77,Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.,10743694_0,0,-1,0,872,0
874,tacrolimus,1,2,5,15,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,0,-1,0,874,0
878,tacrolimus,2,3,17,27,"We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.",10743694_2,0,-1,0,878,0
881,tacrolimus,6,7,37,47,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0,-1,0,881,0
884,tacrolimus,31,32,208,218,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0,-1,0,884,0
903,tacrolimus,1,2,5,15,"When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.",10743694_10,0,-1,0,903,0
955,nimodipine,3,4,22,32,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,0,-1,0,955,0
957,Nimodipine,6,7,40,50,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,0,-1,0,957,0
967,nimodipine,30,31,156,166,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0,-1,0,967,0
969,nimodipine,41,42,198,208,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0,-1,0,969,0
973,Nimodipine,0,1,0,10,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,0,-1,0,973,0
997,nimodipine,20,21,134,144,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,0,-1,0,997,0
999,nimodipine,2,3,13,23,"For low-dose nimodipine, the results were not conclusive.",10835440_11,0,-1,0,999,0
1001,nimodipine,11,12,70,80,These results do not confirm or exclude a neuroprotective property of nimodipine.,10835440_12,0,-1,0,1001,0
1007,Cyclophosphamide,0,1,0,16,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,0,-1,0,1007,0
1136,Cyclosporine,0,1,0,12,Cyclosporine and tacrolimus-associated thrombotic microangiopathy.,11007689_0,0,-1,0,1136,0
1141,cyclosporine,13,14,79,91,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,0,-1,0,1141,0
1142,cyclosporine,7,8,57,69,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,0,-1,0,1142,0
1150,tacrolimus,8,9,42,52,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0,-1,0,1150,0
1152,cyclosporine,23,24,147,159,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0,-1,0,1152,0
1153,tacrolimus,6,7,26,36,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,0,-1,0,1153,0
1155,tacrolimus,6,7,40,50,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,0,-1,0,1155,0
1159,cyclosporine,16,17,105,117,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0,-1,0,1159,0
1160,tacrolimus,18,19,122,132,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0,-1,0,1160,0
1163,cyclosporine,21,22,137,149,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,0,-1,0,1163,0
1165,tacrolimus,2,3,16,26,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,0,-1,0,1165,0
1169,cyclosporine,5,6,31,43,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0,-1,0,1169,0
1170,tacrolimus,7,8,47,57,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0,-1,0,1170,0
1287,methylprednisolone,1,2,10,28,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,0,-1,0,1287,0
1292,methylprednisolone,14,15,77,95,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,0,-1,0,1292,0
1297,methylprednisolone,17,18,110,128,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,0,-1,0,1297,0
1298,methylprednisolone,3,4,14,32,The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition.,11058428_3,0,-1,0,1298,0
1307,methylprednisolone,34,35,211,229,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,0,-1,0,1307,0
1309,methylprednisolone,14,15,84,102,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,0,-1,0,1309,0
1311,rapamycin,2,3,14,23,Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience.,11063349_0,0,-1,0,1311,0
1314,cyclosporine,18,19,103,115,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0,-1,0,1314,0
1316,tacrolimus,23,24,125,135,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0,-1,0,1316,0
1319,rapamycin,11,12,72,81,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,0,-1,0,1319,0
1331,creatinine,18,19,113,123,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,0,-1,0,1331,0
1355,vigabatrin,11,12,77,87,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,0,-1,0,1355,0
1359,vigabatrin,8,9,45,55,Six of the patients were no longer receiving vigabatrin.,11077455_3,0,-1,0,1359,0
1380,vigabatrin,11,12,75,85,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,0,-1,0,1380,0
1383,vigabatrin,9,10,75,85,The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.,11077455_12,0,-1,0,1383,0
1386,dobutamine,8,9,56,66,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,0,-1,0,1386,0
1388,Dobutamine,0,1,0,10,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,0,-1,0,1388,0
1397,dobutamine,19,20,107,117,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,0,-1,0,1397,0
1407,dobutamine,5,6,35,45,"DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.",11078231_7,0,-1,0,1407,0
1414,dobutamine,4,5,29,39,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,0,-1,0,1414,0
1422,dobutamine,10,11,58,68,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0,-1,0,1422,0
1431,dobutamine,4,5,33,43,INTERVENTION: Patients underwent dobutamine stress tests per standard protocol.,11079278_5,0,-1,0,1431,0
1434,dobutamine,1,2,7,17,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,0,-1,0,1434,0
1445,dobutamine,3,4,19,29,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,0,-1,0,1445,0
1480,Paclitaxel,0,1,0,10,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0,1480,0
1481,cisplatin,2,3,12,21,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0,1481,0
1482,gemcitabine,5,6,27,38,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0,-1,0,1482,0
1492,paclitaxel,20,21,104,114,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0,1492,0
1493,cisplatin,22,23,116,125,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0,1493,0
1494,gemcitabine,25,26,131,142,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0,-1,0,1494,0
1501,paclitaxel,26,27,175,185,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0,1501,0
1503,cisplatin,41,42,241,250,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0,1503,0
1505,gemcitabine,57,58,310,321,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0,-1,0,1505,0
1515,paclitaxel,15,16,76,86,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0,1515,0
1516,cisplatin,25,26,112,121,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0,1516,0
1517,gemcitabine,36,37,152,163,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0,-1,0,1517,0
1521,paclitaxel,5,6,32,42,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0,1521,0
1522,cisplatin,7,8,44,53,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0,1522,0
1523,gemcitabine,10,11,59,70,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0,-1,0,1523,0
1532,venlafaxine,10,11,72,83,This concerns 2 male patients who experienced incontinence while taking venlafaxine.,11147747_3,0,-1,0,1532,0
1533,paroxetine,20,21,144,154,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0,-1,0,1533,0
1535,venlafaxine,35,36,224,235,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0,-1,0,1535,0
1557,benzoylecgonine,9,10,61,76,Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme-mediated immunoassay methodology.,11185967_3,0,-1,0,1557,0
1559,benzoylecgonine,3,4,20,35,Plasma samples with benzoylecgonine greater than 150 ng/mL or an amphetamine greater than 500 ng/mL were defined as positive.,11185967_4,0,-1,0,1559,0
1565,benzoylecgonine,23,24,106,121,"RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.",11185967_6,0,-1,0,1565,0
1577,zonisamide,4,5,28,38,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,0,-1,0,1577,0
1616,picrotoxin,21,22,124,134,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,0,-1,0,1616,0
1624,adriamycin,25,26,146,156,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,0,-1,0,1624,0
1667,ketamine-,13,14,73,82,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,0,-1,0,1667,0
1673,cyclophosphamide,10,11,97,113,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0,-1,0,1673,0
1674,cyclophosphamide,16,17,157,173,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0,-1,0,1674,0
1680,cyclophosphamide,24,25,148,164,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,0,-1,0,1680,0
1689,cyclophosphamide,44,45,241,257,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,0,-1,0,1689,0
1707,cyclophosphamide,28,29,204,220,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,0,-1,0,1707,0
1723,cyclophosphamide,6,7,56,72,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,0,-1,0,1723,0
1725,cyclophosphamide,25,26,147,163,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,0,-1,0,1725,0
1727,carboplatin,8,9,42,53,Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.,11245434_2,0,-1,0,1727,0
1731,carboplatin,6,7,40,51,three times/week starting 7 days before carboplatin application.,11245434_4,0,-1,0,1731,0
1732,carboplatin,3,4,16,27,"Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.",11245434_5,0,-1,0,1732,0
1735,carboplatin,1,2,8,19,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,0,-1,0,1735,0
1739,cyclophosphamide,9,10,47,63,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,0,-1,0,1739,0
1748,cyclophosphamide,9,10,79,95,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,0,-1,0,1748,0
1768,losartan,4,5,36,44,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,0,-1,0,1768,0
1772,losartan,25,26,161,169,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,0,-1,0,1772,0
1778,losartan,9,10,41,49,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,0,-1,0,1778,0
1781,losartan,7,8,28,36,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,0,-1,0,1781,0
1789,losartan,9,10,59,67,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,0,-1,0,1789,0
1793,losartan,12,13,81,89,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,0,-1,0,1793,0
1807,cyclosporine-,3,4,17,30,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0,-1,0,1807,0
1808,tacrolimus,5,6,34,44,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0,-1,0,1808,0
1812,cyclosporine,16,17,91,103,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0,-1,0,1812,0
1813,tacrolimus,18,19,107,117,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0,-1,0,1813,0
1819,cyclophosphamide,5,6,44,60,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,0,-1,0,1819,0
1820,cyclophosphamide,9,10,65,81,Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.,11271907_1,0,-1,0,1820,0
1830,anthracycline,4,5,35,48,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,0,-1,0,1830,0
1839,daunorubicin,34,35,221,233,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,0,-1,0,1839,0
2164,"(1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine",23,25,191,242,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,0,-1,0,2164,0
2228,bupivacaine,6,7,37,48,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,0,-1,0,2228,0
2233,Bupivacaine,0,1,0,11,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,0,-1,0,2233,0
2244,bupivacaine,18,19,122,133,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,0,-1,0,2244,0
2249,bupivacaine,26,27,173,184,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,0,-1,0,2249,0
2253,bupivacaine,15,16,106,117,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0,-1,0,2253,0
2255,bupivacaine,38,39,262,273,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0,-1,0,2255,0
2258,risperidone,7,8,61,72,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,0,-1,0,2258,0
2262,risperidone,8,9,50,61,The patient developed RS during dose reduction of risperidone.,11532387_3,0,-1,0,2262,0
2263,trihexyphenidyl,6,7,42,57,The symptom was treated successfully with trihexyphenidyl anticholinergic therapy.,11532387_4,0,-1,0,2263,0
2265,risperidone,19,20,127,138,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,0,-1,0,2265,0
2271,cisapride,8,9,68,77,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0,-1,0,2271,0
2272,terfenadine,10,11,79,90,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0,-1,0,2272,0
2273,terodiline,12,13,95,105,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0,-1,0,2273,0
2283,terfenadine,17,18,87,98,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,0,-1,0,2283,0
2284,terodiline,19,20,103,113,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,0,-1,0,2284,0
2289,terfenadine,13,14,78,89,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0,-1,0,2289,0
2290,terodiline,15,16,91,101,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0,-1,0,2290,0
2291,cisapride,17,18,103,112,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0,-1,0,2291,0
2301,terfenadine,10,11,53,64,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0,-1,0,2301,0
2302,terodiline,16,17,75,85,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0,-1,0,2302,0
2303,cisapride,22,23,95,104,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0,-1,0,2303,0
2307,terfenadine,10,11,49,60,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0,-1,0,2307,0
2308,terodiline,12,13,62,72,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0,-1,0,2308,0
2309,cisapride,14,15,74,83,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0,-1,0,2309,0
2344,Sirolimus,0,1,0,9,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,0,-1,0,2344,0
2349,cyclosporine,5,6,32,44,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0,-1,0,2349,0
2350,tacrolimus,7,8,49,59,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0,-1,0,2350,0
2360,sirolimus,9,10,75,84,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0,-1,0,2360,0
2361,rapamycin,11,12,86,95,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0,-1,0,2361,0
2388,citalopram,7,8,49,59,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,0,-1,0,2388,0
2391,citalopram,8,9,49,59,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,0,-1,0,2391,0
2395,citalopram,8,9,36,46,This may have been a side effect of citalopram as it remitted with redistribution of doses.,11642480_3,0,-1,0,2395,0
2396,sulphasalazine,2,3,11,25,The 3-week sulphasalazine syndrome strikes again.,11672959_0,0,-1,0,2396,0
2397,sulphasalazine,25,26,144,158,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,0,-1,0,2397,0
2417,sulphasalazine,20,21,125,139,"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week sulphasalazine syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine.",11672959_6,0,-1,0,2417,0
2419,sulphasalazine,34,35,203,217,"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week sulphasalazine syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine.",11672959_6,0,-1,0,2419,0
2452,paracetamol,4,5,31,42,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,0,-1,0,2452,0
2455,paracetamol,8,9,59,70,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,0,-1,0,2455,0
2460,paracetamol,11,12,77,88,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,0,-1,0,2460,0
2462,paracetamol,17,18,102,113,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,0,-1,0,2462,0
2465,paracetamol,8,9,72,83,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,0,-1,0,2465,0
2468,paracetamol,14,15,73,84,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,0,-1,0,2468,0
2471,paracetamol,26,27,131,142,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,0,-1,0,2471,0
2475,paracetamol,12,13,76,87,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,0,-1,0,2475,0
2579,cisplatin,5,6,20,29,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0,-1,0,2579,0
2581,amifostine,9,10,44,54,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0,-1,0,2581,0
2584,Cisplatin,24,25,153,162,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0,-1,0,2584,0
2590,cisplatin,16,17,76,85,Older reports suggest an objective response rate of 8% when 60-120 mg/m2 of cisplatin is administered every 3-4 weeks.,11745184_1,0,-1,0,2590,0
2592,cisplatin,8,9,55,64,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0,-1,0,2592,0
2594,cisplatin,15,16,111,120,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0,-1,0,2594,0
2600,amifostine,2,3,11,21,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,0,-1,0,2600,0
2603,Amifostine,0,1,0,10,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0,-1,0,2603,0
2606,cisplatin,16,17,108,117,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0,-1,0,2606,0
2608,cisplatin,3,4,16,25,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,0,-1,0,2608,0
2609,amifostine,5,6,30,40,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,0,-1,0,2609,0
2613,cisplatin,10,11,48,57,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,0,-1,0,2613,0
2614,amifostine,12,13,63,73,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,0,-1,0,2614,0
2618,amifostine,2,3,18,28,"Patients received amifostine, 910 mg/m2 intravenously over 15 minutes.",11745184_7,0,-1,0,2618,0
2619,amifostine,4,5,24,34,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0,-1,0,2619,0
2620,cisplatin,7,8,45,54,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0,-1,0,2620,0
2623,cisplatin,9,10,69,78,Intravenous hydration and mannitol was administered before and after cisplatin.,11745184_9,0,-1,0,2623,0
2630,cisplatin,5,6,32,41,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0,-1,0,2630,0
2631,amifostine,7,8,46,56,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0,-1,0,2631,0
2635,amifostine,16,17,107,117,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0,-1,0,2635,0
2636,cisplatin,18,19,121,130,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0,-1,0,2636,0
2637,Oral contraceptives,0,2,0,19,Oral contraceptives and the risk of myocardial infarction.,11752354_0,0,-1,0,2637,0
2639,oral contraceptives,8,10,46,65,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,0,-1,0,2639,0
2643,desogestrel,17,18,107,118,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0,2643,0
2647,oral contraceptives,28,30,178,197,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0,-1,0,2647,0
2663,oral contraceptive,38,40,220,238,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,0,-1,0,2663,0
2668,oral contraceptives,21,23,116,135,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0,-1,0,2668,0
2670,oral contraceptives,40,42,227,246,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0,-1,0,2670,0
2671,oral contraceptives,4,6,21,40,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,0,-1,0,2671,0
2677,oral contraceptives,59,61,332,351,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,0,-1,0,2677,0
2678,oral contraceptives,9,11,56,75,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0,-1,0,2678,0
2680,oral contraceptives,26,28,180,199,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0,-1,0,2680,0
2682,oral contraceptives,11,13,67,86,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,0,-1,0,2682,0
2723,tacrolimus,7,8,56,66,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,0,-1,0,2723,0
2739,creatinine,20,21,95,105,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,0,-1,0,2739,0
2751,creatinine,13,14,84,94,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0,-1,0,2751,0
2753,creatinine,42,43,271,281,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0,-1,0,2753,0
2755,creatinine,16,17,135,145,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,0,-1,0,2755,0
2774,creatinine,11,12,70,80,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,0,-1,0,2774,0
2776,creatinine,6,7,30,40,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,0,-1,0,2776,0
2840,Risperidone,2,3,12,23,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,0,-1,0,2840,0
2874,risperidone,21,22,110,121,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,0,-1,0,2874,0
2899,metoclopramide,5,6,30,44,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,0,-1,0,2899,0
2903,metoclopramide,6,7,39,53,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0,-1,0,2903,0
2906,procainamide,29,30,179,191,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0,-1,0,2906,0
2909,metoclopramide,24,25,162,176,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,0,-1,0,2909,0
2911,cisapride,8,9,52,61,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,0,-1,0,2911,0
2914,metoclopramide,6,7,37,51,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,0,-1,0,2914,0
2916,Metoclopramide,0,1,0,14,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,0,-1,0,2916,0
2997,anthracycline,21,22,124,137,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,0,-1,0,2997,0
3062,5-azacytidine,6,7,39,52,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,0,-1,0,3062,0
3093,6-hydroxydopamine,12,13,82,99,Erectile function was assessed 6 weeks following uni- and bilateral injections of 6-hydroxydopamine in the substantia nigra nucleus of the brain.,11890511_1,0,-1,0,3093,0
3133,hexamethonium,10,11,72,85,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0,-1,0,3133,0
3135,hexamethonium,5,6,47,60,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0,3135,0
3139,hexamethonium,12,13,108,121,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,0,-1,0,3139,0
3179,Bupropion,0,1,0,9,Bupropion (Zyban) toxicity.,11928786_0,0,-1,0,3179,0
3181,Bupropion,0,1,0,9,Bupropion is a monocyclic antidepressant structurally related to amphetamine.,11928786_1,0,-1,0,3181,0
3185,bupropion,6,7,42,51,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,0,-1,0,3185,0
3191,bupropion,30,31,165,174,"We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion.",11928786_8,0,-1,0,3191,0
3283,risperidone,26,27,162,173,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,0,-1,0,3283,0
3285,risperidone,17,18,125,136,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,0,-1,0,3285,0
3287,Risperidone,0,1,0,11,Risperidone administration was continued and the visual disturbances gradually wore off.,12013711_4,0,-1,0,3287,0
3293,risperidone,21,22,130,141,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,0,-1,0,3293,0
3342,Ifosfamide,0,1,0,10,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,0,-1,0,3342,0
3343,Ifosfamide,0,1,0,10,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,0,-1,0,3343,0
3346,ifosfamide,7,8,46,56,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,0,-1,0,3346,0
3350,ifosfamide,25,26,146,156,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,0,-1,0,3350,0
3359,ifosfamide,3,4,22,32,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,0,-1,0,3359,0
3362,ifosfamide,12,13,71,81,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,0,-1,0,3362,0
3369,Azidothymidine,0,1,0,14,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0,-1,0,3369,0
3425,glycopyrrolate,5,6,35,49,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,0,-1,0,3425,0
3436,glycopyrrolate,13,14,73,87,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,0,-1,0,3436,0
3512,paracetamol,17,18,74,85,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,0,-1,0,3512,0
3564,metoclopramide,4,5,33,47,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,0,-1,0,3564,0
3565,metoclopramide,13,14,88,102,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,0,-1,0,3565,0
3568,metoclopramide,8,9,53,67,We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.,12139551_1,0,-1,0,3568,0
3569,metoclopramide,3,4,21,35,The patient received metoclopramide 10 mg i.v.,12139551_2,0,-1,0,3569,0
3572,metoclopramide,23,24,146,160,"five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.",12139551_3,0,-1,0,3572,0
3576,metoclopramide,10,11,58,72,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,0,-1,0,3576,0
3629,carbachol,5,6,36,45,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,0,-1,0,3629,0
3636,carbachol,11,12,74,83,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,0,-1,0,3636,0
3803,rizatriptan,7,8,52,63,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,0,-1,0,3803,0
3805,Rizatriptan,0,1,0,11,Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.,12464714_1,0,-1,0,3805,0
3810,rizatriptan,12,13,87,98,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,0,-1,0,3810,0
3813,rizatriptan,16,17,79,90,"Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001).",12464714_3,0,-1,0,3813,0
3815,rizatriptan,19,20,110,121,"Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.",12464714_4,0,-1,0,3815,0
3818,rizatriptan,15,16,71,82,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,0,-1,0,3818,0
3819,rizatriptan,10,11,56,67,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,0,-1,0,3819,0
3822,rizatriptan,27,28,140,151,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,0,-1,0,3822,0
3823,rizatriptan,9,10,37,48,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,0,-1,0,3823,0
3825,rizatriptan,24,25,106,117,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,0,-1,0,3825,0
3827,rizatriptan,6,7,30,41,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,0,-1,0,3827,0
3830,Rizatriptan,0,1,0,11,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,0,-1,0,3830,0
3834,rizatriptan,16,17,85,96,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,0,-1,0,3834,0
3837,rizatriptan,6,7,33,44,Recurrence rates were 31.4% with rizatriptan and 15.3% with ergotamine/caffeine.,12464714_11,0,-1,0,3837,0
3841,rizatriptan,17,18,72,83,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,0,-1,0,3841,0
3867,carboplatin,9,10,67,78,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,0,-1,0,3867,0
3875,carboplatin,2,3,11,22,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0,-1,0,3875,0
3877,cisplatin,11,12,64,73,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0,-1,0,3877,0
3879,carboplatin,16,17,101,112,"However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.",12483326_5,0,-1,0,3879,0
3881,carboplatin,10,11,62,73,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,0,-1,0,3881,0
3895,carboplatin,7,8,54,65,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,0,-1,0,3895,0
3899,zonisamide,4,5,38,48,Visual hallucinations associated with zonisamide.,12523465_0,0,-1,0,3899,0
3900,Zonisamide,0,1,0,10,Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.,12523465_1,0,-1,0,3900,0
3906,zonisamide,29,30,195,205,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,0,-1,0,3906,0
3909,zonisamide,14,15,86,96,The only recent change in their treatment was the introduction or increased dosage of zonisamide.,12523465_6,0,-1,0,3909,0
3912,zonisamide,14,15,86,96,"Until then, clinicians need to be aware of this possible complication associated with zonisamide.",12523465_9,0,-1,0,3912,0
3915,carbamazepine,13,14,89,102,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0,-1,0,3915,0
3916,vigabatrin,15,16,107,117,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0,-1,0,3916,0
3927,bupropion,5,6,36,45,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,0,-1,0,3927,0
3928,carbimazole,7,8,50,61,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,0,-1,0,3928,0
3931,bupropion,16,17,94,103,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,0,-1,0,3931,0
3932,carbimazole,18,19,108,119,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,0,-1,0,3932,0
3935,carbimazole,16,17,96,107,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,0,-1,0,3935,0
3936,propranolol,18,19,112,123,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,0,-1,0,3936,0
3937,bupropion,6,7,31,40,He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.,12549952_3,0,-1,0,3937,0
3945,bupropion,3,4,20,29,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,0,-1,0,3945,0
3949,bupropion,11,12,79,88,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0,3949,0
3951,bupropion,32,33,198,207,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0,3951,0
3952,carbimazole,38,39,244,255,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0,3952,0
3954,bupropion,15,16,92,101,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,0,-1,0,3954,0
3974,iodixanol,27,28,169,178,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0,-1,0,3974,0
3978,creatinine,9,10,57,67,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,0,-1,0,3978,0
3983,creatinine,13,14,66,76,The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.,12571256_5,0,-1,0,3983,0
3984,creatinine,8,9,41,51,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0,-1,0,3984,0
3985,creatinine,33,34,164,174,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0,-1,0,3985,0
3986,creatinine,3,4,13,23,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,0,-1,0,3986,0
3988,iodixanol,12,13,92,101,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,0,-1,0,3988,0
3990,creatinine,12,13,47,57,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0,-1,0,3990,0
3991,iodixanol,20,21,91,100,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0,-1,0,3991,0
3993,iodixanol,37,38,182,191,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0,-1,0,3993,0
3996,iodixanol,7,8,30,39,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0,-1,0,3996,0
3997,creatinine,18,19,81,91,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0,-1,0,3997,0
4000,iodixanol,55,56,261,270,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0,-1,0,4000,0
4003,iodixanol,3,4,21,30,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,0,-1,0,4003,0
4005,creatinine,5,6,23,33,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0,-1,0,4005,0
4006,iodixanol,20,21,101,110,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0,-1,0,4006,0
4008,iodixanol,37,38,187,196,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0,-1,0,4008,0
4012,iodixanol,17,18,109,118,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,0,-1,0,4012,0
4036,cyclosporine,9,10,73,85,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0,-1,0,4036,0
4037,tacrolimus,12,13,89,99,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0,-1,0,4037,0
4038,sirolimus,14,15,104,113,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0,-1,0,4038,0
4039,Sirolimus,2,3,12,21,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,0,-1,0,4039,0
4050,cyclosporine,26,27,161,173,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0,-1,0,4050,0
4052,tacrolimus,32,33,183,193,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0,-1,0,4052,0
4175,octreotide,10,11,82,92,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,0,-1,0,4175,0
4212,oral contraceptives,20,22,144,163,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,0,-1,0,4212,0
4253,creatinine,8,9,63,73,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0,-1,0,4253,0
4254,glutathione,16,17,109,120,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0,-1,0,4254,0
4259,creatinine,13,14,96,106,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0,-1,0,4259,0
4273,docetaxel,9,10,70,79,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,0,-1,0,4273,0
4279,docetaxel,24,25,160,169,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,0,-1,0,4279,0
4284,docetaxel,7,8,55,64,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0,-1,0,4284,0
4286,docetaxel,35,36,213,222,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0,-1,0,4286,0
4289,docetaxel,11,12,64,73,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0,-1,0,4289,0
4291,docetaxel,27,28,139,148,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0,-1,0,4291,0
4293,docetaxel,7,8,43,52,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,0,-1,0,4293,0
4298,ticlopidine,11,12,87,98,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,0,-1,0,4298,0
4302,ticlopidine,6,7,51,62,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,0,-1,0,4302,0
4306,ticlopidine,12,13,83,94,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,0,-1,0,4306,0
4308,ticlopidine,7,8,57,68,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,0,-1,0,4308,0
4313,ticlopidine,17,18,106,117,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,0,-1,0,4313,0
4319,ticlopidine,10,11,63,74,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,0,-1,0,4319,0
4323,ticlopidine,12,13,68,79,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0,-1,0,4323,0
4325,clopidogrel,21,22,130,141,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0,-1,0,4325,0
4365,vigabatrin,6,7,39,49,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,0,-1,0,4365,0
4414,tacrolimus,27,28,180,190,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,0,-1,0,4414,0
4417,tacrolimus,17,18,111,121,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,0,-1,0,4417,0
4431,Hydrocortisone acetate,0,2,0,22,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,0,-1,0,4431,0
4502,cyclophosphamide,25,26,155,171,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,0,-1,0,4502,0
4521,bupropion,7,8,64,73,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,0,-1,0,4521,0
4524,bupropion,10,11,83,92,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,0,-1,0,4524,0
4528,bupropion,24,25,171,180,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,0,-1,0,4528,0
4530,bupropion,4,5,17,26,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,0,-1,0,4530,0
4540,17beta-estradiol,5,6,27,43,We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.,12757899_2,0,-1,0,4540,0
4543,17beta-estradiol,5,6,41,57,Rats received subcutaneous injections of 17beta-estradiol (2 microg/rat) or oil once daily for four consecutive days.,12757899_3,0,-1,0,4543,0
4547,17beta-Estradiol,0,1,0,16,17beta-Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males.,12757899_6,0,-1,0,4547,0
4549,17beta-Estradiol,0,1,0,16,17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats.,12757899_7,0,-1,0,4549,0
4679,oral contraceptives,29,31,173,192,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0,-1,0,4679,0
4704,acetylsalicylic acid,7,9,51,71,Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.,12852481_0,0,-1,0,4704,0
4707,acetylsalicylic acid,2,4,9,29,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,0,-1,0,4707,0
4865,gamma-aminobutyric acid,18,20,125,148,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0,-1,0,4865,0
4902,creatinine,23,24,125,135,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0,-1,0,4902,0
4916,oral contraceptive,5,7,42,60,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,0,-1,0,4916,0
4921,oral contraceptives,21,23,119,138,"During a ten-year period, 348 women were studied for a total of 5,877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters.",133615_3,0,-1,0,4921,0
4935,oral contraceptive,19,21,109,127,It appears from these data that hematologic work-ups may be useful in women who are about to start long-term oral contraceptive therapy.,133615_13,0,-1,0,4935,0
5042,creatinine,18,19,109,119,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,0,-1,0,5042,0
5064,dipyridamole,13,14,72,84,"Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole.",1415380_4,0,-1,0,5064,0
5128,amino acid,15,17,124,134,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,0,-1,0,5128,0
5173,ketoconazole,21,22,122,134,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,0,-1,0,5173,0
5174,ketoconazole,17,18,87,99,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,0,-1,0,5174,0
5224,mesna,4,5,26,31,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,0,-1,0,5224,0
5229,ifosfamide,14,15,78,88,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,0,-1,0,5229,0
5231,mesna,15,16,90,95,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,0,-1,0,5231,0
5236,mesna,21,22,84,89,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,0,-1,0,5236,0
5238,mesna,7,8,27,32,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0,5238,0
5239,mesna,17,18,99,104,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0,-1,0,5239,0
5243,mesna,14,15,67,72,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,0,-1,0,5243,0
5247,mesna,12,13,65,70,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0,-1,0,5247,0
5248,mesna,20,21,110,115,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0,-1,0,5248,0
5249,mesna,6,7,46,51,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,0,-1,0,5249,0
5252,mesna,9,10,46,51,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0,-1,0,5252,0
5253,mesna,16,17,78,83,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0,-1,0,5253,0
5297,5-hydroxytriptamine,24,25,147,166,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0,-1,0,5297,0
5313,cyclophosphamide,10,11,60,76,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,0,-1,0,5313,0
5340,carbamazepine,14,15,75,88,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,0,-1,0,5340,0
5344,bicuculline,4,5,32,43,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,0,-1,0,5344,0
5350,bicuculline,5,6,19,30,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0,-1,0,5350,0
5402,paroxetine,11,12,82,92,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,0,-1,0,5402,0
5509,propranolol,19,20,104,115,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,0,-1,0,5509,0
5511,propranolol,6,7,51,62,"Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.",14982270_5,0,-1,0,5511,0
5538,hexamethonium,8,9,63,76,These responses were blocked by systemic pre-administration of hexamethonium chloride (20 mg/kg).,15009014_6,0,-1,0,5538,0
5730,bicuculline,5,6,41,52,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,0,-1,0,5730,0
5747,cyclophosphamide,12,13,74,90,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,0,-1,0,5747,0
5749,cyclophosphamide,16,17,86,102,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,0,-1,0,5749,0
5755,cyclophosphamide,16,17,105,121,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,0,-1,0,5755,0
5764,cyclophosphamide,7,8,40,56,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,0,-1,0,5764,0
5766,cyclophosphamide,12,13,63,79,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,0,-1,0,5766,0
5775,cyclophosphamide,9,10,70,86,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,0,-1,0,5775,0
5788,alpha-methyldopa,14,15,87,103,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,0,-1,0,5788,0
5809,alpha-methyldopa,6,7,38,54,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,0,-1,0,5809,0
5814,alpha-methyldopa,5,6,25,41,SDRR was reduced only by alpha-methyldopa.,15145918_6,0,-1,0,5814,0
5816,alpha-methyldopa,7,8,55,71,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,0,-1,0,5816,0
5822,17beta-estradiol,3,4,22,38,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,0,-1,0,5822,0
5827,alpha-methyldopa,23,24,146,162,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,0,-1,0,5827,0
5881,diclofenac,35,36,209,219,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,0,-1,0,5881,0
5904,dobutamine,20,21,145,155,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,0,-1,0,5904,0
5910,dobutamine,13,14,81,91,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,0,-1,0,5910,0
5915,lignocaine,7,8,55,65,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,0,-1,0,5915,0
5921,lignocaine,12,13,81,91,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,0,-1,0,5921,0
5974,sevoflurane,3,4,15,26,The effects of sevoflurane on lidocaine-induced convulsions.,15278670_0,0,-1,0,5974,0
5975,sevoflurane,3,4,17,28,The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.,15278670_1,0,-1,0,5975,0
5979,sevoflurane,43,44,201,212,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,0,-1,0,5979,0
5981,sevoflurane,17,18,60,71,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0,-1,0,5981,0
5982,sevoflurane,26,27,114,125,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0,-1,0,5982,0
5984,sevoflurane,10,11,72,83,There was no significant difference in the convulsive threshold between sevoflurane and enflurane.,15278670_4,0,-1,0,5984,0
5986,sevoflurane,12,13,76,87,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0,-1,0,5986,0
5988,sevoflurane,28,29,189,200,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0,-1,0,5988,0
5993,sevoflurane,19,20,143,154,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,0,-1,0,5993,0
5999,sevoflurane,4,5,21,32,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,0,-1,0,5999,0
6004,Cyclophosphamide,2,3,14,30,INTRODUCTION: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens.,15325671_1,0,-1,0,6004,0
6009,paclitaxel,5,6,26,36,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0,-1,0,6009,0
6010,cyclophosphamide,10,11,62,78,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0,-1,0,6010,0
6011,carboplatin,15,16,94,105,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0,-1,0,6011,0
6016,cyclophosphamide,14,15,115,131,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,0,-1,0,6016,0
6028,cyclophosphamide,18,19,96,112,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,0,-1,0,6028,0
6037,cyclophosphamide,5,6,41,57,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,0,-1,0,6037,0
6039,salbutamol,4,5,23,33,"Tremor side effects of salbutamol, quantified by a laser pointer technique.",15338796_0,0,-1,0,6039,0
6042,salbutamol,8,9,43,53,"OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.",15338796_1,0,-1,0,6042,0
6049,salbutamol,19,20,133,143,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,0,-1,0,6049,0
6056,Salbutamol,2,3,9,19,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,0,-1,0,6056,0
6062,Yohimbine,0,1,0,9,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,0,-1,0,6062,0
6065,yohimbine,8,9,58,67,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,0,-1,0,6065,0
6068,yohimbine,6,7,35,44,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,0,-1,0,6068,0
6070,yohimbine,3,4,21,30,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,0,-1,0,6070,0
6074,yohimbine,30,31,207,216,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,0,-1,0,6074,0
6076,yohimbine,3,4,17,26,Various doses of yohimbine were used to determine the ideal dose for each patient.,1535072_6,0,-1,0,6076,0
6079,yohimbine,13,14,87,96,RESULTS: Five of the six patients experienced improved sexual functioning after taking yohimbine.,1535072_7,0,-1,0,6079,0
6080,yohimbine,7,8,38,47,One patient who failed to comply with yohimbine treatment had no therapeutic effects.,1535072_8,0,-1,0,6080,0
6083,yohimbine,3,4,16,25,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,0,-1,0,6083,0
6084,yohimbine,9,10,52,61,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,0,-1,0,6084,0
6087,yohimbine,13,14,92,101,Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication.,1535072_11,0,-1,0,6087,0
6091,cyclophosphamide,9,10,72,88,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,0,-1,0,6091,0
6098,mesna,19,20,122,127,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0,-1,0,6098,0
6100,cyclophosphamide,27,28,173,189,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0,-1,0,6100,0
6169,desferrioxamine,3,4,24,39,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,0,-1,0,6169,0
6198,cyclophosphamide,6,7,34,50,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0,-1,0,6198,0
6200,mitoxantrone,11,12,77,89,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0,-1,0,6200,0
6303,adriamycin,23,24,132,142,"Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats.",15572383_3,0,-1,0,6303,0
6309,adriamycin,10,11,53,63,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,0,-1,0,6309,0
6310,adriamycin,5,6,25,35,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,0,-1,0,6310,0
6314,adriamycin,12,13,85,95,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0,-1,0,6314,0
6413,creatinine,14,15,100,110,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,0,-1,0,6413,0
6483,Reserpine-,0,1,0,10,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,0,-1,0,6483,0
6572,amphetamine-,27,28,185,197,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,0,-1,0,6572,0
6715,cyclosporine,5,6,28,40,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0,6715,0
6716,cyclosporine,14,15,75,87,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0,6716,0
6717,tacrolimus,16,17,92,102,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0,-1,0,6717,0
6726,cyclosporine,5,6,35,47,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0,-1,0,6726,0
6727,tacrolimus,7,8,49,59,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0,-1,0,6727,0
6733,cyclosporine,16,17,106,118,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,0,-1,0,6733,0
6815,propofol,5,6,43,51,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,0,-1,0,6815,0
6820,etoposide,9,10,84,93,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0,-1,0,6820,0
6821,daunorubicin,11,12,98,110,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0,-1,0,6821,0
6834,etoposide,36,37,259,268,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0,-1,0,6834,0
6835,daunorubicin,38,39,270,282,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0,-1,0,6835,0
6841,etoposide,10,11,49,58,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0,-1,0,6841,0
6842,daunorubicin,12,13,60,72,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0,-1,0,6842,0
6849,daunorubicin,12,13,85,97,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0,6849,0
6850,etoposide,14,15,102,111,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0,-1,0,6850,0
6860,daunorubicin,25,26,189,201,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,0,-1,0,6860,0
6862,etoposide,6,7,39,48,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,0,-1,0,6862,0
6867,etoposide,13,14,90,99,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,0,-1,0,6867,0
6897,benzoylecgonine,6,7,43,58,Seizures induced by the cocaine metabolite benzoylecgonine in rats.,1592014_0,0,-1,0,6897,0
6900,benzoylecgonine,11,12,63,78,"We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.",1592014_3,0,-1,0,6900,0
6910,cocaine-,3,4,17,25,"The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.",1592014_10,0,-1,0,6910,0
6913,propofol,12,13,83,91,Assessment of the onset and persistence of amnesia during procedural sedation with propofol.,15930398_0,0,-1,0,6913,0
6916,propofol,20,21,127,135,"OBJECTIVES: To assess patients' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol, and correlate their recall with their level of awareness as measured by bispectral index (BIS) monitoring.",15930398_1,0,-1,0,6916,0
6920,propofol,17,18,124,132,"METHODS: This was a prospective, single-intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28, 2002, and October 31, 2003.",15930398_2,0,-1,0,6920,0
6992,methylprednisolone,4,5,35,53,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0,-1,0,6992,0
7126,paclitaxel,19,20,127,137,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0,-1,0,7126,0
7127,carboplatin,21,22,142,153,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0,-1,0,7127,0
7133,paclitaxel,20,21,138,148,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,0,-1,0,7133,0
7134,carboplatin,22,23,153,164,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,0,-1,0,7134,0
7135,paclitaxel,9,10,45,55,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,0,-1,0,7135,0
7137,paclitaxel,30,31,166,176,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,0,-1,0,7137,0
7310,risperidone,11,12,76,87,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,0,-1,0,7310,0
7311,olanzapine,13,14,89,99,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,0,-1,0,7311,0
7351,Aminoglycoside,0,1,0,14,Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost.,16298782_2,0,-1,0,7351,0
7538,nitrendipine,7,8,46,58,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,0,-1,0,7538,0
7539,nitrendipine,11,12,66,78,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,0,-1,0,7539,0
7556,nitrendipine,3,4,18,30,Enalapril but not nitrendipine reduced blood pressure significantly.,1639466_6,0,-1,0,7556,0
7576,Ketoconazole,0,1,0,12,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,0,-1,0,7576,0
7580,Ketoconazole,0,1,0,12,Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval-prolonging drugs.,16403073_1,0,-1,0,7580,0
7587,ketoconazole,24,25,137,149,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,0,-1,0,7587,0
7589,ketoconazole,9,10,54,66,Her QT interval returned to normal upon withdrawal of ketoconazole.,16403073_3,0,-1,0,7589,0
7593,ketoconazole,13,14,66,78,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,0,-1,0,7593,0
7596,ketoconazole,27,28,155,167,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,0,-1,0,7596,0
7717,DEX,58,59,361,364,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,0,-1,0,7717,0
7724,"3,4-methylenedioxymethamphetamine",1,2,9,42,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,0,-1,0,7724,0
7792,glutathione,34,35,237,248,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0,-1,0,7792,0
7963,cinacalcet,8,9,47,57,OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6.,16680561_1,0,-1,0,7963,0
7965,cinacalcet,11,12,56,66,"The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.",16680561_2,0,-1,0,7965,0
7975,cinacalcet,46,47,266,276,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,0,-1,0,7975,0
7981,cinacalcet,19,20,119,129,"Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.",16680561_6,0,-1,0,7981,0
7982,cinacalcet,14,15,81,91,"The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).",16680561_7,0,-1,0,7982,0
7986,cinacalcet,15,16,119,129,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0,-1,0,7986,0
7988,cinacalcet,43,44,263,273,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0,-1,0,7988,0
7989,cinacalcet,6,7,41,51,CONCLUSION: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6.,16680561_10,0,-1,0,7989,0
7991,cinacalcet,8,9,58,68,"These data suggest that during concomitant treatment with cinacalcet, dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6.",16680561_11,0,-1,0,7991,0
8023,paroxetine,9,10,78,88,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,0,-1,0,8023,0
8027,paroxetine,11,12,57,67,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,0,-1,0,8027,0
8028,paroxetine,5,6,19,29,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,0,-1,0,8028,0
8034,aspartate,13,14,76,85,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0,-1,0,8034,0
8035,bromocriptine,3,4,21,34,The patient received bromocriptine and diazepam to treat his symptoms.,16720068_6,0,-1,0,8035,0
8040,paroxetine,22,23,145,155,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,0,-1,0,8040,0
8057,bupivacaine,4,5,32,43,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,0,-1,0,8057,0
8075,carbachol,5,6,33,42,Case report: acute unintentional carbachol intoxication.,16740173_0,0,-1,0,8075,0
8076,carbachol,4,5,33,42,"INTRODUCTION: Intoxications with carbachol, a muscarinic cholinergic receptor agonist are rare.",16740173_1,0,-1,0,8076,0
8085,carbachol,22,23,106,115,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,0,-1,0,8085,0
8086,carbachol,5,6,18,27,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,0,-1,0,8086,0
8087,Carbachol,0,1,0,9,Carbachol concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry.,16740173_6,0,-1,0,8087,0
8109,carbachol,13,14,72,81,"Serum samples from the first and second days contained 3.6 and 1.9 mg/l carbachol, respectively.",16740173_18,0,-1,0,8109,0
8117,carbachol,12,13,66,75,"For the first time, an analytical method for the determination of carbachol in plasma and urine has been developed.",16740173_21,0,-1,0,8117,0
8118,carbachol,2,3,13,22,The analysed carbachol concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260.,16740173_22,0,-1,0,8118,0
8135,Diazepam-,0,1,0,9,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,0,-1,0,8135,0
8136,scopolamine-,2,3,11,23,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,0,-1,0,8136,0
8176,Dex,0,1,0,3,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,0,-1,0,8176,0
8182,dex,34,35,147,150,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,0,-1,0,8182,0
8186,dex,10,11,46,49,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,0,-1,0,8186,0
8193,dex,31,32,140,143,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,0,-1,0,8193,0
8196,dex,39,40,169,172,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,0,-1,0,8196,0
8221,methylprednisolone,34,35,234,252,"This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.",16826348_6,0,-1,0,8221,0
8227,deferoxamine,4,5,31,43,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,0,-1,0,8227,0
8236,deferoxamine,19,20,107,119,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0,-1,0,8236,0
8251,glutathione,10,11,59,70,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,0,-1,0,8251,0
8326,sulpiride,13,14,80,89,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,0,-1,0,8326,0
8327,sulpiride,5,6,31,40,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,0,-1,0,8327,0
8330,sulpiride,5,6,30,39,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,0,-1,0,8330,0
8336,sulpiride,20,21,113,122,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,0,-1,0,8336,0
8353,bupivacaine,18,19,115,126,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,0,-1,0,8353,0
8362,bupivacaine,6,7,36,47,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.",16904497_7,0,-1,0,8362,0
8363,triamcinolone diacetate,8,10,52,75,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.",16904497_7,0,-1,0,8363,0
8426,ouabain,22,23,126,133,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,0,-1,0,8426,0
8480,clopidogrel,26,27,173,184,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,0,-1,0,8480,0
8595,Dex,4,5,21,24,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,0,-1,0,8595,0
8601,Dex,4,5,13,16,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0,-1,0,8601,0
8607,Dex,45,46,181,184,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0,-1,0,8607,0
8611,Dex,10,11,78,81,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0,-1,0,8611,0
8613,Dex,17,18,106,109,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0,-1,0,8613,0
8614,Dex,7,8,46,49,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,0,-1,0,8614,0
8617,Dex,17,18,99,102,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,0,-1,0,8617,0
8634,amino acid,6,8,44,54,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,0,-1,0,8634,0
8651,paroxetine,8,9,59,69,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,0,-1,0,8651,0
8656,sodium citrate,12,14,73,87,The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.,17111419_8,0,-1,0,8656,0
8694,Sirolimus,0,1,0,9,Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase.,17147461_1,0,-1,0,8694,0
8697,rapamycin,19,20,150,159,Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase.,17147461_1,0,-1,0,8697,0
8698,Sirolimus,0,1,0,9,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,0,-1,0,8698,0
8702,sirolimus,1,2,8,17,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,0,-1,0,8702,0
8707,sirolimus,11,12,66,75,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,0,-1,0,8707,0
8714,sirolimus,6,7,32,41,"It has also been suggested that sirolimus directly causes increased glomerular permeability/injury, but evidence for this mechanism is currently inconclusive.",17147461_8,0,-1,0,8714,0
8718,sirolimus,6,7,44,53,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,0,-1,0,8718,0
8724,sirolimus,21,22,132,141,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0,-1,0,8724,0
8725,sirolimus,29,30,168,177,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0,-1,0,8725,0
8731,sirolimus,8,9,60,69,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,0,-1,0,8731,0
8734,sirolimus,4,5,32,41,Proteinuria after conversion to sirolimus in renal transplant recipients.,17175308_0,0,-1,0,8734,0
8736,Sirolimus,0,1,0,9,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,0,-1,0,8736,0
8740,sirolimus,11,12,65,74,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,0,-1,0,8740,0
8759,creatinine,1,2,6,16,Serum creatinine values did not change significantly: 1.98 +/-,17175308_14,0,-1,0,8759,0
8767,creatinine,2,3,11,21,"Mean serum creatinine level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02).",17175308_19,0,-1,0,8767,0
8817,ifosfamide,19,20,121,131,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,0,-1,0,8817,0
8822,ifosfamide,9,10,45,55,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0,-1,0,8822,0
8823,ifosfamide,16,17,77,87,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0,-1,0,8823,0
8825,cisplatin,5,6,26,35,None of them had received cisplatin chemotherapy.,1720453_3,0,-1,0,8825,0
8830,creatinine,22,23,142,152,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0,-1,0,8830,0
8841,ifosfamide,13,14,77,87,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,0,-1,0,8841,0
8845,ifosfamide,18,19,83,93,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,0,-1,0,8845,0
8954,carbachol,3,4,22,31,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,0,-1,0,8954,0
9001,sevoflurane,9,10,57,68,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,0,-1,0,9001,0
9045,carbamazepine,11,12,72,85,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,0,-1,0,9045,0
9054,carbamazepine,26,27,217,230,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,0,-1,0,9054,0
9055,carbamazepine,1,2,8,21,"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.",1728915_6,0,-1,0,9055,0
9056,Dobutamine,0,1,0,10,Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.,1732369_0,0,-1,0,9056,0
9065,dobutamine,21,22,135,145,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,0,-1,0,9065,0
9072,dobutamine,1,2,7,17,"Graded dobutamine infusions of 0.5, 2.5, 5 and 10 micrograms/kg per min were administered.",1732369_4,0,-1,0,9072,0
9075,Dobutamine,0,1,0,10,Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms.,1732369_6,0,-1,0,9075,0
9083,dobutamine,43,44,311,321,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,0,-1,0,9083,0
9090,dobutamine,11,12,86,96,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,0,-1,0,9090,0
9102,adriamycin,16,17,100,110,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,0,-1,0,9102,0
9115,adriamycin,10,11,58,68,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,0,-1,0,9115,0
9200,terbutaline,6,7,62,73,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,0,-1,0,9200,0
9208,Terbutaline,0,1,0,11,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,0,-1,0,9208,0
9214,terbutaline,5,6,26,37,We studied the effects of terbutaline on microglial activation in different brain regions and behavioral outcomes in developing rats.,17400887_4,0,-1,0,9214,0
9217,terbutaline,4,5,24,35,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,0,-1,0,9217,0
9222,terbutaline,6,7,58,69,"Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex, as well as in cerebellar and cerebrocortical white matter.",17400887_6,0,-1,0,9222,0
9228,terbutaline,8,9,48,59,None of these effects occurred in animals given terbutaline on PN 11 to 14.,17400887_7,0,-1,0,9228,0
9232,terbutaline,7,8,42,53,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,0,-1,0,9232,0
9345,dex,18,19,108,111,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,0,-1,0,9345,0
9354,Dex,0,1,0,3,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,0,-1,0,9354,0
9369,methylprednisolone,6,7,48,66,Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space.,17466854_0,0,-1,0,9369,0
9372,methylprednisolone,15,16,98,116,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,0,-1,0,9372,0
9381,lignocaine,25,26,181,191,METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain lignocaine.,17466854_3,0,-1,0,9381,0
9384,methylprednisolone,19,20,66,84,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0,-1,0,9384,0
9393,methylprednisolone,5,6,35,53,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,0,-1,0,9393,0
9456,dobutamine,12,13,85,95,Simultaneous measurements of ECG and brachial artery dP/dtejc were performed at each dobutamine level.,17491223_4,0,-1,0,9456,0
9459,dobutamine,7,8,44,54,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,0,-1,0,9459,0
9514,bromocriptine,32,33,204,217,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,0,-1,0,9514,0
9537,iopamidol,15,16,104,113,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,0,-1,0,9537,0
9539,iodixanol,23,24,162,171,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,0,-1,0,9539,0
9542,iopamidol,16,17,96,105,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,0,-1,0,9542,0
9543,iodixanol,18,19,110,119,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,0,-1,0,9543,0
9548,creatinine,1,2,6,16,Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications.,17562951_3,0,-1,0,9548,0
9567,iopamidol,18,19,74,83,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0,-1,0,9567,0
9568,iodixanol,29,30,120,129,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0,-1,0,9568,0
9571,iopamidol,22,23,92,101,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0,-1,0,9571,0
9572,iodixanol,33,34,137,146,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0,-1,0,9572,0
9575,iopamidol,7,8,53,62,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,0,-1,0,9575,0
9577,iopamidol,23,24,160,169,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0,-1,0,9577,0
9578,iodixanol,25,26,173,182,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0,-1,0,9578,0
9603,maltolyl p-coumarate,4,6,18,38,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,0,-1,0,9603,0
9610,maltolyl p-coumarate,18,20,118,138,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,0,-1,0,9610,0
9614,maltolyl p-coumarate,8,10,46,66,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,0,-1,0,9614,0
9618,Maltolyl p-coumarate,0,2,0,20,Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,17600377_3,0,-1,0,9618,0
9623,maltolyl p-coumarate,7,9,48,68,We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.,17600377_4,0,-1,0,9623,0
9626,maltolyl p-coumarate,4,6,27,47,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,0,-1,0,9626,0
9629,maltolyl p-coumarate,3,5,14,34,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,0,-1,0,9629,0
9635,maltolyl p-coumarate,14,16,76,96,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,0,-1,0,9635,0
9639,lipopolysaccharide,9,10,91,109,Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.,17608141_0,0,-1,0,9639,0
9644,lipopolysaccharide,9,10,40,58,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,0,-1,0,9644,0
9649,Lipopolysaccharide,0,1,0,18,Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.,17608141_3,0,-1,0,9649,0
9652,lipopolysaccharide,2,3,14,32,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,0,-1,0,9652,0
9655,lipopolysaccharide,10,11,37,55,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,0,-1,0,9655,0
9657,lipopolysaccharide,3,4,19,37,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0,9657,0
9661,lipopolysaccharide,28,29,225,243,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0,-1,0,9661,0
9663,lipopolysaccharide,8,9,49,67,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,0,-1,0,9663,0
9691,blood urea nitrogen,10,13,68,87,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0,9691,0
9692,creatinine,16,17,99,109,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0,9692,0
9693,aspartate,20,21,120,129,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0,-1,0,9693,0
9700,creatinine,14,15,74,84,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,0,-1,0,9700,0
9713,levofloxacin,4,5,33,45,Interaction between warfarin and levofloxacin: case series.,17639754_0,0,-1,0,9713,0
9717,Levofloxacin,0,1,0,12,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,0,-1,0,9717,0
9723,levofloxacin,14,15,109,121,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0,-1,0,9723,0
9725,levofloxacin,22,23,164,176,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0,-1,0,9725,0
9726,levofloxacin,20,21,121,133,We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.,17639754_4,0,-1,0,9726,0
9727,levofloxacin,13,14,90,102,Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.,17639754_5,0,-1,0,9727,0
9747,5-fluorouracil,20,21,126,140,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0,-1,0,9747,0
9749,capecitabine,27,28,174,186,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0,-1,0,9749,0
9908,17beta-estradiol,25,26,133,149,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,0,-1,0,9908,0
9930,telithromycin,6,7,41,54,Acute hepatitis attack after exposure to telithromycin.,17919553_0,0,-1,0,9930,0
9938,telithromycin,4,5,23,36,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,0,-1,0,9938,0
9942,aspartate,22,23,107,116,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0,-1,0,9942,0
9947,telithromycin,19,20,104,117,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,0,-1,0,9947,0
9948,Telithromycin,2,3,12,25,DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use.,17919553_9,0,-1,0,9948,0
9954,telithromycin,15,16,78,91,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,0,-1,0,9954,0
9955,telithromycin,21,22,143,156,Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.,17919553_12,0,-1,0,9955,0
9957,telithromycin,16,17,100,113,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,0,-1,0,9957,0
10050,diclofenac,43,44,322,332,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,0,-1,0,10050,0
10053,diclofenac,32,33,151,161,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,0,-1,0,10053,0
10063,diclofenac,30,31,123,133,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,0,-1,0,10063,0
10066,diclofenac,14,15,95,105,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,0,-1,0,10066,0
10072,diclofenac,24,25,167,177,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,0,-1,0,10072,0
10074,diclofenac,2,3,15,25,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,0,-1,0,10074,0
10079,diclofenac,19,20,126,136,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,0,-1,0,10079,0
10094,ciprofloxacin-,6,7,35,49,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,0,-1,0,10094,0
10095,ciprofloxacin-,6,7,35,49,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,0,-1,0,10095,0
10102,paracetamol,11,12,79,90,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,0,-1,0,10102,0
10107,paracetamol,17,18,115,126,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,0,-1,0,10107,0
10111,paracetamol,1,2,2,13,A paracetamol serum level obtained in one of these patients was not in the toxic range.,18004067_3,0,-1,0,10111,0
10117,paracetamol,15,16,106,117,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,0,-1,0,10117,0
10121,paracetamol,4,5,20,31,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0,-1,0,10121,0
10124,paracetamol,27,28,163,174,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0,-1,0,10124,0
10125,propofol,7,8,58,66,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,0,-1,0,10125,0
10127,propofol,6,7,33,41,BACKGROUND: Pain on injection of propofol is unpleasant.,18006530_1,0,-1,0,10127,0
10128,propofol,3,4,21,29,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0,-1,0,10128,0
10130,propofol,15,16,108,116,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0,-1,0,10130,0
10144,propofol,10,11,50,58,"After the target Ce was achieved, the infusion of propofol was started.",18006530_5,0,-1,0,10144,0
10147,propofol,13,14,102,110,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0,-1,0,10147,0
10148,propofol,22,23,161,169,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0,-1,0,10148,0
10159,propofol,9,10,57,65,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0,-1,0,10159,0
10161,propofol,17,18,111,119,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0,-1,0,10161,0
10238,levetiracetam,3,4,26,39,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,0,-1,0,10238,0
10240,levetiracetam,9,10,48,61,BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.,18081909_1,0,-1,0,10240,0
10271,propranolol,16,17,126,137,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0,-1,0,10271,0
10277,yohimbine,41,42,291,300,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0,-1,0,10277,0
10340,sulpiride,7,8,62,71,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,0,-1,0,10340,0
10343,Sulpiride,0,1,0,9,Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.,18162529_5,0,-1,0,10343,0
10357,sulpiride,29,30,156,165,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,0,-1,0,10357,0
10358,Sulpiride,0,1,0,9,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0,-1,0,10358,0
10407,Tacrolimus,0,1,0,10,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,0,-1,0,10407,0
10413,tacrolimus,1,2,9,19,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0,-1,0,10413,0
10414,sirolimus,17,18,109,118,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0,-1,0,10414,0
10422,tacrolimus,20,21,134,144,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,0,-1,0,10422,0
10557,trihexyphenidyl,10,11,72,87,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,0,-1,0,10557,0
10560,trihexyphenidyl,19,20,122,137,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,0,-1,0,10560,0
10570,trihexyphenidyl,8,9,43,58,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,0,-1,0,10570,0
10578,trihexyphenidyl,7,8,31,46,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,0,-1,0,10578,0
10583,trihexyphenidyl,10,11,63,78,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,0,-1,0,10583,0
10593,trihexyphenidyl,16,17,113,128,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,0,-1,0,10593,0
10607,cyclosporine,11,12,72,84,"In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS.",18261172_4,0,-1,0,10607,0
10679,hexamethonium,20,21,138,151,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0,-1,0,10679,0
10735,Amikacin,0,1,0,8,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0,-1,0,10735,0
10736,aminoglycoside,3,4,15,29,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0,-1,0,10736,0
10747,aminoglycoside,15,16,113,127,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0,-1,0,10747,0
10749,amikacin,23,24,188,196,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0,-1,0,10749,0
10751,creatinine,11,12,66,76,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,0,-1,0,10751,0
10752,amikacin,17,18,108,116,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,0,-1,0,10752,0
10802,sulfasalazine,3,4,31,44,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,0,-1,0,10802,0
10818,sulfasalazine,7,8,37,50,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,0,-1,0,10818,0
10823,sulfasalazine,6,7,44,57,The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.,18405372_6,0,-1,0,10823,0
10834,sulfasalazine,7,8,52,65,The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.,18405372_14,0,-1,0,10834,0
10837,sulfasalazine,6,7,51,64,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,0,-1,0,10837,0
10904,amino acid,6,8,58,68,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,0,-1,0,10904,0
10907,amino acid,19,21,118,128,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0,-1,0,10907,0
10908,aspartate,25,26,159,168,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0,-1,0,10908,0
10922,aspartate,18,19,149,158,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,0,-1,0,10922,0
10927,aspartate,26,27,156,165,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,0,-1,0,10927,0
10930,aspartate,26,27,153,162,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,0,-1,0,10930,0
10933,amino acid,23,25,149,159,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0,-1,0,10933,0
10934,aspartate,38,39,256,265,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0,-1,0,10934,0
10938,aspartate,17,18,114,123,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,0,-1,0,10938,0
11008,cyclophosphamide,15,16,114,130,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,0,-1,0,11008,0
11015,cyclophosphamide,14,15,106,122,VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.,18483878_2,0,-1,0,11015,0
11075,terbutaline,6,7,27,38,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,0,-1,0,11075,0
11076,terbutaline,14,15,74,85,"Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2.",1848636_7,0,-1,0,11076,0
11078,terbutaline,9,10,52,63,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0,-1,0,11078,0
11084,terbutaline,6,7,33,44,"In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%).",1848636_9,0,-1,0,11084,0
11091,everolimus,8,9,72,82,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,0,-1,0,11091,0
11107,methylprednisolone,17,18,105,123,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,0,-1,0,11107,0
11109,everolimus,16,17,122,132,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,0,-1,0,11109,0
11177,sevoflurane,12,13,78,89,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,0,-1,0,11177,0
11179,sevoflurane,13,14,94,105,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,0,-1,0,11179,0
11183,sevoflurane,23,24,139,150,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,0,-1,0,11183,0
11196,sevoflurane,33,34,234,245,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,0,-1,0,11196,0
11201,pergolide,11,12,73,82,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,0,-1,0,11201,0
11206,pergolide,17,18,103,112,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,0,-1,0,11206,0
11213,pergolide,11,12,57,66,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,0,-1,0,11213,0
11217,pergolide,13,14,75,84,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,0,-1,0,11217,0
11225,pergolide,28,29,150,159,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,0,-1,0,11225,0
11226,pergolide,7,8,50,59,Severity of regurgitation was not correlated with pergolide cumulative dose.,18560792_11,0,-1,0,11226,0
11228,pergolide,12,13,75,84,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,0,-1,0,11228,0
11230,Pergolide,0,1,0,9,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,0,-1,0,11230,0
11237,pergolide,15,16,102,111,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,0,-1,0,11237,0
11271,adriamycin,9,10,63,73,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,0,-1,0,11271,0
11274,adriamycin,20,21,119,129,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,0,-1,0,11274,0
11277,3-methyladenine,2,3,9,24,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,0,-1,0,11277,0
11281,adriamycin,23,24,119,129,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,0,-1,0,11281,0
11306,adriamycin,2,3,13,23,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,0,-1,0,11306,0
11314,adriamycin,19,20,123,133,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,0,-1,0,11314,0
11317,adriamycin,13,14,83,93,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,0,-1,0,11317,0
11359,rapamycin,16,17,120,129,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0,-1,0,11359,0
11360,sirolimus,23,24,160,169,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0,-1,0,11360,0
11364,sirolimus,5,6,31,40,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0,11364,0
11367,sirolimus,24,25,172,181,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0,11367,0
11368,sirolimus,34,35,244,253,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0,-1,0,11368,0
11419,Adriamycin,6,7,36,46,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,0,-1,0,11419,0
11574,creatinine,4,5,25,35,"Urinary volume and serum creatinine levels recovered to the normal range, with urinary protein disappearing completely within 40 days.",18754075_4,0,-1,0,11574,0
11684,Alpha-lipoic acid,0,2,0,17,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,0,-1,0,11684,0
11693,alpha-lipoic acid,30,32,223,240,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0,-1,0,11693,0
11701,paclitaxel,32,33,191,201,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0,-1,0,11701,0
11702,cisplatin,34,35,206,215,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0,-1,0,11702,0
11704,alpha-lipoic acid,7,9,52,69,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,0,-1,0,11704,0
11709,alpha-lipoic acid,29,31,211,228,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,0,-1,0,11709,0
11710,cisplatin,5,6,34,43,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0,-1,0,11710,0
11711,paclitaxel,7,8,48,58,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0,-1,0,11711,0
11714,Alpha-lipoic acid,0,2,0,17,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0,-1,0,11714,0
11723,paclitaxel,11,12,70,80,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0,-1,0,11723,0
11724,cisplatin,13,14,85,94,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0,-1,0,11724,0
11726,Alpha-lipoic acid,0,2,0,17,"Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.",18809400_7,0,-1,0,11726,0
11731,alpha-lipoic acid,4,6,28,45,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,0,-1,0,11731,0
11770,oral contraceptives,10,12,70,89,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,0,-1,0,11770,0
11773,Oral Contraceptives,7,9,46,65,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,0,-1,0,11773,0
11810,Ifosfamide,0,1,0,10,Ifosfamide continuous infusion without mesna.,1899352_0,0,-1,0,11810,0
11811,mesna,4,5,39,44,Ifosfamide continuous infusion without mesna.,1899352_0,0,-1,0,11811,0
11813,ifosfamide,6,7,39,49,Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna.,1899352_2,0,-1,0,11813,0
11814,Mesna,17,18,116,121,Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna.,1899352_2,0,-1,0,11814,0
11816,ifosfamide,16,17,78,88,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0,-1,0,11816,0
11818,Mesna,29,30,174,179,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0,-1,0,11818,0
11829,Mesna,22,23,132,137,"The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.",1899352_10,0,-1,0,11829,0
11832,ifosfamide,5,6,37,47,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0,-1,0,11832,0
11833,Mesna,11,12,101,106,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0,-1,0,11833,0
11883,green tea,2,4,10,19,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,0,-1,0,11883,0
11887,green tea,11,13,67,76,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0,-1,0,11887,0
11907,green tea,2,4,18,27,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,11907,0
11918,green tea,81,83,422,431,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0,-1,0,11918,0
11921,green tea,8,10,61,70,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,0,-1,0,11921,0
11935,bupropion,7,8,55,64,Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.,19105845_0,0,-1,0,11935,0
11937,bupropion,10,11,70,79,"This is important, since different controlled release formulations of bupropion release the active drug at different rates.",19105845_2,0,-1,0,11937,0
11959,bupropion,21,22,128,137,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,0,-1,0,11959,0
11962,everolimus,4,5,43,53,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0,-1,0,11962,0
11963,tacrolimus,6,7,58,68,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0,-1,0,11963,0
11974,Everolimus,0,1,0,10,"Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.",19135948_2,0,-1,0,11974,0
11975,sirolimus,5,6,28,37,"Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.",19135948_2,0,-1,0,11975,0
11977,everolimus,6,7,30,40,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0,-1,0,11977,0
11978,tacrolimus,8,9,45,55,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0,-1,0,11978,0
12035,paracetamol,20,21,142,153,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,0,-1,0,12035,0
12055,sulphasalazine,10,11,117,131,Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.,19203554_0,0,-1,0,12055,0
12060,sulphasalazine,20,21,141,155,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,0,-1,0,12060,0
12069,sulphasalazine,3,4,22,36,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,0,-1,0,12069,0
12079,sulphasalazine,4,5,24,38,This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.,19203554_7,0,-1,0,12079,0
12184,cyclophosphamide,8,9,47,63,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,0,-1,0,12184,0
12189,cyclophosphamide,11,12,67,83,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,0,-1,0,12189,0
12198,cyclophosphamide,38,39,187,203,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,0,-1,0,12198,0
12200,cyclophosphamide,5,6,30,46,The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2).,19274460_3,0,-1,0,12200,0
12207,cyclophosphamide,8,9,56,72,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,0,-1,0,12207,0
12278,Bradykinin,0,1,0,10,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0,-1,0,12278,0
12280,streptozotocin,11,12,89,103,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0,-1,0,12280,0
12293,bradykinin,66,67,373,383,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0,-1,0,12293,0
12297,bradykinin,11,12,62,72,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,0,-1,0,12297,0
12309,bradykinin,19,20,109,119,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0,-1,0,12309,0
12322,bradykinin,12,13,105,115,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,0,-1,0,12322,0
12411,sirolimus,7,8,67,76,Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.,19356053_0,0,-1,0,12411,0
12413,Sirolimus,2,3,12,21,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,0,-1,0,12413,0
12419,sirolimus,16,17,105,114,To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus.,19356053_2,0,-1,0,12419,0
12421,sirolimus,11,12,91,100,We have encountered several patients who developed substantial proteinuria associated with sirolimus use.,19356053_3,0,-1,0,12421,0
12422,sirolimus,12,13,76,85,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,0,-1,0,12422,0
12423,sirolimus,17,18,121,130,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,0,-1,0,12423,0
12426,sirolimus,26,27,166,175,METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.,19356053_5,0,-1,0,12426,0
12431,creatinine,22,23,139,149,"In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.",19356053_6,0,-1,0,12431,0
12434,sirolimus,10,11,69,78,"Laboratory results were compared between prior, during and following sirolimus use.",19356053_7,0,-1,0,12434,0
12436,sirolimus,16,17,92,101,In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.,19356053_10,0,-1,0,12436,0
12437,sirolimus,5,6,42,51,Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.,19356053_11,0,-1,0,12437,0
12439,sirolimus,6,7,37,46,"In most patients, discontinuation of sirolimus resulted in a decrease, but not resolution, of proteinuria.",19356053_12,0,-1,0,12439,0
12440,Sirolimus,2,3,13,22,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,0,-1,0,12440,0
12442,sirolimus,10,11,52,61,"Proteinuria may improve, but does not resolve, when sirolimus is withdrawn.",19356053_14,0,-1,0,12442,0
12538,salvianolic acid,11,13,77,93,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,0,-1,0,12538,0
12549,aspartate,12,13,96,105,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0,-1,0,12549,0
12551,malondialdehyde,18,19,140,155,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0,-1,0,12551,0
12577,paclitaxel,10,11,90,100,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,0,-1,0,12577,0
12580,paclitaxel,12,13,89,99,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,0,-1,0,12580,0
12581,amino acid,23,25,150,160,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,0,-1,0,12581,0
12706,Sulpiride,0,1,0,9,Sulpiride is a selective D2-receptor antagonist with antipsychotic and antidepressant properties.,1967484_1,0,-1,0,12706,0
12712,sulpiride,15,16,104,113,We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.,1967484_3,0,-1,0,12712,0
12761,sodium nitroprusside,36,38,244,264,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,0,-1,0,12761,0
12769,sodium nitroprusside,34,36,171,191,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,0,-1,0,12769,0
12774,Sodium nitroprusside,0,2,0,20,Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.,1969772_8,0,-1,0,12774,0
12782,levofloxacin,3,4,25,37,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,0,-1,0,12782,0
12785,levofloxacin,17,18,103,115,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,0,-1,0,12785,0
12791,levofloxacin,9,10,52,64,The main search terms utilized were case report and levofloxacin.,19707748_3,0,-1,0,12791,0
12794,levofloxacin,9,10,62,74,Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.,19707748_6,0,-1,0,12794,0
12796,levofloxacin,11,12,76,88,CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.,19707748_7,0,-1,0,12796,0
12804,dextran,3,4,24,31,A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.,19719056_2,0,-1,0,12804,0
12810,dextran,19,20,118,125,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,0,-1,0,12810,0
12847,ouabain,7,8,45,52,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,0,-1,0,12847,0
12855,ouabain,19,20,132,139,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,0,-1,0,12855,0
12860,oxycodone,8,9,71,80,Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.,19729346_0,0,-1,0,12860,0
12864,oxycodone,16,17,116,125,"This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.",19729346_1,0,-1,0,12864,0
12867,oxycodone,17,18,112,121,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,0,-1,0,12867,0
12868,oxycodone,1,2,7,16,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,0,-1,0,12868,0
12885,oxycodone,28,29,183,192,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,0,-1,0,12885,0
12889,oxycodone,18,19,116,125,"PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults.",19729346_7,0,-1,0,12889,0
12927,olanzapine,10,11,56,66,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0,-1,0,12927,0
13013,suxamethonium,27,28,189,202,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,0,-1,0,13013,0
13042,creatinine,12,13,73,83,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,0,-1,0,13042,0
13050,creatinine,20,21,115,125,"The dosing schedule, duration of lithium treatment, and daily dose of lithium did not affect maximum osmolality or creatinine clearance.",1987816_5,0,-1,0,13050,0
13174,creatinine,21,22,139,149,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0,-1,0,13174,0
13190,tacrolimus,5,6,45,55,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,0,-1,0,13190,0
13193,Tacrolimus,0,1,0,10,Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation.,19917396_1,0,-1,0,13193,0
13197,tacrolimus,8,9,63,73,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,0,-1,0,13197,0
13203,tacrolimus,2,3,10,20,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0,-1,0,13203,0
13204,tacrolimus,14,15,77,87,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0,-1,0,13204,0
13205,tacrolimus,10,11,85,95,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,0,-1,0,13205,0
13207,tacrolimus,5,6,23,33,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,0,-1,0,13207,0
13208,tacrolimus,3,4,22,32,"In patients receiving tacrolimus therapy, blood concentration should be carefully controlled and extreme attention paid to cardiac involvement.",19917396_9,0,-1,0,13208,0
13210,Nimodipine,0,1,0,10,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.,19923525_0,0,-1,0,13210,0
13214,nimodipine,5,6,30,40,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,0,-1,0,13214,0
13312,6-hydroxydopamine,12,13,77,94,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,0,-1,0,13312,0
13336,sorafenib,6,7,32,41,"Two weeks before his admission, sorafenib had been started.",19944333_2,0,-1,0,13336,0
13342,sorafenib,2,3,13,22,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,0,-1,0,13342,0
13344,sorafenib,20,21,144,153,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,0,-1,0,13344,0
13348,Sorafenib,0,1,0,9,Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival.,19944333_10,0,-1,0,13348,0
13356,sorafenib,12,13,65,74,Our report may show an adverse effect on the Rho/ROCK pathway by sorafenib use.,19944333_12,0,-1,0,13356,0
13401,propofol,15,16,76,84,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,0,-1,0,13401,0
13453,argatroban,4,5,30,40,Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.,20003049_0,0,-1,0,13453,0
13461,argatroban,18,19,112,122,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,0,-1,0,13461,0
13470,argatroban,16,17,101,111,STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time (ECT) assay.,20003049_4,0,-1,0,13470,0
13472,argatroban,6,7,45,55,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,0,-1,0,13472,0
13473,argatroban,25,26,135,145,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,0,-1,0,13473,0
13477,argatroban,5,6,35,45,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,0,-1,0,13477,0
13480,argatroban,23,24,172,182,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,0,-1,0,13480,0
13487,argatroban,8,9,43,53,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,0,-1,0,13487,0
13505,propranolol,27,28,203,214,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,0,-1,0,13505,0
13515,azidothymidine,8,9,66,80,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,0,-1,0,13515,0
13558,propofol,40,41,256,264,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,0,-1,0,13558,0
13569,propofol,6,7,29,37,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,0,-1,0,13569,0
13574,bupropion,5,6,30,39,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,0,-1,0,13574,0
13578,bupropion,10,11,62,71,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,0,-1,0,13578,0
13583,bupropion,6,7,34,43,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,0,-1,0,13583,0
13595,bupropion,26,27,124,133,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,0,-1,0,13595,0
13597,bupropion,3,4,17,26,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,0,-1,0,13597,0
13601,bupropion,14,15,80,89,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,0,-1,0,13601,0
13602,bupropion,10,11,42,51,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,0,-1,0,13602,0
13608,Bupropion,2,3,13,22,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,0,-1,0,13608,0
13609,bupropion,11,12,74,83,These results provide empirical support for conducting a further study of bupropion.,20067456_13,0,-1,0,13609,0
13634,modafinil,3,4,23,32,Normalizing effects of modafinil on sleep in chronic cocaine users.,20080983_0,0,-1,0,13634,0
13635,modafinil,15,16,89,98,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,0,-1,0,13635,0
13638,modafinil,10,11,80,89,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,0,-1,0,13638,0
13646,modafinil,4,5,23,32,"Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.",20080983_7,0,-1,0,13646,0
13650,modafinil,3,4,14,23,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,0,-1,0,13650,0
13660,modafinil,23,24,151,160,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,0,-1,0,13660,0
13662,Modafinil,0,1,0,9,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,0,-1,0,13662,0
13667,modafinil,3,4,27,36,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,0,-1,0,13667,0
13870,creatinine,12,13,38,48,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,0,-1,0,13870,0
13975,risperidone,7,8,46,57,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,0,-1,0,13975,0
13983,risperidone,17,18,103,114,"METHOD: Medically healthy 7- to 17-year-old males chronically treated, in a naturalistic setting, with risperidone were recruited for this cross-sectional study through child psychiatry outpatient clinics between November 2005 and June 2007.",20331935_2,0,-1,0,13983,0
13999,risperidone,18,19,80,91,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,0,-1,0,13999,0
14017,risperidone,8,9,45,56,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,0,-1,0,14017,0
14039,yohimbine,12,13,85,94,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0,-1,0,14039,0
14046,yohimbine,15,16,83,92,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,0,-1,0,14046,0
14047,yohimbine,2,3,13,22,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,0,-1,0,14047,0
14053,tacrolimus,5,6,47,57,Rosaceiform dermatitis associated with topical tacrolimus treatment.,20466178_0,0,-1,0,14053,0
14054,tacrolimus,17,18,104,114,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,0,-1,0,14054,0
14061,tacrolimus,7,8,51,61,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,0,-1,0,14061,0
14122,cisplatin,2,3,13,22,injection of cisplatin (5 mg/kg).,20510337_2,0,-1,0,14122,0
14124,cisplatin,21,22,102,111,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,0,-1,0,14124,0
14126,blood urea nitrogen,4,7,35,54,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0,-1,0,14126,0
14127,creatinine,9,10,65,75,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0,-1,0,14127,0
14128,cisplatin,15,16,107,116,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0,-1,0,14128,0
14131,glutathione,12,13,95,106,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0,-1,0,14131,0
14138,cisplatin,53,54,368,377,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0,-1,0,14138,0
14141,cisplatin,8,9,56,65,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,0,-1,0,14141,0
14166,asenapine,4,5,23,32,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.,20520283_0,0,-1,0,14166,0
14169,Asenapine,0,1,0,9,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,0,-1,0,14169,0
14174,asenapine,18,19,122,131,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,0,-1,0,14174,0
14175,asenapine,28,29,159,168,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,0,-1,0,14175,0
14177,asenapine,26,27,170,179,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0,-1,0,14177,0
14180,asenapine,68,69,359,368,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0,-1,0,14180,0
14183,asenapine,21,22,123,132,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,0,-1,0,14183,0
14190,asenapine,22,23,84,93,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,0,-1,0,14190,0
14194,asenapine,21,22,85,94,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,0,-1,0,14194,0
14199,asenapine,9,10,59,68,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,0,-1,0,14199,0
14203,nelarabine,3,4,21,31,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0,-1,0,14203,0
14204,etoposide,5,6,33,42,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0,-1,0,14204,0
14205,cyclophosphamide,8,9,48,64,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0,-1,0,14205,0
14208,nelarabine,6,7,24,34,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0,-1,0,14208,0
14210,etoposide,14,15,54,63,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0,-1,0,14210,0
14212,cyclophosphamide,19,20,73,89,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0,-1,0,14212,0
14229,etoposide,14,15,87,96,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,0,-1,0,14229,0
14230,cyclophosphamide,16,17,101,117,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,0,-1,0,14230,0
14246,adriamycin,2,3,10,20,Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.,2054792_0,0,-1,0,14246,0
14266,salbutamol,5,6,55,65,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,0,-1,0,14266,0
14271,salbutamol,14,15,81,91,The patient noticed that before these episodes he had been using an inhalator of salbutamol.,20552622_4,0,-1,0,14271,0
14283,Salbutamol,2,3,12,22,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,0,-1,0,14283,0
14287,salbutamol,21,22,111,121,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,0,-1,0,14287,0
14328,amino acid,22,24,153,163,"Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing, escape-like behavior, and immobility.",20558148_2,0,-1,0,14328,0
14465,Suxamethonium,0,1,0,13,Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.,20633755_0,0,-1,0,14465,0
14467,Suxamethonium,0,1,0,13,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,0,-1,0,14467,0
14494,Curcumin,0,1,0,8,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,0,-1,0,14494,0
14497,carbamazepine,10,11,86,99,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,0,-1,0,14497,0
14499,carbamazepine,6,7,44,57,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,0,-1,0,14499,0
14505,Curcumin,0,1,0,8,"Curcumin has shown antioxidant, anti-inflammatory and neuro-protective properties.",20667451_3,0,-1,0,14505,0
14507,curcumin,14,15,82,90,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,0,-1,0,14507,0
14508,phenobarbitone-,17,18,109,124,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,0,-1,0,14508,0
14512,curcumin,3,4,32,40,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0,-1,0,14512,0
14513,carbamazepine,7,8,65,78,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0,-1,0,14513,0
14518,carbamazepine,10,11,53,66,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0,-1,0,14518,0
14519,malondialdehyde,14,15,80,95,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0,-1,0,14519,0
14520,glutathione,17,18,108,119,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0,-1,0,14520,0
14521,carbamazepine,5,6,41,54,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,0,-1,0,14521,0
14523,curcumin,1,2,12,20,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,0,-1,0,14523,0
14527,Curcumin,0,1,0,8,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0,-1,0,14527,0
14529,carbamazepine,18,19,130,143,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0,-1,0,14529,0
14530,curcumin,4,5,24,32,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0,-1,0,14530,0
14534,carbamazepine,24,25,171,184,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0,-1,0,14534,0
14535,curcumin,4,5,26,34,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,0,-1,0,14535,0
14536,carbamazepine,18,19,118,131,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,0,-1,0,14536,0
14589,sorafenib,31,32,221,230,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0,-1,0,14589,0
14613,olanzapine,20,21,128,138,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0,-1,0,14613,0
14658,capecitabine,2,3,10,22,Safety of capecitabine: a review.,20722491_0,0,-1,0,14658,0
14660,5-fluorouracil,9,10,58,72,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,0,-1,0,14660,0
14662,capecitabine,14,15,84,96,AREAS COVERED IN THIS REVIEW: This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety.,20722491_2,0,-1,0,14662,0
14663,capecitabine,16,17,82,94,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,0,-1,0,14663,0
14667,capecitabine,8,9,50,62,We also explore different dosing and schedules of capecitabine administration.,20722491_4,0,-1,0,14667,0
14668,Capecitabine,4,5,19,31,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,0,-1,0,14668,0
14675,capecitabine,7,8,44,56,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,0,-1,0,14675,0
14677,Capecitabine,0,1,0,12,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,0,-1,0,14677,0
14758,neurotensin,3,4,20,31,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,0,-1,0,14758,0
14765,neurotensin,20,21,147,158,"Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum, and systemic administration of a neurotensin analog could produce antiparkinsonian effects.",20882060_2,0,-1,0,14765,0
14768,neurotensin,10,11,63,74,The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.,20882060_3,0,-1,0,14768,0
14771,neurotensin,5,6,32,43,RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.,20882060_5,0,-1,0,14771,0
14776,neurotensin,6,7,62,73,Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration.,20882060_6,0,-1,0,14776,0
14778,neurotensin,1,2,4,15,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0,-1,0,14778,0
14781,neurotensin,16,17,127,138,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0,-1,0,14781,0
14782,neurotensin,5,6,35,46,CONCLUSION: Activation of pallidal neurotensin receptors may be involved in neurotensin-induced antiparkinsonian effects.,20882060_8,0,-1,0,14782,0
14820,6-hydroxydopamine,63,64,330,347,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,0,-1,0,14820,0
14907,Perhexiline maleate,0,2,0,19,Perhexiline maleate and peripheral neuropathy.,220563_0,0,-1,0,14907,0
14910,perhexiline maleate,11,13,71,90,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,0,-1,0,14910,0
14927,4'-0-tetrahydropyranyladriamycin,5,6,19,51,A phase I study of 4'-0-tetrahydropyranyladriamycin.,2224762_0,0,-1,0,14927,0
14930,4'-0-tetrahydropyranyladriamycin,10,11,42,74,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,0,-1,0,14930,0
14970,desferrioxamine,8,9,64,79,Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.,2234245_0,0,-1,0,14970,0
14973,desferrioxamine,10,11,70,85,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,0,-1,0,14973,0
14985,Desferrioxamine,0,1,0,15,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,0,-1,0,14985,0
14989,desferrioxamine,10,11,65,80,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,0,-1,0,14989,0
14992,desferrioxamine,15,16,113,128,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,0,-1,0,14992,0
15001,azidothymidine,17,18,96,110,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,0,-1,0,15001,0
15034,mazindol,5,6,34,42,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,0,-1,0,15034,0
15039,mazindol,7,8,44,52,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,0,-1,0,15039,0
15045,mazindol,23,24,139,147,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,0,-1,0,15045,0
15046,Mazindol,0,1,0,8,Mazindol did not benefit strength at any point in the study.,2266990_5,0,-1,0,15046,0
15048,mazindol,4,5,29,37,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0,-1,0,15048,0
15053,mazindol,35,36,152,160,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0,-1,0,15053,0
15054,mazindol,3,4,14,22,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0,-1,0,15054,0
15058,mazindol,29,30,158,166,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0,-1,0,15058,0
15063,Mazindol,0,1,0,8,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,0,-1,0,15063,0
15068,cycloheximide,5,6,36,49,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0,-1,0,15068,0
15076,cycloheximide,16,17,120,133,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,0,-1,0,15076,0
15085,alpha-methyldopa,6,7,36,52,The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.,227508_2,0,-1,0,15085,0
15097,alpha-methyldopa,29,30,177,193,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,0,-1,0,15097,0
15145,ifosfamide,5,6,37,47,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,0,-1,0,15145,0
15150,cisplatin,11,12,76,85,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0,-1,0,15150,0
15152,ifosfamide,28,29,174,184,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0,-1,0,15152,0
15158,Ifosfamide,0,1,0,10,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,0,-1,0,15158,0
15160,ifosfamide,11,12,62,72,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0,-1,0,15160,0
15161,cisplatin,20,21,122,131,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0,-1,0,15161,0
15163,ifosfamide,5,6,28,38,We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.,2320800_7,0,-1,0,15163,0
15225,bupivacaine,19,20,106,117,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,0,-1,0,15225,0
15293,dipyridamole,8,9,48,60,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,0,-1,0,15293,0
15297,Dipyridamole,0,1,0,12,Dipyridamole significantly increased coronary blood flow before and after 7.5 or 15 mm/kg i.v.,2348231_6,0,-1,0,15297,0
15421,picrotoxin,6,7,32,42,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0,-1,0,15421,0
15425,bicuculline,26,27,143,154,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0,-1,0,15425,0
15436,picrotoxin,7,8,43,53,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,0,-1,0,15436,0
15512,amantadine,4,5,33,43,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,0,-1,0,15512,0
15514,amantadine,3,4,14,24,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,0,-1,0,15514,0
15521,Amantadine,0,1,0,10,Amantadine treatment produced a biphasic effect on mouse motility.,2484011_3,0,-1,0,15521,0
15527,amantadine,1,2,11,21,Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive.,2484011_5,0,-1,0,15527,0
15532,amantadine,27,28,172,182,"The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment.",2484011_6,0,-1,0,15532,0
15534,amantadine,2,3,20,30,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,0,-1,0,15534,0
15538,amantadine,2,3,15,25,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,0,-1,0,15538,0
15544,amantadine,11,12,85,95,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,0,-1,0,15544,0
15547,amantadine,7,8,49,59,The results suggest a strain-dependent effect of amantadine on motility and indicate a differential response to the acute and multiple dose regimens used.,2484011_10,0,-1,0,15547,0
15551,amantadine,22,23,122,132,The BALB/C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine.,2484011_11,0,-1,0,15551,0
15558,amantadine,41,42,286,296,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0,-1,0,15558,0
15562,cyclophosphamide,9,10,77,93,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,0,-1,0,15562,0
15563,ifosfamide,11,12,97,107,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,0,-1,0,15563,0
15575,mesna,21,22,122,127,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,0,-1,0,15575,0
15587,carbamazepine,2,3,20,33,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,0,-1,0,15587,0
15590,carbamazepine,8,9,48,61,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,0,-1,0,15590,0
15594,carbamazepine,11,12,56,69,This is the first report of such an unusual reaction to carbamazepine.,2522601_2,0,-1,0,15594,0
15597,Azidothymidine,17,18,114,128,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,0,-1,0,15597,0
15665,propranolol,20,21,138,149,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,0,-1,0,15665,0
15705,adriamycin,7,8,33,43,"Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.",2559236_2,0,-1,0,15705,0
15780,alfentanil,19,20,118,128,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,0,-1,0,15780,0
15795,alfentanil,6,7,32,42,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,0,-1,0,15795,0
15839,citalopram,10,11,77,87,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0,-1,0,15839,0
15840,5-azacytidine,0,1,0,13,5-azacytidine potentiates initiation induced by carcinogens in rat liver.,2578334_0,0,-1,0,15840,0
15843,5-azacytidine,22,23,134,147,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,0,-1,0,15843,0
15854,2-acetylaminofluorene,27,28,182,203,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,0,-1,0,15854,0
15879,bupivacaine,5,6,40,51,"Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).",2594614_1,0,-1,0,15879,0
15886,bupivacaine,21,22,117,128,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0,-1,0,15886,0
15889,bupivacaine,2,3,13,24,injection of bupivacaine were ineffective.,2594614_4,0,-1,0,15889,0
15891,bupivacaine,13,14,61,72,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,0,-1,0,15891,0
15946,methyl dopa,12,14,75,86,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,0,-1,0,15946,0
15953,phenylacetic acid,14,16,103,120,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,0,-1,0,15953,0
15956,diclofenac,21,22,147,157,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,0,-1,0,15956,0
15958,ketoconazole,7,8,53,65,Arterial hypertension as a complication of prolonged ketoconazole treatment.,2632720_0,0,-1,0,15958,0
15960,ketoconazole,14,15,77,89,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,0,-1,0,15960,0
15961,ketoconazole,14,15,89,101,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,0,-1,0,15961,0
15965,11-deoxycortisol,9,10,55,71,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,0,-1,0,15965,0
15967,11-deoxycortisol,13,14,73,89,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,0,-1,0,15967,0
15969,ketoconazole,10,11,62,74,Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.,2632720_5,0,-1,0,15969,0
15988,bradykinin,40,41,228,238,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,0,-1,0,15988,0
16005,nitroprusside,6,7,41,54,A randomized comparison of labetalol and nitroprusside for induced hypotension.,2696505_0,0,-1,0,16005,0
16013,Nitroprusside,0,1,0,13,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0,-1,0,16013,0
16017,nitroprusside,31,32,196,209,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0,-1,0,16017,0
16020,nitroprusside,8,9,55,68,It was concluded that labetalol offers advantages over nitroprusside.,2696505_6,0,-1,0,16020,0
16126,carbamazepine,1,2,8,21,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,0,-1,0,16126,0
16128,carbamazepine,3,4,15,28,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,0,-1,0,16128,0
16133,lidocaine-,8,9,51,61,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,0,-1,0,16133,0
16142,lidocaine-,15,16,74,84,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,0,-1,0,16142,0
16158,creatinine,7,8,48,58,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,0,-1,0,16158,0
16160,creatinine,6,7,33,43,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0,-1,0,16160,0
16162,creatinine,25,26,132,142,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0,-1,0,16162,0
16176,creatinine,5,6,29,39,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,0,-1,0,16176,0
16190,oral contraceptive,9,11,42,60,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,0,-1,0,16190,0
16205,terbutaline,11,12,62,73,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,0,-1,0,16205,0
16208,terbutaline,5,6,27,38,"In the 7-hour period after terbutaline administration, plasma samples were taken for determination of plasma potassium levels and drug concentrations.",2826064_4,0,-1,0,16208,0
16212,terbutaline,12,13,74,85,The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects.,2826064_5,0,-1,0,16212,0
16214,terbutaline,10,11,46,57,"Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.",2826064_6,0,-1,0,16214,0
16215,terbutaline,4,5,19,30,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,0,-1,0,16215,0
16242,Flestolol,0,1,0,9,Flestolol: an ultra-short-acting beta-adrenergic blocking agent.,2870085_0,0,-1,0,16242,0
16244,Flestolol,0,1,0,9,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,0,-1,0,16244,0
16249,Flestolol,0,1,0,9,Flestolol is metabolized by plasma esterases and has an elimination half-life of approximately 6.5 minutes.,2870085_2,0,-1,0,16249,0
16253,flestolol,5,6,31,40,"In long-term infusion studies, flestolol was well tolerated at the effective beta-blocking dose (5 micrograms/kg/min) for up to seven days.",2870085_4,0,-1,0,16253,0
16255,Flestolol,0,1,0,9,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,0,-1,0,16255,0
16258,flestolol,16,17,131,140,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,0,-1,0,16258,0
16260,Flestolol,0,1,0,9,Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.,2870085_6,0,-1,0,16260,0
16264,flestolol,5,6,46,55,Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers.,2870085_7,0,-1,0,16264,0
16268,Flestolol,0,1,0,9,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,0,-1,0,16268,0
16272,flestolol,6,7,34,43,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,0,-1,0,16272,0
16274,flestolol,4,5,21,30,"It is concluded that flestolol is a potent, well-tolerated, ultra-short-acting beta-adrenergic blocking agent.",2870085_11,0,-1,0,16274,0
16277,flestolol,2,3,7,16,Use of flestolol in the critical care setting is currently undergoing investigation.,2870085_12,0,-1,0,16277,0
16295,Propranolol,0,1,0,11,Propranolol had no effect on stimulus-induced overflow in either group.,2886572_7,0,-1,0,16295,0
16309,bromocriptine,12,13,111,124,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,0,-1,0,16309,0
16311,bromocriptine,5,6,26,39,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,0,-1,0,16311,0
16319,bromocriptine,33,34,223,236,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,0,-1,0,16319,0
16333,bromocriptine,13,14,81,94,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,0,-1,0,16333,0
16349,bromocriptine,15,16,95,108,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,0,-1,0,16349,0
16355,bromocriptine,30,31,200,213,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,0,-1,0,16355,0
16366,aspartate,24,25,139,148,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,0,-1,0,16366,0
16392,picrotoxin,20,21,143,153,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,0,-1,0,16392,0
16408,sulfasalazine,25,26,179,192,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,0,-1,0,16408,0
16410,sulfasalazine,4,5,23,36,"After cessation of the sulfasalazine and completion of a six-week course of corticosteroids, these problems resolved over a period of four to six months.",2894766_2,0,-1,0,16410,0
16416,sulfasalazine,3,4,19,32,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,0,-1,0,16416,0
16463,carbamazepine,1,2,8,21,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,0,-1,0,16463,0
16465,Carbamazepine,0,1,0,13,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,0,-1,0,16465,0
16488,dipyridamole,10,11,87,99,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,0,-1,0,16488,0
16491,dipyridamole,16,17,89,101,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,0,-1,0,16491,0
16590,6-hydroxydopamine,26,27,163,180,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0,-1,0,16590,0
16725,ketoconazole,4,5,34,46,Hepatic reactions associated with ketoconazole in the United Kingdom.,3101906_0,0,-1,0,16725,0
16727,Ketoconazole,0,1,0,12,Ketoconazole was introduced in the United Kingdom in 1981.,3101906_1,0,-1,0,16727,0
16739,ketoconazole,9,10,52,64,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,0,-1,0,16739,0
16743,ketoconazole,18,19,126,138,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,0,-1,0,16743,0
16787,alfentanil,27,28,203,213,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,0,-1,0,16787,0
16797,alfentanil,15,16,100,110,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,0,-1,0,16797,0
16799,alfentanil,20,21,109,119,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0,16799,0
16800,alfentanil,36,37,214,224,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0,16800,0
16802,alfentanil,5,6,34,44,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,0,-1,0,16802,0
16836,oral contraceptives,6,8,48,67,Three patients developed chorea while receiving oral contraceptives.,3123611_1,0,-1,0,16836,0
16850,alfentanil,7,8,58,68,"Following instrumentation, halothane was discontinued and alfentanil (125 mu/kg) administered iv during emergence from halothane anesthesia.",3125768_4,0,-1,0,16850,0
16859,alfentanil,16,17,77,87,"In five rats that did not become rigid, ICP and CVP did not change following alfentanil.",3125768_7,0,-1,0,16859,0
16860,alfentanil,9,10,66,76,"These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.",3125768_8,0,-1,0,16860,0
16944,cis-platin,8,9,69,79,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,0,-1,0,16944,0
16945,5-fluorouracil,10,11,84,98,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,0,-1,0,16945,0
16947,cis-platin,5,6,22,32,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,0,-1,0,16947,0
16977,Etoposide,7,8,39,48,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0,-1,0,16977,0
16978,Cyclophosphamide,12,13,71,87,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0,-1,0,16978,0
16980,Cisplatin,17,18,106,115,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0,-1,0,16980,0
16981,Etoposide,14,15,71,80,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0,-1,0,16981,0
16982,Cyclophosphamide,16,17,85,101,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0,-1,0,16982,0
17031,sodium nitroprusside,27,29,160,180,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,0,-1,0,17031,0
17033,nitroprusside,1,2,7,20,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,0,-1,0,17033,0
17043,nitroprusside,5,6,23,36,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,0,-1,0,17043,0
17048,Nitroprusside,0,1,0,13,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,0,-1,0,17048,0
17056,nitroprusside,5,6,24,37,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,0,-1,0,17056,0
17063,nitroprusside,4,5,25,38,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,0,-1,0,17063,0
17067,nitroprusside,1,2,7,20,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,0,-1,0,17067,0
17096,cyclosporine,4,5,12,24,"In group I, cyclosporine was given before the procedure at a loading dose of 17.5 mg/kg and then continued after the procedure to keep a whole blood level about 1000 ng/ml.",3311455_2,0,-1,0,17096,0
17099,cyclosporine,4,5,13,25,"In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week.",3311455_3,0,-1,0,17099,0
17103,blood urea nitrogen,12,15,77,96,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,0,-1,0,17103,0
17104,creatinine,17,18,107,117,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,0,-1,0,17104,0
17107,cyclosporine,15,16,106,118,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,0,-1,0,17107,0
17110,creatinine,17,18,91,101,"Despite this improvement in late renal function, group II still shows a slow rise in serum creatinine.",3311455_6,0,-1,0,17110,0
17111,cyclosporine,8,9,42,54,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,0,-1,0,17111,0
17122,sodium nitroprusside,27,29,127,147,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,0,-1,0,17122,0
17158,carbamazepine,6,7,37,50,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0,-1,0,17158,0
17159,carbamazepine,19,20,130,143,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0,-1,0,17159,0
17160,carbamazepine,26,27,175,188,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0,-1,0,17160,0
17166,fluphenazine enanthate,17,19,116,138,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,0,-1,0,17166,0
17184,paracetamol,13,14,80,91,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,0,-1,0,17184,0
17213,paracetamol,1,2,5,16,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0,-1,0,17213,0
17218,paracetamol,32,33,218,229,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0,-1,0,17218,0
17221,paracetamol,12,13,67,78,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,0,-1,0,17221,0
17248,glutathione,16,17,91,102,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,0,-1,0,17248,0
17346,sparteine,22,23,138,147,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0,-1,0,17346,0
17356,sparteine,30,31,149,158,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,0,-1,0,17356,0
17420,deferoxamine,8,9,63,75,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,0,-1,0,17420,0
17422,deferoxamine,24,25,181,193,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,0,-1,0,17422,0
17423,deferoxamine,1,2,5,17,"When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic.",3503576_3,0,-1,0,17423,0
17425,deferoxamine,9,10,53,65,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,0,-1,0,17425,0
17429,deferoxamine,14,15,113,125,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0,-1,0,17429,0
17430,deferoxamine,26,27,210,222,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0,-1,0,17430,0
17432,deferoxamine,18,19,105,117,"Based on these data, a plan of management was developed that allows effective yet safe administration of deferoxamine.",3503576_7,0,-1,0,17432,0
17435,deferoxamine,6,7,46,58,Moderate abnormalities require a reduction of deferoxamine to 25 mg/kg per dose with careful monitoring.,3503576_10,0,-1,0,17435,0
17504,cefonicid,4,5,27,36,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,0,-1,0,17504,0
17505,cefazedone,6,7,41,51,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,0,-1,0,17505,0
17514,cefonicid,10,11,69,78,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,0,-1,0,17514,0
17515,cefazedone,12,13,82,92,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,0,-1,0,17515,0
17518,cefonicid,23,24,135,144,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,0,-1,0,17518,0
17519,cefazedone,29,30,162,172,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,0,-1,0,17519,0
17523,cefonicid,16,17,105,114,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,0,-1,0,17523,0
17532,cefonicid,9,10,53,62,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,0,-1,0,17532,0
17533,cefazedone,11,12,66,76,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,0,-1,0,17533,0
17580,paracetamol,19,20,83,94,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,0,-1,0,17580,0
17588,paracetamol,30,31,138,149,"In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market.",3670965_7,0,-1,0,17588,0
17618,bromocriptine,4,5,32,45,Postpartum psychosis induced by bromocriptine.,3686155_0,0,-1,0,17618,0
17620,bromocriptine,16,17,113,126,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,0,-1,0,17620,0
17621,Bromocriptine,0,1,0,13,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,0,-1,0,17621,0
17625,bromocriptine,4,5,29,42,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,0,-1,0,17625,0
17643,cyclosporine,3,4,12,24,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,0,-1,0,17643,0
17653,ketoconazole,26,27,163,175,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,0,-1,0,17653,0
17687,5-fluorouracil,3,4,21,35,Allergic reaction to 5-fluorouracil infusion.,3719553_0,0,-1,0,17687,0
17689,5-fluorouracil,11,12,88,102,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,0,-1,0,17689,0
17705,amiloride,28,29,198,207,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,0,-1,0,17705,0
17708,amiloride,15,16,107,116,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,0,-1,0,17708,0
17712,amiloride,2,3,12,21,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,0,-1,0,17712,0
17748,trihexyphenidyl,3,4,19,34,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,0,-1,0,17748,0
17751,trihexyphenidyl,11,12,74,89,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,0,-1,0,17751,0
17753,trihexyphenidyl,5,6,29,44,The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs.,3769769_3,0,-1,0,17753,0
17871,etoposide,4,5,24,33,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,0,-1,0,17871,0
17874,etoposide,4,5,34,43,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,0,-1,0,17874,0
17894,aminoglycoside,18,19,144,158,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,0,-1,0,17894,0
17898,amikacin,10,11,82,90,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,0,-1,0,17898,0
17900,amikacin,6,7,35,43,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,0,-1,0,17900,0
17906,creatinine,11,12,61,71,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0,-1,0,17906,0
17907,creatinine,14,15,79,89,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0,-1,0,17907,0
17946,5-fluorouracil,3,4,20,34,Cardiac toxicity of 5-fluorouracil.,3952818_0,0,-1,0,17946,0
17950,5-fluorouracil,18,19,103,117,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,0,-1,0,17950,0
18012,cyclophosphamide,5,6,28,44,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,0,-1,0,18012,0
18025,Cyclophosphamide,0,1,0,16,Cyclophosphamide therapy increases the risk of carcinoma of the bladder.,3970039_7,0,-1,0,18025,0
18028,cyclophosphamide,15,16,110,126,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,0,-1,0,18028,0
18083,bupivacaine,12,13,70,81,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0,-1,0,18083,0
18124,paracetamol,2,3,13,24,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,0,-1,0,18124,0
18128,paracetamol,19,20,97,108,Groups of male and female inbred Leeds strain rats were fed diets containing either 0.5% or 1.0% paracetamol by weight for up to 18 months.,4090988_2,0,-1,0,18128,0
18139,paracetamol,12,13,67,78,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,0,-1,0,18139,0
18170,Suxamethonium,0,1,0,13,Suxamethonium infusion rate and observed fasciculations.,435349_0,0,-1,0,18170,0
18172,Suxamethonium,0,1,0,13,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,0,-1,0,18172,0
18189,metoclopramide,9,10,64,78,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,0,-1,0,18189,0
18256,propranolol,18,19,89,100,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,0,-1,0,18256,0
18260,propranolol,6,7,51,62,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,0,-1,0,18260,0
18269,propranolol,5,6,40,51,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,0,-1,0,18269,0
18274,propranolol,23,24,155,166,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,0,-1,0,18274,0
18278,propranolol,20,21,143,154,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,0,-1,0,18278,0
18285,propranolol,37,38,236,247,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,0,-1,0,18285,0
18287,propranolol,10,11,52,63,No corneal disease is known to have occurred in the propranolol group.,6115999_7,0,-1,0,18287,0
18290,propranolol,2,3,7,18,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,0,-1,0,18290,0
18300,5-hydroxytryptophan,9,10,63,82,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,0,-1,0,18300,0
18331,sulphasalazine,3,4,27,41,Possible teratogenicity of sulphasalazine.,6133211_0,0,-1,0,18331,0
18333,sulphasalazine,15,16,95,109,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,0,-1,0,18333,0
18346,sulphasalazine,10,11,54,68,"Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.",6133211_6,0,-1,0,18346,0
18365,creatinine,55,56,305,315,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0,-1,0,18365,0
18386,cisplatin,24,25,191,200,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,0,-1,0,18386,0
18545,salmon calcitonin,4,6,23,40,"injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system, were investigated in male rats.",6293644_2,0,-1,0,18545,0
18588,ammonium acetate,2,4,18,34,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,0,-1,0,18588,0
18648,propranolol,5,6,35,46,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,0,-1,0,18648,0
18653,propranolol,25,26,108,119,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,0,-1,0,18653,0
18659,propranolol,14,15,89,100,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,0,-1,0,18659,0
18662,propranolol,4,5,29,40,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0,-1,0,18662,0
18663,propranolol,15,16,102,113,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0,-1,0,18663,0
18669,MESNA,13,14,114,119,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,0,-1,0,18669,0
18673,MESNA,14,15,103,108,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0,-1,0,18673,0
18675,ifosfamide,21,22,149,159,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0,-1,0,18675,0
18680,MESNA,0,1,0,5,"MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.",6402369_2,0,-1,0,18680,0
18685,MESNA,9,10,51,56,In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions (total 31%).,6402369_4,0,-1,0,18685,0
18696,MESNA,7,8,50,55,There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.,6402369_7,0,-1,0,18696,0
18699,MESNA,6,7,34,39,"Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include IF, simplifies the treatment and provides optimum protection for the urinary epithelium.",6402369_8,0,-1,0,18699,0
18703,MESNA,3,4,21,26,Protection with oral MESNA is particularly suitable for outpatients.,6402369_9,0,-1,0,18703,0
18705,carbamazepine,10,11,65,78,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,0,-1,0,18705,0
18707,carbamazepine,11,12,48,61,"Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.",6415512_1,0,-1,0,18707,0
18711,carbamazepine,2,3,9,22,"When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.",6415512_2,0,-1,0,18711,0
18719,picrotoxin,26,27,159,169,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0,-1,0,18719,0
18722,bicuculline,35,36,206,217,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0,-1,0,18722,0
18729,picrotoxin,25,26,153,163,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0,-1,0,18729,0
18730,bicuculline,27,28,168,179,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0,-1,0,18730,0
18759,creatinine,21,22,138,148,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,0,-1,0,18759,0
18764,glycopyrrolate,0,1,0,14,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0,-1,0,18764,0
18765,suxamethonium,14,15,105,118,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0,-1,0,18765,0
18766,glycopyrrolate,5,6,39,53,The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v.,6466532_2,0,-1,0,18766,0
18769,suxamethonium,16,17,115,128,"immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied.",6466532_3,0,-1,0,18769,0
18771,glycopyrrolate,13,14,73,87,A control group was included for comparison with the lower dose range of glycopyrrolate and atropine.,6466532_4,0,-1,0,18771,0
18777,glycopyrrolate,5,6,30,44,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0,-1,0,18777,0
18780,suxamethonium,31,32,200,213,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0,-1,0,18780,0
18829,polyethylene glycol 400,2,5,10,33,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,0,-1,0,18829,0
18832,polyethylene glycol 400,9,12,45,68,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0,-1,0,18832,0
18836,adriamycin,28,29,138,148,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0,-1,0,18836,0
18887,sodium citrate,19,21,133,147,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0,-1,0,18887,0
18932,adriamycin,2,3,15,25,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,0,-1,0,18932,0
18934,Adriamycin,0,1,0,10,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,0,-1,0,18934,0
18944,Adriamycin,4,5,25,35,"The beneficial effect of Adriamycin appears obvious and might be related to the drug itself, the early and repeated instillations after TUR, or both.",6640832_13,0,-1,0,18944,0
19059,metoclopramide,7,8,39,53,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,0,-1,0,19059,0
19060,metoclopramide,21,22,123,137,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,0,-1,0,19060,0
19062,metoclopramide,2,3,9,23,"When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.",6727060_3,0,-1,0,19062,0
19064,aminoglycoside,3,4,23,37,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,0,-1,0,19064,0
19080,aminoglycosides,2,3,10,25,All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium.,6728084_6,0,-1,0,19080,0
19088,aminoglycosides,2,3,6,21,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,0,-1,0,19088,0
19136,adriamycin,6,7,49,59,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0,-1,0,19136,0
19138,adriamycin,15,16,112,122,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0,-1,0,19138,0
19141,adriamycin,13,14,80,90,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,0,-1,0,19141,0
19145,adriamycin,14,15,87,97,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,0,-1,0,19145,0
19146,adriamycin,4,5,25,35,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,0,-1,0,19146,0
19191,cycloheximide,132,133,800,813,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0,-1,0,19191,0
19193,cycloheximide,169,170,1012,1025,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0,-1,0,19193,0
19256,carbachol,10,11,68,77,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,0,-1,0,19256,0
19261,carbachol,49,50,292,301,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,0,-1,0,19261,0
19264,carbachol,13,14,95,104,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,0,-1,0,19264,0
19266,carbachol,13,14,76,85,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,0,-1,0,19266,0
19271,carbachol,28,29,180,189,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,0,-1,0,19271,0
19274,carbachol,9,10,69,78,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,0,-1,0,19274,0
19329,aspartate,27,28,170,179,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,0,-1,0,19329,0
19334,creatinine,35,36,214,224,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,0,-1,0,19334,0
19335,creatinine,6,7,37,47,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0,-1,0,19335,0
19432,thiopentone,3,4,24,35,Midazolam compared with thiopentone as an induction agent.,7102237_0,0,-1,0,19432,0
19435,thiopentone,35,36,196,207,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0,-1,0,19435,0
19438,thiopentone,9,10,52,63,"On the whole, the differences between midazolam and thiopentone had no apparent clinical consequences.",7102237_3,0,-1,0,19438,0
19455,bupivacaine,13,14,62,73,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0,-1,0,19455,0
19458,bupivacaine,4,5,30,41,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,0,-1,0,19458,0
19483,bupivacaine,8,9,74,85,"Neurologic effects of subarachnoid administration of 2-chloroprocaine-CE, bupivacaine, and low pH normal saline in dogs.",7199841_0,0,-1,0,19483,0
19488,bupivacaine,20,21,96,107,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,0,-1,0,19488,0
19493,bupivacaine,6,7,34,45,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,0,-1,0,19493,0
19500,bupivacaine,8,9,46,57,"The spinal cords of the animals that received bupivacaine, low pH normal saline (pH 3.0), or normal saline did not show abnormal findings.",7199841_7,0,-1,0,19500,0
19509,procainamide,17,18,117,129,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,0,-1,0,19509,0
19511,procainamide,6,7,33,45,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,0,-1,0,19511,0
19519,procainamide,16,17,100,112,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,0,-1,0,19519,0
19521,procainamide,5,6,35,47,These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.,7234705_8,0,-1,0,19521,0
19558,busulfan,7,8,33,41,"In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites, periodic urinary cytology is suggested in patients on long-term therapy.",7269015_4,0,-1,0,19558,0
19565,Adriamycin,15,16,75,85,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,0,-1,0,19565,0
19611,sodium nitroprusside,3,5,27,47,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0,-1,0,19611,0
19612,saralasin,7,8,61,70,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0,-1,0,19612,0
19614,sodium nitroprusside,18,20,111,131,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,0,-1,0,19614,0
19617,saralasin,17,18,89,98,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,0,-1,0,19617,0
19630,saralasin,30,31,191,200,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,0,-1,0,19630,0
19631,saralasin,30,31,191,200,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,0,-1,0,19631,0
19657,aminoglycoside,8,9,50,64,Nearly 3.2 million people in this country receive aminoglycoside antibiotics annually.,7420681_2,0,-1,0,19657,0
19680,adriamycin,4,5,27,37,The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.,7423039_1,0,-1,0,19680,0
19683,Adriamycin,0,1,0,10,Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture.,7423039_2,0,-1,0,19683,0
19702,Creatinine,0,1,0,10,"Creatinine clearance, maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long-term lithium for more than one year.",7437994_3,0,-1,0,19702,0
19718,adriamycin,11,12,65,75,Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.,7449470_1,0,-1,0,19718,0
19725,amiloride,7,8,71,80,Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.,7453952_0,0,-1,0,19725,0
19726,amiloride,3,4,14,23,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,0,-1,0,19726,0
19730,Amiloride,0,1,0,9,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,0,-1,0,19730,0
19732,amiloride,6,7,32,41,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,0,-1,0,19732,0
19737,amiloride,13,14,99,108,"In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.",7453952_6,0,-1,0,19737,0
19739,amiloride,5,6,27,36,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0,-1,0,19739,0
19741,amiloride,21,22,162,171,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0,-1,0,19741,0
19743,terbutaline,4,5,45,56,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,0,-1,0,19743,0
19746,terbutaline,11,12,83,94,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,0,-1,0,19746,0
19754,carbimazole,14,15,101,112,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,0,-1,0,19754,0
19762,carbimazole,8,9,52,63,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,0,-1,0,19762,0
19764,carbimazole,12,13,71,82,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,0,-1,0,19764,0
19766,carbimazole,22,23,135,146,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,0,-1,0,19766,0
19832,rapamycin,23,24,111,120,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,0,-1,0,19832,0
19849,rapamycin,27,28,166,175,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,0,-1,0,19849,0
19853,rapamycin,17,18,112,121,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0,-1,0,19853,0
19860,carboplatin,6,7,33,44,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,0,-1,0,19860,0
19861,Carboplatin,0,1,0,11,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,0,-1,0,19861,0
19865,carboplatin,11,12,63,74,We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.,7565311_2,0,-1,0,19865,0
19872,paramethasone,5,6,37,50,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,0,-1,0,19872,0
19879,paramethasone,10,11,47,60,"In the two patients, skin and ELISA tests with paramethasone were negative, as was the prick test with each of its excipients.",7582165_5,0,-1,0,19879,0
19887,paramethasone,4,5,27,40,These results suggest that paramethasone caused pseudoallergic reactions in our patients.,7582165_8,0,-1,0,19887,0
19889,paramethasone,3,4,31,44,"Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.",7582165_9,0,-1,0,19889,0
19892,paramethasone,14,15,73,86,"To our knowledge, this is the first report of a pseudo-allergy caused by paramethasone.",7582165_11,0,-1,0,19892,0
19956,etoposide,11,12,84,93,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,0,-1,0,19956,0
19961,folinic acid,8,10,37,49,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,0,-1,0,19961,0
19964,folinic acid,15,17,86,98,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,0,-1,0,19964,0
19970,folinic acid,37,39,198,210,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0,-1,0,19970,0
19985,folinic acid,3,5,16,28,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,0,-1,0,19985,0
20077,malondialdehyde,4,5,26,41,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,0,-1,0,20077,0
20083,malondialdehyde,17,18,131,146,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,0,-1,0,20083,0
20086,malondialdehyde,1,2,7,22,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,0,-1,0,20086,0
20091,malondialdehyde,2,3,17,32,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0,-1,0,20091,0
20095,nitroprusside,46,47,311,324,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0,-1,0,20095,0
20098,malondialdehyde,63,64,424,439,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0,-1,0,20098,0
20099,malondialdehyde,8,9,52,67,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,0,-1,0,20099,0
20175,dobutamine,30,31,180,190,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0,-1,0,20175,0
20196,creatinine,7,8,46,56,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,0,-1,0,20196,0
20197,blood urea nitrogen,9,12,58,77,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,0,-1,0,20197,0
20201,creatinine,19,20,90,100,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,0,-1,0,20201,0
20206,creatinine,6,7,28,38,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,0,-1,0,20206,0
20255,ouabain,2,3,11,18,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,0,-1,0,20255,0
20263,ouabain,5,6,27,34,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,0,-1,0,20263,0
20267,ouabain,26,27,169,176,"Because the protocol was long and involved interventions which might affect the determinations, we also studied in nine patients using an identical protocol except that ouabain administration was omitted.",783197_4,0,-1,0,20267,0
20270,ouabain,14,15,109,116,"Left ventricular end-diastolic pressure and left ventricular end-diastolic volume fell in each patient given ouabain, even though they were initially elevated in only two patients.",783197_5,0,-1,0,20270,0
20274,ouabain,40,41,219,226,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,0,-1,0,20274,0
20281,ouabain,9,10,70,77,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,0,-1,0,20281,0
20283,ouabain,26,27,172,179,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,0,-1,0,20283,0
20288,ouabain,24,25,165,172,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,0,-1,0,20288,0
20343,5-fluorouracil,8,9,51,65,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0,-1,0,20343,0
20344,folinic acid,10,12,70,82,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0,-1,0,20344,0
20348,etoposide,11,12,87,96,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0,-1,0,20348,0
20349,5-fluorouracil,14,15,108,122,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0,-1,0,20349,0
20350,folinic acid,21,23,150,162,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0,-1,0,20350,0
20354,5-fluorouracil,35,36,195,209,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,0,-1,0,20354,0
20355,folinic acid,37,39,214,226,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,0,-1,0,20355,0
20357,5-fluorouracil,11,12,65,79,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0,-1,0,20357,0
20358,folinic acid,13,15,84,96,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0,-1,0,20358,0
20359,folinic acid,1,3,8,20,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0,-1,0,20359,0
20363,5-fluorouracil,16,17,103,117,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0,-1,0,20363,0
20369,carbamazepine,3,4,20,33,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,0,-1,0,20369,0
20372,Carbamazepine,0,1,0,13,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,0,-1,0,20372,0
20388,Bupivacaine,0,1,0,11,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0,-1,0,20388,0
20389,bupivacaine,16,17,93,104,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0,-1,0,20389,0
20393,bupivacaine,20,21,101,112,The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine.,7880714_6,0,-1,0,20393,0
20418,octreotide,7,8,51,61,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,0,-1,0,20418,0
20420,Octreotide,0,1,0,10,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,0,-1,0,20420,0
20421,octreotide,28,29,173,183,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,0,-1,0,20421,0
20436,octreotide,3,4,15,25,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,0,-1,0,20436,0
20495,methylprednisolone,5,6,29,47,The patient was treated with methylprednisolone and gradually improved.,7919560_4,0,-1,0,20495,0
20611,coniine,2,3,10,17,Effect of coniine on the developing chick embryo.,8073369_0,0,-1,0,20611,0
20612,Coniine,0,1,0,7,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,0,-1,0,20612,0
20617,coniine,2,3,9,16,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,0,-1,0,20617,0
20620,coniine,13,14,69,76,The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick.,8073369_4,0,-1,0,20620,0
20621,coniine,2,3,18,25,"Concentrations of coniine and nicotine sulfate were 0.015%, 0.03%, 0.075%, 0.15%, 0.75%, 1.5%, 3%, and 6% and 1%, 5%, and 10%, respectively.",8073369_5,0,-1,0,20621,0
20623,coniine,14,15,87,94,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,0,-1,0,20623,0
20624,coniine,5,6,32,39,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,0,-1,0,20624,0
20629,coniine,16,17,78,85,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,0,-1,0,20629,0
20709,propranolol,12,13,73,84,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0,-1,0,20709,0
20713,yohimbine,2,3,9,18,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,0,-1,0,20713,0
20721,ifosfamide,18,19,113,123,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,0,-1,0,20721,0
20723,ifosfamide,5,6,38,48,All patients were receiving high-dose ifosfamide as part of their bone marrow transplant procedure.,8111719_4,0,-1,0,20723,0
20746,bepridil,14,15,80,88,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,0,-1,0,20746,0
20749,bupivacaine,2,3,8,19,dose of bupivacaine.,8231633_3,0,-1,0,20749,0
20755,bupivacaine,4,5,27,38,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0,-1,0,20755,0
20757,bepridil,29,30,209,217,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0,-1,0,20757,0
20780,cyclophosphamide,10,11,60,76,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,0,-1,0,20780,0
20858,daunorubicin,1,2,10,22,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,0,-1,0,20858,0
20863,daunorubicin,16,17,98,110,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,0,-1,0,20863,0
20873,daunorubicin,7,8,40,52,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,0,-1,0,20873,0
20883,losartan,37,38,250,258,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0,-1,0,20883,0
20975,oral contraceptives,13,15,78,97,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,0,-1,0,20975,0
20980,oral contraceptives,17,19,104,123,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,0,-1,0,20980,0
21033,cresyl violet,5,7,47,60,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,0,-1,0,21033,0
21076,octreotide,10,11,67,77,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,0,-1,0,21076,0
21083,octreotide,26,27,184,194,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,0,-1,0,21083,0
21086,octreotide,3,4,22,32,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,0,-1,0,21086,0
21088,octreotide,3,4,20,30,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,0,-1,0,21088,0
21091,octreotide,25,26,164,174,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,0,-1,0,21091,0
21093,octreotide,14,15,94,104,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,0,-1,0,21093,0
21209,creatinine,5,6,30,40,"Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.",8494478_3,0,-1,0,21209,0
21274,vinorelbine,4,5,18,29,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,0,-1,0,21274,0
21279,vinorelbine,25,26,167,178,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,0,-1,0,21279,0
21348,Thiopentone,0,1,0,11,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0,-1,0,21348,0
21350,propofol,3,4,29,37,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0,-1,0,21350,0
21352,propofol,3,4,24,32,This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia.,8595686_1,0,-1,0,21352,0
21355,propofol,23,24,135,143,"In a randomized, double-blind trial, 90 women were allocated to receive one of three treatments prior to induction of anaesthesia with propofol.",8595686_2,0,-1,0,21355,0
21358,thiopentone,29,30,103,114,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,0,-1,0,21358,0
21361,propofol,18,19,92,100,Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1).,8595686_4,0,-1,0,21361,0
21380,propofol,9,10,57,65,"Assessing their overall satisfaction, 89.7% would choose propofol anaesthesia again.",8595686_9,0,-1,0,21380,0
21381,propofol,10,11,65,73,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0,-1,0,21381,0
21383,thiopentone,17,18,120,131,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0,-1,0,21383,0
21496,paclitaxel,9,10,68,78,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,0,-1,0,21496,0
21498,Paclitaxel,0,1,0,10,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,0,-1,0,21498,0
21504,paclitaxel,6,7,31,41,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,0,-1,0,21504,0
21510,paclitaxel,9,10,54,64,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,0,-1,0,21510,0
21516,Paclitaxel,0,1,0,10,Paclitaxel 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication.,8643966_7,0,-1,0,21516,0
21531,Paclitaxel,0,1,0,10,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,0,-1,0,21531,0
21537,paclitaxel,5,6,30,40,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0,-1,0,21537,0
21540,paclitaxel,21,22,135,145,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0,-1,0,21540,0
21543,paclitaxel,5,6,22,32,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0,-1,0,21543,0
21544,cisplatin,7,8,38,47,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0,-1,0,21544,0
21549,paclitaxel,11,12,83,93,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,0,-1,0,21549,0
21557,paclitaxel,14,15,85,95,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0,-1,0,21557,0
21558,cisplatin,19,20,127,136,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0,-1,0,21558,0
21567,paclitaxel,15,16,75,85,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0,-1,0,21567,0
21569,cisplatin,28,29,146,155,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0,-1,0,21569,0
21570,paclitaxel,5,6,39,49,"The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.",8643971_8,0,-1,0,21570,0
21573,paclitaxel,1,2,5,15,"With paclitaxel doses of 200 mg/m2 and higher, granulocyte colony-stimulating factor 5 micrograms/kg/d is given (days 4 through 12).",8643971_10,0,-1,0,21573,0
21588,paclitaxel,8,9,53,63,Results thus far suggest no dose-response effect for paclitaxel doses above 200 mg/m2.,8643971_19,0,-1,0,21588,0
21589,Paclitaxel,0,1,0,10,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,0,-1,0,21589,0
21590,carboplatin,3,4,25,36,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,0,-1,0,21590,0
21595,paclitaxel,12,13,62,72,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0,-1,0,21595,0
21598,carboplatin,32,33,173,184,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0,-1,0,21598,0
21600,paclitaxel,44,45,251,261,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0,-1,0,21600,0
21602,carboplatin,4,5,18,29,The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.,8643973_2,0,-1,0,21602,0
21605,carboplatin,6,7,22,33,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0,-1,0,21605,0
21606,paclitaxel,23,24,110,120,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0,-1,0,21606,0
21614,paclitaxel,6,7,36,46,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0,-1,0,21614,0
21617,carboplatin,21,22,136,147,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0,-1,0,21617,0
21621,paclitaxel,8,9,46,56,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0,-1,0,21621,0
21623,carboplatin,12,13,71,82,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0,-1,0,21623,0
21624,propranolol,5,6,46,57,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,0,-1,0,21624,0
21628,propranolol,16,17,108,119,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,0,-1,0,21628,0
21641,methylprednisolone,18,19,89,107,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,0,-1,0,21641,0
21697,mesna,4,5,42,47,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,0,-1,0,21697,0
21700,ifosfamide,8,9,54,64,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0,-1,0,21700,0
21701,mesna,15,16,104,109,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0,-1,0,21701,0
21703,Mesna,0,1,0,5,"Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.",8677458_2,0,-1,0,21703,0
21707,mesna,5,6,46,51,The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access.,8677458_3,0,-1,0,21707,0
21712,mesna,19,20,120,125,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0,-1,0,21712,0
21713,mesna,29,30,175,180,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0,-1,0,21713,0
21716,mesna,6,7,57,62,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,0,-1,0,21716,0
21719,ifosfamide,24,25,162,172,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,0,-1,0,21719,0
21729,lignocaine,11,12,67,77,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,0,-1,0,21729,0
21730,lignocaine,12,13,54,64,"Fifty-four patients, aged 27-90 years, who were given lignocaine 5% in 6.8% glucose solution for spinal anaesthesia were studied.",8686832_1,0,-1,0,21730,0
21737,lignocaine,14,15,77,87,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,0,-1,0,21737,0
21747,streptozotocin,20,21,139,153,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,0,-1,0,21747,0
21818,tacrolimus,6,7,54,64,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,0,-1,0,21818,0
21822,tacrolimus,19,20,108,118,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,0,-1,0,21822,0
21826,dipyridamole,23,24,139,151,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0,-1,0,21826,0
21887,5-fluorouracil,18,19,93,107,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0,-1,0,21887,0
21889,cyclophosphamide,23,24,119,135,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0,-1,0,21889,0
21897,creatinine,4,5,27,37,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0,-1,0,21897,0
21898,creatinine,22,23,124,134,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0,-1,0,21898,0
21901,creatinine,14,15,75,85,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0,-1,0,21901,0
21902,creatinine,26,27,143,153,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0,-1,0,21902,0
21906,creatinine,15,16,92,102,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0,-1,0,21906,0
21907,creatinine,21,22,136,146,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0,-1,0,21907,0
21911,creatinine,18,19,105,115,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0,-1,0,21911,0
21912,creatinine,24,25,141,151,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0,-1,0,21912,0
22010,paroxetine,7,8,44,54,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,0,-1,0,22010,0
22046,tacrolimus,11,12,80,90,Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.,8829025_0,0,-1,0,22046,0
22049,tacrolimus,14,15,93,103,The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996.,8829025_1,0,-1,0,22049,0
22050,tacrolimus,5,6,33,43,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,0,-1,0,22050,0
22053,creatinine,13,14,98,108,Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months.,8829025_4,0,-1,0,22053,0
22056,tacrolimus,12,13,90,100,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,0,-1,0,22056,0
22143,Venlafaxine,0,1,0,11,Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine.,8888541_3,0,-1,0,22143,0
22146,venlafaxine,15,16,75,86,He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.,8888541_5,0,-1,0,22146,0
22167,oral contraceptives,16,18,76,95,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,0,-1,0,22167,0
22169,dipyridamole,6,7,30,42,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,0,-1,0,22169,0
22176,Cyclophosphamide,0,1,0,16,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,0,-1,0,22176,0
22179,cyclophosphamide,13,14,74,90,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,0,-1,0,22179,0
22181,cyclophosphamide,20,21,89,105,MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.,8911359_2,0,-1,0,22181,0
22188,Cyclophosphamide,2,3,13,29,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,0,-1,0,22188,0
22245,bradykinin,4,5,22,32,Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_0,0,-1,0,22245,0
22250,bradykinin,13,14,73,83,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,0,-1,0,22250,0
22255,dextran,11,12,92,99,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,0,-1,0,22255,0
22260,dextran,12,13,101,108,"Phenylephrine infusion increased arterial pressure, arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups.",8955532_4,0,-1,0,22260,0
22263,bradykinin,19,20,135,145,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,0,-1,0,22263,0
22271,glycinamide ribonucleotide,6,8,43,69,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,0,-1,0,22271,0
22300,benzoylecgonine,6,7,39,54,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,0,-1,0,22300,0
22320,aminoglycosides,17,18,121,136,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,0,-1,0,22320,0
22360,venlafaxine,13,14,76,87,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,0,-1,0,22360,0
22362,venlafaxine,5,6,26,37,"After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.",9034419_3,0,-1,0,22362,0
22364,venlafaxine,10,11,53,64,"She was admitted to the medical intensive care unit, venlafaxine was discontinued, and no further sequelae were seen.",9034419_4,0,-1,0,22364,0
22368,venlafaxine,7,8,62,73,"Based on nonoverdose pharmacokinetics and pharmacodynamics of venlafaxine and the potential risks of available interventions, no emergent therapy was instituted.",9034419_6,0,-1,0,22368,0
22429,adriamycin,12,13,94,104,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,0,-1,0,22429,0
22453,adriamycin,48,49,262,272,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0,-1,0,22453,0
22480,dextran,23,24,132,139,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,0,-1,0,22480,0
22554,pilocarpine-,4,5,37,49,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,0,-1,0,22554,0
22565,"pilocarpine-,",28,30,231,244,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,0,-1,0,22565,0
22601,pilocarpine-,11,12,81,93,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,0,-1,0,22601,0
22632,risperidone,4,5,36,47,Neuroleptic malignant syndrome with risperidone.,9165568_0,0,-1,0,22632,0
22635,Risperidone,0,1,0,11,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,0,-1,0,22635,0
22640,risperidone,14,15,87,98,The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.,9165568_3,0,-1,0,22640,0
22645,risperidone,10,11,84,95,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,0,-1,0,22645,0
22646,risperidone,5,6,42,53,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0,-1,0,22646,0
22648,bromocriptine,12,13,97,110,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0,-1,0,22648,0
22651,risperidone,11,12,78,89,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,0,-1,0,22651,0
22654,sumatriptan,7,8,35,46,The site of common side effects of sumatriptan.,9195768_0,0,-1,0,22654,0
22655,sumatriptan,7,8,54,65,"Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.",9195768_1,0,-1,0,22655,0
22659,amikacin,4,5,35,43,Macula toxicity after intravitreal amikacin.,9199746_0,0,-1,0,22659,0
22660,aminoglycosides,4,5,34,49,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,0,-1,0,22660,0
22663,amikacin,8,9,39,47,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,0,-1,0,22663,0
22664,amikacin,14,15,90,98,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,0,-1,0,22664,0
22688,propranolol,24,25,163,174,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0,-1,0,22688,0
22692,propranolol,5,6,22,33,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,0,-1,0,22692,0
22695,propranolol,11,12,68,79,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,0,-1,0,22695,0
22719,aspartate,1,2,4,13,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,0,-1,0,22719,0
22724,azidothymidine,5,6,32,46,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,0,-1,0,22724,0
22779,17beta-estradiol,4,5,30,46,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,0,-1,0,22779,0
22916,"1,1-dichloro-2,2,2-trifluoroethane",21,22,129,163,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0,-1,0,22916,0
22917,"1-chloro-1,2,2,2-tetrafluoroethane",27,28,179,213,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0,-1,0,22917,0
22919,"1-bromo-1-chloro-2,2,2-trifluoroethane",9,10,50,88,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,0,-1,0,22919,0
22946,danazol,10,11,75,82,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,0,-1,0,22946,0
22948,danazol,18,19,95,102,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,0,-1,0,22948,0
23066,bromocriptine,13,14,107,120,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,0,-1,0,23066,0
23079,Bromocriptine,0,1,0,13,Bromocriptine was definitely effective in cases with prolactin greater than 35 ng./ml.,9334596_19,0,-1,0,23079,0
23089,risperidone,4,5,33,44,Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.,9351491_0,0,-1,0,23089,0
23091,Risperidone,0,1,0,11,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,0,-1,0,23091,0
23095,risperidone,6,7,45,56,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,0,-1,0,23095,0
23099,risperidone,4,5,24,35,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0,-1,0,23099,0
23107,risperidone,38,39,241,252,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0,-1,0,23107,0
23108,risperidone,1,2,5,16,Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses.,9351491_4,0,-1,0,23108,0
23111,risperidone,12,13,90,101,There was no significant difference between occupancy levels obtained with haloperidol or risperidone.,9351491_5,0,-1,0,23111,0
23113,risperidone,8,9,64,75,Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.,9351491_6,0,-1,0,23113,0
23115,risperidone,13,14,79,90,"Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.",9351491_7,0,-1,0,23115,0
23120,mitoxantrone,8,9,60,72,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,0,-1,0,23120,0
23129,mitoxantrone,3,4,30,42,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0,-1,0,23129,0
23130,5-fluorouracil,6,7,54,68,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0,-1,0,23130,0
23135,mitoxantrone,18,19,124,136,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,0,-1,0,23135,0
23141,anthracycline,6,7,37,50,Seven patients had been treated with anthracycline.,9390208_6,0,-1,0,23141,0
23145,mitoxantrone,16,17,88,100,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,0,-1,0,23145,0
23163,ticlopidine,9,10,56,67,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,0,-1,0,23163,0
23273,3-aminopropyl-diethoxy-methyl-phosphinic acid,38,40,296,341,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,23273,0
23278,5-hydroxytryptamine4,52,53,419,439,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,23278,0
23279,2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester,54,58,451,517,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,23279,0
23281,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine,63,64,569,625,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0,-1,0,23281,0
23355,prilocaine,14,15,72,82,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,0,-1,0,23355,0
23356,bupivacaine,24,25,115,126,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,0,-1,0,23356,0
23357,prilocaine,2,3,15,25,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0,-1,0,23357,0
23359,bupivacaine,19,20,99,110,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0,-1,0,23359,0
23362,prilocaine,12,13,70,80,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0,-1,0,23362,0
23363,bupivacaine,17,18,97,108,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0,-1,0,23363,0
23367,bupivacaine,11,12,82,93,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,0,-1,0,23367,0
23371,bupivacaine,21,22,130,141,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,0,-1,0,23371,0
23386,prilocaine,11,12,78,88,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0,-1,0,23386,0
23387,bupivacaine,13,14,93,104,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0,-1,0,23387,0
23390,bupivacaine,21,22,149,160,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,0,-1,0,23390,0
23392,Prilocaine,0,1,0,10,Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine.,9523805_3,0,-1,0,23392,0
23394,prilocaine,9,10,66,76,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0,-1,0,23394,0
23395,bupivacaine,13,14,96,107,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0,-1,0,23395,0
23401,prilocaine,42,43,252,262,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0,23401,0
23402,bupivacaine,51,52,288,299,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0,23402,0
23409,prilocaine,16,17,94,104,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0,-1,0,23409,0
23410,bupivacaine,31,32,160,171,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0,-1,0,23410,0
23411,prilocaine,11,12,63,73,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0,-1,0,23411,0
23412,bupivacaine,28,29,146,157,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0,-1,0,23412,0
23413,Prilocaine,2,3,13,23,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,0,-1,0,23413,0
23416,methylprednisolone,2,3,9,27,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,0,-1,0,23416,0
23428,methylprednisolone,21,22,128,146,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,0,-1,0,23428,0
23444,Cisapride,0,1,0,9,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,0,-1,0,23444,0
23453,cisapride,12,13,75,84,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,0,-1,0,23453,0
23457,cisapride,2,3,20,29,"After discontinuing cisapride, the QT interval returned to normal and symptoms did not recur.",9545159_5,0,-1,0,23457,0
23459,cisapride,7,8,38,47,"We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4, including diltiazem.",9545159_6,0,-1,0,23459,0
23486,levofloxacin,3,4,25,37,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,0,-1,0,23486,0
23488,levofloxacin,9,10,48,60,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,0,-1,0,23488,0
23517,levofloxacin,7,8,43,55,Adverse events considered to be related to levofloxacin administration were reported by 29 patients (9%).,9564988_12,0,-1,0,23517,0
23520,levofloxacin,9,10,52,64,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,0,-1,0,23520,0
23563,suxamethonium,21,22,125,138,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,0,-1,0,23563,0
23565,suxamethonium,5,6,33,46,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,0,-1,0,23565,0
23572,suxamethonium,35,36,213,226,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,0,-1,0,23572,0
23573,suxamethonium,11,12,66,79,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,0,-1,0,23573,0
23598,"5,7-dichlorokynurenic acid",0,2,0,26,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,0,-1,0,23598,0
23613,Carboplatin,0,1,0,11,Carboplatin toxic effects on the peripheral nervous system of the rat.,9636837_0,0,-1,0,23613,0
23615,carboplatin,6,7,33,44,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0,-1,0,23615,0
23617,cisplatin,13,14,71,80,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0,-1,0,23617,0
23674,5-hydroxytryptophan,23,24,123,142,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,0,-1,0,23674,0
23694,cisapride,2,3,11,20,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,0,-1,0,23694,0
23701,cisapride,15,16,82,91,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,0,-1,0,23701,0
23710,cisapride,32,33,188,197,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,0,-1,0,23710,0
23712,cisapride,14,15,124,133,RESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups.,9669632_4,0,-1,0,23712,0
23718,cisapride,23,24,135,144,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,-1,0,23718,0
23723,cisapride,59,60,282,291,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,-1,0,23723,0
23730,cisapride,95,96,436,445,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0,-1,0,23730,0
23743,cisapride,29,30,164,173,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,0,-1,0,23743,0
23747,cisapride,9,10,65,74,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0,-1,0,23747,0
23750,cisapride,25,26,122,131,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0,-1,0,23750,0
23753,Cisapride,2,3,12,21,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,0,-1,0,23753,0
23790,pethidine,7,8,63,72,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,0,-1,0,23790,0
23791,pethidine,9,10,67,76,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,0,-1,0,23791,0
23794,pethidine,2,3,12,21,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,0,-1,0,23794,0
23801,pethidine,6,7,44,53,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0,-1,0,23801,0
23803,pethidine,15,16,104,113,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0,-1,0,23803,0
23805,pethidine,4,5,19,28,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,0,-1,0,23805,0
23840,tacrolimus,10,11,64,74,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,0,-1,0,23840,0
23850,appetite suppressants,8,10,65,86,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,0,-1,0,23850,0
23855,appetite suppressants,20,22,127,148,The importance of this association was evaluated in Belgium while this country still had no restriction on the prescription of appetite suppressants.,9727773_2,0,-1,0,23855,0
23859,appetite-suppressants,2,3,12,33,Exposure to appetite-suppressants was assessed on the basis of hospital records and standardized interview.,9727773_4,0,-1,0,23859,0
23862,appetite suppressants,7,9,50,71,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,0,-1,0,23862,0
23864,appetite suppressants,12,14,63,84,"Five patients died before the interview, all of them had taken appetite suppressants.",9727773_6,0,-1,0,23864,0
23866,appetite suppressants,17,19,97,118,"In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.",9727773_7,0,-1,0,23866,0
23868,appetite suppressants,7,9,37,58,"The patients who had been exposed to appetite suppressants tended to be on average more severely ill, and to have a shorter median delay between onset of symptoms and diagnosis.",9727773_8,0,-1,0,23868,0
23871,appetite suppressants,6,8,41,62,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,0,-1,0,23871,0
23873,appetite suppressants,2,4,10,31,Intake of appetite suppressants may accelerate the progression of the disease.,9727773_10,0,-1,0,23873,0
23875,carbamazepine,3,4,21,34,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0,-1,0,23875,0
23876,vigabatrin,5,6,39,49,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0,-1,0,23876,0
23877,Carbamazepine,0,1,0,13,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,0,-1,0,23877,0
23878,vigabatrin,2,3,18,28,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,0,-1,0,23878,0
23880,carbamazepine,17,18,114,127,"Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on.",9746003_2,0,-1,0,23880,0
23882,Vigabatrin,0,1,0,10,Vigabatrin was also used in the treatment of two children.,9746003_3,0,-1,0,23882,0
23884,carbamazepine,9,10,62,75,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,0,-1,0,23884,0
23886,carbamazepine,23,24,152,165,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,0,-1,0,23886,0
23887,vigabatrin,7,8,45,55,Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment.,9746003_5,0,-1,0,23887,0
23912,carbamazepine,8,9,61,74,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,0,-1,0,23912,0
24038,acetylsalicylic acid,2,4,11,31,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0,-1,0,24038,0
24039,dipyridamole,5,6,33,45,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0,-1,0,24039,0
24055,acetylsalicylic acid,10,12,91,111,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0,-1,0,24055,0
24056,dipyridamole,13,14,115,127,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0,-1,0,24056,0
24062,Acetylsalicylic acid,0,2,0,20,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0,-1,0,24062,0
24063,dipyridamole,3,4,22,34,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0,-1,0,24063,0
24097,tacrolimus,9,10,74,84,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,0,-1,0,24097,0
24102,tacrolimus,17,18,119,129,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,0,-1,0,24102,0
24129,creatinine,2,3,10,20,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,0,-1,0,24129,0
24231,3alpha-tropyl 2-(p-bromophenyl)propionate,19,21,136,177,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0,-1,0,24231,0
24285,creatinine,2,3,16,26,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,0,-1,0,24285,0
24301,propranolol,5,6,52,63,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,24301,0
24302,hexamethonium,22,23,141,154,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,24302,0
24303,carbachol,24,25,158,167,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0,-1,0,24303,0
24354,adriamycin,3,4,11,21,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,0,-1,0,24354,0
83,orthostatic hypotension,15,17,98,121,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,-1,1,1,83,1
90,orthostatic hypotension,46,48,274,297,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,-1,1,1,90,1
95,orthostatic hypotension,6,8,38,61,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,-1,1,1,95,1
98,orthostatic hypotension,4,6,19,42,A lesser degree of orthostatic hypotension occurred with standing.,10091617_7,-1,1,1,98,1
99,Orthostatic hypotension,0,2,0,23,Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.,10091617_8,-1,1,1,99,1
107,orthostatic hypotension,18,20,125,148,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,-1,1,1,107,1
123,platelet aggregation,12,14,86,106,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,1,1,123,1
129,platelet aggregation,29,31,161,181,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,1,1,129,1
130,blood coagulation,32,34,186,203,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,1,1,130,1
191,neurotoxicity,10,11,53,66,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,-1,1,1,191,1
194,neurotoxicity,7,8,29,42,"In the other 3 cases, direct neurotoxicity was also probable, but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology.",10225068_5,-1,1,1,194,1
249,hypothyroid,13,14,80,91,"RESULTS: Hypothyroidism developed in 40 patients, excluding 8 patients who were hypothyroid at baseline.",10354657_8,-1,1,1,249,1
282,brain damage,9,11,57,69,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,-1,1,1,282,1
283,ischemic stroke,12,14,80,95,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,-1,1,1,283,1
286,ischemic stroke,8,10,67,82,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,-1,1,1,286,1
288,brain damage,14,16,95,107,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,1,1,288,1
309,hemolytic anemia,2,4,14,30,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,-1,1,1,309,1
317,hemolytic anemia,17,19,131,147,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,-1,1,1,317,1
322,hemolytic anemia,7,9,38,54,Eight of these cases of severe immune hemolytic anemia are described.,10411803_3,-1,1,1,322,1
333,platelet aggregation,1,3,8,28,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,1,1,333,1
335,platelet aggregation,4,6,21,41,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,1,1,335,1
337,platelet aggregation,21,23,144,164,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,1,1,337,1
471,neurotoxicity,39,40,152,165,"Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 neurotoxicity.",10526274_15,-1,1,1,471,1
474,myelosuppression,8,9,40,56,This age group had an increased risk of myelosuppression.,10526274_19,-1,1,1,474,1
572,locomotor hyperactivity,4,6,34,57,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,1,1,572,1
587,artery calcification,1,3,17,37,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,1,1,587,1
589,artery calcification,23,25,167,187,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,1,1,589,1
594,artery calcification,14,16,83,103,The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.,10669626_1,-1,1,1,594,1
597,artery calcification,4,6,16,36,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,-1,1,1,597,1
598,artery calcification,9,11,65,85,"To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.",10669626_4,-1,1,1,598,1
604,artery calcification,24,26,160,180,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,1,1,604,1
607,artery calcification,7,9,53,73,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,1,1,607,1
609,artery calcification,32,34,215,235,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,1,1,609,1
611,artery calcification,60,62,383,403,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,1,1,611,1
614,artery calcification,8,10,76,96,This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.,10669626_7,-1,1,1,614,1
616,artery calcification,15,17,94,114,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,-1,1,1,616,1
626,artery calcification,13,15,67,87,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,1,1,626,1
629,artery calcification,36,38,197,217,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,1,1,629,1
635,artery calcification,11,13,56,76,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,-1,1,1,635,1
681,breast cancer,15,17,87,100,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,1,1,681,1
682,hemolytic anemia,27,29,162,178,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,1,1,682,1
684,hemolytic anemia,20,22,135,151,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,1,1,684,1
716,hemolytic anemia,17,19,118,134,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,-1,1,1,716,1
772,cardiac hypertrophy,6,8,46,65,Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.,10721819_3,-1,1,1,772,1
847,hyperalgesia,12,13,95,107,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,-1,1,1,847,1
851,hyperalgesia,23,24,141,153,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,-1,1,1,851,1
862,hyperalgesia,25,26,142,154,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,-1,1,1,862,1
864,hyperalgesia,9,10,67,79,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,-1,1,1,864,1
865,hyperalgesia,6,7,46,58,Lidocaine reduced the area of punctate-evoked hyperalgesia significantly.,10743446_8,-1,1,1,865,1
869,hyperalgesia,11,12,73,85,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,-1,1,1,869,1
870,hyperalgesia,18,19,116,128,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,-1,1,1,870,1
886,neurotoxicity,5,6,38,51,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,886,1
889,nephrotoxicity,22,23,108,122,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,889,1
890,neurotoxicity,47,48,217,230,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,890,1
891,nephrotoxicity,57,58,248,262,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,891,1
892,hepatotoxicity,68,69,285,299,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,892,1
895,hemolytic anemia,88,90,378,394,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,1,1,895,1
906,aggressive behavior,3,5,35,54,Development of apomorphine-induced aggressive behavior: comparison of adult male and female Wistar rats.,10791295_0,-1,1,1,906,1
909,aggressive behavior,12,14,67,86,The development of apomorphine-induced (1.0 mg/kg s.c. once daily) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets.,10791295_1,-1,1,1,909,1
912,aggressive behavior,12,14,81,100,"In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.",10791295_2,-1,1,1,912,1
913,aggressive behavior,15,17,111,130,"In conclusion, the present study demonstrates gender differences in the development of the apomorphine-induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method.",10791295_4,-1,1,1,913,1
916,rheumatoid arthritis,4,6,34,54,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,-1,1,1,916,1
917,rheumatoid arthritis,6,8,34,54,We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.,1079693_1,-1,1,1,917,1
933,cocaine abuse,3,5,27,40,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,-1,1,1,933,1
937,cocaine abuse,9,11,66,79,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,-1,1,1,937,1
941,cocaine abuse,18,20,103,116,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,1,1,941,1
965,ischemic stroke,8,10,47,62,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,1,1,965,1
1137,thrombotic microangiopathy,3,5,39,65,Cyclosporine and tacrolimus-associated thrombotic microangiopathy.,11007689_0,-1,1,1,1137,1
1138,thrombotic microangiopathy,3,5,19,45,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,1,1,1138,1
1265,neuropathic pain,31,33,191,207,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,1,1,1265,1
1271,dry mouth,19,21,93,102,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,1,1,1271,1
1285,neuropathic pain,12,14,77,93,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,1,1,1285,1
1329,hepatotoxicity,43,44,207,221,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,1,1,1329,1
1330,nephrotoxicity,10,11,56,70,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,-1,1,1,1330,1
1396,coronary spasm,14,16,78,92,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,-1,1,1,1396,1
1402,variant angina,14,16,85,99,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,-1,1,1,1402,1
1403,Coronary spasm,0,2,0,14,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,-1,1,1,1403,1
1415,coronary spasm,7,9,52,66,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,-1,1,1,1415,1
1420,coronary spasm,18,20,102,116,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,1,1,1420,1
1455,parkinsonian,27,28,157,169,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,-1,1,1,1455,1
1463,parkinsonian,50,51,260,272,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,1,1,1463,1
1465,parkinsonian,21,22,123,135,The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian 'off' signs.,11099450_4,-1,1,1,1465,1
1467,parkinsonian,11,12,80,92,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1,1467,1
1469,parkinsonian,29,30,190,202,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1,1469,1
1471,parkinsonian,48,49,324,336,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,1,1,1471,1
1568,drug abuse,24,26,132,142,"As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population.",11185967_9,-1,1,1,1568,1
1672,cardiotoxicity,1,2,8,22,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,-1,1,1,1672,1
1676,breast cancer,25,27,223,236,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,-1,1,1,1676,1
1683,breast cancer,39,41,298,311,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,1,1,1683,1
1691,Cardiotoxicity,0,1,0,14,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,1,1,1691,1
1698,cardiotoxicity,21,22,102,116,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,1,1,1698,1
1705,cardiotoxicity,12,13,91,105,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,1,1,1705,1
1803,polyneuropathy,16,17,95,109,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,1,1,1803,1
1824,cardiotoxicity,8,9,66,80,Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.,11279304_0,-1,1,1,1824,1
1828,cardiotoxicity,11,12,90,104,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,1,1,1828,1
1829,cardiotoxicity,1,2,4,18,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,-1,1,1,1829,1
1831,cardiac dysfunction,21,23,149,168,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,-1,1,1,1831,1
1836,cardiotoxicity,25,26,159,173,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,-1,1,1,1836,1
1862,cardiotoxicity,17,18,118,132,These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline-induced cardiotoxicity.,11279304_12,-1,1,1,1862,1
1956,ventricular tachycardia,20,22,143,166,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,1,1,1956,1
1974,ventricular arrhythmias,17,19,122,145,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,-1,1,1,1974,1
1975,Nephrotoxicity,0,1,0,14,Nephrotoxicity of combined cephalothin-gentamicin regimen.,1130930_0,-1,1,1,1975,1
1977,acute tubular necrosis,3,6,23,45,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,1,1,1977,1
1981,nephrotoxicity,16,17,94,108,Patients who are given this drug regimen should be observed very carefully for early signs of nephrotoxicity.,1130930_2,-1,1,1,1981,1
1987,nephrotoxicity,14,15,108,122,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,1,1,1987,1
1989,cardiotoxicity,21,22,181,195,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,1,1,1989,1
1998,nephrotoxicity,18,19,123,137,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,1,1,1998,1
2001,cardiotoxicity,28,29,209,223,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,1,1,2001,1
2113,thrombotic microangiopathy,14,16,86,112,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,1,1,2113,1
2115,interstitial nephritis,21,23,144,166,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,1,1,2115,1
2116,acute tubular necrosis,25,28,172,194,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,1,1,2116,1
2123,thrombotic microangiopathy,8,10,51,77,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,1,1,2123,1
2200,interstitial nephritis,2,4,25,47,Ranitidine-induced acute interstitial nephritis in a cadaveric renal allograft.,11431197_0,-1,1,1,2200,1
2205,interstitial nephritis,8,10,54,76,This drug occasionally has been associated with acute interstitial nephritis in native kidneys.,11431197_2,-1,1,1,2205,1
2207,interstitial nephritis,7,9,45,67,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,-1,1,1,2207,1
2221,hepatotoxicity,24,25,144,158,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,-1,1,1,2221,1
2222,Liver disease,0,2,0,13,Liver disease caused by propylthiouracil.,1147734_0,-1,1,1,2222,1
2225,liver disease,18,20,94,107,This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease.,1147734_2,-1,1,1,2225,1
2254,cardiac arrest,25,27,182,196,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,1,1,2254,1
2277,ventricular tachycardia,10,12,49,72,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,1,1,2277,1
2353,nephrotoxicity,21,22,145,159,"Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.",11583940_2,-1,1,1,2353,1
2354,nephrotoxicity,1,2,6,20,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,-1,1,1,2354,1
2355,nephrotoxicity,22,23,126,140,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,-1,1,1,2355,1
2357,nephrotoxicity,3,4,18,32,Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases.,11583940_4,-1,1,1,2357,1
2362,nephrotoxicity,16,17,106,120,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,1,1,2362,1
2389,major depression,17,19,97,113,Current estimates suggest that between 0.4% and 8.3% of children and adolescents are affected by major depression.,11642480_1,-1,1,1,2389,1
2392,major depression,14,16,86,102,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,-1,1,1,2392,1
2399,rheumatoid arthritis,28,30,177,197,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,-1,1,1,2399,1
2507,hemolytic anemia,4,6,44,60,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,-1,1,1,2507,1
2520,hemolytic anemia,12,14,96,112,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,1,1,2520,1
2551,mitochondrial dysfunction,27,29,148,173,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,1,1,2551,1
2582,breast carcinoma,13,15,71,87,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,1,1,2582,1
2587,breast carcinoma,38,40,253,269,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,1,1,2587,1
2595,nephrotoxicity,19,20,128,142,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2595,1
2596,ototoxicity,21,22,144,155,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2596,1
2597,neurotoxicity,24,25,161,174,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2597,1
2598,breast carcinoma,34,36,216,232,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2598,1
2610,nephrotoxicity,15,16,109,123,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,-1,1,1,2610,1
2611,ototoxicity,17,18,125,136,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,-1,1,1,2611,1
2615,breast carcinoma,20,22,128,144,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,-1,1,1,2615,1
2702,hyperalgesia,21,22,138,150,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,1,1,2702,1
2707,hyperalgesia,19,20,125,137,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,1,1,2707,1
2715,neuropathic pain,15,17,105,121,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,-1,1,1,2715,1
2717,End-stage renal disease,0,3,0,23,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,1,1,2717,1
2728,end-stage renal disease,17,20,90,113,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,1,1,2728,1
2732,chronic renal failure,11,14,74,95,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,1,1,2732,1
2745,renal dysfunction,12,14,57,74,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,1,1,2745,1
2816,thromboembolic,19,20,134,148,PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.,11827497_6,-1,1,1,2816,1
2821,thromboembolic,35,36,192,206,"RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.",11827497_8,-1,1,1,2821,1
2838,hyperprolactinemia,3,4,33,51,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,-1,1,1,2838,1
2845,hyperprolactinemia,20,21,123,141,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,-1,1,1,2845,1
2852,hyperprolactinemia,14,15,102,120,These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.,11838826_3,-1,1,1,2852,1
2854,hyperprolactinemia,7,8,58,76,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,-1,1,1,2854,1
2857,hyperprolactinemia,13,14,92,110,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,-1,1,1,2857,1
2880,hyperprolactinemia,11,12,80,98,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,-1,1,1,2880,1
2924,neurotoxicity,8,9,47,60,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,-1,1,1,2924,1
2930,neurotoxicity,22,23,129,142,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,-1,1,1,2930,1
2995,cardiotoxicity,10,11,63,77,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,-1,1,1,2995,1
3000,cardiotoxicity,14,15,84,98,"Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.",11861791_3,-1,1,1,3000,1
3008,cardiac dysfunction,32,34,200,219,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,1,1,3008,1
3021,cardiac dysfunction,6,8,45,64,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,-1,1,1,3021,1
3027,cardiotoxicity,7,8,41,55,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,-1,1,1,3027,1
3034,Nephrotoxicity,18,19,122,136,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,1,1,3034,1
3055,exencephaly,3,4,27,38,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,-1,1,1,3055,1
3057,exencephaly,22,23,164,175,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,-1,1,1,3057,1
3058,exencephaly,7,8,47,58,"Anencephaly has been suggested to develop from exencephaly; however, there is little direct experimental evidence to support this, and the mechanism of transformation remains unclear.",11875660_1,-1,1,1,3058,1
3061,exencephaly,3,4,16,27,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,-1,1,1,3061,1
3065,exencephaly,7,8,50,61,We confirmed several cases of transformation from exencephaly to anencephaly.,11875660_4,-1,1,1,3065,1
3066,exencephalic,7,8,28,40,"However, in many cases, the exencephalic brain tissue was preserved with more or less reduction during this period.",11875660_5,-1,1,1,3066,1
3067,exencephaly,9,10,58,69,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,-1,1,1,3067,1
3068,exencephalic,16,17,95,107,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,-1,1,1,3068,1
3070,exencephalic,7,8,40,52,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,-1,1,1,3070,1
3071,exencephalic,29,30,174,186,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,-1,1,1,3071,1
3074,exencephaly,6,7,52,63,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,1,1,3074,1
3078,exencephalic,23,24,160,172,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,1,1,3078,1
3080,exencephalic,35,36,227,239,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,1,1,3080,1
3082,exencephalic,15,16,102,114,"From observations of the vasculature, altered distribution patterns of vessels were identified in the exencephalic head.",11875660_9,-1,1,1,3082,1
3083,exencephalic,7,8,46,58,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,1,1,3083,1
3086,exencephalic,29,30,212,224,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,1,1,3086,1
3088,exencephaly,43,44,308,319,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,1,1,3088,1
3109,acute myocardial infarction,10,13,82,109,Infarct-avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction.,11897407_1,-1,1,1,3109,1
3118,acute myocardial infarction,21,24,130,157,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,-1,1,1,3118,1
3187,cardiac arrhythmias,4,6,30,49,"Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest.",11928786_6,-1,1,1,3187,1
3188,cardiac arrest,15,17,106,120,"Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest.",11928786_6,-1,1,1,3188,1
3221,glomerulosclerosis,52,53,240,258,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,1,1,3221,1
3297,aplastic anemia,7,9,67,82,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,-1,1,1,3297,1
3300,aplastic anemia,8,10,58,73,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,-1,1,1,3300,1
3306,aplastic anemia,11,13,86,101,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,-1,1,1,3306,1
3309,metabolic acidosis,9,11,58,76,Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.,12042105_2,-1,1,1,3309,1
3344,asterixis,4,5,42,51,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,-1,1,1,3344,1
3360,asterixis,11,12,70,79,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,-1,1,1,3360,1
3361,asterixis,8,9,42,51,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,1,1,3361,1
3466,nephrotoxicity,21,22,122,136,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,1,1,3466,1
3508,cardiac arrest,2,4,18,32,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,1,1,3508,1
3523,cardiac arrest,8,10,42,56,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,-1,1,1,3523,1
3547,thromboembolic,4,5,22,36,Data to establish the thromboembolic risk were incomplete.,12109865_8,-1,1,1,3547,1
3563,Cardiac arrest,0,2,0,14,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,-1,1,1,3563,1
3566,cardiac arrest,18,20,128,142,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,-1,1,1,3566,1
3575,cardiac arrest,6,8,33,47,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,-1,1,1,3575,1
3711,locomotor hyperactivity,15,17,104,127,Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.,12369736_0,-1,1,1,3711,1
3716,locomotor hyperactivity,30,32,171,194,The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.,12369736_1,-1,1,1,3716,1
3731,locomotor hyperactivity,20,22,140,163,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,-1,1,1,3731,1
3897,Visual hallucinations,0,2,0,21,Visual hallucinations associated with zonisamide.,12523465_0,-1,1,1,3897,1
3902,visual hallucinations,1,3,9,30,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,-1,1,1,3902,1
3904,visual hallucinations,22,24,141,162,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,-1,1,1,3904,1
3907,visual hallucinations,3,5,19,40,"During monitoring, visual hallucinations did not correlate with EEG readings, nor did video recording capture any of the described events.",12523465_4,-1,1,1,3907,1
3908,visual hallucinations,6,8,37,58,None of the patients had experienced visual hallucinations before this event.,12523465_5,-1,1,1,3908,1
3926,Acute liver failure,0,3,0,19,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,-1,1,1,3926,1
3938,acute liver failure,2,5,13,32,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,-1,1,1,3938,1
3941,liver injury,8,10,63,75,Liver biopsy showed evidence of nonspecific drug-induced acute liver injury.,12549952_5,-1,1,1,3941,1
3943,coagulopathy,8,9,52,64,His condition was further complicated by sepsis and coagulopathy.,12549952_6,-1,1,1,3943,1
3946,hepatotoxicity,5,6,38,52,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,-1,1,1,3946,1
3948,hepatotoxicity,8,9,53,67,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,-1,1,1,3948,1
3950,acute liver failure,25,28,155,174,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,-1,1,1,3950,1
4015,renal injury,5,7,49,61,Prenatal dexamethasone programs hypertension and renal injury in the rat.,12574103_0,-1,1,1,4015,1
4018,renal injury,20,22,132,144,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,-1,1,1,4018,1
4028,glomerulosclerosis,15,16,86,104,Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.,12574103_7,-1,1,1,4028,1
4031,glomerulosclerosis,16,17,98,116,"This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.",12574103_8,-1,1,1,4031,1
4095,myocardial damage,11,13,60,77,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,-1,1,1,4095,1
4104,myocardial damage,13,15,75,92,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,1,1,4104,1
4151,myocardial damage,19,21,108,125,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,1,1,4151,1
4165,cardiotoxicity,63,64,366,380,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,1,1,4165,1
4168,pulmonary hypertension,3,5,33,55,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,-1,1,1,4168,1
4173,Pulmonary hypertension,0,2,0,22,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,-1,1,1,4173,1
4244,nephrotoxicity,25,26,130,144,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,1,1,4244,1
4252,Nephrotoxicity,0,1,0,14,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,1,1,4252,1
4264,tubular necrosis,67,69,348,364,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,1,1,4264,1
4270,chronic renal failure,17,20,99,120,"Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure, and on the mechanism(s) involved.",12617329_6,-1,1,1,4270,1
4274,prostate cancer,17,19,145,160,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,-1,1,1,4274,1
4277,prostate cancer,18,20,122,137,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,1,1,4277,1
4283,prostate cancer,14,16,76,91,"PATIENTS: Seventy men, aged 50-80 years, with advanced androgen-independent prostate cancer.",12627929_4,-1,1,1,4283,1
4294,prostate cancer,12,14,73,88,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,-1,1,1,4294,1
4316,hepatotoxicity,9,10,48,62,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,-1,1,1,4316,1
4373,visual field defects,15,18,97,117,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,1,1,4373,1
4396,dystonia,2,3,31,39,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,1,1,4396,1
4403,dystonia,12,13,88,96,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,1,1,4403,1
4409,neurotoxicity,8,9,69,82,MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.,12695819_0,-1,1,1,4409,1
4427,neurotoxicity,14,15,105,118,Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus-induced neurotoxicity.,12695819_8,-1,1,1,4427,1
4487,myocardial injury,9,11,50,67,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,-1,1,1,4487,1
4489,myocardial injury,9,11,56,73,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,-1,1,1,4489,1
4492,myocardial injury,12,14,56,73,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,-1,1,1,4492,1
4587,prostate cancer,5,7,45,60,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,-1,1,1,4587,1
4588,prostate cancer,15,17,100,115,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,1,1,4588,1
4616,prostate cancer,7,9,48,63,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,1,1,4616,1
4628,prostate cancer,15,17,96,111,CONCLUSION: Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,12820454_14,-1,1,1,4628,1
4631,neurotoxicity,17,18,108,121,Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.,12842176_0,-1,1,1,4631,1
4849,interstitial nephritis,2,4,28,50,Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.,12911170_0,-1,1,1,4849,1
4850,autoimmune hemolytic anemia,5,8,55,82,Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.,12911170_0,-1,1,1,4850,1
4853,interstitial nephritis,9,11,70,92,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,-1,1,1,4853,1
4854,hemolytic anemia,12,14,97,113,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,-1,1,1,4854,1
4856,interstitial nephritis,10,12,60,82,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,-1,1,1,4856,1
4857,autoimmune hemolytic anemia,13,16,87,114,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,-1,1,1,4857,1
4858,Hemolytic anemia,0,2,0,16,Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.,12911170_4,-1,1,1,4858,1
4859,interstitial nephritis,3,5,21,43,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,-1,1,1,4859,1
4860,end-stage renal disease,11,14,87,110,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,-1,1,1,4860,1
4914,blood coagulation,3,5,26,43,Progestational agents and blood coagulation.,133615_0,-1,1,1,4914,1
4915,Thromboembolic,0,1,0,14,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,1,1,4915,1
4922,blood coagulation,7,9,48,65,"Significant increases in certain factors of the blood coagulation and fibrinolysin systems (factors I,II,VII,VIII,IX, and X and plasminogen) were observed in the treated groups.",133615_4,-1,1,1,4922,1
4925,blood coagulation,5,7,25,42,"All four had an abnormal blood coagulation profile, suggesting ""hypercoagulability"" before initiation of therapy.",133615_6,-1,1,1,4925,1
4932,thromboembolic,9,10,72,86,Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen.,133615_12,-1,1,1,4932,1
4936,Orthostatic hypotension,0,2,0,23,Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.1.,1355091_0,-1,1,1,4936,1
4946,Orthostatic hypotension,0,2,0,23,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,-1,1,1,4946,1
4954,orthostatic hypotension,6,8,34,57,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,1,1,4954,1
4967,orthostatic hypotension,8,10,44,67,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,-1,1,1,4967,1
5019,chronic renal failure,9,12,70,91,Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.,1378968_0,-1,1,1,5019,1
5038,glomerulosclerosis,10,11,72,90,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,-1,1,1,5038,1
5052,chronic renal failure,4,7,17,38,"In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli.",1378968_11,-1,1,1,5052,1
5060,Hemolytic-uremic syndrome,0,2,0,25,Hemolytic-uremic syndrome associated with ingestion of quinine.,1415380_0,-1,1,1,5060,1
5062,Hemolytic-uremic syndrome,0,2,0,25,"Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature.",1415380_1,-1,1,1,5062,1
5068,hemolytic-uremic syndrome,1,3,19,44,Quinine-associated hemolytic-uremic syndrome probably occurs more often than is recognized.,1415380_7,-1,1,1,5068,1
5106,sexual dysfunction,2,4,15,33,Depression and sexual dysfunction have been related to side effects of topical beta-blockers.,1428568_1,-1,1,1,5106,1
5125,neurotoxicity,3,4,39,52,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,-1,1,1,5125,1
5158,hemolytic anemia,2,4,25,41,Cefotetan-induced immune hemolytic anemia.,1445986_0,-1,1,1,5158,1
5159,hemolytic anemia,1,3,7,23,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,-1,1,1,5159,1
5169,hemolytic anemia,18,20,134,150,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,-1,1,1,5169,1
5179,parkinsonian,5,6,47,59,Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.,14568327_0,-1,1,1,5179,1
5282,dilated cardiomyopathy,1,3,11,33,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,-1,1,1,5282,1
5284,dilated cardiomyopathy,6,8,36,58,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,1,1,5284,1
5327,psychotic symptoms,5,7,28,46,"This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.",14698717_3,-1,1,1,5327,1
5397,sexual dysfunction,12,14,87,105,"A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.",14742097_0,-1,1,1,5397,1
5400,sexual dysfunction,32,34,218,236,"The objective of this study was to determine whether ephedrine, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced sexual dysfunction.",14742097_1,-1,1,1,5400,1
5417,breast cancer,7,9,42,55,Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition?,14745746_0,-1,1,1,5417,1
5422,breast cancer,8,10,54,67,This pilot study examines whether hormone therapy for breast cancer affects cognition.,14745746_2,-1,1,1,5422,1
5425,breast cancer,25,27,132,145,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,1,1,5425,1
5436,breast cancer,20,22,135,148,The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer.,14745746_6,-1,1,1,5436,1
5594,cardiac arrhythmias,4,6,29,48,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,-1,1,1,5594,1
5596,cardiac toxicity,1,3,4,20,The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.,15042318_2,-1,1,1,5596,1
5604,liver injury,24,26,162,174,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,1,1,5604,1
5606,liver injury,11,13,76,88,PATIENT: A 58-year-old woman with a clinical diagnosis of dilevalol-induced liver injury.,1504402_2,-1,1,1,5606,1
5622,liver injury,28,30,216,228,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,1,1,5622,1
5719,temporal lobe epilepsy,11,14,63,85,Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy.,15120741_0,-1,1,1,5719,1
5744,temporal lobe epilepsy,29,32,208,230,"These data support the hypothesis that SE-induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains, resembling rat models of human temporal lobe epilepsy.",15120741_6,-1,1,1,5744,1
5745,bladder cancer,1,3,8,22,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,1,1,5745,1
5748,bladder cancer,9,11,50,64,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,-1,1,1,5748,1
5753,bladder cancer,15,17,93,107,"Through linkage with the Swedish Cancer Register, all subjects in this cohort diagnosed with bladder cancer were identified.",15130900_3,-1,1,1,5753,1
5756,bladder cancer,18,20,126,140,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,-1,1,1,5756,1
5759,bladder cancer,7,9,37,51,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,1,1,5759,1
5762,bladder cancer,22,24,128,142,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,1,1,5762,1
5765,bladder cancer,3,5,12,26,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,-1,1,1,5765,1
5770,bladder cancer,4,6,22,36,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,1,1,5770,1
5772,bladder cancer,25,27,134,148,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,1,1,5772,1
5776,bladder cancer,14,16,103,117,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,1,1,5776,1
5868,thrombotic,15,16,136,146,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,1,1,5868,1
5869,thrombotic,9,10,57,67,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,-1,1,1,5869,1
5874,rheumatoid arthritis,19,21,141,161,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,1,1,5874,1
5877,thrombotic,4,5,32,42,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,1,1,5877,1
5879,thrombotic,16,17,113,123,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,1,1,5879,1
5883,rheumatoid arthritis,59,61,332,352,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,1,1,5883,1
5887,thrombotic,5,6,42,52,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,1,1,5887,1
5888,thrombotic,4,5,20,30,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,-1,1,1,5888,1
5889,Thrombotic,0,1,0,10,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,1,1,5889,1
5897,thrombotic,32,33,184,194,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,1,1,5897,1
5899,rheumatoid arthritis,43,45,267,287,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,1,1,5899,1
5908,mitral regurgitation,15,17,118,138,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,-1,1,1,5908,1
6001,Cardiac toxicity,0,2,0,16,Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.,15325671_0,-1,1,1,6001,1
6003,breast cancer,11,13,107,120,Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.,15325671_0,-1,1,1,6003,1
6014,breast cancer,26,28,176,189,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,-1,1,1,6014,1
6015,breast cancer,9,11,75,88,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,1,1,6015,1
6030,cardiac toxicity,4,6,48,64,Incidence of transient cyclophosphamide-related cardiac toxicity (10%) is comparable to previous recorded literature.,15325671_6,-1,1,1,6030,1
6119,gallbladder disease,7,9,53,72,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,1,1,6119,1
6131,gallbladder disease,19,21,73,92,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,1,1,6131,1
6135,endometrial cancer,48,50,172,190,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,1,1,6135,1
6140,gallbladder disease,22,24,136,155,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,1,1,6140,1
6142,endometrial cancer,29,31,185,203,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,1,1,6142,1
6154,orthostatic hypotension,10,12,68,91,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,1,1,6154,1
6171,sensorineural hearing loss,17,20,79,105,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,-1,1,1,6171,1
6187,cardiotoxicity,3,4,31,45,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,1,1,6187,1
6197,cardiac toxicity,6,8,32,48,The number of deaths related to cardiac toxicity is low.,15517007_6,-1,1,1,6197,1
6296,renal damage,13,15,106,118,Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage.,15572383_0,-1,1,1,6296,1
6302,renal damage,15,17,86,98,"Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats.",15572383_3,-1,1,1,6302,1
6311,nephrotic,7,8,45,54,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,1,1,6311,1
6313,glomerulosclerosis,17,18,115,133,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,1,1,6313,1
6321,glomerulosclerosis,8,9,48,66,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,1,1,6321,1
6324,renal damage,13,15,100,112,CONCLUSION: Individual differences in renal ACE activity predict the severity of adriamycin-induced renal damage in this outbred rat strain.,15572383_13,-1,1,1,6324,1
6327,renal damage,17,19,110,122,This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage.,15572383_14,-1,1,1,6327,1
6353,Hemolytic anemia,21,23,157,173,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,1,1,6353,1
6356,hemolytic anemia,3,5,29,45,"Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.",15580403_1,-1,1,1,6356,1
6380,interstitial nephritis,2,4,16,38,Recurrent acute interstitial nephritis induced by azithromycin.,15602202_0,-1,1,1,6380,1
6386,interstitial nephritis,7,9,48,70,"Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.",15602202_3,-1,1,1,6386,1
6387,renal injury,21,23,140,152,"Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.",15602202_3,-1,1,1,6387,1
6421,hyperprolactinemia,13,14,83,101,Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.,15638391_0,-1,1,1,6421,1
6422,hyperprolactinemia,11,12,53,71,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,-1,1,1,6422,1
6552,pseudolithiasis,2,3,31,46,Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.,15737522_0,-1,1,1,6552,1
6554,pseudolithiasis,8,9,43,58,It is well known that ceftriaxone leads to pseudolithiasis in some patients.,15737522_1,-1,1,1,6554,1
6557,pseudolithiasis,24,25,152,167,"Clinical and experimental studies also suggest that situations causing gallbladder dysfunction, such as fasting, may have a role for the development of pseudolithiasis.",15737522_2,-1,1,1,6557,1
6558,pseudolithiasis,13,14,83,98,"In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.",15737522_3,-1,1,1,6558,1
6563,pseudolithiasis,7,8,43,58,"Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age, sex, duration of the treatment and starvation variables.",15737522_5,-1,1,1,6563,1
6565,pseudolithiasis,6,7,34,49,"After cessation of the treatment, pseudolithiasis resolved spontaneously within a short period.",15737522_6,-1,1,1,6565,1
6566,pseudolithiasis,3,4,17,32,The incidence of pseudolithiasis is not affected by fasting.,15737522_7,-1,1,1,6566,1
6571,psychotic symptoms,13,15,92,110,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,1,1,6571,1
6577,psychotic symptoms,15,17,98,116,"Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and stereotypies appears to be at least in part dose-related.",15764424_4,-1,1,1,6577,1
6670,hepatotoxicity,13,14,99,113,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,1,1,6670,1
6686,hepatotoxicity,13,14,83,97,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,1,1,6686,1
6699,thrombotic microangiopathy,3,5,16,42,Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation.,15859940_0,-1,1,1,6699,1
6701,Thrombotic microangiopathy,2,4,12,38,OBJECTIVES: Thrombotic microangiopathy is a well-known problem in patients following renal transplantation.,15859940_1,-1,1,1,6701,1
6704,thrombotic microangiopathy,4,6,30,56,"In postrenal transplantation, thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome.",15859940_2,-1,1,1,6704,1
6705,hemolytic uremic syndrome,11,14,82,107,"In postrenal transplantation, thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome.",15859940_2,-1,1,1,6705,1
6706,thrombotic microangiopathy,7,9,36,62,We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature.,15859940_3,-1,1,1,6706,1
6708,thrombotic microangiopathy,9,11,53,79,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,-1,1,1,6708,1
6713,thrombotic microangiopathy,5,7,23,49,RESULTS: Five cases of thrombotic microangiopathy were found.,15859940_6,-1,1,1,6713,1
6718,thrombotic microangiopathy,6,8,31,57,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,1,1,6718,1
6722,hemolytic uremic syndrome,10,13,59,84,"CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome.",15859940_10,-1,1,1,6722,1
6724,hemolytic uremic syndrome,22,25,150,175,"CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome.",15859940_10,-1,1,1,6724,1
6731,thrombotic microangiopathy,7,9,41,67,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,-1,1,1,6731,1
6734,thrombotic microangiopathy,8,10,39,65,"In the current study, the frequency of thrombotic microangiopathy was similar to the percentage reported in the literature (20%).",15859940_13,-1,1,1,6734,1
6818,myelosuppression,3,4,29,45,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,-1,1,1,6818,1
6826,myelosuppression,26,27,186,202,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,1,1,6826,1
6827,cardiac toxicity,28,30,207,223,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,1,1,6827,1
6829,cardiotoxicity,10,11,83,97,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,1,1,6829,1
6847,myelosuppression,7,8,47,63,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,1,1,6847,1
6854,myelosuppression,32,33,226,242,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,1,1,6854,1
6984,hyperalgesia,23,24,143,155,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,1,1,6984,1
6986,hyperalgesia,28,29,190,202,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,1,1,6986,1
7052,myocardial injury,3,5,33,50,Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers.,1601297_0,-1,1,1,7052,1
7055,myocardial injury,15,17,87,104,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,1,1,7055,1
7151,myoclonic jerks,22,24,140,155,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,1,1,7151,1
7283,hyperammonemia,8,9,50,64,It is usually but not necessarily associated with hyperammonemia.,16181582_3,-1,1,1,7283,1
7352,ototoxicity,1,2,6,17,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,1,1,7352,1
7355,sensorineural hearing loss,33,36,198,224,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,1,1,7355,1
7401,secondary hyperalgesia,30,32,199,221,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,-1,1,1,7401,1
7402,Secondary hyperalgesia,0,2,0,22,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,1,1,7402,1
7404,hyperalgesia,7,8,71,83,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,1,1,7404,1
7405,neuropathic pain,11,13,101,117,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,1,1,7405,1
7408,hyperalgesia,12,13,83,95,Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization.,16330766_3,-1,1,1,7408,1
7413,neuropathic pain,17,19,83,99,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,-1,1,1,7413,1
7423,secondary hyperalgesia,31,33,223,245,"Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.",16330766_5,-1,1,1,7423,1
7453,temporal lobe epilepsy,52,55,298,320,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,1,1,7453,1
7560,glomerulosclerosis,9,10,55,73,"Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.",1639466_8,-1,1,1,7560,1
7564,glomerulosclerosis,2,3,13,31,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,-1,1,1,7564,1
7669,dry mouth,16,18,69,78,Only one case (3.3%) withdrew from the present study due to a severe dry mouth.,16471092_10,-1,1,1,7669,1
7751,memory impairment,6,8,28,45,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,1,1,7751,1
7774,myocardial damage,21,23,108,125,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,1,1,7774,1
7900,hepatocellular carcinoma,14,16,74,98,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,1,1,7900,1
7901,liver disease,19,21,114,127,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,1,1,7901,1
7906,hemolytic anemia,25,27,156,172,"Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.",16629641_3,-1,1,1,7906,1
7913,hemolytic anemia,23,25,147,163,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,1,1,7913,1
7930,drug abuse,21,23,148,158,Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse.,16634859_8,-1,1,1,7930,1
7997,visual loss,25,27,148,159,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,-1,1,1,7997,1
8015,visual loss,8,10,59,70,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,1,1,8015,1
8032,extrapyramidal symptoms,26,28,118,141,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,1,1,8032,1
8165,bone marrow suppression,13,16,92,115,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,1,1,8165,1
8166,hepatotoxicity,18,19,129,143,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,1,1,8166,1
8168,hyperammonemia,23,24,162,176,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,1,1,8168,1
8202,Peripheral neuropathy,0,2,0,21,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,1,1,8202,1
8217,peripheral neuropathy,5,7,51,72,Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.,16826348_5,-1,1,1,8217,1
8222,peripheral neuropathy,4,6,27,48,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,-1,1,1,8222,1
8229,neurotoxicity,7,8,71,84,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,-1,1,1,8229,1
8239,neurotoxicity,31,32,163,176,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,1,1,8239,1
8258,neuronal damage,9,11,62,77,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,-1,1,1,8258,1
8260,Cerebral haemorrhage,0,2,0,20,Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions.,16858720_0,-1,1,1,8260,1
8266,cerebral haemorrhage,40,42,251,271,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,1,1,8266,1
8269,cerebral haemorrhage,16,18,127,147,Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.,16858720_2,-1,1,1,8269,1
8271,cerebral haemorrhage,6,8,33,53,"RESULTS: Among 593 patients with cerebral haemorrhage, 59 (10%) were assessed as related to warfarin treatment.",16858720_4,-1,1,1,8271,1
8398,hepatocellular carcinoma,13,15,68,92,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,1,1,8398,1
8422,ventricular arrhythmias,9,11,67,90,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,-1,1,1,8422,1
8496,extrapyramidal symptoms,3,5,27,50,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,1,1,8496,1
8501,extrapyramidal symptoms,4,6,24,47,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,1,1,8501,1
8519,Extrapyramidal symptoms,0,2,0,23,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,-1,1,1,8519,1
8693,renal dysfunction,3,5,37,54,Sirolimus-associated proteinuria and renal dysfunction.,17147461_0,-1,1,1,8693,1
8711,renal damage,11,13,68,80,A common risk factor appears to be presence of pre-existing chronic renal damage.,17147461_6,-1,1,1,8711,1
8755,nephrotic,9,10,69,78,Twenty-eight percent of patients showed increased proteinuria to the nephrotic range.,17175308_11,-1,1,1,8755,1
8757,interstitial nephritis,14,16,116,138,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,-1,1,1,8757,1
8811,aggressive behavior,23,25,123,142,"Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.",17194457_12,-1,1,1,8811,1
8902,temporal lobe epilepsy,10,13,68,90,"QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.",17242861_3,-1,1,1,8902,1
8918,temporal lobe epilepsy,14,17,106,128,This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy.,17242861_11,-1,1,1,8918,1
8999,Cardiac arrest,0,2,0,14,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,-1,1,1,8999,1
9010,cardiac arrest,7,9,54,68,There are no previous reports of clonidine-associated cardiac arrest in a child undergoing induction of anesthesia.,17263743_5,-1,1,1,9010,1
9034,liver injury,8,10,45,57,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,-1,1,1,9034,1
9041,cardiac dysfunction,1,3,22,41,Carbamazepine-induced cardiac dysfunction.,1728915_0,-1,1,1,9041,1
9043,sinus bradycardia,3,5,15,32,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,-1,1,1,9043,1
9047,cardiac dysfunction,12,14,81,100,"From the analysis of these cases, two distinct forms of carbamazepine-associated cardiac dysfunction emerged.",1728915_3,-1,1,1,9047,1
9182,hypothyroid,2,3,14,25,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,1,1,9182,1
9432,locomotor hyperactivity,1,3,20,43,Amphetamine-induced locomotor hyperactivity was similar in all groups.,17490864_6,-1,1,1,9432,1
9473,acute myocardial infarction,17,20,116,143,Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.,1749407_1,-1,1,1,9473,1
9475,acute myocardial infarction,10,13,73,100,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,-1,1,1,9475,1
9492,thrombotic,8,9,40,50,"Finally, the contribution of a primary, thrombotic effect of cocaine has not been excluded.",1749407_9,-1,1,1,9492,1
9584,liver disease,32,34,201,214,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,1,1,9584,1
9588,cardiac arrest,24,26,126,140,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,1,1,9588,1
9599,liver damage,10,12,63,75,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,1,1,9599,1
9604,cognitive deficits,8,10,51,69,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,-1,1,1,9604,1
9619,cognitive deficits,6,8,44,62,Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,17600377_3,-1,1,1,9619,1
9677,rhabdomyolysis,1,2,7,21,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,1,1,9677,1
9682,rhabdomyolysis,19,20,113,127,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,1,1,9682,1
9702,rhabdomyolysis,5,6,24,38,DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.,17615423_7,-1,1,1,9702,1
9728,leukoencephalopathy,1,2,8,27,Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.,17682013_0,-1,1,1,9728,1
9730,leukoencephalopathy,4,5,24,43,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,1,1,9730,1
9744,leukoencephalopathy,8,9,43,62,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,-1,1,1,9744,1
9762,leukoencephalopathy,7,8,58,77,CONCLUSIONS: Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed.,17682013_11,-1,1,1,9762,1
9770,pulmonary hypertension,6,8,46,68,Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.,17702969_0,-1,1,1,9770,1
9773,pulmonary hypertension,12,14,104,126,Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.,17702969_2,-1,1,1,9773,1
9774,pulmonary hypertension,17,19,108,130,"The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents.",17702969_3,-1,1,1,9774,1
9781,pulmonary hypertension,10,12,65,87,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,1,1,9781,1
9797,pulmonary hypertension,13,15,76,98,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,-1,1,1,9797,1
9801,peripheral neuropathy,4,6,39,60,Disulfiram-induced transient optic and peripheral neuropathy: a case report.,17786501_0,-1,1,1,9801,1
9803,peripheral neuropathy,9,11,35,56,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,1,1,9803,1
9931,hepatotoxicity,3,4,36,50,INTRODUCTION: Antibiotic-associated hepatotoxicity is rare.,17919553_1,-1,1,1,9931,1
9933,hepatic injury,9,11,54,68,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,-1,1,1,9933,1
10005,Dilated cardiomyopathy,2,4,12,34,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,1,1,10005,1
10042,rheumatoid arthritis,5,7,47,67,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,1,1,10042,1
10051,rheumatoid arthritis,47,49,350,370,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,1,1,10051,1
10101,Acute liver failure,0,3,0,19,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,-1,1,1,10101,1
10104,hepatotoxicity,11,12,63,77,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,-1,1,1,10104,1
10114,hepatotoxicity,7,8,45,59,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,-1,1,1,10114,1
10214,peripheral neuropathy,1,3,6,27,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,1,1,10214,1
10226,polyneuropathy,10,11,72,86,A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy.,18023325_8,-1,1,1,10226,1
10236,polyneuropathy,18,19,114,128,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,-1,1,1,10236,1
10241,idiopathic epilepsy,7,9,43,62,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,1,1,10241,1
10332,Hyperprolactinemia,0,1,0,18,Hyperprolactinemia can reduce fertility and libido.,18162529_1,-1,1,1,10332,1
10334,hyperprolactinemia,5,6,32,50,We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.,18162529_3,-1,1,1,10334,1
10339,hyperprolactinemia,1,2,8,26,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,-1,1,1,10339,1
10370,hyperprolactinemia,11,12,66,84,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,-1,1,1,10370,1
10411,metabolic acidosis,11,13,80,98,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,1,1,10411,1
10421,mitochondrial dysfunction,14,16,86,111,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,-1,1,1,10421,1
10499,thrombotic,2,3,11,21,"Similarly, thrombotic risk increased with age and OD values.",18208574_10,-1,1,1,10499,1
10518,myelosuppression,7,8,35,51,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,1,1,10518,1
10520,thromboembolic,7,8,38,52,Of concern was the occurrence of four thromboembolic events.,18217897_7,-1,1,1,10520,1
10535,hyperalgesia,5,6,24,36,"To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.",18221780_3,-1,1,1,10535,1
10597,renal dysfunction,5,7,42,59,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,-1,1,1,10597,1
10623,renal dysfunction,14,16,94,111,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,-1,1,1,10623,1
10706,thromboembolic,7,8,34,48,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,1,1,10706,1
10741,nephrotoxicity,3,4,32,46,"To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.",18356633_3,-1,1,1,10741,1
10750,nephrotoxicity,3,4,18,32,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,-1,1,1,10750,1
10753,nephrotoxicity,3,4,18,32,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,-1,1,1,10753,1
10758,nephrotoxicity,3,4,18,32,"The occurrence of nephrotoxicity was similar between the two dosing regimens, but the distribution of risk factors was variable between the two groups.",18356633_8,-1,1,1,10758,1
10800,Hepatotoxicity,0,1,0,14,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,-1,1,1,10800,1
10817,hepatotoxicity,5,6,19,33,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,-1,1,1,10817,1
10822,hepatotoxicity,4,5,24,38,The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.,18405372_6,-1,1,1,10822,1
10826,interstitial nephritis,11,13,59,81,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,-1,1,1,10826,1
10832,hepatotoxicity,1,2,13,27,Drug-related hepatotoxicity was judged probable or highly probable in 8 patients.,18405372_13,-1,1,1,10832,1
10833,hepatotoxicity,5,6,32,46,The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.,18405372_14,-1,1,1,10833,1
10835,hepatotoxicity,3,4,20,34,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,-1,1,1,10835,1
10840,neurotoxicity,1,2,24,37,Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.,18410508_0,-1,1,1,10840,1
10851,neurotoxicity,21,22,113,126,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,1,1,10851,1
10854,neurotoxicity,33,34,189,202,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,1,1,10854,1
10860,neurotoxicity,30,31,172,185,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,1,1,10860,1
10986,liver disease,14,16,62,75,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,1,1,10986,1
11097,Neurotoxicity,0,1,0,13,Neurotoxicity is a potentially serious toxic effect.,18503483_2,-1,1,1,11097,1
11159,renal dysfunction,2,4,34,51,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,-1,1,1,11159,1
11161,renal damage,4,6,46,58,"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.",18541230_5,-1,1,1,11161,1
11198,Valvular heart disease,0,3,0,22,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,-1,1,1,11198,1
11221,mitral regurgitation,22,24,83,103,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,1,1,11221,1
11231,valvular heart disease,7,10,47,69,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,1,1,11231,1
11262,platelet aggregation,2,4,20,40,The heparin-induced platelet aggregation test was negative in these patients.,18589141_12,-1,1,1,11262,1
11324,cardiotoxic,13,14,70,81,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,1,1,11324,1
11332,cardiac dysfunction,4,6,24,43,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,-1,1,1,11332,1
11344,cardiac dysfunction,6,8,22,41,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,1,1,11344,1
11418,cardiotoxicity,10,11,73,87,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,1,1,11418,1
11421,cardiotoxicity,14,15,83,97,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,-1,1,1,11421,1
11424,cardiotoxicity,13,14,103,117,"Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin-induced cardiotoxicity.",18674790_2,-1,1,1,11424,1
11434,cardiotoxicity,39,40,208,222,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,1,1,11434,1
11436,cardiotoxicity,23,24,104,118,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,1,1,11436,1
11437,cardiac dysfunction,25,27,120,139,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,1,1,11437,1
11460,cardiotoxicity,11,12,83,97,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,1,1,11460,1
11488,vasospasm,11,12,83,92,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,-1,1,1,11488,1
11495,vasospasm,22,23,165,174,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,-1,1,1,11495,1
11497,vasospasm,11,12,69,78,Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.,18726058_5,-1,1,1,11497,1
11508,sensorineural hearing loss,12,15,69,95,One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss.,18726058_12,-1,1,1,11508,1
11511,vasospasm,8,9,53,62,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,-1,1,1,11511,1
11530,fulminant hepatic failure,8,11,55,80,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,-1,1,1,11530,1
11535,hepatotoxicity,19,20,119,133,The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.,18752389_4,-1,1,1,11535,1
11539,hepatotoxicity,19,20,125,139,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,1,1,11539,1
11552,hepatotoxicity,34,35,258,272,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,1,1,11552,1
11556,hepatotoxicity,8,9,68,82,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,-1,1,1,11556,1
11559,hepatotoxicity,6,7,40,54,Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.,18752389_13,-1,1,1,11559,1
11599,nephrotic,5,6,39,48,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,-1,1,1,11599,1
11647,myocardial injury,12,14,81,98,Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.,18808529_0,-1,1,1,11647,1
11648,myocardial damage,4,6,39,56,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,1,1,11648,1
11686,neurotoxicity,6,7,52,65,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,-1,1,1,11686,1
11689,neurotoxicity,11,12,92,105,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,1,1,11689,1
11695,peripheral neuropathy,9,11,50,71,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,-1,1,1,11695,1
11716,neurotoxicity,8,9,78,91,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,-1,1,1,11716,1
11725,neurotoxicity,15,16,103,116,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,-1,1,1,11725,1
11799,dystonia,5,6,24,32,The major effect was on dystonia subscore.,18951540_5,-1,1,1,11799,1
11848,ventricular tachycardia,3,5,10,33,A case of ventricular tachycardia related to caffeine pretreatment.,18997632_0,-1,1,1,11848,1
11856,ventricular tachycardia,22,24,133,156,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,1,1,11856,1
11857,ventricular arrhythmias,20,22,136,159,"Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias.",18997632_4,-1,1,1,11857,1
11985,mucositis,11,12,64,73,"All patients engrafted, and only 1 patient experienced grade IV mucositis.",19135948_4,-1,1,1,11985,1
12025,ototoxicity,5,6,35,46,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,1,1,12025,1
12033,Renal papillary necrosis,0,3,0,24,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,-1,1,1,12033,1
12099,renal injury,30,32,194,206,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,-1,1,1,12099,1
12111,glomerular sclerosis,18,20,89,109,"HS diet for 4 wk caused a progressive increase in BP, protein and albumin excretion, and glomerular sclerosis in male DS rats, which were attenuated by castration.",19211690_9,-1,1,1,12111,1
12113,renal injury,9,11,60,72,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,-1,1,1,12113,1
12117,renal injury,8,10,64,76,Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.,19211690_11,-1,1,1,12117,1
12151,parkinsonian,9,10,75,87,There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months.,19234905_6,-1,1,1,12151,1
12257,Cardiotoxicity,0,1,0,14,Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.,19300240_2,-1,1,1,12257,1
12267,akinetic,13,14,112,120,Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.,19300240_7,-1,1,1,12267,1
12281,hyperalgesia,13,14,112,124,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,1,1,12281,1
12310,hyperalgesia,23,24,136,148,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,-1,1,1,12310,1
12319,hyperalgesia,2,3,26,38,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,-1,1,1,12319,1
12327,neuropathic pain,21,23,150,166,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,-1,1,1,12327,1
12415,nephrotoxicity,17,18,105,119,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,-1,1,1,12415,1
12473,gallbladder disease,17,19,96,115,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,1,1,12473,1
12493,breast cancer,33,35,182,195,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,1,1,12493,1
12494,gallbladder disease,36,38,200,219,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,1,1,12494,1
12497,gallbladder disease,13,15,100,119,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,1,1,12497,1
12498,breast cancer,40,42,240,253,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,1,1,12498,1
12522,secondary hyperalgesia,8,10,72,94,Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.,19387625_0,-1,1,1,12522,1
12523,secondary hyperalgesia,17,19,104,126,"However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.",19387625_2,-1,1,1,12523,1
12524,secondary hyperalgesia,8,10,46,68,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,1,1,12524,1
12529,secondary hyperalgesia,12,14,74,96,"Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.",19387625_4,-1,1,1,12529,1
12533,secondary hyperalgesia,15,17,123,145,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,-1,1,1,12533,1
12565,cardiac dysfunction,14,16,107,126,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,-1,1,1,12565,1
12566,myocardial injury,17,19,131,148,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,-1,1,1,12566,1
12570,myocardial damage,9,11,72,89,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,-1,1,1,12570,1
12576,neurotoxicity,8,9,73,86,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,-1,1,1,12576,1
12578,peripheral neuropathy,1,3,6,27,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,1,1,12578,1
12585,peripheral neuropathy,14,16,100,121,"This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.",19473225_2,-1,1,1,12585,1
12588,ovarian cancer,1,3,12,26,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,1,1,12588,1
12595,neurotoxicity,17,18,106,119,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,1,1,12595,1
12600,neurotoxicity,19,20,130,143,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,-1,1,1,12600,1
12711,dystonia,9,10,64,72,We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.,1967484_3,-1,1,1,12711,1
12842,ventricular tachycardia,17,19,114,137,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,1,1,12842,1
12970,neuronal damage,18,20,110,125,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,-1,1,1,12970,1
12984,neuronal damage,8,10,62,77,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,1,1,12984,1
13003,neuronal damage,22,24,149,164,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,-1,1,1,13003,1
13015,cardiac toxicity,4,6,27,43,Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.,19820426_0,-1,1,1,13015,1
13019,dilated cardiomyopathy,9,11,52,74,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,1,1,13019,1
13196,cardiac toxicity,5,7,33,49,"However, adverse effects include cardiac toxicity.",19917396_2,-1,1,1,13196,1
13211,memory impairment,2,4,20,37,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.,19923525_0,-1,1,1,13211,1
13274,Hemolytic anemia,0,2,0,16,Hemolytic anemia associated with the use of omeprazole.,1992636_0,-1,1,1,13274,1
13283,hemolytic anemia,17,19,94,110,We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.,1992636_4,-1,1,1,13283,1
13287,hemolytic anemia,9,11,55,71,"The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.",1992636_8,-1,1,1,13287,1
13313,akinetic,10,11,55,63,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,1,1,13313,1
13333,acute myocardial infarction,1,4,18,45,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,-1,1,1,13333,1
13482,coagulopathy,32,33,230,242,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,-1,1,1,13482,1
13489,coagulopathy,17,18,103,115,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,-1,1,1,13489,1
13491,cardiac arrhythmias,3,5,33,52,Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.,2004_0,-1,1,1,13491,1
13496,ventricular tachycardia,20,22,122,145,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,1,1,13496,1
13501,ventricular arrhythmias,1,3,4,27,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,-1,1,1,13501,1
13509,cardiac arrhythmias,1,3,6,25,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,1,1,13509,1
13575,sexual dysfunction,8,10,48,66,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,-1,1,1,13575,1
13579,sexual dysfunction,17,19,103,121,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,1,1,13579,1
13689,mitral regurgitation,31,33,151,171,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,1,1,13689,1
13708,variant angina,12,14,95,109,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,-1,1,1,13708,1
13711,variant angina,13,15,97,111,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,1,1,13711,1
13716,variant angina,4,6,21,35,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,-1,1,1,13716,1
13717,coronary spasm,7,9,37,51,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,-1,1,1,13717,1
13730,variant angina,26,28,162,176,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,-1,1,1,13730,1
13735,meth mouth,4,6,24,34,"Oral manifestations of ""meth mouth"": a case report.",20098969_0,-1,1,1,13735,1
13738,meth mouth,18,20,88,98,"AIM: The aim of the documentation of this clinical case is to make clinicians aware of ""meth mouth"" and the medical risks associated with this serious condition.",20098969_1,-1,1,1,13738,1
13747,meth mouth,17,19,105,115,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,1,1,13747,1
13758,meth mouth,21,23,122,132,"SUMMARY: The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of ""meth mouth."" Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.",20098969_8,-1,1,1,13758,1
13764,meth mouth,10,12,73,83,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,-1,1,1,13764,1
13768,diabetic nephropathy,7,9,54,74,The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.,20103708_0,-1,1,1,13768,1
13769,Diabetic nephropathy,2,4,11,31,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,1,1,13769,1
13776,diabetic nephropathy,13,15,77,97,"Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy.",20103708_3,-1,1,1,13776,1
13780,diabetic nephropathy,13,15,76,96,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1,13780,1
13782,diabetic nephropathy,21,23,136,156,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1,13782,1
13783,diabetic nephropathy,27,29,192,212,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,1,1,13783,1
13787,diabetic nephropathy,6,8,32,52,RESULTS: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels.,20103708_5,-1,1,1,13787,1
13792,renal damage,14,16,96,108,"In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced renal damage.",20103708_6,-1,1,1,13792,1
13795,renal injury,19,21,115,127,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,-1,1,1,13795,1
13801,diabetic nephropathy,16,18,106,126,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,-1,1,1,13801,1
13818,diabetic nephropathy,12,14,70,90,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,-1,1,1,13818,1
13821,diabetic nephropathy,37,39,221,241,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,-1,1,1,13821,1
13876,renal damage,22,24,112,124,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,1,1,13876,1
13882,renal injury,27,29,114,126,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,1,1,13882,1
13884,renal injury,43,45,182,194,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,1,1,13884,1
13895,acute liver failure,2,5,33,52,"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.",20196116_0,-1,1,1,13895,1
13897,acute liver failure,3,6,42,61,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,1,1,13897,1
13978,hyperprolactinemia,15,16,93,111,OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.,20331935_1,-1,1,1,13978,1
13997,Hyperprolactinemia,2,3,9,27,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,-1,1,1,13997,1
14001,hyperprolactinemia,12,13,88,106,Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.,20331935_7,-1,1,1,14001,1
14018,hyperprolactinemia,20,21,116,134,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,-1,1,1,14018,1
14019,hyperprolactinemia,10,11,65,83,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,-1,1,1,14019,1
14065,acute lymphoblastic leukemia,7,10,57,85,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,-1,1,1,14065,1
14067,acute lymphoblastic leukemia,11,14,73,101,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,1,1,14067,1
14074,peripheral neuropathy,10,12,84,105,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,1,1,14074,1
14078,leukoencephalopathy,5,6,48,67,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,1,1,14078,1
14079,temporal lobe epilepsy,20,23,103,125,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,1,1,14079,1
14159,liver disease,12,14,82,95,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,-1,1,1,14159,1
14192,Extrapyramidal symptoms,0,2,0,23,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,-1,1,1,14192,1
14201,extrapyramidal symptoms,21,23,133,156,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,-1,1,1,14201,1
14231,neurotoxicity,9,10,73,86,Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.,20533999_0,-1,1,1,14231,1
14397,memory impairment,42,44,292,309,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,1,1,14397,1
14578,memory impairment,13,15,86,103,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,-1,1,1,14578,1
14582,cognitive deficits,18,20,108,126,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,1,1,14582,1
14653,memory impairment,16,18,108,125,The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.,2071257_1,-1,1,1,14653,1
14676,hand-foot syndrome,17,19,104,122,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,-1,1,1,14676,1
14712,acute liver failure,7,10,73,92,Long-term prognosis for transplant-free survivors of paracetamol-induced acute liver failure.,20735774_0,-1,1,1,14712,1
14714,acute liver failure,9,12,79,98,BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown.,20735774_1,-1,1,1,14714,1
14715,acute liver failure,6,9,44,63,AIM: To examine whether paracetamol-induced acute liver failure increases long-term mortality.,20735774_2,-1,1,1,14715,1
14717,liver injury,11,13,83,95,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,-1,1,1,14717,1
14722,liver injury,16,18,107,119,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,-1,1,1,14722,1
14723,acute liver failure,21,24,130,149,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,-1,1,1,14723,1
14725,liver injury,15,17,109,121,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,1,1,14725,1
14726,acute liver failure,20,23,136,155,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,1,1,14726,1
14729,acute liver failure,49,52,273,292,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,1,1,14729,1
14730,liver disease,54,56,301,314,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,1,1,14730,1
14731,acute liver failure,7,10,54,73,These observations speak against long-term effects of acute liver failure.,20735774_7,-1,1,1,14731,1
14734,acute liver failure,22,25,148,167,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,-1,1,1,14734,1
14735,acute liver failure,3,6,33,52,CONCLUSIONS: Paracetamol-induced acute liver failure did not affect long-term mortality.,20735774_9,-1,1,1,14735,1
14788,leukoencephalopathy,18,19,122,141,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,-1,1,1,14788,1
14798,leukoencephalopathy,3,4,31,50,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,-1,1,1,14798,1
14902,renal toxicity,1,3,10,24,"Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.",21418164_6,-1,1,1,14902,1
14908,peripheral neuropathy,3,5,24,45,Perhexiline maleate and peripheral neuropathy.,220563_0,-1,1,1,14908,1
14909,Peripheral neuropathy,0,2,0,21,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,-1,1,1,14909,1
14945,mucositis,17,18,101,110,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,1,1,14945,1
14946,Myelosuppression,0,1,0,16,Myelosuppression was more in patients with hepatic dysfunction.,2224762_9,-1,1,1,14946,1
15028,chronic renal failure,12,15,77,98,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,-1,1,1,15028,1
15050,dry mouth,13,15,73,82,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,1,1,15050,1
15100,Neurotoxicity,0,1,0,13,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,-1,1,1,15100,1
15110,peripheral neuropathy,14,16,77,98,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,1,1,15110,1
15112,peripheral neuropathy,3,5,23,44,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,-1,1,1,15112,1
15117,stress incontinence,1,3,17,36,Prazosin-induced stress incontinence.,2304736_0,-1,1,1,15117,1
15118,stress incontinence,4,6,18,37,"A case of genuine stress incontinence due to prazosin, a common antihypertensive drug, is presented.",2304736_1,-1,1,1,15118,1
15130,stress incontinence,4,6,26,45,"Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.",2304736_7,-1,1,1,15130,1
15139,coronary spasm,13,15,73,87,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,1,1,15139,1
15146,breast cancer,9,11,66,79,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,-1,1,1,15146,1
15148,breast cancer,5,7,37,50,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,1,1,15148,1
15189,hyperalgesia,4,5,37,49,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,1,1,15189,1
15195,hyperalgesia,11,12,80,92,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,1,1,15195,1
15224,apnoea,5,6,43,49,The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i.v.,2334618_2,-1,1,1,15224,1
15233,apnoea,10,11,48,54,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,1,1,15233,1
15258,Cardiac arrhythmias,0,2,0,19,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,-1,1,1,15258,1
15281,ventricular arrhythmias,14,16,98,121,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,-1,1,1,15281,1
15303,cerebral haemorrhage,15,17,80,100,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,1,1,15303,1
15304,cerebral haemorrhage,8,10,43,63,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,1,1,15304,1
15309,Cerebral haemorrhage,0,2,0,20,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,-1,1,1,15309,1
15312,cerebral haemorrhage,4,6,21,41,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,1,1,15312,1
15314,parkinsonian,35,36,217,229,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,1,1,15314,1
15342,hepatocellular carcinoma,22,24,160,184,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,-1,1,1,15342,1
15387,ventricular arrhythmias,7,9,62,85,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,-1,1,1,15387,1
15390,ventricular arrhythmias,10,12,78,101,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,1,1,15390,1
15468,cardiac toxicity,7,9,46,62,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,1,1,15468,1
15655,major depression,12,14,89,105,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,1,1,15655,1
15684,hyperalgesia,20,21,141,153,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,-1,1,1,15684,1
15689,hyperalgesia,8,9,37,49,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,-1,1,1,15689,1
15725,renal injury,21,23,106,118,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,-1,1,1,15725,1
15739,glomerular sclerosis,9,11,56,76,Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats.(ABSTRACT TRUNCATED AT 250 WORDS),2559236_10,-1,1,1,15739,1
15809,akinetic,7,8,42,50,"The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)",2569282_11,-1,1,1,15809,1
15818,hepatotoxicity,16,17,103,117,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,1,1,15818,1
15982,Renal damage,0,2,0,12,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,-1,1,1,15982,1
16039,renal dysfunction,28,30,125,142,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,1,1,16039,1
16043,tubular necrosis,45,47,214,230,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,1,1,16043,1
16050,tubular necrosis,34,36,155,171,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,1,1,16050,1
16057,tubular necrosis,32,34,148,164,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,1,1,16057,1
16312,prolactinoma,7,8,43,55,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,1,1,16312,1
16318,prolactinoma,23,24,173,185,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,1,1,16318,1
16326,prolactinoma,20,21,148,160,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,-1,1,1,16326,1
16337,prolactinoma,1,2,4,16,"The prolactinoma cells at this time were well granulated, with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae.",2887062_7,-1,1,1,16337,1
16346,prolactinoma,23,24,177,189,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,-1,1,1,16346,1
16551,hypothyroid,8,9,46,57,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,-1,1,1,16551,1
16552,hypothyroid,12,13,78,89,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,-1,1,1,16552,1
16691,rheumatoid arthritis,7,9,44,64,Toxicity due to remission inducing drugs in rheumatoid arthritis.,3084782_0,-1,1,1,16691,1
16693,rheumatoid arthritis,3,5,26,46,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,1,1,16693,1
16729,hepatotoxicity,15,16,90,104,"By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug, including five deaths.",3101906_2,-1,1,1,16729,1
16731,hepatotoxicity,14,15,65,79,"The mean age of patients in the 16 probable cases was 57.9, with hepatotoxicity being more common in women.",3101906_5,-1,1,1,16731,1
16744,hepatic injury,23,25,167,181,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,-1,1,1,16744,1
16746,hepatotoxicity,1,2,13,27,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,-1,1,1,16746,1
16748,hepatotoxicity,12,13,75,89,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,1,1,16748,1
16758,hemolytic uremic syndrome,3,6,23,48,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,-1,1,1,16758,1
16760,Hemolytic Uremic Syndrome,3,6,23,48,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,1,1,16760,1
16891,cardiotoxicity,8,9,46,60,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,1,1,16891,1
16894,cardiotoxic,24,25,138,149,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,1,1,16894,1
16909,cardiotoxicity,7,8,46,60,"None of the other patients developed clinical cardiotoxicity, nor did the studied parameters change.",3137399_8,-1,1,1,16909,1
16911,cardiotoxicity,17,18,98,112,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,1,1,16911,1
16957,cardiotoxicity,3,4,17,31,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,-1,1,1,16957,1
16960,cardiotoxicity,5,6,25,39,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,1,1,16960,1
16998,locomotor hyperactivity,4,6,40,63,Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.,3220106_0,-1,1,1,16998,1
17023,locomotor hyperactivity,8,10,65,88,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,1,1,17023,1
17082,vasospasm,5,6,22,31,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,-1,1,1,17082,1
17106,nephrotoxicity,9,10,55,69,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,-1,1,1,17106,1
17112,nephrotoxicity,12,13,73,87,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,-1,1,1,17112,1
17179,metabolic acidosis,3,5,29,47,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,1,1,17179,1
17181,metabolic acidosis,3,5,10,28,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,1,1,17181,1
17187,Sexual dysfunction,0,2,0,18,Sexual dysfunction among patients with arthritis.,3409645_0,-1,1,1,17187,1
17188,sexual dysfunction,5,7,34,52,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,1,1,17188,1
17189,rheumatoid arthritis,13,15,94,114,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,1,1,17189,1
17205,sexual dysfunction,18,20,108,126,"Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with sexual dysfunction, sexual dissatisfaction and being female.",3409645_6,-1,1,1,17205,1
17215,renal papillary necrosis,12,15,92,116,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,1,1,17215,1
17219,renal papillary necrosis,3,6,12,36,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,1,1,17219,1
17222,renal papillary necrosis,15,18,95,119,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,1,1,17222,1
17239,hemolytic anemia,3,5,30,46,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,-1,1,1,17239,1
17244,hemolytic anemia,16,18,82,98,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,1,1,17244,1
17261,hemolytic anemia,25,27,128,144,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,-1,1,1,17261,1
17290,breast cancer,13,15,66,79,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,1,1,17290,1
17291,ovarian cancer,16,18,81,95,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,1,1,17291,1
17292,hepatotoxicity,2,3,20,34,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,1,1,17292,1
17293,nephrotoxicity,8,9,63,77,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,1,1,17293,1
17302,nephrotoxicity,12,13,69,83,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,-1,1,1,17302,1
17303,renal toxicity,22,24,131,145,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,-1,1,1,17303,1
17304,Hepatotoxicity,0,1,0,14,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,-1,1,1,17304,1
17369,prostate cancer,3,5,28,43,Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.,3461217_0,-1,1,1,17369,1
17384,prostate cancer,19,21,96,111,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,1,1,17384,1
17419,neurotoxicity,4,5,27,40,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,-1,1,1,17419,1
17421,neurotoxicity,3,4,20,33,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,-1,1,1,17421,1
17431,ototoxicity,29,30,242,253,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,-1,1,1,17431,1
17444,Nephrotoxicity,0,1,0,14,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,-1,1,1,17444,1
17447,Ototoxicity,0,1,0,11,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,1,1,17447,1
17457,ototoxicity,4,5,43,54,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,-1,1,1,17457,1
17464,rheumatoid arthritis,6,8,42,62,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,1,1,17464,1
17465,rheumatoid arthritis,4,6,35,55,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,1,1,17465,1
17486,vasospasm,1,2,8,17,Intense vasospasm with threatened gangrene arose in the arm used for the infusion.,3564823_3,-1,1,1,17486,1
17488,vasospasm,24,25,161,170,"Since the cranial condition precluded use of more usual methods, lidocaine was given intra-arterially, with careful cardiovascular monitoring, to counteract the vasospasm.",3564823_4,-1,1,1,17488,1
17539,renal damage,4,6,29,41,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,1,1,17539,1
17548,nephrotoxicity,4,5,30,44,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,1,1,17548,1
17572,renal damage,28,30,178,190,It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage.,3653576_8,-1,1,1,17572,1
17646,renal toxicity,18,20,108,122,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,-1,1,1,17646,1
17657,nephrotoxicity,3,4,10,24,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,-1,1,1,17657,1
17686,Allergic reaction,0,2,0,17,Allergic reaction to 5-fluorouracil infusion.,3719553_0,-1,1,1,17686,1
17688,allergic reaction,1,3,3,20,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,1,1,17688,1
17695,allergic reaction,12,14,89,106,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,-1,1,1,17695,1
17699,cardiac arrhythmias,15,17,92,111,It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.,3732088_1,-1,1,1,17699,1
17728,rheumatoid arthritis,9,11,70,90,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,-1,1,1,17728,1
17730,rheumatoid arthritis,19,21,137,157,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,-1,1,1,17730,1
17752,sinus bradycardia,6,8,38,55,"The patient developed, paradoxically, sinus bradycardia.",3769769_2,-1,1,1,17752,1
17762,carcinogenesis,26,27,124,138,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,1,1,17762,1
17770,carcinogenesis,8,9,40,54,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,1,1,17770,1
17778,akinetic,47,48,255,263,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,-1,1,1,17778,1
17780,akinetic,24,25,132,140,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,1,1,17780,1
17794,rhabdomyolysis,4,5,18,32,A case of massive rhabdomyolysis following molindone administration.,3782049_0,-1,1,1,17794,1
17796,Rhabdomyolysis,0,1,0,14,Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop.,3782049_1,-1,1,1,17796,1
17800,rhabdomyolysis,13,14,83,97,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,-1,1,1,17800,1
17801,rhabdomyolysis,11,12,70,84,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,1,1,17801,1
17818,renal dysfunction,20,22,124,141,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,-1,1,1,17818,1
17847,acute lymphoblastic leukemia,3,6,21,49,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,1,1,17847,1
17864,mucositis,16,17,116,125,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,-1,1,1,17864,1
17868,acute lymphoblastic leukemia,16,19,119,147,High-dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia.,3856631_7,-1,1,1,17868,1
17889,nephrotoxicity,17,18,73,87,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,1,1,17889,1
17890,ototoxicity,31,32,125,136,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,1,1,17890,1
17892,nephrotoxicity,9,10,74,88,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,1,1,17892,1
17893,ototoxicity,11,12,93,104,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,1,1,17893,1
17896,nephrotoxicity,3,4,24,38,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,-1,1,1,17896,1
17902,nephrotoxicity,13,14,86,100,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,-1,1,1,17902,1
17925,nephrotoxicity,22,23,130,144,"When the parameters were examined individually, duration of therapy and total AUC correlated significantly (P less than .05) with nephrotoxicity.",3950060_5,-1,1,1,17925,1
17945,Cardiac toxicity,0,2,0,16,Cardiac toxicity of 5-fluorouracil.,3952818_0,-1,1,1,17945,1
17955,coronary spasm,4,6,24,38,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,1,1,17955,1
17956,cardiotoxicity,11,12,59,73,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,1,1,17956,1
17980,Hepatotoxicity,0,1,0,14,Hepatotoxicity of amiodarone.,3962737_0,-1,1,1,17980,1
17983,hepatotoxicity,17,18,104,118,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,-1,1,1,17983,1
17985,hepatic injury,8,10,46,60,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,1,1,17985,1
17990,carcinogenesis,9,10,64,78,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,-1,1,1,17990,1
17997,prostate cancer,17,19,99,114,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,1,1,17997,1
18001,prostate cancer,27,29,154,169,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,1,1,18001,1
18002,prostate cancer,10,12,52,67,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,-1,1,1,18002,1
18007,prostate cancer,14,16,112,127,Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer.,3969369_6,-1,1,1,18007,1
18008,rheumatoid arthritis,6,8,40,60,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,-1,1,1,18008,1
18011,rheumatoid arthritis,16,18,101,121,Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis.,3970039_1,-1,1,1,18011,1
18026,rheumatoid arthritis,9,11,59,79,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,-1,1,1,18026,1
18029,rheumatoid arthritis,9,11,53,73,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,1,1,18029,1
18032,rheumatoid arthritis,37,39,233,253,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,1,1,18032,1
18053,peripheral neuropathy,11,13,94,115,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,1,1,18053,1
18069,sinus bradycardia,19,21,128,145,Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.,4008111_2,-1,1,1,18069,1
18145,hepatic injury,2,4,12,26,Patterns of hepatic injury induced by methyldopa.,424937_0,-1,1,1,18145,1
18146,liver disease,3,5,21,34,Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977.,424937_1,-1,1,1,18146,1
18153,hepatic injury,13,15,117,131,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,1,1,18153,1
18197,dystonia,13,14,83,91,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,1,1,18197,1
18203,liver damage,16,18,113,125,Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.,4812392_4,-1,1,1,18203,1
18218,hepatotoxicity,7,8,45,59,We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.,48362_5,-1,1,1,18218,1
18229,platelet aggregation,9,11,83,103,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,-1,1,1,18229,1
18295,myoclonic jerks,8,10,72,87,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,-1,1,1,18295,1
18298,myoclonic jerks,7,9,38,53,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,-1,1,1,18298,1
18307,myoclonic jerks,30,32,136,151,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,-1,1,1,18307,1
18379,Thrombotic microangiopathy,0,2,0,26,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,1,1,18379,1
18383,thrombotic microangiopathy,5,7,39,65,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,1,1,18383,1
18389,thrombotic,3,4,16,26,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,1,1,18389,1
18390,hemolytic-uremic syndrome,9,11,63,88,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,1,1,18390,1
18398,thrombotic microangiopathy,19,21,97,123,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,-1,1,1,18398,1
18403,bone marrow suppression,39,42,255,278,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,1,1,18403,1
18404,cardiac hypertrophy,3,5,37,56,Development of isoproterenol-induced cardiac hypertrophy.,6203632_0,-1,1,1,18404,1
18405,cardiac hypertrophy,3,5,19,38,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,1,1,18405,1
18448,rheumatoid arthritis,10,12,67,87,Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.,6216862_0,-1,1,1,18448,1
18452,rheumatoid arthritis,25,27,173,193,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,1,1,18452,1
18457,rheumatoid arthritis,28,30,164,184,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,1,1,18457,1
18497,milk fever,11,13,57,67,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,1,1,18497,1
18500,milk fever,30,32,159,169,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,1,1,18500,1
18509,milk fever,25,27,140,150,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1,18509,1
18510,milk fever,31,33,173,183,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1,18510,1
18512,milk fever,46,48,252,262,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,1,1,18512,1
18522,Peripheral neuropathy,0,2,0,21,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,1,1,18522,1
18525,autonomic neuropathy,7,9,41,61,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,-1,1,1,18525,1
18586,hyperammonemia,5,6,31,45,Modification of drug action by hyperammonemia.,6323692_0,-1,1,1,18586,1
18595,hyperammonemia,2,3,6,20,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,1,1,18595,1
18600,liver disease,24,26,158,171,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,1,1,18600,1
18618,hyperammonemia,4,5,22,36,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,1,1,18618,1
18640,dry mouth,15,17,88,97,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,1,1,18640,1
18787,liver disease,1,3,15,28,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,1,1,18787,1
18865,thromboembolic,12,13,81,95,"Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.",6615052_2,-1,1,1,18865,1
18870,thromboembolic,7,8,34,48,"The 20 deaths, 52 hemorrhagic and thromboembolic complications, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder.",6615052_5,-1,1,1,18870,1
18874,platelet aggregation,17,19,94,114,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,-1,1,1,18874,1
18902,ventricular tachycardia,3,5,28,51,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,1,1,18902,1
18908,ventricular tachycardia,9,11,68,91,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,-1,1,1,18908,1
18910,ventricular tachycardia,11,13,75,98,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,1,1,18910,1
18911,cardiac arrest,23,25,119,133,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,1,1,18911,1
19042,Renal papillary necrosis,0,3,0,24,Renal papillary necrosis due to naproxen.,6699841_0,-1,1,1,19042,1
19043,rheumatoid arthritis,4,6,23,43,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,1,1,19043,1
19048,renal papillary necrosis,26,29,160,184,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,1,1,19048,1
19056,renal toxicity,21,23,145,159,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,-1,1,1,19056,1
19133,visual loss,3,5,17,28,The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered.,6747681_11,-1,1,1,19133,1
19134,Cardiotoxic,0,1,0,11,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,-1,1,1,19134,1
19152,autonomic neuropathy,31,33,220,240,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,1,1,19152,1
19153,autonomic neuropathy,39,41,271,291,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,1,1,19153,1
19157,autonomic neuropathy,29,31,181,201,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,-1,1,1,19157,1
19160,autonomic neuropathy,53,55,332,352,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,-1,1,1,19160,1
19162,autonomic neuropathy,20,22,140,160,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,-1,1,1,19162,1
19279,cardiac arrhythmias,5,7,36,55,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,1,1,19279,1
19320,fulminant hepatic failure,24,27,157,182,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,-1,1,1,19320,1
19323,fulminant hepatic failure,22,25,128,153,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,1,1,19323,1
19325,fulminant hepatic failure,37,40,241,266,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,1,1,19325,1
19359,Visual loss,0,2,0,11,"Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.",7059267_2,-1,1,1,19359,1
19361,visual loss,15,17,105,116,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,1,1,19361,1
19375,nephrotic,28,29,147,156,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,-1,1,1,19375,1
19381,nephrotic,4,5,20,29,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,-1,1,1,19381,1
19388,nephrotic,12,13,78,87,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,-1,1,1,19388,1
19393,nephrotic,14,15,73,82,It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism.,7066357_12,-1,1,1,19393,1
19395,aplastic anemia,1,3,6,21,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,-1,1,1,19395,1
19399,aplastic anemia,5,7,28,43,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,-1,1,1,19399,1
19401,aplastic anemia,4,6,19,34,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,-1,1,1,19401,1
19404,aplastic anemia,7,9,36,51,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,1,1,19404,1
19437,apnoea,16,17,98,104,"Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.",7102237_2,-1,1,1,19437,1
19486,neurotoxicity,16,17,84,97,The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated.,7199841_2,-1,1,1,19486,1
19504,ventricular tachycardia,2,4,34,57,Procainamide-induced polymorphous ventricular tachycardia.,7234705_0,-1,1,1,19504,1
19506,ventricular tachycardia,5,7,49,72,Seven cases of procainamide-induced polymorphous ventricular tachycardia are presented.,7234705_1,-1,1,1,19506,1
19507,ventricular tachycardia,5,7,31,54,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,-1,1,1,19507,1
19510,ventricular tachycardia,23,25,161,184,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,-1,1,1,19510,1
19515,ventricular tachycardia,11,13,78,101,These patients had Q-T prolongation and recurrent syncope due to polymorphous ventricular tachycardia.,7234705_4,-1,1,1,19515,1
19520,ventricular tachycardia,20,22,135,158,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,-1,1,1,19520,1
19524,ventricular tachycardia,15,17,113,136,These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.,7234705_8,-1,1,1,19524,1
19537,aplastic anemia,1,3,6,21,Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.,7263204_0,-1,1,1,19537,1
19539,aplastic anemia,10,12,65,80,"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.",7263204_1,-1,1,1,19539,1
19541,aplastic anemia,4,6,16,31,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,-1,1,1,19541,1
19545,aplastic anemia,19,21,134,149,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,-1,1,1,19545,1
19581,myocardial damage,2,4,10,27,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,-1,1,1,19581,1
19587,ventricular tachycardia,1,3,8,31,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,-1,1,1,19587,1
19589,ventricular tachycardia,6,8,28,51,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,-1,1,1,19589,1
19596,ventricular tachycardia,3,5,23,46,Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia.,7292072_3,-1,1,1,19596,1
19597,ventricular tachycardia,14,16,105,128,Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia.,7292072_3,-1,1,1,19597,1
19600,fulminant hepatic failure,5,8,39,64,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,1,1,19600,1
19604,fulminant hepatic failure,7,10,44,69,Cerebral edema may complicate the course of fulminant hepatic failure.,7337133_1,-1,1,1,19604,1
19605,fulminant hepatic failure,7,10,54,79,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,1,1,19605,1
19633,sexual dysfunction,3,5,25,43,Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.,7416947_0,-1,1,1,19633,1
19655,nephrotoxicity,1,2,9,23,Clinical nephrotoxicity of tobramycin and gentamicin.,7420681_0,-1,1,1,19655,1
19658,ototoxicity,8,9,66,77,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,1,1,19658,1
19659,nephrotoxicity,10,11,82,96,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,1,1,19659,1
19675,endometrial cancer,25,27,169,187,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,1,1,19675,1
19679,cardiotoxic,1,2,4,15,The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.,7423039_1,-1,1,1,19679,1
19717,Cardiac toxicity,0,2,0,16,Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.,7449470_1,-1,1,1,19717,1
19723,cardiotoxicity,22,23,151,165,"A patient is reported who developed progressive cardiomyopathy two and one-half years after receiving 580 mg/m2 which apparently represents late, late cardiotoxicity.",7449470_3,-1,1,1,19723,1
19771,hepatotoxicity,2,3,10,24,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,-1,1,1,19771,1
19823,Nephrotoxicity,0,1,0,14,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,1,1,19823,1
19912,platelet aggregation,13,15,81,101,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,1,1,19912,1
19965,bone marrow suppression,22,25,154,177,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,-1,1,1,19965,1
19983,myelosuppression,13,14,81,97,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,1,1,19983,1
19996,hepatic injury,14,16,98,112,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,-1,1,1,19996,1
20032,cardiac arrhythmias,2,4,13,32,Seizures and cardiac arrhythmias have complicated its use in adult patients.,7651879_2,-1,1,1,20032,1
20106,renal toxicity,6,8,45,59,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,-1,1,1,20106,1
20124,renal toxicity,22,24,128,142,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,-1,1,1,20124,1
20180,renal dysfunction,7,9,57,74,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,-1,1,1,20180,1
20209,renal dysfunction,12,14,90,107,CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.,7791169_8,-1,1,1,20209,1
20243,aggressive behavior,38,40,216,235,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,1,1,20243,1
20361,neurotoxicity,12,13,72,85,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,-1,1,1,20361,1
20374,extrapyramidal symptoms,26,28,127,150,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,-1,1,1,20374,1
20498,allergic reaction,16,18,109,126,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,1,1,20498,1
20564,platelet aggregation,16,18,117,137,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,-1,1,1,20564,1
20634,allergic reactions,1,3,10,28,Immediate allergic reactions to amoxicillin.,8092427_0,-1,1,1,20634,1
20635,allergic reactions,7,9,41,59,A large group of patients with suspected allergic reactions to beta-lactam antibiotics was evaluated.,8092427_1,-1,1,1,20635,1
20671,allergic reaction,19,21,100,117,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,1,1,20671,1
20679,acute myocardial infarction,13,16,98,125,Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.,809711_0,-1,1,1,20679,1
20681,acute myocardial infarction,9,12,67,94,"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.",809711_1,-1,1,1,20681,1
20698,acute myocardial infarction,18,21,120,147,Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.,809711_7,-1,1,1,20698,1
20701,parkinsonian,7,8,37,49,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,-1,1,1,20701,1
20712,parkinsonian,30,31,171,183,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,1,1,20712,1
20718,neurotoxicity,3,4,38,51,Hallucinations and ifosfamide-induced neurotoxicity.,8111719_0,-1,1,1,20718,1
20719,neurotoxicity,8,9,51,64,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,-1,1,1,20719,1
20726,neurotoxicity,11,12,70,83,CONCLUSIONS: Hallucinations may be the sole or first manifestation of neurotoxicity.,8111719_7,-1,1,1,20726,1
20728,neurotoxicity,17,18,119,132,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,-1,1,1,20728,1
20768,rheumatoid arthritis,8,10,79,99,Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.,8267029_0,-1,1,1,20768,1
20769,rheumatoid arthritis,4,6,25,45,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,-1,1,1,20769,1
20801,Hyperalgesia,0,1,0,12,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,-1,1,1,20801,1
20805,hyperalgesia,18,19,118,130,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,-1,1,1,20805,1
20807,hyperalgesia,4,5,34,46,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,1,1,20807,1
20872,cardiotoxicity,5,6,25,39,There was no evidence of cardiotoxicity.,8305357_10,-1,1,1,20872,1
20931,penile pain,3,5,30,41,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,1,1,20931,1
20934,penile pain,6,8,35,46,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,1,1,20934,1
20938,penile pain,31,33,195,206,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,1,1,20938,1
20945,penile pain,18,20,93,104,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,1,1,20945,1
20947,penile pain,42,44,206,217,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,1,1,20947,1
20948,penile pain,7,9,37,48,"From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication, which can be overcome by elevating the pH to a neutral level.",8386779_8,-1,1,1,20948,1
20970,Peripheral neuropathy,0,2,0,21,Peripheral neuropathy occurred in 12 patients and pancreatitis in six.,8387218_9,-1,1,1,20970,1
21097,motor disability,6,8,34,50,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,1,1,21097,1
21142,rheumatoid arthritis,3,5,17,37,Apparent cure of rheumatoid arthritis by bone marrow transplantation.,8441146_0,-1,1,1,21142,1
21144,rheumatoid arthritis,13,15,86,106,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,1,1,21144,1
21148,aplastic anemia,6,8,29,44,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,-1,1,1,21148,1
21160,ventricular tachycardia,6,8,41,64,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,-1,1,1,21160,1
21197,rhabdomyolysis,2,3,11,25,Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.,8492347_0,-1,1,1,21197,1
21205,nephrotoxicity,1,2,22,36,Ciprofloxacin-induced nephrotoxicity in patients with cancer.,8494478_0,-1,1,1,21205,1
21206,Nephrotoxicity,0,1,0,14,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,-1,1,1,21206,1
21211,interstitial nephritis,1,3,9,31,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,-1,1,1,21211,1
21234,visual hallucinations,1,3,26,47,Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.,8546130_0,-1,1,1,21234,1
21235,chronic renal failure,7,10,66,87,Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.,8546130_0,-1,1,1,21235,1
21236,Visual hallucinations,0,2,0,21,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,1,1,21236,1
21237,chronic renal failure,7,10,42,63,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,1,1,21237,1
21238,visual hallucinations,5,7,32,53,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,1,1,21238,1
21241,end-stage renal disease,9,12,42,65,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,1,1,21241,1
21249,chronic renal failure,12,15,77,98,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,-1,1,1,21249,1
21296,neurotoxicity,8,9,45,58,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,-1,1,1,21296,1
21393,cardiotoxicity,1,2,5,19,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,-1,1,1,21393,1
21404,cardiac toxicity,9,11,37,53,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,1,1,21404,1
21406,ventricular arrhythmias,27,29,142,165,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,1,1,21406,1
21418,cardiotoxicity,4,5,37,51,"The incidence of doxorubicin-induced cardiotoxicity is high and increases with follow-up, irrespective of cumulative dose.",8600333_9,-1,1,1,21418,1
21422,cardiotoxicity,18,19,110,124,The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity.,8600333_11,-1,1,1,21422,1
21502,breast carcinoma,25,27,168,184,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,1,1,21502,1
21524,polyneuropathy,4,5,13,27,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,-1,1,1,21524,1
21525,polyneuropathy,19,20,92,106,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,-1,1,1,21525,1
21555,ovarian cancer,53,55,342,356,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,1,1,21555,1
21592,ovarian cancer,10,12,77,91,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,-1,1,1,21592,1
21599,ovarian cancer,41,43,235,249,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,1,1,21599,1
21610,myelosuppression,7,8,50,66,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,1,1,21610,1
21611,Neurotoxicity,0,1,0,13,Neurotoxicity was largely moderate.,8643973_6,-1,1,1,21611,1
21632,dystonia,9,10,68,76,"Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not.",8649546_3,-1,1,1,21632,1
21675,chronic renal failure,9,12,51,72,Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.,8669433_0,-1,1,1,21675,1
21679,chronic renal failure,21,24,137,158,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,1,1,21679,1
21680,end-stage renal disease,25,28,163,186,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,1,1,21680,1
21689,chronic renal failure,32,35,176,197,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,1,1,21689,1
21723,allergic reactions,3,5,18,36,Other symptoms of allergic reactions were not clinically detectable.,8682684_5,-1,1,1,21723,1
21742,diabetic nephropathy,15,17,127,147,Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.,8690168_0,-1,1,1,21742,1
21836,apnoea,5,6,52,58,Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.,871943_1,-1,1,1,21836,1
21883,renal toxicity,9,11,61,75,Effect of some anticancer drugs and combined chemotherapy on renal toxicity.,8739323_0,-1,1,1,21883,1
21925,nephrotoxicity,4,5,26,40,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,1,1,21925,1
21952,liver injury,36,38,239,251,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,-1,1,1,21952,1
21973,liver damage,34,36,188,200,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,-1,1,1,21973,1
21982,hepatic damage,21,23,130,144,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,-1,1,1,21982,1
21992,cognitive deficits,30,32,169,187,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,1,1,21992,1
22001,cognitive deficits,19,21,129,147,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,1,1,22001,1
22037,ventricular arrhythmias,3,5,17,40,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,1,1,22037,1
22054,nephrotoxicity,9,10,59,73,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,-1,1,1,22054,1
22147,myoclonic jerks,19,21,101,116,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,1,1,22147,1
22159,rhabdomyolysis,20,21,107,121,The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of rhabdomyolysis.,8888541_12,-1,1,1,22159,1
22164,hemolytic uremic syndrome,10,13,52,77,Late recovery of renal function in a woman with the hemolytic uremic syndrome.,891050_0,-1,1,1,22164,1
22165,hemolytic uremic syndrome,6,9,26,51,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,-1,1,1,22165,1
22177,bladder cancer,2,4,28,42,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,-1,1,1,22177,1
22182,bladder cancer,22,24,117,131,MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.,8911359_2,-1,1,1,22182,1
22230,hepatic damage,5,7,30,44,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,1,1,22230,1
22231,hyperammonemia,9,10,53,67,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,1,1,22231,1
22236,allergic reaction,17,19,95,112,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,1,1,22236,1
22240,cardiac arrest,3,5,20,34,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,-1,1,1,22240,1
22242,cardiac arrest,6,8,33,47,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,-1,1,1,22242,1
22244,allergic reaction,21,23,123,140,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,-1,1,1,22244,1
22288,mucositis,2,3,21,30,Thrombocytopenia and mucositis were the major toxicities.,8958188_6,-1,1,1,22288,1
22304,rhabdomyolysis,34,35,230,244,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,1,1,22304,1
22306,sensorineural hearing loss,3,6,16,42,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,-1,1,1,22306,1
22309,sensorineural hearing loss,28,31,145,171,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,-1,1,1,22309,1
22317,Ototoxicity,0,1,0,11,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,-1,1,1,22317,1
22359,major depression,7,9,39,55,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,-1,1,1,22359,1
22396,acute liver failure,9,12,72,91,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,-1,1,1,22396,1
22399,acute liver failure,20,23,136,155,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,1,1,22399,1
22452,cardiotoxic,44,45,239,250,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,1,1,22452,1
22466,haemodilution,8,9,71,84,Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.,9088814_0,-1,1,1,22466,1
22470,haemodilution,9,10,78,91,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,-1,1,1,22470,1
22475,haemodilution,37,38,164,177,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,1,1,22475,1
22477,haemodilution,54,55,249,262,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,1,1,22477,1
22478,Haemodilution,0,1,0,13,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,-1,1,1,22478,1
22503,haemodilution,17,18,111,124,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,1,1,22503,1
22505,hyperprolactinemia,9,10,46,64,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,1,1,22505,1
22508,hyperprolactinemia,19,20,119,137,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,-1,1,1,22508,1
22511,hyperprolactinemia,20,21,107,125,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,-1,1,1,22511,1
22617,nephrotic,42,43,234,243,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,1,1,22617,1
22639,extrapyramidal symptoms,11,13,58,81,The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.,9165568_3,-1,1,1,22639,1
22641,extrapyramidal symptoms,5,7,27,50,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,-1,1,1,22641,1
22718,breast carcinoma,15,17,108,124,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,-1,1,1,22718,1
22860,dilated cardiomyopathy,19,21,176,198,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,1,1,22860,1
22862,dilated cardiomyopathy,8,10,46,68,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,1,1,22862,1
22874,parkinsonian,17,18,100,112,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,1,1,22874,1
22909,liver disease,2,4,12,25,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,1,1,22909,1
22913,hepatotoxicity,6,7,46,60,Limited studies in animals indicate potential hepatotoxicity of some of these compounds.,9284778_2,-1,1,1,22913,1
22914,liver disease,5,7,31,44,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,1,1,22914,1
22920,hepatotoxicity,26,27,190,204,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,-1,1,1,22920,1
22921,liver disease,13,15,65,78,We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.,9284778_6,-1,1,1,22921,1
22940,liver injury,16,18,93,105,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,1,1,22940,1
22942,hepatotoxicity,5,6,32,46,"Although the exact mechanism of hepatotoxicity of these agents is not known, the results suggest that trifluoroacetyl-altered liver proteins are involved.",9284778_13,-1,1,1,22942,1
22956,temporal lobe epilepsy,7,10,60,82,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,-1,1,1,22956,1
22963,temporal lobe epilepsy,19,22,121,143,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,1,1,22963,1
22972,brain damage,24,26,154,166,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,1,1,22972,1
23028,ventricular tachycardia,1,3,23,46,Clarithromycin-induced ventricular tachycardia.,9326871_0,-1,1,1,23028,1
23036,Cardiotoxicity,0,1,0,14,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,1,1,23036,1
23055,low sexual desire,16,19,96,113,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,-1,1,1,23055,1
23061,low sexual desire,10,13,81,98,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,-1,1,1,23061,1
23067,hyperprolactinemia,15,16,125,143,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,1,1,23067,1
23074,low sexual desire,6,9,42,59,"Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.",9334596_13,-1,1,1,23074,1
23077,prolactinoma,2,3,7,19,Only 1 prolactinoma was discovered.,9334596_16,-1,1,1,23077,1
23085,low sexual desire,15,18,85,102,We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.,9334596_24,-1,1,1,23085,1
23087,low sexual desire,8,11,48,65,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",9334596_25,-1,1,1,23087,1
23097,psychotic symptoms,16,18,124,142,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,-1,1,1,23097,1
23119,breast cancer,5,7,43,56,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,1,1,23119,1
23126,breast cancer,4,6,32,45,"For previously treated advanced breast cancer, there is no standard second-line therapy.",9390208_1,-1,1,1,23126,1
23134,breast cancer,15,17,107,120,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,1,1,23134,1
23153,cardiotoxicity,3,4,22,36,Major toxicities were cardiotoxicity and leukopenia.,9390208_15,-1,1,1,23153,1
23156,breast cancer,5,7,34,47,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,-1,1,1,23156,1
23158,aplastic anemia,1,3,20,35,Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.,9401499_0,-1,1,1,23158,1
23159,aplastic anemia,9,11,63,78,"In this study, three Chinese patients with ticlopidine-induced aplastic anemia were reported and another 13 patients in the English literature were reviewed.",9401499_1,-1,1,1,23159,1
23165,bone marrow suppression,17,20,95,118,There seemed to be no direct correlation between the dose or duration used and the severity of bone marrow suppression.,9401499_6,-1,1,1,23165,1
23166,aplastic anemia,3,5,34,49,Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.,9401499_7,-1,1,1,23166,1
23313,rheumatoid arthritis,3,5,19,39,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,-1,1,1,23313,1
23352,sensorineural hearing loss,21,24,113,139,"Up until now, the only factor studied has been the effect of the diameter of the spinal needle on post-operative sensorineural hearing loss.",9522143_2,-1,1,1,23352,1
23463,parkinsonian,4,5,33,45,Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.,9549528_0,-1,1,1,23463,1
23468,parkinsonian,33,34,195,207,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,1,1,23468,1
23475,parkinsonian,21,22,151,163,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,1,1,23475,1
23522,breast cancer,8,10,62,75,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,1,1,23522,1
23524,breast cancer,19,21,104,117,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,-1,1,1,23524,1
23525,breast cancer,30,32,172,185,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,-1,1,1,23525,1
23526,endometrial cancer,6,8,45,63,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,-1,1,1,23526,1
23527,breast cancer,18,20,123,136,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,-1,1,1,23527,1
23529,endometrial cancer,2,4,9,27,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,1,1,23529,1
23530,breast cancer,6,8,44,57,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,1,1,23530,1
23531,breast cancer,24,26,123,136,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,1,1,23531,1
23534,endometrial cancer,11,13,72,90,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,-1,1,1,23534,1
23544,endometrial cancer,3,5,14,32,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,-1,1,1,23544,1
23547,endometrial cancer,19,21,123,141,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,-1,1,1,23547,1
23548,endometrial cancer,9,11,50,68,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,-1,1,1,23548,1
23549,breast cancer,19,21,119,132,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,-1,1,1,23549,1
23552,breast cancer,11,13,74,87,Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer.,9579567_10,-1,1,1,23552,1
23555,breast cancer,5,7,32,45,Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.,9579567_12,-1,1,1,23555,1
23558,breast cancer,14,16,92,105,A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.,9579567_13,-1,1,1,23558,1
23560,cardiac arrest,1,3,22,36,Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.,9587734_0,-1,1,1,23560,1
23561,cardiac arrest,7,9,39,53,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,-1,1,1,23561,1
23566,cardiac arrest,9,11,64,78,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,-1,1,1,23566,1
23575,autoimmune hemolytic anemia,3,6,17,44,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,1,1,23575,1
23578,autoimmune hemolytic anemia,31,34,208,235,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,-1,1,1,23578,1
23625,Neurotoxicity,0,1,0,13,"Neurotoxicity was assessed for behavioral (tail-flick test), neurophysiological (nerve conduction velocity in the tail nerve), morphological, morphometrical and analytical effects.",9636837_4,-1,1,1,23625,1
23632,neurotoxicity,7,8,64,77,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,1,1,23632,1
23646,neurotoxicity,31,32,167,180,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,1,1,23646,1
23651,drug abuse,8,10,61,71,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,-1,1,1,23651,1
23677,locomotor hyperactivity,7,9,43,66,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,1,1,23677,1
23756,breast cancer,2,4,14,27,Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.,9672273_0,-1,1,1,23756,1
23760,breast cancer,9,11,62,75,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,-1,1,1,23760,1
23762,endometrial cancer,22,24,137,155,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,-1,1,1,23762,1
23767,breast cancer,28,30,147,160,"METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy.",9672273_4,-1,1,1,23767,1
23771,breast cancer,10,12,60,73,The primary endpoints are the occurrence of and deaths from breast cancer.,9672273_9,-1,1,1,23771,1
23774,breast cancer,3,5,12,25,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,-1,1,1,23774,1
23775,breast cancer,15,17,74,87,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,-1,1,1,23775,1
23778,breast cancer,7,9,50,63,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,-1,1,1,23778,1
23780,breast cancer,38,40,238,251,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,-1,1,1,23780,1
23786,breast cancer,19,21,115,128,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_16,-1,1,1,23786,1
23789,breast cancer,5,7,26,39,There were no deaths from breast cancer recorded in women in the study.,9672273_18,-1,1,1,23789,1
23848,primary pulmonary hypertension,3,6,18,48,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,-1,1,1,23848,1
23851,Primary pulmonary hypertension,0,3,0,30,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,-1,1,1,23851,1
23856,primary pulmonary hypertension,3,6,26,56,Thirty-five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months (1992-1994) in Belgium.,9727773_3,-1,1,1,23856,1
23865,primary pulmonary hypertension,6,9,31,61,"In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.",9727773_7,-1,1,1,23865,1
23872,primary pulmonary hypertension,16,19,106,136,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,-1,1,1,23872,1
23885,myoclonic jerks,15,17,103,118,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,-1,1,1,23885,1
23939,extrapyramidal symptoms,12,14,91,114,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,1,1,23939,1
23944,orthostatic hypotension,37,39,232,255,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,1,1,23944,1
23947,sexual dysfunction,47,49,304,322,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,1,1,23947,1
23954,sexual dysfunction,29,31,167,185,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,1,1,23954,1
23960,ischemic stroke,10,12,68,83,The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.,9799166_1,-1,1,1,23960,1
24040,myocardial injury,11,13,89,106,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,-1,1,1,24040,1
24041,myocardial injury,6,8,43,60,A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.,983936_1,-1,1,1,24041,1
24043,acute myocardial infarction,30,33,199,226,A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.,983936_1,-1,1,1,24043,1
24070,cardiotoxic,8,9,51,62,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,1,1,24070,1
24073,cardiotoxicity,21,22,144,158,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,1,1,24073,1
24085,cardiotoxic,5,6,36,47,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,-1,1,1,24085,1
24089,cardiotoxic,2,3,14,25,The low-grade cardiotoxic changes were enhanced by the additional doxorubicin treatment.,9848575_7,-1,1,1,24089,1
24092,cardiotoxicity,11,12,62,76,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,-1,1,1,24092,1
24093,cardiotoxicity,17,18,125,139,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,-1,1,1,24093,1
24199,valvular heart disease,2,5,9,31,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,1,1,24199,1
24216,mitral regurgitation,16,18,98,118,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,1,1,24216,1
24218,mitral regurgitation,43,45,266,286,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,1,1,24218,1
24220,valvular heart disease,22,25,98,120,"RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.",9867728_8,-1,1,1,24220,1
24225,valvular heart disease,10,13,54,76,CONCLUSION: Users of diet medications are at risk for valvular heart disease.,9867728_11,-1,1,1,24225,1
24287,nephrotoxicity,23,24,115,129,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,-1,1,1,24287,1
24313,nephrotoxicity,12,13,78,92,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,-1,1,1,24313,1
12,effects of,7,9,43,53,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,2,12,-1
16,sham-operated,15,16,63,76,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,2,16,-1
22,crossover period,37,39,204,220,"Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.",10027919_8,-1,-1,2,22,-1
70,movements of right,28,31,151,169,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,2,70,-1
75,effects of,13,15,92,102,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,2,75,-1
76,drug withdrawal,15,17,103,118,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,2,76,-1
88,consequences of,26,28,149,164,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,-1,-1,2,88,-1
108,non-selective,11,12,76,89,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,2,108,-1
111,effects of,3,5,19,29,Further studies on effects of irrigation solutions on rat bladders.,1009330_0,-1,-1,2,111,-1
112,effects of,4,6,23,33,Further studies on the effects of certain irrigating fluids on the rat bladder for 18 hours are reported.,1009330_1,-1,-1,2,112,-1
113,degradation product p-choloroaniline,6,9,32,68,The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.,1009330_2,-1,-1,2,113,-1
120,Effects of,0,2,0,10,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,2,120,-1
126,bisbenzylisoquinoline structure,16,18,87,118,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,2,126,-1
127,effects of,8,10,52,62,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,2,127,-1
135,positive control,49,51,199,215,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,2,135,-1
137,dependently,21,22,120,131,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,2,137,-1
143,human-citrated plasma,36,38,194,215,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,2,143,-1
154,Sprague Dawley rats,10,13,61,80,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,2,154,-1
156,NAG activity,5,7,24,36,"Total protein, albumin, NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days.",10193809_2,-1,-1,2,156,-1
157,protein electrophoretic pattern,8,11,41,72,"Total protein, albumin, NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days.",10193809_2,-1,-1,2,157,-1
159,isoenzyme,23,24,118,127,"The morphological appearance of the kidneys was examined on days three, four, six, eight and thirty three and the NAG isoenzyme patterns on days zero, four, eight and thirty three.",10193809_3,-1,-1,2,159,-1
163,molecular weight,9,11,65,81,Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards.,10193809_5,-1,-1,2,163,-1
165,Protein droplets,0,2,0,16,Protein droplets first appeared prominent in tubular cells on day four.,10193809_6,-1,-1,2,165,-1
167,Peak urine NAG,0,3,0,14,Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets (day six onwards).,10193809_7,-1,-1,2,167,-1
176,hyperbaric,7,8,52,62,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,2,176,-1
179,1997.Six,29,30,179,187,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,2,179,-1
181,Pharmaceutical Insurance,43,45,270,294,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,2,181,-1
184,hyperbaric,7,8,50,60,All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.,10225068_1,-1,-1,2,184,-1
199,total dose,18,20,110,120,We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg.,10225068_7,-1,-1,2,199,-1
206,immunosuppressive agent,9,11,49,72,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,-1,-1,2,206,-1
217,dexamethasone-induced apoptosis,15,17,105,136,"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.",10328196_4,-1,-1,2,217,-1
223,drug-induced apoptosis,7,9,36,58,"These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.",10328196_6,-1,-1,2,223,-1
226,inflammatory mediators,22,24,143,165,"These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.",10328196_6,-1,-1,2,226,-1
228,systemic therapies,11,13,79,97,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,2,228,-1
241,St. Mary's Hospital,6,10,39,58,"SETTING: Affective Disorders Clinic at St. Mary's Hospital, Montreal.",10354657_4,-1,-1,2,241,-1
243,control group,1,3,4,17,The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.,10354657_6,-1,-1,2,243,-1
245,hospital's,15,17,102,112,The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.,10354657_6,-1,-1,2,245,-1
255,associated with,11,13,75,90,"Thus, lithium treatment counteracted the decrease in plasma calcium levels associated with aging.",10354657_13,-1,-1,2,255,-1
260,cocaine-dependent,12,13,90,107,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,2,260,-1
263,substance-induced,14,15,88,105,This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders.,10365197_1,-1,-1,2,263,-1
265,cocaine-dependent,1,2,4,21,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,2,265,-1
271,DSM-IV diagnosis,3,5,20,36,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,2,271,-1
291,caudate nucleus,32,34,207,222,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,2,291,-1
292,treated with,2,4,10,22,Rats were treated with seven day intravenous infusion of fucoidan (30 micrograms h-1) or vehicle.,10406016_4,-1,-1,2,292,-1
306,anti-inflammatory agents,4,6,31,55,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,-1,-1,2,306,-1
307,hemodiluting agents,7,9,60,79,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,-1,-1,2,307,-1
310,associated with,4,6,31,46,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,-1,-1,2,310,-1
318,cefotetan-induced,9,10,38,55,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,2,318,-1
323,Effects of,0,2,0,10,Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.,10414674_0,-1,-1,2,323,-1
336,pretreatment,20,21,131,143,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,2,336,-1
340,APPT,13,14,75,79,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,-1,-1,2,340,-1
342,antithrombin III,20,22,112,128,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,-1,-1,2,342,-1
348,recurarization,3,4,10,24,A case of recurarization in the recovery room is reported.,10457883_1,-1,-1,2,348,-1
352,recurarization,9,10,58,72,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,2,352,-1
361,ASA,13,14,88,91,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,-1,-1,2,361,-1
367,ASA,24,25,117,120,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,2,367,-1
371,associated with,4,6,28,43,"However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.",10520387_4,-1,-1,2,371,-1
375,lead-induced,8,9,50,62,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,-1,-1,2,375,-1
379,lead-induced,13,14,75,87,"This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.",10523326_2,-1,-1,2,379,-1
380,Sprague-Dawley rats,1,3,5,24,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,2,380,-1
404,no effect,4,6,30,39,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,2,404,-1
407,control group,19,21,103,116,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,2,407,-1
409,cell-free preparations,13,15,84,106,The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.,10523326_8,-1,-1,2,409,-1
410,associated with,9,11,59,74,"In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.",10523326_9,-1,-1,2,410,-1
413,iNOS,20,21,134,138,"In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.",10523326_9,-1,-1,2,413,-1
415,lead-associated inhibition,12,14,55,81,"This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.",10523326_10,-1,-1,2,415,-1
437,migraineurs,12,13,76,87,"In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.",10524660_8,-1,-1,2,437,-1
441,migraine with aura,13,16,76,94,The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.,10524660_10,-1,-1,2,441,-1
447,Oncopaz Cooperative Group,0,3,0,25,Oncopaz Cooperative Group.,10526274_1,-1,-1,2,447,-1
456,NSCLC,20,21,115,120,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,2,456,-1
462,sixty-five courses,4,6,21,39,"RESULTS: One hundred sixty-five courses were administered, with a median of 3.",10526274_9,-1,-1,2,462,-1
464,confidence interval,10,12,39,58,"The overall response rate was 26% (95% confidence interval, 15-41%).",10526274_11,-1,-1,2,464,-1
468,1-year survival,10,12,52,67,The median time to progression was 16 weeks and the 1-year survival rate was 33%. Toxicity was mild.,10526274_14,-1,-1,2,468,-1
473,age group,1,3,5,14,This age group had an increased risk of myelosuppression.,10526274_19,-1,-1,2,473,-1
475,granulocyte-colony stimulating factor,5,8,34,71,Therefore the prophylactic use of granulocyte-colony stimulating factor should be considered with this treatment.,10526274_20,-1,-1,2,475,-1
476,New chemotherapy combinations,0,3,0,29,New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC.,10526274_21,-1,-1,2,476,-1
501,double-blind,19,20,97,109,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,2,501,-1
502,placebo-controlled trial,21,23,111,135,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,2,502,-1
506,time-to-event analysis,2,4,8,30,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,2,506,-1
515,older age,11,13,67,76,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,2,515,-1
523,associated with,3,5,14,29,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,2,523,-1
525,risk ratio,28,30,161,171,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,2,525,-1
526,RR,31,32,173,175,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,2,526,-1
527,confidence interval,40,42,200,219,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,2,527,-1
528,RR,53,54,260,262,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,2,528,-1
530,associated with,4,6,30,45,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,2,530,-1
532,RR,18,19,113,115,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,2,532,-1
534,RR,34,35,167,169,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,2,534,-1
536,RR,9,10,60,62,"Conversely, enalapril had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes.",10539815_11,-1,-1,2,536,-1
537,RR,23,24,110,112,"Conversely, enalapril had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes.",10539815_11,-1,-1,2,537,-1
540,RR,15,16,84,86,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,-1,-1,2,540,-1
541,RR,31,32,150,152,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,-1,-1,2,541,-1
558,NRA0160,0,1,0,7,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,-1,-1,2,558,-1
564,Ki values,39,41,198,207,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,-1,-1,2,564,-1
574,MAP-induced stereotyped behavior,4,7,34,66,"NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given.",10579464_5,-1,-1,2,574,-1
579,prepulse inhibition,8,10,63,82,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,-1,-1,2,579,-1
582,(PCP)-induced,7,8,64,77,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,-1,-1,2,582,-1
585,antipsychotic activities,8,10,52,76,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,2,585,-1
599,ad libitum diet,27,30,161,176,"To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.",10669626_4,-1,-1,2,599,-1
600,restricted diet,33,35,188,203,"To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.",10669626_4,-1,-1,2,600,-1
603,ad libitum-fed rats,18,21,122,141,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,2,603,-1
606,growth-inhibited group,30,32,205,227,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,2,606,-1
610,ad libitum-fed rats,46,49,289,308,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,-1,2,610,-1
623,treatment times,21,23,114,129,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,2,623,-1
630,no effect,4,6,31,40,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,2,630,-1
647,drug-induced,22,23,156,168,These studies were conducted to examine the differential response to a drug challenge under varied experimental test conditions routinely employed to study drug-induced behavioral and neurophysiological responses in rodents.,10683478_1,-1,-1,2,647,-1
652,apomorphine-induced activity,11,13,79,107,From such experiments there is evidence that characterization and detection of apomorphine-induced activity in rodents critically depends upon the test conditions employed.,10683478_3,-1,-1,2,652,-1
653,critically depends,15,17,119,137,From such experiments there is evidence that characterization and detection of apomorphine-induced activity in rodents critically depends upon the test conditions employed.,10683478_3,-1,-1,2,653,-1
654,test conditions,16,18,110,125,"In rats, detection of apomorphine-induced hyperactivity was facilitated by a period of acclimatization to the test conditions.",10683478_4,-1,-1,2,654,-1
657,home test cage,19,22,136,150,"In mice, apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage.",10683478_6,-1,-1,2,657,-1
658,Drug-induced gross,0,2,0,18,"Drug-induced gross activity counts were increased in the novel exploratory box only, while measures of stereotypic behavior were similar in both.",10683478_7,-1,-1,2,658,-1
661,apomorphine-induced locomotion,3,5,13,43,"By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box.",10683478_8,-1,-1,2,661,-1
662,exploratory box,11,13,76,91,"By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box.",10683478_8,-1,-1,2,662,-1
663,turnover ratios,1,3,9,24,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,2,663,-1
665,exposed to,20,22,87,97,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,2,665,-1
666,exploratory box,23,25,102,117,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,2,666,-1
667,home cage,29,31,141,150,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,2,667,-1
668,apomorphine-induced reductions,2,4,9,39,"However, apomorphine-induced reductions in striatal dopamine turnover were detected in both novel and home cage environments.",10683478_10,-1,-1,2,668,-1
680,antiestrogenic drug,6,8,21,40,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,-1,2,680,-1
683,TAM-induced,19,20,123,134,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,-1,2,683,-1
692,TAM-induced,28,29,184,195,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,2,692,-1
694,hemoglobin oxidation,10,12,64,84,This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.,10704919_7,-1,-1,2,694,-1
695,TAM-induced,17,18,118,129,This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.,10704919_7,-1,-1,2,695,-1
698,TAM-induced cell,20,22,119,135,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,2,698,-1
704,membrane-cytoskeleton,9,10,55,76,"However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially bound to band 3.",10704919_10,-1,-1,2,704,-1
728,cardiac (Na,18,20,111,122,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,-1,-1,2,728,-1
733,4-week,1,2,6,12,"After 4-week administration of L-NAME, the systolic blood pressure (SBP) increased by 36%.",10706004_5,-1,-1,2,733,-1
736,SBP,11,12,68,71,"After 4-week administration of L-NAME, the systolic blood pressure (SBP) increased by 36%.",10706004_5,-1,-1,2,736,-1
738,control value,11,13,64,77,"Two weeks after terminating the treatment, the SBP recovered to control value.",10706004_6,-1,-1,2,738,-1
741,Vmax values,16,18,79,90,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,-1,-1,2,741,-1
742,NO-deficient,21,22,108,120,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,-1,-1,2,742,-1
744,Vmax,6,7,32,36,"During activation with Na+, the Vmax remained unchanged, however the K(Na) increased by 50%, indicating a profound decrease in the affinity of the Na+-binding site in NO-deficient rats.",10706004_8,-1,-1,2,744,-1
747,NO-deficient,31,32,167,179,"During activation with Na+, the Vmax remained unchanged, however the K(Na) increased by 50%, indicating a profound decrease in the affinity of the Na+-binding site in NO-deficient rats.",10706004_8,-1,-1,2,747,-1
750,ATP-binding site,19,21,105,121,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,-1,-1,2,750,-1
751,Km value,27,29,152,160,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,-1,-1,2,751,-1
752,K(Na) value,1,4,4,15,The K(Na) value for Na+ returned to control value.,10706004_10,-1,-1,2,752,-1
754,control value,8,10,36,49,The K(Na) value for Na+ returned to control value.,10706004_10,-1,-1,2,754,-1
757,consequence of,16,18,123,137,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,-1,-1,2,757,-1
758,Na+-binding,19,20,151,162,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,-1,-1,2,758,-1
762,control values,6,8,36,50,"After recovery of blood pressure to control values, the extrusion of Na+ from cardiac cells was normalized, as revealed by restoration of the (Na,K)-ATPase activity.",10706004_12,-1,-1,2,762,-1
766,Effects of,0,2,0,10,Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.,10721819_0,-1,-1,2,766,-1
777,Bromocriptine-induced,0,1,0,21,"Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.",10721819_5,-1,-1,2,777,-1
785,isoproterenol-induced maximal,10,12,80,109,"In isolated perfused heart preparations from isoproterenol-pretreated rats, the isoproterenol-induced maximal increase in left ventricular systolic pressure was significantly reduced, compared with saline-pretreated rats (the EC50 of the isoproterenol-induced increase in left ventricular systolic pressure was enhanced approximately 22-fold).",10721819_8,-1,-1,2,785,-1
788,EC50,28,29,226,230,"In isolated perfused heart preparations from isoproterenol-pretreated rats, the isoproterenol-induced maximal increase in left ventricular systolic pressure was significantly reduced, compared with saline-pretreated rats (the EC50 of the isoproterenol-induced increase in left ventricular systolic pressure was enhanced approximately 22-fold).",10721819_8,-1,-1,2,788,-1
789,isoproterenol-induced increase,31,33,238,268,"In isolated perfused heart preparations from isoproterenol-pretreated rats, the isoproterenol-induced maximal increase in left ventricular systolic pressure was significantly reduced, compared with saline-pretreated rats (the EC50 of the isoproterenol-induced increase in left ventricular systolic pressure was enhanced approximately 22-fold).",10721819_8,-1,-1,2,789,-1
792,cardiac beta-adrenoceptor,25,27,184,209,"These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.",10721819_9,-1,-1,2,792,-1
811,ultrasound production,11,13,72,93,"Previous investigations have determined that, in response to clonidine, ultrasound production increases through the 2nd-week postpartum and decreases thereafter.",10737864_2,-1,-1,2,811,-1
815,effects of,8,10,42,52,"Therefore, in the present experiment, the effects of clonidine administration (0.5 mg/kg) on cardiac rate and ultrasound production were examined in 2-, 8-, 15-, and 20-day-old rats.",10737864_4,-1,-1,2,815,-1
819,ultrasound production,10,12,64,85,This experiment is discussed with regard to the hypothesis that ultrasound production is the acoustic by-product of a physiological maneuver that compensates for clonidine's detrimental effects on cardiovascular function.,10737864_6,-1,-1,2,819,-1
822,Recurrent use of,0,3,0,16,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,-1,-1,2,822,-1
828,associated with,13,15,83,98,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,2,828,-1
832,Transnational case-control study,3,6,12,44,"Data from a Transnational case-control study were used to assess the risk of VTE for the latter patterns of use, while accounting for duration of use.",10739826_2,-1,-1,2,832,-1
839,CI:0.3-1.2,18,21,84,94,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,2,839,-1
840,CI:0.7-2.4,38,41,173,183,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,2,840,-1
841,associated with,9,11,56,71,We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills.,10739826_6,-1,-1,2,841,-1
849,brush-evoked,13,14,84,96,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,-1,-1,2,849,-1
850,punctate-evoked,19,20,116,131,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,-1,-1,2,850,-1
852,double-blind,4,5,17,29,"In a randomized, double-blind, placebo-controlled, crossover study, we studied 12 volunteers in three experiments.",10743446_2,-1,-1,2,852,-1
853,placebo-controlled,6,7,31,49,"In a randomized, double-blind, placebo-controlled, crossover study, we studied 12 volunteers in three experiments.",10743446_2,-1,-1,2,853,-1
854,crossover study,8,10,51,66,"In a randomized, double-blind, placebo-controlled, crossover study, we studied 12 volunteers in three experiments.",10743446_2,-1,-1,2,854,-1
861,brush-evoked,22,23,109,121,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,-1,-1,2,861,-1
863,brush-evoked,6,7,34,46,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,-1,-1,2,863,-1
867,no effect,11,13,59,68,It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain.,10743446_9,-1,-1,2,867,-1
871,tacrolimus-related adverse effects,2,5,13,47,Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.,10743694_0,-1,-1,2,871,-1
876,cyclosporine-based immunosuppression,11,13,75,111,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,-1,-1,2,876,-1
887,insulin-dependent,11,12,59,76,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,2,887,-1
894,PTLD,77,78,347,351,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,2,894,-1
898,late-conversion,1,2,6,21,"Among late-conversion patients, 37 (90.2%) had improvement/resolution; in 4 (9.8%), adverse effects persisted.",10743694_7,-1,-1,2,898,-1
902,/- 362,13,15,66,72,"Sixty-two patients (88.6%) are alive with functioning grafts 686 +/- 362 days (range, 154-1433 days) after conversion.",10743694_9,-1,-1,2,902,-1
907,Wistar rats,12,14,92,103,Development of apomorphine-induced aggressive behavior: comparison of adult male and female Wistar rats.,10791295_0,-1,-1,2,907,-1
930,keratoconjunctivitis sicca,1,3,8,34,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,2,930,-1
934,prognostic indicators,8,10,54,75,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,-1,-1,2,934,-1
935,subarachnoid hemorrhage,5,7,26,49,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,-1,-1,2,935,-1
938,statistical model,13,15,62,79,"However, no study in the literature has reported the use of a statistical model to analyze the variables that influence outcome.",10807237_2,-1,-1,2,938,-1
939,control group,6,8,31,44,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,-1,2,939,-1
945,study group,6,8,29,40,RESULTS: The patients in the study group were significantly younger than the patients in the control group (P < 0.002).,10807237_6,-1,-1,2,945,-1
946,control group,16,18,93,106,RESULTS: The patients in the study group were significantly younger than the patients in the control group (P < 0.002).,10807237_6,-1,-1,2,946,-1
947,study group,4,6,19,30,"In patients in the study group, all aneurysms were located in the anterior circulation.",10807237_7,-1,-1,2,947,-1
949,/-,16,17,81,83,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,2,949,-1
950,/-,22,23,103,105,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,2,950,-1
951,Hess grade,2,4,9,19,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,2,951,-1
953,published literature,3,5,16,36,"Contrary to the published literature, this group did reasonably well with aggressive management.",10807237_12,-1,-1,2,953,-1
958,INWEST,12,13,79,85,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,2,958,-1
959,nimodipine-induced reduction,18,20,115,143,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,2,959,-1
961,BP,24,25,163,165,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,2,961,-1
970,BP,4,5,32,34,The correlation between average BP change during the first 2 days and the outcome at day 21 was analyzed.,10835440_4,-1,-1,2,970,-1
974,statistically significant,5,7,35,60,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,2,974,-1
975,systolic BP,9,11,74,85,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,2,975,-1
976,SBP,12,13,87,90,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,2,976,-1
977,diastolic BP,15,17,96,108,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,2,977,-1
978,DBP,18,19,110,113,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,2,978,-1
984,P=0,25,26,160,163,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,2,984,-1
988,n/N=9/26,54,55,245,253,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,-1,2,988,-1
989,n/N=62/92,71,72,322,331,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,-1,2,989,-1
1002,freely-moving,3,4,37,50,Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.,10840460_0,-1,-1,2,1002,-1
1009,antitumoral agent,6,8,26,43,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,2,1009,-1
1013,effects of,1,3,4,14,The effects of morphine (0.5 to 4 mg./kg.,10840460_5,-1,-1,2,1013,-1
1014,CP-induced,4,5,9,19,i.v.) on CP-induced behavioral modifications were tested administered alone and after naloxone (1 mg./kg.,10840460_6,-1,-1,2,1014,-1
1017,CP-induced,11,12,55,65,"Finally, to show that the bladder is essential for the CP-induced behavioral modifications, female rats also received CP at doses of 200 mg./kg.",10840460_9,-1,-1,2,1017,-1
1019,intravesical route,2,4,7,25,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,2,1019,-1
1020,intravesical route,2,4,7,25,by the intravesical route and of 5 mg./kg.,10840460_12,-1,-1,2,1020,-1
1025,dose-dependently,1,2,9,25,Morphine dose-dependently reversed these behavioral disorders.,10840460_14,-1,-1,2,1025,-1
1033,intravesically,0,1,0,14,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,2,1033,-1
1040,therapeutic approach,38,40,248,268,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,2,1040,-1
1044,average age,8,10,44,55,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,2,1044,-1
1047,level-I trauma center,41,44,221,242,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,2,1047,-1
1049,body weight,35,37,209,220,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,2,1049,-1
1054,average time,3,5,13,25,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,2,1054,-1
1055,intravenous administration,6,8,31,57,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,2,1055,-1
1056,average time,35,37,204,216,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,2,1056,-1
1057,average score,1,3,4,17,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,-1,2,1057,-1
1058,Children's Hospital,6,9,35,54,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,-1,2,1058,-1
1061,Ninety-nine percent (sixty-eight,0,4,0,32,Ninety-nine percent (sixty-eight) of the sixty-nine parents present during the reduction were pleased with the sedation and would allow it to be used again in a similar situation.,10901305_10,-1,-1,2,1061,-1
1062,sixty-nine parents,7,9,41,59,Ninety-nine percent (sixty-eight) of the sixty-nine parents present during the reduction were pleased with the sedation and would allow it to be used again in a similar situation.,10901305_10,-1,-1,2,1062,-1
1070,board-certified physicians,21,23,128,154,"Ketamine should only be used in an environment such as the emergency department, where proper one-on-one monitoring is used and board-certified physicians skilled in airway management are directly involved in the care of the patient.",10901305_16,-1,-1,2,1070,-1
1072,Prednisolone-induced muscle dysfunction,0,3,0,39,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,-1,-1,2,1072,-1
1074,effects of,3,5,20,30,"We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression.",10910842_2,-1,-1,2,1074,-1
1084,food restricted,9,11,37,52,A fourth group of rats was pair fed (food restricted) with the P100 rats for 7 days (FR group).,10910842_4,-1,-1,2,1084,-1
1087,nerve-evoked,5,6,14,26,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,2,1087,-1
1090,dose-response curves,18,20,93,113,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,2,1090,-1
1095,AChRs,39,40,231,236,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,2,1095,-1
1115,/-,22,23,106,108,The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.,10910842_9,-1,-1,2,1115,-1
1116,/-,32,33,135,137,The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.,10910842_9,-1,-1,2,1116,-1
1118,/-,41,42,162,164,The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.,10910842_9,-1,-1,2,1118,-1
1123,muscle mass (,5,8,36,49,"The evoked tensions correlated with muscle mass (r(2) = 0.32, P < 0.001), however, not with expression of AChR. The 50% effective dose of d-tubocurarine did not correlate with muscle mass or AChR expression.",10910842_11,-1,-1,2,1123,-1
1129,dose-dependent,10,11,77,91,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,2,1129,-1
1134,dose-dependent,7,8,41,55,We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.,10910842_14,-1,-1,2,1134,-1
1139,TMA,6,7,47,50,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,-1,2,1139,-1
1140,associated with,8,10,52,67,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,-1,2,1140,-1
1147,inciting agent,10,12,63,77,"However, for recipients of organ transplantation, removing the inciting agent is not without the attendant risk of precipitating acute rejection and graft loss.",11007689_3,-1,-1,2,1147,-1
1154,TMA,21,22,128,131,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,-1,-1,2,1154,-1
1162,TMA,14,15,97,100,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,-1,-1,2,1162,-1
1166,immunosuppressive agent,6,8,45,68,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,-1,-1,2,1166,-1
1184,off-periods,35,36,261,272,A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.,11009181_3,-1,-1,2,1184,-1
1186,off-time,7,8,63,71,"Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.",11009181_4,-1,-1,2,1186,-1
1187,add-on therapy,31,33,184,198,"Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.",11009181_4,-1,-1,2,1187,-1
1197,cholinergic system,11,13,65,83,"OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.",11022397_1,-1,-1,2,1197,-1
1199,Alzheimer's disease,31,34,189,208,"OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.",11022397_1,-1,-1,2,1199,-1
1202,tropicamide-induced,13,14,58,77,"This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.",11022397_2,-1,-1,2,1202,-1
1206,Randomized double-blind controlled trial,2,6,8,48,DESIGN: Randomized double-blind controlled trial.,11022397_4,-1,-1,2,1206,-1
1215,randomized order,7,9,30,46,All eye drops were given in a randomized order.,11022397_10,-1,-1,2,1215,-1
1218,Buschke Selective Reminding Test,31,35,161,193,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,-1,-1,2,1218,-1
1220,time points,6,8,32,43,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,2,1220,-1
1222,scopolamine-induced impairment,15,17,97,127,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,2,1222,-1
1224,young volunteers,10,12,65,81,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,2,1224,-1
1227,time point,19,21,126,136,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,2,1227,-1
1228,elderly group,1,3,4,17,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,2,1228,-1
1229,pilocarpine-induced net decrease,7,10,46,78,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,2,1229,-1
1231,young group,27,29,162,173,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,2,1231,-1
1232,young group,3,5,18,29,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,2,1232,-1
1233,elderly group,7,9,35,48,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,2,1233,-1
1234,scopolamine-induced impairment,11,13,61,91,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,2,1234,-1
1246,placebo-controlled,3,4,11,29,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,2,1246,-1
1251,nonsteroidal anti-inflammatory,37,39,212,242,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,2,1251,-1
1254,control subjects,13,15,84,100,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,2,1254,-1
1259,double-blind,17,18,107,119,"Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.",11027905_0,-1,-1,2,1259,-1
1260,double-dose study,21,23,132,149,"Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.",11027905_0,-1,-1,2,1260,-1
1266,slow bolus,1,3,2,12,"A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.",11027905_3,-1,-1,2,1266,-1
1267,subhypnotic doses,4,6,16,33,"A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.",11027905_3,-1,-1,2,1267,-1
1268,double-blind,31,32,160,172,"A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.",11027905_3,-1,-1,2,1268,-1
1269,double-dose study,35,37,185,202,"A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.",11027905_3,-1,-1,2,1269,-1
1272,Mini-Mental State Examination (MMSE),42,48,166,202,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1272,-1
1274,T0,64,65,279,281,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1274,-1
1275,T30,71,72,305,308,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1275,-1
1276,T60,77,78,323,326,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1276,-1
1277,T120,83,84,342,346,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1277,-1
1278,T180,90,91,366,370,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,2,1278,-1
1284,T30,8,9,49,52,A significant difference in MMSE was observed at T30 in patients who received 0.50 mg/kg of ketamine.,11027905_10,-1,-1,2,1284,-1
1302,steroid myopathy,2,4,9,25,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,2,1302,-1
1306,steroid myopathy,26,28,162,178,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,2,1306,-1
1323,Tac nephrotoxicity,8,10,47,65,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,2,1323,-1
1325,Tac toxicity,17,19,85,97,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,2,1325,-1
1328,PTLD,34,35,179,183,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,2,1328,-1
1335,Pneumocystis carinii pneumonia,6,9,39,69,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,2,1335,-1
1352,vigabatrin-attributed visual field constriction,14,18,120,167,"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.",11077455_0,-1,-1,2,1352,-1
1358,vigabatrin-attributed visual field loss,15,19,107,146,"The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.",11077455_2,-1,-1,2,1358,-1
1361,Humphrey Visual Field Analyzer,11,15,66,96,METHODS: The central and peripheral fields were examined with the Humphrey Visual Field Analyzer.,11077455_4,-1,-1,2,1361,-1
1379,associated with,9,11,59,74,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,-1,-1,2,1379,-1
1404,intracoronary injection,5,7,30,53,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,-1,-1,2,1404,-1
1410,ST,10,11,52,54,"Of the 51 patients, 7 patients showed asynergy with ST elevation.",11078231_8,-1,-1,2,1410,-1
1425,single-photon emission computed tomography imaging,17,22,114,164,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,-1,-1,2,1425,-1
1428,double-blind,4,5,20,32,"DESIGN: Randomized, double-blind, placebo-controlled trial.",11079278_2,-1,-1,2,1428,-1
1429,placebo-controlled trial,6,8,34,58,"DESIGN: Randomized, double-blind, placebo-controlled trial.",11079278_2,-1,-1,2,1429,-1
1433,standard protocol,8,10,61,78,INTERVENTION: Patients underwent dobutamine stress tests per standard protocol.,11079278_5,-1,-1,2,1433,-1
1435,no therapy,5,7,29,39,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,-1,-1,2,1435,-1
1437,resting predobutamine heart rate,6,10,34,66,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,2,1437,-1
1443,No significant,0,2,0,14,No significant differences were found in any parameter between metoprolol and metoprolol-glucagon.,11079278_11,-1,-1,2,1443,-1
1452,globus pallidus internus,13,16,73,97,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,-1,-1,2,1452,-1
1453,GPi,17,18,99,102,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,-1,-1,2,1453,-1
1457,timed tests,20,22,152,163,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,-1,-1,2,1457,-1
1458,Core Assessment Program,23,26,165,188,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,-1,-1,2,1458,-1
1462,ventral volume,44,46,222,236,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,2,1462,-1
1474,somatotopy,11,12,72,82,"We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias, especially along the dorsoventral trajectory used in pallidotomy.",11099450_7,-1,-1,2,1474,-1
1475,GPi,17,18,109,112,"We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias, especially along the dorsoventral trajectory used in pallidotomy.",11099450_7,-1,-1,2,1475,-1
1489,NSCLC,18,19,133,138,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,2,1489,-1
1495,NSCLC,30,31,175,180,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,-1,-1,2,1495,-1
1496,chemotherapy-naive,2,3,24,42,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1496,-1
1500,treated with,21,23,145,157,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1500,-1
1502,Day 1,38,40,234,239,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1502,-1
1504,Day 1,53,55,299,304,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1504,-1
1506,Days 1,69,71,373,379,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,2,1506,-1
1510,examinable,12,13,62,72,RESULTS: All the patients were examined for toxicity; 34 were examinable for response.,11135224_6,-1,-1,2,1510,-1
1512,confidence interval,14,16,65,84,"An objective response was observed in 73.5% of the patients (95% confidence interval [CI], 55.6-87.1%), including 4 complete responses (11.7%).",11135224_7,-1,-1,2,1512,-1
1513,intention-to-treat,2,3,13,31,"According to intention-to-treat, the overall response rate was 71.4% (95% CI, 53. 7-85.4%).",11135224_8,-1,-1,2,1513,-1
1514,response rate,6,8,45,58,"According to intention-to-treat, the overall response rate was 71.4% (95% CI, 53. 7-85.4%).",11135224_8,-1,-1,2,1514,-1
1524,NSCLC,20,21,127,132,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,-1,-1,2,1524,-1
1539,secondary to,5,7,41,53,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,-1,-1,2,1539,-1
1543,inbred mouse strains,8,11,64,84,Acute cocaine-induced seizures: differential sensitivity of six inbred mouse strains.,11166519_0,-1,-1,2,1543,-1
1545,inbred stains,7,9,37,50,Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine.,11166519_1,-1,-1,2,1545,-1
1554,C57BL/6J mice,9,11,41,54,"EEG recordings were made in SJL, A/J and C57BL/6J mice revealing a close correspondence between electrical activity and behavior.",11166519_6,-1,-1,2,1554,-1
1597,prescribing therapy,15,17,101,120,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,2,1597,-1
1603,BS line,11,13,70,77,Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to seizures induced by a single i.p.,11206082_1,-1,-1,2,1603,-1
1604,BR line,17,19,94,101,Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to seizures induced by a single i.p.,11206082_1,-1,-1,2,1604,-1
1605,i.p.,26,28,135,139,Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to seizures induced by a single i.p.,11206082_1,-1,-1,2,1605,-1
1609,diazepam-induced anxiolysis,2,4,12,39,"We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.",11206082_4,-1,-1,2,1609,-1
1611,diazepam-induced sedation,10,12,74,99,"We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.",11206082_4,-1,-1,2,1611,-1
1629,control groups,4,6,26,40,Rats were stratified into control groups and ADR-induced nephropathy groups.,11208990_4,-1,-1,2,1629,-1
1630,group 1,8,10,41,48,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,2,1630,-1
1631,group 2,16,18,80,87,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,2,1631,-1
1642,ADR-nephropathy,8,9,57,72,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,2,1642,-1
1643,ADR-nephropathy,13,14,97,112,In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.,11208990_10,-1,-1,2,1643,-1
1644,ADR-nephropathy,4,5,16,31,"However, in the ADR-nephropathy group, numerous apoptotic cells were identified in the tubulointerstitial areas.",11208990_12,-1,-1,2,1644,-1
1654,ADR-induced,17,18,107,118,CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR-induced nephrosis.,11208990_15,-1,-1,2,1654,-1
1656,barbiturate-induced narcosis,5,7,29,57,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,2,1656,-1
1657,drug-induced narcosis,16,18,95,116,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,2,1657,-1
1659,intraperitoneally,4,5,36,53,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,2,1659,-1
1660,pre-treated,8,9,69,80,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,2,1660,-1
1664,barbiturate narcosis,14,16,78,98,"In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.",11226639_4,-1,-1,2,1664,-1
1668,diazepam-induced narcosis,15,17,86,111,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,2,1668,-1
1671,mechanism of action,17,20,104,123,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,2,1671,-1
1678,Liposome Company,11,13,77,93,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,2,1678,-1
1679,Elan Corporation,14,16,95,111,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,2,1679,-1
1681,doxorubicin cardiotoxicity,27,29,187,213,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,2,1681,-1
1682,first-line treatment,35,37,263,283,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,2,1682,-1
1684,MBC,42,43,313,316,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,2,1684,-1
1694,CHF,23,24,171,174,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,2,1694,-1
1708,first-line therapy,30,32,224,242,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,2,1708,-1
1720,mg/kg)-induced,22,23,103,117,"L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.",11243580_5,-1,-1,2,1720,-1
1728,long-lasting reduction,18,20,85,107,Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.,11245434_2,-1,-1,2,1728,-1
1730,times/week,1,2,6,16,three times/week starting 7 days before carboplatin application.,11245434_4,-1,-1,2,1730,-1
1733,DS-sarcoma,8,9,47,57,"Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.",11245434_5,-1,-1,2,1733,-1
1734,hind food dorsum,19,22,99,115,"Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.",11245434_5,-1,-1,2,1734,-1
1737,treated with,3,5,17,29,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,-1,-1,2,1737,-1
1746,nonanemic controls,18,20,102,120,"In the group where anemia was prevented by rHuEPO treatment, growth delay was comparable with that of nonanemic controls (13.3 days).",11245434_9,-1,-1,2,1746,-1
1747,chemotherapy-induced,4,5,27,47,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,-1,2,1747,-1
1751,Propylthiouracil-induced perinuclear-staining,0,2,0,45,Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis.,11250767_0,-1,-1,2,1751,-1
1759,perinuclear-staining antineutrophil cytoplasmic autoantibodies,6,10,46,108,Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO).,11250767_5,-1,-1,2,1759,-1
1763,treated with,8,10,52,64,"Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of prednisone, which alleviated her symptoms.",11250767_6,-1,-1,2,1763,-1
1765,associated with,13,15,100,115,A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.,11250767_7,-1,-1,2,1765,-1
1777,systolic dysfunction losartan,3,6,14,43,Due to severe systolic dysfunction losartan was prescribed.,11256525_3,-1,-1,2,1777,-1
1818,secondary to,3,5,31,43,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,-1,-1,2,1818,-1
1827,dose-related,10,11,77,89,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,-1,2,1827,-1
1841,treated with,6,8,43,55,Thirteen patients with acute leukemia were treated with a DNR-containing regimen.,11279304_4,-1,-1,2,1841,-1
1844,radionuclide angiography,5,7,38,62,Cardiac functions were evaluated with radionuclide angiography before chemotherapies.,11279304_5,-1,-1,2,1844,-1
1848,radionuclide angiography,18,20,91,115,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,-1,-1,2,1848,-1
1855,radionuclide angiography,34,36,198,222,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,2,1855,-1
1863,Effects of,0,2,0,10,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,-1,-1,2,1863,-1
1871,acute L-type Ca(2) channel blockade,7,13,41,76,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,2,1871,-1
1873,consistent with,17,19,93,108,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,2,1873,-1
1875,Ca(2+) channel,24,28,135,149,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,2,1875,-1
1884,mean duration,11,13,63,76,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,2,1884,-1
1887,8+/-4,21,22,113,118,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,2,1887,-1
1890,control conditions,12,14,96,114,Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil.,11282081_7,-1,-1,2,1890,-1
1897,cycle length of AF,49,53,272,290,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,2,1897,-1
1899,AF cycle length,6,9,30,45,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,2,1899,-1
1909,normal dogs,6,8,38,49,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,-1,-1,2,1909,-1
1914,associated with,17,19,89,104,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,2,1914,-1
1921,headache-free,17,18,100,113,The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.,11284996_3,-1,-1,2,1921,-1
1924,area under,6,8,36,46,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,2,1924,-1
1932,NO-induced,5,6,33,43,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,-1,-1,2,1932,-1
1933,associated with,10,12,70,85,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,-1,-1,2,1933,-1
1935,torsade de pointes,1,4,20,38,Fluconazole-induced torsade de pointes.,11302406_0,-1,-1,2,1935,-1
1957,NSVT,23,24,168,172,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,2,1957,-1
1985,dna damage,4,6,22,32,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,2,1985,-1
1988,doxorubicin-induced,20,21,161,180,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,2,1988,-1
1997,(AAP)-induced,17,18,109,122,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,2,1997,-1
1999,(AMI)-induced,21,22,150,163,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,2,1999,-1
2000,(DOX)-induced,27,28,195,208,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,2,2000,-1
2007,i.p.,19,21,99,103,"For the cytoprotection study, animals were orally gavaged 100 mg/Kg GSPE for 7-10 days followed by i.p.",11334364_4,-1,-1,2,2007,-1
2012,serum chemistry,6,8,41,56,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,2,2012,-1
2016,endonuclease-dependent,24,25,124,146,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,2,2016,-1
2017,stained tissues,40,42,251,266,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,2,2017,-1
2031,DNA fragmentation,13,15,101,118,"Additionally, histopathological alterations mirrored both serum chemistry changes and the pattern of DNA fragmentation.",11334364_10,-1,-1,2,2031,-1
2046,AMI-induced,10,11,53,64,"Additionally, this may have been the first report on AMI-induced apoptotic death in the lung tissue.",11334364_14,-1,-1,2,2046,-1
2049,bioavailability,10,11,67,82,"Taken together, these events undoubtedly establish GSPE's abundant bioavailability, and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo.",11334364_15,-1,-1,2,2049,-1
2052,associated with,3,5,38,53,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,2,2052,-1
2070,interfere with,15,17,108,122,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,2,2070,-1
2072,DSM-IV criteria,8,10,44,59,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,2,2072,-1
2074,naturalistic treatment,14,16,84,106,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,2,2074,-1
2080,Semi-structured Affective,93,95,545,570,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,2,2080,-1
2090,associated with,29,31,191,206,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,-1,-1,2,2090,-1
2092,associated with,7,9,44,59,CONCLUSION: The frequency of mood switching associated with acute antidepressant therapy may be reduced by lithium treatment.,11379838_9,-1,-1,2,2092,-1
2102,PTCR,21,22,144,148,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,2,2102,-1
2103,prospective study,13,15,82,99,"Although such an association is of practical and theoretical importance, only one prospective study has tried to confirm it.",11391224_2,-1,-1,2,2103,-1
2125,Henoch-Schonlein nephritis,14,16,96,122,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,2,2125,-1
2130,PTCR,15,16,99,103,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,2,2130,-1
2132,PTCR,24,25,143,147,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,2,2132,-1
2141,diabetes insipidus,8,10,49,67,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,-1,2,2141,-1
2142,diabetes insipidus,4,6,26,44,A case of lithium-induced diabetes insipidus is reported.,1141447_1,-1,-1,2,2142,-1
2144,cells lining,9,11,60,72,At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron.,1141447_2,-1,-1,2,2144,-1
2146,Caffeine-induced,0,1,0,16,Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products.,11419773_0,-1,-1,2,2146,-1
2151,guarana health drink,22,25,158,178,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,2,2151,-1
2156,anti-cocaine effects,13,15,119,139,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,2,2156,-1
2160,Swiss Webster mice,13,16,89,107,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,2,2160,-1
2174,pre-treatment,4,5,23,36,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,2,2174,-1
2178,post-treatment,2,3,10,24,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,-1,-1,2,2178,-1
2180,cocaine-induced lethality,6,8,46,71,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,-1,-1,2,2180,-1
2193,anti-cocaine,7,8,44,56,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,-1,-1,2,2193,-1
2199,cocaine-induced behaviors,18,20,112,137,"Together, the data suggests that functional antagonism of sigma receptors is capable of attenuating a number of cocaine-induced behaviors.",11426838_10,-1,-1,2,2199,-1
2214,associated with,2,4,21,36,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,2,2214,-1
2227,ropivacaine-infused rats,10,12,74,98,"Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats.",11524350_0,-1,-1,2,2227,-1
2231,lethal doses,9,11,55,67,We also compared the ability to resuscitate rats after lethal doses of these local anesthetics.,11524350_2,-1,-1,2,2231,-1
2241,cumulative doses,1,3,4,20,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,2,2241,-1
2245,cumulative doses,1,3,4,20,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,2,2245,-1
2269,effects of,4,6,50,60,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,-1,-1,2,2269,-1
2275,Torsades de pointes,0,3,0,19,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,2,2275,-1
2296,drug exposures,28,30,170,184,"On the basis that only free drug in the systemic circulation will elicit a pharmacological response target, free concentrations in plasma were selected to mimic the free drug exposures in man.",11569530_6,-1,-1,2,2296,-1
2297,Infusion regimens,0,2,0,17,Infusion regimens were designed that rapidly achieved and maintained target-free concentrations of these drugs in plasma and data on the relationship between free concentration and changes in MAPD were obtained for these compounds.,11569530_7,-1,-1,2,2297,-1
2298,target-free,9,10,69,80,Infusion regimens were designed that rapidly achieved and maintained target-free concentrations of these drugs in plasma and data on the relationship between free concentration and changes in MAPD were obtained for these compounds.,11569530_7,-1,-1,2,2298,-1
2311,data underline,1,3,6,20,These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic/pharmacodynamic studies.,11569530_11,-1,-1,2,2311,-1
2312,therapeutic ratio,8,10,46,63,These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic/pharmacodynamic studies.,11569530_11,-1,-1,2,2312,-1
2316,AIDS.OBJECTIVE,7,8,50,64,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,2,2316,-1
2321,intravenous infusion,13,15,97,117,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,2,2321,-1
2329,associated with,8,10,38,53,"To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.",11573852_10,-1,-1,2,2329,-1
2346,calcineurin-free immunosuppression,5,7,40,74,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,-1,-1,2,2346,-1
2358,immunosuppressive agents,3,5,23,47,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,-1,2,2358,-1
2364,paper reviews,1,3,5,18,This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients.,11583940_7,-1,-1,2,2364,-1
2368,accidental intrathecal vincristin administration,4,8,33,81,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,2,2368,-1
2377,Neurofilament,9,10,68,81,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,-1,-1,2,2377,-1
2407,associated with,8,10,48,63,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,2,2407,-1
2420,Intravenous administration,0,2,0,26,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,-1,-1,2,2420,-1
2425,15-minute infusion,21,23,136,154,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,-1,-1,2,2425,-1
2426,double-blind study,9,11,49,67,"METHODS: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital.",11679859_2,-1,-1,2,2426,-1
2428,central-city teaching hospital,17,20,101,131,"METHODS: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital.",11679859_2,-1,-1,2,2428,-1
2430,Study participants,0,2,0,18,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,2,2430,-1
2431,bolus group,18,20,126,137,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,2,2431,-1
2433,intravenous infusion,36,38,216,236,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,2,2433,-1
2434,15-minute period,40,42,246,262,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,2,2434,-1
2435,infusion group,43,45,264,278,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,2,2435,-1
2436,akathisia,10,11,67,76,The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration.,11679859_5,-1,-1,2,2436,-1
2441,study participants,7,9,37,55,Seventy-three percent (73/99) of the study participants were treated for headache and 70% (70/99) for nausea.,11679859_10,-1,-1,2,2441,-1
2442,bolus group,2,4,7,18,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,-1,-1,2,2442,-1
2444,infusion group,21,23,83,97,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,-1,-1,2,2444,-1
2445,confidence interval,29,31,116,135,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,-1,-1,2,2445,-1
2446,infusion groups,6,8,37,52,The difference between the bolus and infusion groups in the percentage of participants who saw a 50% reduction in their headache intensity within 30 minutes was 11.8% (95% CI -9.6% to 33.3%).,11679859_12,-1,-1,2,2446,-1
2487,double-masked,34,35,177,190,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,-1,2,2487,-1
2499,statistically significant,31,33,189,214,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,-1,-1,2,2499,-1
2503,data quantify,1,3,6,19,These data quantify the modest bradycardia associated with ophthalmic beta-blocker therapy in a typical patient population on therapy for glaucoma.,11704023_11,-1,-1,2,2503,-1
2504,associated with,6,8,43,58,These data quantify the modest bradycardia associated with ophthalmic beta-blocker therapy in a typical patient population on therapy for glaucoma.,11704023_11,-1,-1,2,2504,-1
2511,cost-effectiveness,10,11,80,98,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,2,2511,-1
2517,Combination therapy,0,2,0,19,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,-1,2,2517,-1
2528,Decision-analytic techniques,0,2,0,28,Decision-analytic techniques were used to estimate the cost of treating RIHA.,11705128_5,-1,-1,2,2528,-1
2532,treated with,26,28,119,131,"RESULTS: RIHA, defined as a reduction in hemoglobin to less than 100 g/L, occurs in approximately 7% to 9% of patients treated with combination therapy.",11705128_7,-1,-1,2,2532,-1
2534,standard of care,1,4,4,20,The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.,11705128_8,-1,-1,2,2534,-1
2536,clinically significant,7,9,41,63,We estimated the direct cost of treating clinically significant RIHA to be  170 per patient receiving combination therapy per 48-week treatment course (range  68- 692).,11705128_9,-1,-1,2,2536,-1
2539,48-week treatment course,20,23,126,150,We estimated the direct cost of treating clinically significant RIHA to be  170 per patient receiving combination therapy per 48-week treatment course (range  68- 692).,11705128_9,-1,-1,2,2539,-1
2540,one-way sensitivity analyses,4,7,19,47,The results of the one-way sensitivity analyses ranged from  57 to  317.,11705128_10,-1,-1,2,2540,-1
2542,clinically significant,22,24,112,134,"In comparison, the cost of 48 weeks of combination therapy is  16,459. CONCLUSIONS: The direct cost of treating clinically significant RIHA is 1% ( 170/ 16,459) of drug treatment costs.",11705128_11,-1,-1,2,2542,-1
2544,drug treatment costs,33,36,164,184,"In comparison, the cost of 48 weeks of combination therapy is  16,459. CONCLUSIONS: The direct cost of treating clinically significant RIHA is 1% ( 170/ 16,459) of drug treatment costs.",11705128_11,-1,-1,2,2544,-1
2546,real-world population,15,17,84,105,Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.,11705128_12,-1,-1,2,2546,-1
2553,in vivo,6,8,45,52,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,2,2553,-1
2558,quantitation,10,11,68,80,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,2,2558,-1
2569,Molecularly,0,1,0,11,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,-1,-1,2,2569,-1
2572,/-,8,9,37,39,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,2,2572,-1
2586,third-line treatment,34,36,218,238,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,-1,2,2586,-1
2588,Older reports,0,2,0,13,Older reports suggest an objective response rate of 8% when 60-120 mg/m2 of cisplatin is administered every 3-4 weeks.,11745184_1,-1,-1,2,2588,-1
2593,associated with,13,15,95,110,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,-1,2,2593,-1
2626,response rate,8,10,51,64,Six partial responses were observed for an overall response rate of 16%.,11745184_13,-1,-1,2,2626,-1
2627,stopped treatment,6,8,20,37,Most patients (57%) stopped treatment because of disease progression.,11745184_14,-1,-1,2,2627,-1
2649,population-based,50,51,302,318,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,2,2649,-1
2665,confidence interval,51,53,287,306,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,2,2665,-1
2667,confidence interval,9,11,44,63,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,-1,-1,2,2667,-1
2669,confidence interval,28,30,156,175,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,-1,-1,2,2669,-1
2675,confidence interval,33,35,173,192,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,-1,-1,2,2675,-1
2691,capsaicin-evoked,27,28,154,170,"The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.",11752998_2,-1,-1,2,2691,-1
2692,Drug Administration,5,7,28,47,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,2,2692,-1
2695,open-label,26,27,163,173,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,2,2695,-1
2696,dose-escalating trial,28,30,175,196,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,2,2696,-1
2697,double-blind,41,42,251,263,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,2,2697,-1
2698,placebo-controlled trial,43,45,265,289,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,2,2698,-1
2699,Cerebrospinal fluid,0,2,0,19,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,2,2699,-1
2709,h.,30,31,205,207,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,2,2709,-1
2710,residence time,34,36,221,235,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,2,2710,-1
2713,consistent with,4,6,27,42,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,-1,-1,2,2713,-1
2714,preliminary reports,9,11,60,79,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,-1,-1,2,2714,-1
2716,cerebrospinal fluid,27,29,176,195,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,-1,-1,2,2716,-1
2748,control patients,2,4,14,30,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,2,2748,-1
2759,odds ratios,43,45,287,298,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,2,2759,-1
2763,control group,37,39,185,198,"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.",11773892_12,-1,-1,2,2763,-1
2770,high rate,16,18,82,91,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,2,2770,-1
2780,cortical application,3,5,29,49,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,2,2780,-1
2782,Fibrin sealants,2,4,12,27,BACKGROUND: Fibrin sealants (FS) derived from human plasma are frequently used in neurosurgery.,11807648_1,-1,-1,2,2782,-1
2785,natural fibrinolysis inhibitor,13,16,71,101,"In order to increase clot stability, FS typically contain aprotinin, a natural fibrinolysis inhibitor.",11807648_2,-1,-1,2,2785,-1
2818,platelet factor 4,14,17,107,124,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,2,2818,-1
2828,re-exposure,42,43,225,236,"On readmission, 11 patients received therapeutic heparin, which worsened the patients' clinical condition and, in all 11 cases, decreased the platelet count (mean at readmission, 143 x 10(9) cells/L; mean nadir after heparin re-exposure, 39 x 10(9) cells/L).",11827497_11,-1,-1,2,2828,-1
2830,heparin-induced antibodies,5,7,31,57,Results of serologic tests for heparin-induced antibodies were positive in all patients.,11827497_12,-1,-1,2,2830,-1
2831,alternative anticoagulants,3,5,31,57,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,-1,-1,2,2831,-1
2832,thrombolytic drugs,10,12,73,91,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,-1,-1,2,2832,-1
2837,risperidone-induced,2,3,13,32,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,-1,-1,2,2837,-1
2849,associated with,10,12,76,91,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,2,2849,-1
2853,risperidone-induced,6,7,38,57,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,-1,-1,2,2853,-1
2862,risperidone-induced elevations,29,31,149,179,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,2,2862,-1
2867,/-,57,58,290,292,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,2,2867,-1
2868,serum prolactin levels,1,4,5,27,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,-1,-1,2,2868,-1
2869,/-,13,14,72,74,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,-1,-1,2,2869,-1
2873,/-,10,11,57,59,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,-1,-1,2,2873,-1
2875,/-,25,26,133,135,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,-1,-1,2,2875,-1
2879,risperidone-induced,10,11,60,79,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,-1,-1,2,2879,-1
2882,exposure to,11,13,69,80,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,-1,-1,2,2882,-1
2885,right rotator cuff,19,22,122,140,CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia.,11847945_2,-1,-1,2,2885,-1
2888,peak concentration,7,9,47,65,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,-1,-1,2,2888,-1
2895,halothane hepatitis,11,13,71,90,"DISCUSSION: The clinical and histologic picture of this case resembles halothane hepatitis, which has a significant mortality rate.",11847945_7,-1,-1,2,2895,-1
2897,anesthetic agent,6,8,34,50,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_8,-1,-1,2,2897,-1
2901,torsade de pointes,14,17,77,95,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,2,2901,-1
2904,prokinetic drug,13,15,86,101,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,-1,-1,2,2904,-1
2920,receptor-mediated signaling,7,9,29,56,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,2,2920,-1
2934,dopaminergic,3,4,14,26,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,-1,-1,2,2934,-1
2938,anti-amnesic effects,7,9,63,83,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,-1,-1,2,2938,-1
2941,memory-enhancing neurosteroids,14,16,79,109,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,2,2941,-1
2946,GABAergic systems,18,20,129,146,The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems.,11860495_2,-1,-1,2,2946,-1
2948,positive modulator,10,12,59,77,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,-1,-1,2,2948,-1
2951,negative modulator,20,22,127,145,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,-1,-1,2,2951,-1
2955,amnesic-like effects,8,10,39,59,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,-1,-1,2,2955,-1
2961,GABA(A)R function,28,30,178,195,"To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function.",11860495_5,-1,-1,2,2961,-1
2974,effects of,10,12,46,56,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,-1,-1,2,2974,-1
2987,nuclear enzyme,3,5,18,32,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,2,2987,-1
2989,oxidant-mediated DNA damage,12,15,71,98,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,2,2989,-1
2999,DOX-induced,13,14,72,83,"Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.",11861791_3,-1,-1,2,2999,-1
3003,genetic deletion,9,11,48,64,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,2,3003,-1
3004,pharmacological inhibition,12,14,68,94,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,2,3004,-1
3015,PARP-1+/+ mice,13,15,96,110,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,-1,-1,2,3015,-1
3017,BALB/c mice,5,7,38,49,Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle.,11861791_7,-1,-1,2,3017,-1
3023,DOX-induced,6,7,43,54,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,2,3023,-1
3025,metalloproteinase,19,20,138,155,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,2,3025,-1
3032,associated with,13,15,101,116,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,2,3032,-1
3056,mouse exo utero development system,9,14,79,113,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,-1,-1,2,3056,-1
3060,late-gestation,19,20,121,135,We examined this theory using the exo utero development system that allows direct and sequential observations of mid- to late-gestation mouse embryos.,11875660_2,-1,-1,2,3060,-1
3064,re-observed,25,26,135,146,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,-1,-1,2,3064,-1
3077,surface ectoderm,19,21,136,152,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,-1,2,3077,-1
3094,substantia nigra nucleus,15,18,107,131,Erectile function was assessed 6 weeks following uni- and bilateral injections of 6-hydroxydopamine in the substantia nigra nucleus of the brain.,11890511_1,-1,-1,2,3094,-1
3095,uni-,15,16,90,94,Behavioral apomorphine-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals.,11890511_2,-1,-1,2,3095,-1
3098,electrical stimulation,4,6,36,58,"Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals.",11890511_3,-1,-1,2,3098,-1
3099,cavernous nerve,8,10,66,81,"Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals.",11890511_3,-1,-1,2,3099,-1
3100,substantia nigra,3,5,15,31,Lesions of the substantia nigra were confirmed by histology.,11890511_4,-1,-1,2,3100,-1
3101,substantia nigra,12,14,80,96,Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats.,11890511_5,-1,-1,2,3101,-1
3102,substantia nigra,3,5,15,31,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,2,3102,-1
3108,Infarct-avid radiopharmaceuticals,0,2,0,33,Infarct-avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction.,11897407_1,-1,-1,2,3108,-1
3113,infarct-avid,2,3,6,18,A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ.,11897407_3,-1,-1,2,3113,-1
3123,S(h)UV,10,11,88,94,Thirty minutes after 99mTc-glucarate administration the standardised heart uptake value S(h)UV was 4.7 in infarcted rat heart which is six times more than in normal rats.,11897407_7,-1,-1,2,3123,-1
3128,ideal agent,22,24,119,130,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,2,3128,-1
3129,effects of,5,7,22,32,"In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated.",11900788_1,-1,-1,2,3129,-1
3130,dose-dependent,6,7,36,50,Morphine but not nicotine induced a dose-dependent catalepsy.,11900788_2,-1,-1,2,3130,-1
3131,Intraperitoneal,0,1,0,15,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,-1,-1,2,3131,-1
3136,Intraperitoneal,0,1,0,15,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,-1,-1,2,3136,-1
3137,intraperitoneal,7,8,52,67,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,-1,-1,2,3137,-1
3138,intracerebroventricular,9,10,71,94,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,-1,-1,2,3138,-1
3141,morphine catalepsy,4,6,22,40,"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.",11900788_7,-1,-1,2,3141,-1
3145,Force overflow,0,2,0,14,Force overflow and levodopa-induced dyskinesias in Parkinson's disease.,11912119_0,-1,-1,2,3145,-1
3154,grip-lift paradigm,19,21,99,117,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,-1,-1,2,3154,-1
3160,ON-,31,32,116,119,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,2,3160,-1
3162,Parkinson's disease - LID,9,14,45,70,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,2,3162,-1
3169,ON-state,11,12,77,85,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,-1,2,3169,-1
3170,peak force,17,19,101,111,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,-1,2,3170,-1
3175,ON-drug,14,15,88,95,A close relationship was seen between the overshooting of forces and dyskinesias in the ON-drug condition.,11912119_12,-1,-1,2,3175,-1
3184,sustained-release formulation,3,5,9,38,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,-1,-1,2,3184,-1
3192,treated with,3,5,24,36,Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.,11928786_9,-1,-1,2,3192,-1
3193,treated with,12,14,93,105,Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.,11928786_9,-1,-1,2,3193,-1
3199,Glomerular epithelial protein 1,0,4,0,31,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,-1,-1,2,3199,-1
3201,podocyte receptor membrane protein,9,13,46,80,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,-1,-1,2,3201,-1
3211,RNase protection assay,31,34,188,210,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,-1,-1,2,3211,-1
3213,Puromycin aminonucleoside nephrosis,0,3,0,35,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,2,3213,-1
3214,intraperitoneal,7,8,58,73,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,2,3214,-1
3224,/- 79.6 x,17,20,77,86,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,-1,-1,2,3224,-1
3225,/-,35,36,144,146,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,-1,-1,2,3225,-1
3227,/-,14,15,83,85,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,-1,-1,2,3227,-1
3228,/-,19,20,97,99,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,-1,-1,2,3228,-1
3242,reserpine-treated mice,5,7,32,54,Behavioral effects of MK-801 on reserpine-treated mice.,11999899_0,-1,-1,2,3242,-1
3243,effects of,1,3,4,14,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,2,3243,-1
3248,dopamine-related behaviors,20,22,119,145,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,2,3248,-1
3261,reserpine-treated mice,11,13,71,93,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,-1,2,3261,-1
3263,control mice,14,16,83,95,"On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.",11999899_8,-1,-1,2,3263,-1
3266,observation test,11,13,54,70,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,2,3266,-1
3270,effects of,46,48,261,271,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,2,3270,-1
3272,tardive dsykinesia,26,28,172,190,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,2,3272,-1
3273,glutamatergic blockage,1,3,4,26,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,-1,-1,2,3273,-1
3277,Risperidone-associated,0,1,0,22,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,2,3277,-1
3289,six-month,2,3,9,18,"During a six-month follow-up period, there was no recurrence of visual disturbances.",12013711_5,-1,-1,2,3289,-1
3291,self-limiting,11,12,63,76,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,-1,-1,2,3291,-1
3294,interfere with,23,25,145,159,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,-1,-1,2,3294,-1
3295,case reports,4,6,25,37,Conclusions based on two case reports should be taken with appropriate caution.,12013711_7,-1,-1,2,3295,-1
3298,antithymocyte,4,5,23,36,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,-1,-1,2,3298,-1
3308,antiepileptic medication,5,7,35,59,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,-1,-1,2,3308,-1
3310,secondary to,13,15,89,101,Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.,12042105_2,-1,-1,2,3310,-1
3314,calcium phosphate nephrolithiasis,28,31,165,198,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,2,3314,-1
3318,chronic treatment,8,10,74,91,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,-1,-1,2,3318,-1
3319,antinociceptive,4,5,24,39,This work evaluates the antinociceptive and constipating effects of the combination of 3.2 mg/kg s.c.,12063090_1,-1,-1,2,3319,-1
3322,chronically treated,4,6,25,44,metamizol in acutely and chronically treated (once a day for 12 days) rats.,12063090_3,-1,-1,2,3322,-1
3323,antinociceptive effects,5,7,17,40,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,-1,-1,2,3323,-1
3329,antinociceptive,10,11,78,93,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,2,3329,-1
3330,139+/-36 units area,26,29,179,198,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,2,3330,-1
3332,combination-induced antinociception,18,20,109,144,Antinociceptive effect of morphine was reduced in chronically treated rats (39+/-10 vs. 18+/-5 au) while the combination-induced antinociception was remained similar as an acute treatment (298+/-7 vs. 280+/-17 au).,12063090_6,-1,-1,2,3332,-1
3333,acute treatment,25,27,172,187,Antinociceptive effect of morphine was reduced in chronically treated rats (39+/-10 vs. 18+/-5 au) while the combination-induced antinociception was remained similar as an acute treatment (298+/-7 vs. 280+/-17 au).,12063090_6,-1,-1,2,3333,-1
3334,opioidergic system,25,27,153,171,"Acute antinociceptive effects of the combination were partially prevented by 3.2 mg/kg naloxone s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed.",12063090_7,-1,-1,2,3334,-1
3336,chronic treatment,18,20,104,121,"In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.",12063090_8,-1,-1,2,3336,-1
3349,drug use,23,25,138,146,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,2,3349,-1
3365,associated with,36,38,238,253,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,-1,2,3365,-1
3381,AZT-treated mice,29,31,167,183,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,-1,-1,2,3381,-1
3387,antagonistic effect,6,8,34,53,We tested the hypothesis that the antagonistic effect of IL-3 and EPO on erythroid cells may be mediated by endothelial cells.,12090760_3,-1,-1,2,3387,-1
3399,pre-treated,16,17,115,126,There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO.,12090760_5,-1,-1,2,3399,-1
3403,ultrafiltration,6,7,51,66,Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.,12090760_6,-1,-1,2,3403,-1
3415,mixture).A,11,12,65,75,"Ketamine in war/tropical surgery (a final tribute to the racemic mixture).A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients, aged from 6 weeks to 70 years, undergoing limb and abdominal surgery including caesarian sections and interventions in neonates.",12091028_0,-1,-1,2,3415,-1
3417,Somalia civil,24,26,171,184,"Ketamine in war/tropical surgery (a final tribute to the racemic mixture).A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients, aged from 6 weeks to 70 years, undergoing limb and abdominal surgery including caesarian sections and interventions in neonates.",12091028_0,-1,-1,2,3417,-1
3418,north Uganda,31,33,204,216,"Ketamine in war/tropical surgery (a final tribute to the racemic mixture).A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients, aged from 6 weeks to 70 years, undergoing limb and abdominal surgery including caesarian sections and interventions in neonates.",12091028_0,-1,-1,2,3418,-1
3421,sophisticated equipment,12,14,65,88,Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air/oxygen only.,12091028_1,-1,-1,2,3421,-1
3422,pulse oximeters,16,18,97,112,Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air/oxygen only.,12091028_1,-1,-1,2,3422,-1
3423,spontaneous ventilation breathing air/oxygen,23,27,143,187,Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air/oxygen only.,12091028_1,-1,-1,2,3423,-1
3424,premedication,1,2,6,19,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,-1,-1,2,3424,-1
3426,local anaesthesia,7,9,54,71,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,-1,-1,2,3426,-1
3433,anaesthetic blocks,1,3,6,24,Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.,12091028_5,-1,-1,2,3433,-1
3435,antisialogue,1,2,3,15,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,-1,-1,2,3435,-1
3446,association with,11,13,74,90,"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children, where case fatality rates as high as 50% to 80% have been reported.",12093990_2,-1,-1,2,3446,-1
3460,DNA viruses,14,16,83,94,"Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.",12093990_6,-1,-1,2,3460,-1
3461,in vitro,22,24,145,153,"Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.",12093990_6,-1,-1,2,3461,-1
3469,DESIGN/METHODS,0,1,0,14,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,-1,-1,2,3469,-1
3481,compassionate-use protocol,6,8,44,70,Intravenous ribavirin was administered on a compassionate-use protocol.,12093990_16,-1,-1,2,3481,-1
3498,antiviral treatment,20,22,134,153,"Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.",12093990_23,-1,-1,2,3498,-1
3501,treated with,10,12,62,74,CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.,12093990_24,-1,-1,2,3501,-1
3502,diagnostic techniques,5,7,32,53,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,-1,2,3502,-1
3503,polymerase chain reaction,10,13,63,88,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,-1,2,3503,-1
3506,anti-adenoviral therapies,25,27,167,192,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,-1,-1,2,3506,-1
3507,toxic therapy,43,45,289,302,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,-1,-1,2,3507,-1
3513,treated with,13,15,81,93,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,-1,-1,2,3513,-1
3515,intravenous fluids,18,20,117,135,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,-1,-1,2,3515,-1
3516,Eighteen hours,0,2,0,14,Eighteen hours after the overdose he had two generalised tonic-clonic seizures.,12101159_3,-1,-1,2,3516,-1
3521,diltiazem overdose,16,18,98,116,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,-1,-1,2,3521,-1
3546,case reports,8,10,41,53,RESULTS: There were eight series and six case reports.,12109865_6,-1,-1,2,3546,-1
3558,mid-,2,3,8,12,Data on mid- and long-term LMWH administration in these patients are sparse.,12109865_12,-1,-1,2,3558,-1
3567,intravenous injection,5,7,28,49,We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.,12139551_1,-1,-1,2,3567,-1
3570,h.,4,5,21,23,"five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.",12139551_3,-1,-1,2,3570,-1
3592,fibroblast growth factor,28,31,180,204,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,2,3592,-1
3596,intravenous infusion,8,10,50,70,Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.,12180796_2,-1,-1,2,3596,-1
3599,ED-1-positive cells,11,13,87,106,"Irrespective of theophylline administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.",12180796_3,-1,-1,2,3599,-1
3603,ED-1-positive cells,29,31,196,215,"Irrespective of theophylline administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.",12180796_3,-1,-1,2,3603,-1
3606,ED-1-positive cells,42,44,268,287,"Irrespective of theophylline administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.",12180796_3,-1,-1,2,3606,-1
3608,peak expression,5,7,31,46,"These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models.",12180796_4,-1,-1,2,3608,-1
3614,iNOS,15,16,80,84,"On the other hand, TGF-beta1 was not considered to have a suppressive effect on iNOS expression in these models.",12180796_5,-1,-1,2,3614,-1
3616,convulsant,8,9,75,85,The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.,12198388_0,-1,-1,2,3616,-1
3620,septo-hippocampal cholinergic pathway,3,6,16,53,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,-1,-1,2,3620,-1
3624,cholinergic activity,5,7,31,51,"Thus, the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity.",12198388_2,-1,-1,2,3624,-1
3630,timed tail vein,10,13,66,81,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,-1,-1,2,3630,-1
3634,reverse dialysis twice,4,7,25,47,"Potassium was applied by reverse dialysis twice, separated by 75 min.",12198388_6,-1,-1,2,3634,-1
3640,basal release,10,12,58,71,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,2,3640,-1
3661,postsynaptic receptor desensitization,16,19,106,143,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,-1,-1,2,3661,-1
3666,nociceptive muscle,8,10,52,70,This study tested the hypothesis that activation of nociceptive muscle afferent fibers would be linked to an increased excitability of the human jaw-stretch reflex and whether this process would be sensitive to length and velocity of the stretch.,12202650_2,-1,-1,2,3666,-1
3673,stretch device,13,15,87,101,"Short-latency reflex responses were evoked in the masseter and temporalis muscles by a stretch device with different velocities and displacements before, during, and after the pain.",12202650_4,-1,-1,2,3673,-1
3688,rat's,18,20,109,114,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,-1,-1,2,3688,-1
3697,selective group II,32,35,206,224,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,-1,-1,2,3697,-1
3698,haloperidol-treated animals,44,46,280,307,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,-1,-1,2,3698,-1
3699,AIDA,0,1,0,4,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,2,3699,-1
3707,Effects of,0,2,0,10,Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.,12369736_0,-1,-1,2,3707,-1
3714,subregions,16,17,103,113,The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.,12369736_1,-1,-1,2,3714,-1
3717,Wistar rats,1,3,5,16,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,2,3717,-1
3724,accumbal subregion,4,6,19,37,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,2,3724,-1
3754,iceberg?The,12,13,56,67,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,-1,-1,2,3754,-1
3762,angiogenic factor,24,26,150,167,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,-1,-1,2,3762,-1
3763,vascular endothelial growth factor (VEGF)165,27,32,169,213,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,-1,-1,2,3763,-1
3764,intra-patient dose,15,17,83,101,PATIENTS AND METHODS: 29 patients were enrolled on a study of thalidomide using an intra-patient dose escalation schedule.,12448656_2,-1,-1,2,3764,-1
3766,status 2,16,18,92,100,Fifty-nine per cent of patients had had previous therapy with IL-2 and 52% were performance status 2 or 3.,12448656_4,-1,-1,2,3766,-1
3773,consistent with,5,7,30,45,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,-1,-1,2,3773,-1
3776,lower doses,16,18,101,112,"Administration of doses over 800 mg/day was difficult to achieve in this patient population, however lower doses were practical.",12448656_10,-1,-1,2,3776,-1
3784,control group,4,6,14,27,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,2,3784,-1
3796,Twenty-four hours,0,2,0,17,"Twenty-four hours later, any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management.",12452237_7,-1,-1,2,3796,-1
3797,structured questionaire,12,14,77,100,"Twenty-four hours later, any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management.",12452237_7,-1,-1,2,3797,-1
3833,drug intake,29,31,185,196,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,2,3833,-1
3839,active treatments,1,3,5,22,Both active treatments were well tolerated.,12464714_12,-1,-1,2,3839,-1
3846,in vivo,24,26,138,145,"We generated beta2(-/-) mice to investigate the role of beta2 in control of sodium channel density, localization, and function in neurons in vivo.",12481039_2,-1,-1,2,3846,-1
3849,sodium channels,17,19,109,124,Measurements of [(3)H]saxitoxin (STX) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.,12481039_3,-1,-1,2,3849,-1
3854,compound action,4,6,20,35,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,-1,-1,2,3854,-1
3855,optic nerve,8,10,49,60,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,-1,-1,2,3855,-1
3857,sodium channels,34,36,219,234,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,-1,-1,2,3857,-1
3869,treatment regimens,2,4,13,31,"With current treatment regimens including combined surgery, radiation and chemotherapy, the average life expectancy of the patients is limited to approximately 1 year.",12483326_2,-1,-1,2,3869,-1
3870,combined surgery,5,7,42,58,"With current treatment regimens including combined surgery, radiation and chemotherapy, the average life expectancy of the patients is limited to approximately 1 year.",12483326_2,-1,-1,2,3870,-1
3874,treatment regimen,14,16,107,124,"Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen.",12483326_3,-1,-1,2,3874,-1
3886,carboplatin toxicity,7,9,47,67,Various ocular symptoms and findings caused by carboplatin toxicity were seen.,12483326_8,-1,-1,2,3886,-1
3887,treated with,4,6,16,28,RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection.,12483326_9,-1,-1,2,3887,-1
3898,associated with,2,4,22,37,Visual hallucinations associated with zonisamide.,12523465_0,-1,-1,2,3898,-1
3901,broad-spectrum antiepileptic drug,3,6,16,49,Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.,12523465_1,-1,-1,2,3901,-1
3911,associated with,12,14,70,85,"Until then, clinicians need to be aware of this possible complication associated with zonisamide.",12523465_9,-1,-1,2,3911,-1
3913,Anti-epileptic drugs-induced de novo,0,4,0,36,Anti-epileptic drugs-induced de novo absence seizures.,12536034_0,-1,-1,2,3913,-1
3917,drug-induced de novo,8,11,51,71,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,-1,-1,2,3917,-1
3919,gamma-aminobutyric acid-transmitted thalamocortical circuitry,1,5,4,65,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,-1,-1,2,3919,-1
3920,drug-induced de novo,1,4,8,28,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,-1,-1,2,3920,-1
3924,drug-induced aggravation,3,5,19,43,The possibility of drug-induced aggravation should be considered whenever an unexpected increase in seizure frequency and/or new seizure types appear following a change in drug treatment.,12536034_6,-1,-1,2,3924,-1
3930,associated with,11,13,60,75,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,-1,-1,2,3930,-1
3947,Naranjo probability scale,15,18,95,120,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,-1,-1,2,3947,-1
3969,double-blind,7,8,36,48,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,2,3969,-1
3981,peak increase,6,8,30,43,The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.,12571256_5,-1,-1,2,3981,-1
3987,significantly less,6,8,48,66,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,-1,-1,2,3987,-1
3989,peak increase,9,11,30,43,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,2,3989,-1
3995,confidence interval,51,53,260,279,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,2,3995,-1
3999,odds ratio,47,49,222,232,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,2,3999,-1
4001,confidence interval,62,64,295,314,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,2,4001,-1
4002,No patient,0,2,0,10,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,2,4002,-1
4010,confidence interval,54,56,276,295,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,2,4010,-1
4025,control rats,28,30,151,163,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,-1,-1,2,4025,-1
4029,control rats,17,19,110,122,Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.,12574103_7,-1,-1,2,4029,-1
4048,Sprague-Dawley rats,21,23,121,140,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,2,4048,-1
4061,Sprague-Dawley rats,51,53,269,288,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,2,4061,-1
4097,Cardiac troponins I,2,5,12,31,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,-1,-1,2,4097,-1
4111,control group,6,8,30,43,Ten rats received saline as a control group.,12589964_4,-1,-1,2,4111,-1
4116,CK-MB,22,23,101,106,"cTnI was measured with Access(R) (ng/ml) and a research immunoassay (pg/ml), and compared with cTnT, CK-MB mass and CK.",12589964_5,-1,-1,2,4116,-1
4126,9-week,14,15,82,88,RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.,12589964_8,-1,-1,2,4126,-1
4147,cTnT,7,8,56,60,"A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes, and between LV diameters/BW and histological findings.",12589964_20,-1,-1,2,4147,-1
4148,LV diameters/BW,18,20,125,140,"A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes, and between LV diameters/BW and histological findings.",12589964_20,-1,-1,2,4148,-1
4157,cross-reactivities,20,21,113,131,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,2,4157,-1
4179,streptomycin-induced vestibulotoxicity,5,7,39,77,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,2,4179,-1
4180,guinea pig,9,11,85,95,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,2,4180,-1
4181,streptomycin-induced vestibulotoxicity,5,7,39,77,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,2,4181,-1
4183,guinea pigs,10,12,94,105,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,2,4183,-1
4185,radical scavenger,4,6,18,35,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,2,4185,-1
4190,osmotic pump,8,10,50,62,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,2,4190,-1
4192,intraperitoneally,25,26,113,130,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,2,4192,-1
4197,streptomycin-induced vestibulotoxicity,6,8,48,86,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,2,4197,-1
4202,case-control study,21,23,143,161,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,2,4202,-1
4210,associated with,13,15,85,100,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,2,4210,-1
4217,case-control study,14,16,89,107,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,2,4217,-1
4218,PCOS,33,34,197,201,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,2,4218,-1
4222,age-adjusted,3,4,13,25,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,-1,-1,2,4222,-1
4226,confidence interval,17,19,97,116,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,-1,-1,2,4226,-1
4229,case-control analysis,22,24,126,147,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,2,4229,-1
4230,odds ratio,27,29,165,175,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,2,4230,-1
4231,OR(adj,30,31,177,183,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,2,4231,-1
4236,associated with,10,12,59,74,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,2,4236,-1
4240,gentamicin nephrotoxicity,8,10,43,68,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,2,4240,-1
4245,treated with,2,4,10,22,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,2,4245,-1
4263,GM-induced,65,66,328,338,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,2,4263,-1
4271,mechanism(s),24,26,133,145,"Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure, and on the mechanism(s) involved.",12617329_6,-1,-1,2,4271,-1
4281,randomized phase II trial,6,10,36,61,DESIGN: Retrospective analysis of a randomized phase II trial.,12627929_2,-1,-1,2,4281,-1
4287,4-week cycle,1,3,5,17,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,-1,-1,2,4287,-1
4297,published cases,25,27,166,181,"OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.",12639165_1,-1,-1,2,4297,-1
4303,in vitro,9,11,80,88,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,-1,-1,2,4303,-1
4304,healthy controls,18,20,117,133,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,-1,-1,2,4304,-1
4307,English literature,23,25,144,162,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,-1,-1,2,4307,-1
4315,drug's,7,9,41,47,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,-1,-1,2,4315,-1
4317,T-cell stimulation study,15,18,84,108,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,-1,-1,2,4317,-1
4326,protein expression,9,11,50,68,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,-1,-1,2,4326,-1
4331,molecular mechanism(s),1,4,4,26,The molecular mechanism(s) leading to salt retention has not been completely elucidated.,12653683_2,-1,-1,2,4331,-1
4332,rate-limiting constituent,1,3,4,29,The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC).,12653683_3,-1,-1,2,4332,-1
4339,Sprague-Dawley rats,17,19,116,135,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,-1,-1,2,4339,-1
4347,up-regulation,2,3,14,27,A significant up-regulation of alphaENaC and betaENaC mRNA abundance on days 1 and 2 preceded sodium retention on days 2 and 3.,12653683_9,-1,-1,2,4347,-1
4350,down-regulation,2,3,12,27,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,-1,-1,2,4350,-1
4353,mRNA expression,9,11,65,80,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,-1,-1,2,4353,-1
4354,return of,28,30,173,182,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,-1,-1,2,4354,-1
4355,control values,33,35,203,217,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,-1,-1,2,4355,-1
4366,cocaine-induced,9,10,60,75,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,-1,-1,2,4366,-1
4369,non-receptor,1,2,5,17,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,-1,-1,2,4369,-1
4370,de novo,5,7,47,54,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,-1,-1,2,4370,-1
4374,VFD,19,20,119,122,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,2,4374,-1
4375,associated with,21,23,124,139,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,2,4375,-1
4376,effects of,30,32,186,196,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,2,4376,-1
4379,cocaine-induced,37,38,225,240,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,2,4379,-1
4384,sub-chronic exposure,18,20,93,113,"METHODS: Using in vivo microdialysis, we compared acute exposure (450 mg/kg) to an identical sub-chronic exposure (150 mg/kg per day for 3 days), followed by 1- or 3-day washout.",12684739_4,-1,-1,2,4384,-1
4387,Sub-chronic,2,3,9,20,"RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.",12684739_6,-1,-1,2,4387,-1
4390,Sub-chronic low dose,2,5,13,33,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,2,4390,-1
4392,cocaine-induced,12,13,80,95,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,2,4392,-1
4395,Levodopa-induced,0,1,0,16,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,2,4395,-1
4402,levodopa-induced,10,11,57,73,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,2,4402,-1
4425,ADC,12,13,57,60,The remaining 1 patient (20.0%) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis.,12695819_7,-1,-1,2,4425,-1
4429,L-arginine-nitric oxide system,2,5,12,42,A deficient L-arginine-nitric oxide system is implicated in cortisol-induced hypertension.,12707296_1,-1,-1,2,4429,-1
4434,Crossover studies,0,2,0,17,Crossover studies were performed 2 weeks apart.,12707296_5,-1,-1,2,4434,-1
4440,C. Forearm,30,32,182,192,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,-1,-1,2,4440,-1
4454,cortisol-induced,3,4,17,33,We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.,12707296_12,-1,-1,2,4454,-1
4458,collagenase-induced,8,9,44,63,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,-1,-1,2,4458,-1
4465,ICH,1,2,3,6,"In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume.",12716030_3,-1,-1,2,4465,-1
4469,ICH,1,2,3,6,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,2,4469,-1
4471,hemoglobin assay,5,7,33,49,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,2,4471,-1
4481,over-the-counter cold,10,12,57,78,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,2,4481,-1
4482,weight-control preparations,14,16,92,119,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,2,4482,-1
4485,Several reports,0,2,0,15,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,-1,-1,2,4485,-1
4490,weight control,23,25,133,147,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,-1,-1,2,4490,-1
4494,associated with,11,13,70,85,"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.",12734532_6,-1,-1,2,4494,-1
4507,CK,1,2,4,6,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,2,4507,-1
4510,Routine controls,0,2,0,16,"Routine controls revealed markedly elevated CK levels of 1,700 U/l.",12739036_7,-1,-1,2,4510,-1
4515,deltoid muscle,6,8,27,41,"Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.",12739036_9,-1,-1,2,4515,-1
4516,SLE-induced,3,4,31,42,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,2,4516,-1
4518,drug-induced side effects,10,13,87,112,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,2,4518,-1
4523,associated with,7,9,49,64,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,-1,-1,2,4523,-1
4527,investigational,16,17,94,109,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,-1,-1,2,4527,-1
4529,active control,27,29,187,201,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,-1,-1,2,4529,-1
4536,ovariectomized rats,2,4,18,37,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,2,4536,-1
4541,ovariectomized female,10,12,62,83,We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.,12757899_2,-1,-1,2,4541,-1
4542,subcutaneous injections,2,4,14,37,Rats received subcutaneous injections of 17beta-estradiol (2 microg/rat) or oil once daily for four consecutive days.,12757899_3,-1,-1,2,4542,-1
4546,CA1 hippocampal,6,8,37,52,The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE.,12757899_5,-1,-1,2,4546,-1
4548,ovariectomized rats,10,12,60,79,17beta-Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males.,12757899_6,-1,-1,2,4548,-1
4550,argyrophilic,3,4,29,41,17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats.,12757899_7,-1,-1,2,4550,-1
4555,effects of,5,7,32,42,These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex-related differences in the hormonal environment.,12757899_9,-1,-1,2,4555,-1
4560,associated with,4,6,21,36,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,-1,-1,2,4560,-1
4590,stage C,13,15,94,101,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,2,4590,-1
4592,stage D1,21,23,123,131,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,2,4592,-1
4601,upper limits,22,24,120,132,"Patients with stage D2-3 disease, abnormal hemoglobin level or renal and liver function tests that were higher than the upper limits were excluded from the study.",12820454_5,-1,-1,2,4601,-1
4606,CAB-induced,1,2,5,16,This CAB-induced anemia was normochromic and normocytic.,12820454_9,-1,-1,2,4606,-1
4609,post-CAB,3,4,14,22,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,2,4609,-1
4610,mean value,12,14,61,71,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,2,4610,-1
4612,mean value,36,38,156,166,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,2,4612,-1
4613,/-,41,42,176,178,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,2,4613,-1
4615,CAB-induced,4,5,26,37,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,-1,2,4615,-1
4617,T baseline values,14,17,96,113,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,-1,2,4617,-1
4619,stage C,49,51,215,222,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,-1,2,4619,-1
4620,stage D1,52,54,230,238,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,-1,2,4620,-1
4622,subcutaneous injections,9,11,61,84,Severe and clinically evident anemia was easily corrected by subcutaneous injections (3 times/week for 1 month) of recombinant erythropoietin (rHuEPO-beta).,12820454_13,-1,-1,2,4622,-1
4627,CAB-induced,8,9,58,69,CONCLUSION: Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,12820454_14,-1,-1,2,4627,-1
4632,Oral administration,0,2,0,19,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,-1,-1,2,4632,-1
4634,dose-dependent,25,26,104,118,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,-1,-1,2,4634,-1
4641,exposure of,17,19,107,118,A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose (2.5 mg/kg) of lindane was increased from 5 days to 15 or 21 days.,12842176_2,-1,-1,2,4641,-1
4653,antibody inhibition,12,14,86,105,"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.",12842176_5,-1,-1,2,4653,-1
4664,P450 2E1 catalysed reactions,51,55,297,325,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,2,4664,-1
4665,P450-mediated metabolism,4,6,20,44,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,2,4665,-1
4667,inducible,36,37,232,241,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,2,4667,-1
4681,Danish National Register of Patients,4,9,18,54,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,-1,-1,2,4681,-1
4688,Danish Drug Statistics,9,12,58,80,Sales statistics of COCs and CPA/EE were provided through Danish Drug Statistics.,12851669_4,-1,-1,2,4688,-1
4689,time frame,4,6,20,30,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,2,4689,-1
4712,gestational day,26,28,156,171,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,2,4712,-1
4724,multiple dose study,72,75,214,233,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,2,4724,-1
4727,VSDs,13,14,92,96,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,2,4727,-1
4731,VSDs,33,34,172,176,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,2,4731,-1
4732,Cook JC,37,39,189,196,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,2,4732,-1
4735,single dose studies,1,4,3,22,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,2,4735,-1
4740,multiple dose study,10,13,41,60,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,2,4740,-1
4741,high-dose group,17,19,80,95,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,2,4741,-1
4743,dose groups,26,28,126,137,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,2,4743,-1
4752,single dose studies,29,32,163,182,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,2,4752,-1
4758,double-blind multicenter study,19,22,133,163,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,-1,-1,2,4758,-1
4760,Multicenter Study Group,8,11,63,86,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,2,4760,-1
4771,flumazenil-treated patients,9,11,30,57,"After 5 minutes, 80/115 (70%) flumazenil-treated patients, compared with 21/63 (33%) placebo-treated patients, were completely awake and alert, as indicated by a score of 5 on the Observer's Assessment of Alertness/Sedation Scale.",1286498_4,-1,-1,2,4771,-1
4773,Observer's Assessment,37,40,180,201,"After 5 minutes, 80/115 (70%) flumazenil-treated patients, compared with 21/63 (33%) placebo-treated patients, were completely awake and alert, as indicated by a score of 5 on the Observer's Assessment of Alertness/Sedation Scale.",1286498_4,-1,-1,2,4773,-1
4775,5-minute assessment,15,17,79,98,Ninety-five percent of patients in each group who attained a score of 5 at the 5-minute assessment showed no loss of alertness throughout the 180-minute assessment period.,1286498_5,-1,-1,2,4775,-1
4777,Finger-to-Nose Test,8,10,71,90,Flumazenil-treated patients also performed significantly better on the Finger-to-Nose Test and the recall of pictures shown at the 5-minute assessment.,1286498_6,-1,-1,2,4777,-1
4778,5-minute assessment,18,20,131,150,Flumazenil-treated patients also performed significantly better on the Finger-to-Nose Test and the recall of pictures shown at the 5-minute assessment.,1286498_6,-1,-1,2,4778,-1
4781,flumazenil-treated patients,6,8,21,48,"Thirty-nine (30%) of flumazenil-treated patients, compared with 17 (25%) of placebo-treated patients had one or more drug-related adverse experiences.",1286498_8,-1,-1,2,4781,-1
4783,drug-related,23,24,117,129,"Thirty-nine (30%) of flumazenil-treated patients, compared with 17 (25%) of placebo-treated patients had one or more drug-related adverse experiences.",1286498_8,-1,-1,2,4783,-1
4796,/-,18,19,65,67,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,2,4796,-1
4797,/-,26,27,103,105,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,2,4797,-1
4799,/-,50,51,208,210,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,2,4799,-1
4800,/-,57,58,233,235,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,2,4800,-1
4801,cases/person-years,12,13,56,74,"Delirium was diagnosed in 14 (10.1 % incidence, or 1.48 cases/person-years of exposure); 71.4 % of cases were moderate or severe.",12905102_4,-1,-1,2,4801,-1
4803,co-treatment,3,4,24,36,"Associated factors were co-treatment with other centrally antimuscarinic agents, poor clinical outcome, older age, and longer hospitalization (by 17.5 days, increasing cost); sex, diagnosis or medical co-morbidity, and daily clozapine dose, which fell with age, were unrelated.",12905102_5,-1,-1,2,4803,-1
4808,fell with,42,44,247,256,"Associated factors were co-treatment with other centrally antimuscarinic agents, poor clinical outcome, older age, and longer hospitalization (by 17.5 days, increasing cost); sex, diagnosis or medical co-morbidity, and daily clozapine dose, which fell with age, were unrelated.",12905102_5,-1,-1,2,4808,-1
4810,associated with,10,12,74,89,"Delirium was inconsistently recognized clinically in milder cases and was associated with increased length-of-stay and higher costs, and inferior clinical outcome.",12905102_7,-1,-1,2,4810,-1
4816,methamphetamine-induced,11,12,66,89,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,-1,-1,2,4816,-1
4818,associated with,15,17,120,135,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,-1,-1,2,4818,-1
4823,selective antagonist,1,3,2,22,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,-1,-1,2,4823,-1
4829,sc)-induced,10,11,66,77,"Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced hyperthermia and reduced basal body temperature.",12907309_5,-1,-1,2,4829,-1
4835,methamphetamine-induced,18,19,112,135,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,-1,-1,2,4835,-1
4838,associated with,6,8,40,55,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,-1,-1,2,4838,-1
4839,methamphetamine-induced,12,13,77,100,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,-1,-1,2,4839,-1
4841,Methylphenidate-induced,0,1,0,23,Methylphenidate-induced obsessive-compulsive symptoms in an elderly man.,12907924_0,-1,-1,2,4841,-1
4843,Alzheimer's disease,8,11,65,84,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,-1,-1,2,4843,-1
4873,anticonvulsant effect,29,31,276,297,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,2,4873,-1
4875,Swiss-Webster mice,44,46,379,397,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,2,4875,-1
4882,associated with,12,14,89,104,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,2,4882,-1
4884,convulsant,8,9,68,78,These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse.,12921865_8,-1,-1,2,4884,-1
4885,effects of,28,30,193,203,These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse.,12921865_8,-1,-1,2,4885,-1
4892,"1,100-bed private university hospital",37,41,217,254,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,-1,-1,2,4892,-1
4893,treatment group,6,8,27,42,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,2,4893,-1
4896,control group,1,3,4,17,The control group received fluids (mean 3 liters).,1300436_4,-1,-1,2,4896,-1
4899,average dose,16,18,112,124,"Radiological studies were mostly angiographies performed with both ionic and non-ionic contrast material, at an average dose of 245 ml.",1300436_5,-1,-1,2,4899,-1
4903,/-,27,28,146,148,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,2,4903,-1
4904,/-,32,33,160,162,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,2,4904,-1
4906,control group,45,47,215,228,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,2,4906,-1
4907,/-,51,52,240,242,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,2,4907,-1
4908,/-,56,57,253,255,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,2,4908,-1
4919,ten-year study,22,24,158,172,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,-1,2,4919,-1
4920,ten-year period,2,4,9,24,"During a ten-year period, 348 women were studied for a total of 5,877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters.",133615_3,-1,-1,2,4920,-1
4924,"factors I,II",13,17,92,104,"Significant increases in certain factors of the blood coagulation and fibrinolysin systems (factors I,II,VII,VIII,IX, and X and plasminogen) were observed in the treated groups.",133615_4,-1,-1,2,4924,-1
4928,base-line values,16,18,107,123,"One of these patients developed a myocardial infarction before receiving any medication, shortly after the base-line values were obtained.",133615_8,-1,-1,2,4928,-1
4930,blood group,9,11,38,49,All four patients were of the A or AB blood group.,133615_11,-1,-1,2,4930,-1
4934,work-ups,7,8,44,52,It appears from these data that hematologic work-ups may be useful in women who are about to start long-term oral contraceptive therapy.,133615_13,-1,-1,2,4934,-1
4937,chronic prazosin-pretreated conscious spontaneously,8,12,74,125,Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.1.,1355091_0,-1,-1,2,4937,-1
4938,2-adrenoceptor function,12,14,87,110,Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats (SHR).,1355091_1,-1,-1,2,4938,-1
4955,SHR,10,11,65,68,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,2,4955,-1
4957,SHR,28,29,125,128,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,2,4957,-1
4960,Conscious SHR,2,4,3,16,3. Conscious SHR were treated for 4 days with prazosin at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade.,1355091_6,-1,-1,2,4960,-1
4963,chronic alpha 1-adrenoceptor blockade,19,23,83,120,3. Conscious SHR were treated for 4 days with prazosin at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade.,1355091_6,-1,-1,2,4963,-1
4964,conscious SHR,2,4,7,20,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,2,4964,-1
4965,untreated SHR,15,17,80,93,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,2,4965,-1
4979,conscious SHR,50,52,246,259,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,2,4979,-1
4981,effects of,5,7,33,43,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,2,4981,-1
4985,SHR,16,17,86,89,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,-1,-1,2,4985,-1
4986,SHR,25,26,139,142,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,-1,-1,2,4986,-1
4987,noradrenaline-induced pressor effect,7,10,50,86,"Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)",1355091_13,-1,-1,2,4987,-1
4990,SHR.(ABSTRACT,36,37,235,248,"Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)",1355091_13,-1,-1,2,4990,-1
4992,morphine-induced increase,5,7,32,57,Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.,137340_0,-1,-1,2,4992,-1
4995,morphine-induced,7,8,40,56,The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.,137340_1,-1,-1,2,4995,-1
4997,subcutaneous administration,1,3,4,31,The subcutaneous administration of 10 mg/kg of morphine-HC1 produced a marked increase in locomotor activity in mice.,137340_2,-1,-1,2,4997,-1
5003,Pretreatment,0,1,0,12,"Pretreatment of mice with alpha-methyltyrosine (20 mg/kg i.p., one hour), an inhibitor of tyrosine hydroxylase, significantly decreased the activity-increasing effects of morphine.",137340_5,-1,-1,2,5003,-1
5010,adrenergic neurons,17,19,119,137,The study suggests that the activity-increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain. And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses.,137340_7,-1,-1,2,5010,-1
5011,consistent with,27,29,172,187,The study suggests that the activity-increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain. And the results are consistent with the hypothesis that morphine acts by retarding the release of acetylcholine at some central cholinergic synapses.,137340_7,-1,-1,2,5011,-1
5015,Effects of,0,2,0,10,Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.,1378968_0,-1,-1,2,5015,-1
5018,lithium-induced,8,9,54,69,Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.,1378968_0,-1,-1,2,5018,-1
5025,Wistar rats,2,4,15,26,"Newborn female Wistar rats were fed a lithium-containing diet (50 mmol/kg) for 8 weeks and then randomized to normal diet, HP diet (40 vs. 19%), NX or HP+NX for another 8 weeks.",1378968_2,-1,-1,2,5025,-1
5027,normal diet,20,22,110,121,"Newborn female Wistar rats were fed a lithium-containing diet (50 mmol/kg) for 8 weeks and then randomized to normal diet, HP diet (40 vs. 19%), NX or HP+NX for another 8 weeks.",1378968_2,-1,-1,2,5027,-1
5037,filtration fraction,8,10,52,71,"Consequently, lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion.",1378968_5,-1,-1,2,5037,-1
5061,associated with,2,4,26,41,Hemolytic-uremic syndrome associated with ingestion of quinine.,1415380_0,-1,-1,2,5061,-1
5066,pharmacological treatment,6,8,31,56,"However, it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement.",1415380_6,-1,-1,2,5066,-1
5069,Crohn's disease,2,5,13,28,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,2,5069,-1
5074,T-cell,6,7,35,41,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,2,5074,-1
5077,Crohn's disease,11,14,62,77,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,2,5077,-1
5084,Crohn's disease,1,4,6,21,Eight Crohn's disease patients were included.,1420741_3,-1,-1,2,5084,-1
5087,grading score,10,12,69,82,The disease activity was primarily measured by a modified individual grading score.,1420741_5,-1,-1,2,5087,-1
5091,pre-treatment,3,4,16,29,All reversed to pre-treatment levels after cessation of treatment.,1420741_9,-1,-1,2,5091,-1
5092,pilot study,4,6,20,31,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,2,5092,-1
5094,Crohn's disease,18,21,103,118,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,2,5094,-1
5100,propranolol toxicity,4,6,34,54,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,2,5100,-1
5102,propranolol toxicity,12,14,78,98,An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.,1423339_1,-1,-1,2,5102,-1
5104,associated with,4,6,29,44,Changes in depressive status associated with topical beta-blockers.,1428568_0,-1,-1,2,5104,-1
5116,DMS-III-R criteria,14,16,115,133,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,-1,-1,2,5116,-1
5117,six-month,2,3,11,20,"During the six-month follow up, depression was quantified through the Beck and Zung-Conde scales every two months.",1428568_4,-1,-1,2,5117,-1
5120,double blind cross-over study,2,6,5,34,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,2,5120,-1
5124,depression-inducer,10,11,56,74,These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.,1428568_6,-1,-1,2,5124,-1
5126,striatal,5,6,60,68,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,-1,-1,2,5126,-1
5145,dose-dependent,6,7,38,52,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,-1,-1,2,5145,-1
5150,dose-dependently,20,21,128,144,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,-1,-1,2,5150,-1
5157,Cefotetan-induced immune,0,2,0,24,Cefotetan-induced immune hemolytic anemia.,1445986_0,-1,-1,2,5157,-1
5160,drug-adsorption mechanism,6,8,33,58,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,-1,-1,2,5160,-1
5162,Cefotetan-dependent antibodies,0,2,0,30,Cefotetan-dependent antibodies were detected in the patient's serum and in an eluate prepared from his red blood cells.,1445986_3,-1,-1,2,5162,-1
5163,patient's,6,8,52,61,Cefotetan-dependent antibodies were detected in the patient's serum and in an eluate prepared from his red blood cells.,1445986_3,-1,-1,2,5163,-1
5167,warm-reactive autoantibodies,20,22,121,149,"The eluate also reacted weakly with red blood cells in the absence of cefotetan, suggesting the concomitant formation of warm-reactive autoantibodies.",1445986_4,-1,-1,2,5167,-1
5168,consistent with,15,17,105,120,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,-1,-1,2,5168,-1
5170,drug-adsorption,24,25,176,191,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,-1,-1,2,5170,-1
5172,Ketoconazole-induced neurologic sequelae,0,3,0,40,Ketoconazole-induced neurologic sequelae.,14513889_0,-1,-1,2,5172,-1
5185,macaque monkeys,1,3,6,21,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,-1,-1,2,5185,-1
5188,response to,27,29,172,183,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,-1,-1,2,5188,-1
5195,no sooner,33,35,212,221,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,2,5195,-1
5200,cross-sensitization,7,8,52,71,A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.,14596845_0,-1,-1,2,5200,-1
5204,cross-sensitization,16,17,105,124,The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine.,14596845_2,-1,-1,2,5204,-1
5207,cyclic diet,18,20,92,103,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,2,5207,-1
5208,12-h deprivation,21,23,107,123,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,2,5208,-1
5215,control groups,18,20,120,134,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,2,5215,-1
5218,ad libitum chow,40,43,250,265,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,2,5218,-1
5222,chow produces,17,19,106,119,"These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the dopamine system.",14596845_8,-1,-1,2,5222,-1
5228,side-effect,10,11,45,56,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,2,5228,-1
5232,IFS-induced,20,21,118,129,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,-1,-1,2,5232,-1
5234,Wistar rats,3,5,14,25,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,2,5234,-1
5250,IFS-induced,11,12,78,89,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,-1,-1,2,5250,-1
5258,associated with,2,4,17,32,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,2,5258,-1
5265,ATRA therapy,12,14,81,93,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,2,5265,-1
5275,short course,3,5,22,34,All patients received short course of steroids.,14648024_5,-1,-1,2,5275,-1
5299,female migraineurs,1,3,8,26,Fifteen female migraineurs (without aura) and eight controls participated in the study.,14659530_2,-1,-1,2,5299,-1
5301,time schedule,14,16,69,82,In those subjects who had no migraine attack (11 subjects) a similar time schedule was used.,14659530_5,-1,-1,2,5301,-1
5315,Conservative treatment,0,2,0,22,"Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.",1468485_2,-1,-1,2,5315,-1
5318,absolute pressure,7,9,37,54,"We then used hyperbaric oxygen at an absolute pressure of 2 atm, 5 days a week for 8 consecutive weeks.",1468485_3,-1,-1,2,5318,-1
5333,amygdala-kindled,18,19,122,138,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,2,5333,-1
5341,subprotective doses,19,21,107,126,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,2,5341,-1
5356,GABAergic neurotransmission,21,23,154,181,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,-1,-1,2,5356,-1
5357,L-type,26,27,198,204,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,-1,-1,2,5357,-1
5359,Mitochondrial DNA,0,2,0,17,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,-1,-1,2,5359,-1
5361,doxorubicin nephrosis,10,12,70,91,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,-1,-1,2,5361,-1
5369,respiratory chain components,14,17,92,120,Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components.,14736955_6,-1,-1,2,5369,-1
5370,mitochondrial,7,8,40,53,"Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion.",14736955_7,-1,-1,2,5370,-1
5372,base pair,20,22,112,121,"Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion.",14736955_7,-1,-1,2,5372,-1
5379,short-term',2,4,4,15,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,2,5379,-1
5385,mtDNA-encoded respiratory chain subunit COX-I. Injury,25,31,168,221,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,2,5385,-1
5386,nucleus-encoded mitochondrial,41,43,297,326,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,2,5386,-1
5387,cytoplasmic enzymes,44,46,330,349,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,2,5387,-1
5388,long-term' group,4,7,18,34,Kidneys from the 'long-term' group showed more mtDNA deletions than in 'short-term' animals and these were not observed in the other groups.,14736955_12,-1,-1,2,5388,-1
5390,short-term',14,16,72,83,Kidneys from the 'long-term' group showed more mtDNA deletions than in 'short-term' animals and these were not observed in the other groups.,14736955_12,-1,-1,2,5390,-1
5392,mtDNA-encoded respiratory chain function,18,22,129,169,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,-1,-1,2,5392,-1
5394,placebo-controlled,3,4,14,32,"A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.",14742097_0,-1,-1,2,5394,-1
5395,crossover study,5,7,34,49,"A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.",14742097_0,-1,-1,2,5395,-1
5396,SSRI-induced,10,11,67,79,"A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.",14742097_0,-1,-1,2,5396,-1
5403,eight-week,15,16,112,122,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,2,5403,-1
5404,double-blind,17,18,124,136,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,2,5404,-1
5405,placebo-controlled,19,20,138,156,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,2,5405,-1
5406,cross-over study,21,23,158,174,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,2,5406,-1
5407,effects of,25,27,182,192,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,2,5407,-1
5408,self-report,33,34,214,225,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,2,5408,-1
5415,placebo-controlled trials,7,9,54,79,These findings highlight the importance of conducting placebo-controlled trials for this condition.,14742097_4,-1,-1,2,5415,-1
5416,hormone therapy,1,3,5,20,Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition?,14745746_0,-1,-1,2,5416,-1
5421,hormone therapy,5,7,34,49,This pilot study examines whether hormone therapy for breast cancer affects cognition.,14745746_2,-1,-1,2,5421,-1
5423,randomised trial of anastrozole,4,8,28,59,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,2,5423,-1
5427,control group,3,5,18,31,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,2,5427,-1
5431,length of,8,10,59,68,Patient group performance was not significantly related to length of treatment or measures of psychological morbidity.,14745746_5,-1,-1,2,5431,-1
5444,Food and,4,6,27,35,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,-1,-1,2,5444,-1
5455,anti-tumor agent,3,5,18,34,Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.,14975762_1,-1,-1,2,5455,-1
5459,cardiac p300,2,4,21,33,"Doxorubicin depletes cardiac p300, a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes.",14975762_2,-1,-1,2,5459,-1
5460,transcriptional coactivator,6,8,37,64,"Doxorubicin depletes cardiac p300, a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes.",14975762_2,-1,-1,2,5460,-1
5463,doxorubicin-induced apoptosis,9,11,48,77,"However, the role of p300 in protection against doxorubicin-induced apoptosis is unknown.",14975762_3,-1,-1,2,5463,-1
5465,overexpressing,2,3,16,30,Transgenic mice overexpressing p300 in the heart and wild-type mice were subjected to doxorubicin treatment.,14975762_4,-1,-1,2,5465,-1
5467,wild-type mice,8,10,53,67,Transgenic mice overexpressing p300 in the heart and wild-type mice were subjected to doxorubicin treatment.,14975762_4,-1,-1,2,5467,-1
5468,wild-type mice,2,4,14,28,"Compared with wild-type mice, transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha-sarcomeric actin.",14975762_5,-1,-1,2,5468,-1
5469,transgenic mice,5,7,30,45,"Compared with wild-type mice, transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha-sarcomeric actin.",14975762_5,-1,-1,2,5469,-1
5475,wild-type mice,6,8,49,63,Doxorubicin induced myocardial cell apoptosis in wild-type mice but not in transgenic mice.,14975762_6,-1,-1,2,5475,-1
5476,transgenic mice,11,13,75,90,Doxorubicin induced myocardial cell apoptosis in wild-type mice but not in transgenic mice.,14975762_6,-1,-1,2,5476,-1
5483,overexpression,4,5,32,46,These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.,14975762_8,-1,-1,2,5483,-1
5491,white woman,10,12,53,64,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,2,5491,-1
5507,antithyroid agent,8,10,58,75,Methimazole is a widely used and generally well-tolerated antithyroid agent.,14982270_1,-1,-1,2,5507,-1
5519,trigemino-parasympathetic reflex,13,15,94,126,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,2,5519,-1
5544,vasoactive intestinal polypeptide,34,37,159,192,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,2,5544,-1
5545,dura mater,45,47,228,238,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,2,5545,-1
5558,BChEs,26,27,173,178,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,2,5558,-1
5571,control rats,1,3,4,16,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,2,5571,-1
5581,DFP toxicity,8,10,63,75,Atropine-MK801 did not offer any additional protection against DFP toxicity.,15036754_9,-1,-1,2,5581,-1
5585,stage IIIE,5,7,47,57,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,2,5585,-1
5597,associated with,4,6,35,50,The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.,15042318_2,-1,-1,2,5597,-1
5598,aggressive chemotherapy,7,9,55,78,The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.,15042318_2,-1,-1,2,5598,-1
5602,ex vivo,13,15,89,96,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,2,5602,-1
5610,healthy subject,9,11,57,72,A similar protocol was performed with lymphocytes from a healthy subject.,1504402_4,-1,-1,2,5610,-1
5618,healthy subject,8,10,50,65,No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions.,1504402_7,-1,-1,2,5618,-1
5631,control group,20,22,106,119,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,2,5631,-1
5635,inner stripe,11,13,71,83,The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.,15075188_6,-1,-1,2,5635,-1
5658,protein abundances,4,6,17,35,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,-1,-1,2,5658,-1
5674,associated with,36,38,213,228,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,-1,-1,2,5674,-1
5680,pyridoxine-dependent behavioral disorder,1,4,2,42,A pyridoxine-dependent behavioral disorder unmasked by isoniazid.,150790_0,-1,-1,2,5680,-1
5684,pharmacologic doses,3,5,22,41,The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms.,150790_2,-1,-1,2,5684,-1
5691,kynurenine pathway,7,9,43,61,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,2,5691,-1
5692,tryptophan metabolism,10,12,65,86,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,2,5692,-1
5694,Pallidal stimulation,0,2,0,20,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,2,5694,-1
5704,nucleus ventralis intermedius,15,18,107,136,"Another lesioning procedure, ventrolateral thalamotomy, has become a powerful alternative to stimulate the nucleus ventralis intermedius, producing high long-term success rates and low morbidity rates.",15096016_2,-1,-1,2,5704,-1
5706,Pallidal stimulation,0,2,0,20,Pallidal stimulation has not met with the same success.,15096016_3,-1,-1,2,5706,-1
5707,literature pallidotomy,3,5,17,39,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,2,5707,-1
5710,Pallidal stimulation,0,2,0,20,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,-1,-1,2,5710,-1
5718,dentate gyrus,4,6,28,41,Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy.,15120741_0,-1,-1,2,5718,-1
5721,mossy fiber,21,23,136,147,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,2,5721,-1
5723,CD1 mice,27,29,173,181,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,2,5723,-1
5727,ventral hippocampus,16,18,101,120,Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice.,15120741_2,-1,-1,2,5727,-1
5729,untreated mice,21,23,150,164,Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice.,15120741_2,-1,-1,2,5729,-1
5734,control mice,31,33,210,222,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,-1,-1,2,5734,-1
5738,repetitive afterdischarges,23,25,127,153,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,-1,-1,2,5738,-1
5739,photostimulation,2,3,16,32,Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.,15120741_5,-1,-1,2,5739,-1
5754,case-control study,7,9,36,54,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,-1,-1,2,5754,-1
5757,odds ratios,21,23,147,158,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,-1,-1,2,5757,-1
5763,Wegener's granulomatosis,30,33,171,195,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,2,5763,-1
5767,confidence interval,20,22,95,114,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,-1,-1,2,5767,-1
5768,associated with,7,9,42,57,"Treatment duration longer than 1 year was associated with an eightfold increased risk (OR = 7.7, 95% CI 0.9 to 69).",15130900_8,-1,-1,2,5768,-1
5771,Wegener's granulomatosis,17,20,91,115,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,2,5771,-1
5773,Wegener's granulomatosis,42,45,229,253,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,2,5773,-1
5774,dose-response,6,7,35,48,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,-1,2,5774,-1
5781,I1-imidazoline receptor-mediated,7,9,61,93,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,-1,-1,2,5781,-1
5786,intraperitoneal,5,6,27,42,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,-1,-1,2,5786,-1
5794,sham-operated,42,43,276,289,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,-1,-1,2,5794,-1
5795,ovariectomized,44,45,294,308,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,-1,-1,2,5795,-1
5802,beat-to-beat intervals,29,31,190,212,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,-1,-1,2,5802,-1
5803,SDRR,32,33,214,218,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,-1,-1,2,5803,-1
5804,root mean square,36,39,228,244,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,-1,-1,2,5804,-1
5805,R-wave-to-R-wave,43,44,274,290,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,-1,-1,2,5805,-1
5807,sham-operated,1,2,3,16,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,2,5807,-1
5810,associated with,18,20,117,132,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,2,5810,-1
5811,standard deviation,22,24,147,165,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,2,5811,-1
5813,SDRR,0,1,0,4,SDRR was reduced only by alpha-methyldopa.,15145918_6,-1,-1,2,5813,-1
5817,rilmenidine hypotension,15,17,101,124,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,2,5817,-1
5828,sham-operated levels,25,27,166,186,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,-1,-1,2,5828,-1
5843,medication labeling,15,17,101,120,Our case illustrates the serious consequences of medical errors that can be avoided through improved medication labeling and staff supervision.,15188772_4,-1,-1,2,5843,-1
5848,alcoholic extract,8,10,32,49,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,2,5848,-1
5851,protective effect,8,10,46,63,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,2,5851,-1
5857,isoproterenol-induced rats,33,35,175,201,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,2,5857,-1
5859,isoproterenol-induced decrease,3,5,18,48,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,-1,-1,2,5859,-1
5861,ADP-stimulated,16,17,111,125,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,-1,-1,2,5861,-1
5866,Effects of,0,2,0,10,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,-1,2,5866,-1
5880,nonselective NSAID,32,34,189,207,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,2,5880,-1
5886,nonusers,35,36,142,150,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,2,5886,-1
5891,treatment groups,13,15,63,79,The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses.,15266215_8,-1,-1,2,5891,-1
5892,Short-,0,1,0,6,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,2,5892,-1
5893,intermediate-term,2,3,11,28,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,2,5893,-1
5894,supratherapeutic,14,15,80,96,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,2,5894,-1
5898,nonselective,36,37,214,226,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,2,5898,-1
5916,ventilation tubes,15,17,97,114,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,-1,-1,2,5916,-1
5919,IST,7,8,44,47,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,-1,-1,2,5919,-1
5931,dose-dependent,14,15,86,100,"Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.",15275829_1,-1,-1,2,5931,-1
5939,functional receptors,16,18,89,109,"A gene cluster comprises the alpha3, alpha5 and beta4 subunits, which coassemble to form functional receptors.",15275829_3,-1,-1,2,5939,-1
5957,/- mice,2,4,8,15,alpha3 +/- mice were partially resistant to nicotine-induced seizures when compared to wild-type littermates.,15275829_7,-1,-1,2,5957,-1
5963,/- brains,14,16,76,85,mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 +/- brains.,15275829_8,-1,-1,2,5963,-1
5968,warfarin-associated,3,4,15,34,Time trends in warfarin-associated hemorrhage.,15276120_0,-1,-1,2,5968,-1
5970,Women's Hospital,9,12,65,81,"The annual incidence of warfarin-related bleeding at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.",15276120_1,-1,-1,2,5970,-1
5973,effects of,1,3,4,14,The effects of sevoflurane on lidocaine-induced convulsions.,15278670_0,-1,-1,2,5973,-1
5976,/-,12,13,49,51,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,2,5976,-1
5977,/-,32,33,147,149,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,2,5977,-1
5980,/-,7,8,30,32,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,-1,-1,2,5980,-1
5990,mmHg,19,20,129,133,"However, there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg.",15278670_6,-1,-1,2,5990,-1
5992,potassium channels,7,9,49,67,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,-1,-1,2,5992,-1
5996,/-,16,17,74,76,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,2,5996,-1
5997,/- 2.5 mg,21,24,90,99,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,2,5997,-1
5998,statistically significant,32,34,125,150,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,2,5998,-1
6000,lidocaine toxicity,10,12,66,84,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,-1,2,6000,-1
6006,conditioning regimens,14,16,94,115,INTRODUCTION: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens.,15325671_1,-1,-1,2,6006,-1
6012,triple sequential,18,20,111,128,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,-1,-1,2,6012,-1
6021,CHF,34,35,264,267,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,2,6021,-1
6033,entire group,15,17,90,102,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,2,6033,-1
6035,No association,0,2,0,14,No association was found with other pretreatment characteristics.,15325671_8,-1,-1,2,6035,-1
6040,laser pointer technique,9,12,51,74,"Tremor side effects of salbutamol, quantified by a laser pointer technique.",15338796_0,-1,-1,2,6040,-1
6043,low-priced method,15,17,86,103,"OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.",15338796_1,-1,-1,2,6043,-1
6045,reference values,11,13,64,80,"Aim of the study was to determine sensitivity, reproducibility, reference values and the agreement with a questionnaire.",15338796_3,-1,-1,2,6045,-1
6046,laser pointer technique,7,10,37,60,METHODS: Tremor was measured using a laser pointer technique.,15338796_4,-1,-1,2,6046,-1
6050,concentric circles,14,16,68,86,"Subjects were asked to aim at the centre of a target, subdivided in concentric circles, from 5 m distance.",15338796_6,-1,-1,2,6050,-1
6051,millimetres radius,12,14,69,87,The circle in which the participant succeeded to aim was recorded in millimetres radius.,15338796_7,-1,-1,2,6051,-1
6057,dose-dependent,11,12,77,91,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,-1,-1,2,6057,-1
6059,no significant,3,5,23,37,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,-1,-1,2,6059,-1
6061,reproducible method,25,27,132,151,"DISCUSSION: Quantifying tremor by using an inexpensive laser pointer is, with the exception of children (<12 years) a sensitive and reproducible method.",15338796_18,-1,-1,2,6061,-1
6077,ideal dose,9,11,54,64,Various doses of yohimbine were used to determine the ideal dose for each patient.,1535072_6,-1,-1,2,6077,-1
6093,standard practice,1,3,3,20,"As standard practice at our institution, patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation.",1545575_2,-1,-1,2,6093,-1
6095,prophylactically,19,20,116,132,"As standard practice at our institution, patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation.",1545575_2,-1,-1,2,6095,-1
6099,hepatic metabolite,24,26,151,169,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,-1,-1,2,6099,-1
6109,associated with,4,6,27,42,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,2,6109,-1
6115,multicenter,10,11,59,70,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,-1,-1,2,6115,-1
6116,double-blind trial,14,16,84,102,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,-1,-1,2,6116,-1
6125,RR,24,25,139,141,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,2,6125,-1
6126,confidence interval,30,32,152,171,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,2,6126,-1
6130,RR,8,9,48,50,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,2,6130,-1
6132,RR,22,23,94,96,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,2,6132,-1
6134,RR,36,37,144,146,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,2,6134,-1
6136,RR,51,52,192,194,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,2,6136,-1
6143,LEVEL OF,0,2,0,8,LEVEL OF EVIDENCE: I,15458908_10,-1,-1,2,6143,-1
6144,controlled-release formula,22,24,125,151,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,-1,-1,2,6144,-1
6145,general rule,27,29,167,179,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,-1,-1,2,6145,-1
6149,standard approach,19,21,119,136,The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment.,1549199_2,-1,-1,2,6149,-1
6157,drug interactions,22,24,159,176,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,2,6157,-1
6164,beta-thalassemic,5,6,37,53,Long term audiological evaluation of beta-thalassemic patients.,15515654_0,-1,-1,2,6164,-1
6166,young adults,23,25,132,144,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,-1,-1,2,6166,-1
6167,beta-thalassemia major,26,28,150,172,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,-1,-1,2,6167,-1
6168,transfusion-chelation program,6,8,31,60,All patients were on a regular transfusion-chelation program maintaining a mean hemoglobin level of 9.5 gr/dl.,15515654_3,-1,-1,2,6168,-1
6176,serum ferritin levels,7,10,51,72,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,-1,-1,2,6176,-1
6194,phase I,12,14,70,77,"Worldwide, over 650 patients have been transplanted in the context of phase I and II clinical trials.",15517007_2,-1,-1,2,6194,-1
6204,European Group,18,20,92,106,"The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation autoimmune disease database, and to propose a safe approach to such patients.",15517007_9,-1,-1,2,6204,-1
6221,food-frequency questionnaire,5,7,25,53,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,2,6221,-1
6235,associated with,10,12,56,71,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,2,6235,-1
6243,antimycobacterial agent,3,5,17,40,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,-1,-1,2,6243,-1
6250,short-,13,14,87,93,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,2,6250,-1
6251,intermediate-,15,16,95,108,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,2,6251,-1
6260,RNFL,29,30,136,140,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,2,6260,-1
6261,analysis protocol,31,33,142,159,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,2,6261,-1
6262,optic nerve,8,10,49,60,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,-1,-1,2,6262,-1
6266,EMB-induced,6,7,32,43,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,2,6266,-1
6269,patient A,27,29,145,154,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,2,6269,-1
6271,patient B,43,45,218,227,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,2,6271,-1
6273,patient C,55,57,274,283,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,2,6273,-1
6278,patients B,16,18,77,87,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,-1,-1,2,6278,-1
6281,EMB-induced,9,10,52,63,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,2,6281,-1
6283,consistent with,2,4,8,23,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,2,6283,-1
6285,parvo-cellular,12,13,86,100,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,2,6285,-1
6286,small-caliber,16,17,111,124,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,2,6286,-1
6287,papillo-macular bundle,21,23,143,165,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,2,6287,-1
6291,EMB-induced,7,8,40,51,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,2,6291,-1
6295,renal ACE,3,5,26,35,Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage.,15572383_0,-1,-1,2,6295,-1
6300,renal ACE,8,10,58,67,This raises the hypothesis that individual differences in renal ACE activity are involved in renal susceptibility to inflicted damage.,15572383_2,-1,-1,2,6300,-1
6306,cortical homogenates,9,11,53,73,METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.,15572383_4,-1,-1,2,6306,-1
6308,Wistar rats,21,23,123,134,METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.,15572383_4,-1,-1,2,6308,-1
6315,renal interstitial alpha-smooth muscle actin,21,26,116,160,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,-1,2,6315,-1
6318,glomerular alpha-smooth muscle actin,56,60,278,314,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,-1,2,6318,-1
6319,glomerular desmin,68,70,338,355,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,-1,2,6319,-1
6320,renal ACE,1,3,9,18,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,2,6320,-1
6325,renal ACE,7,9,49,58,This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage.,15572383_14,-1,-1,2,6325,-1
6331,hypoxia-responsive reporter vector,8,11,34,68,"In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.",15579441_2,-1,-1,2,6331,-1
6332,hypoxia-responsive element,13,15,77,103,"In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.",15579441_2,-1,-1,2,6332,-1
6333,vascular endothelial growth factor untranslated region,19,25,114,168,"In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.",15579441_2,-1,-1,2,6333,-1
6340,hypoxia-responsive,3,4,18,36,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,-1,-1,2,6340,-1
6343,vascular endothelial growth factor,35,39,229,263,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,-1,-1,2,6343,-1
6348,labeled-positive cells,18,20,130,152,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,2,6348,-1
6365,group A,20,22,108,115,"After reduction of ribavirin, 27 of 37 patients could continue combination therapy for a total of 24 weeks (group A).",15580403_5,-1,-1,2,6365,-1
6370,group B,31,33,197,204,"However, 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their <8.5 g/dl hemoglobin values decreased to or anemia-related severe side effects occurred (group B).",15580403_6,-1,-1,2,6370,-1
6372,B. RESULTS,15,17,87,97,"We assessed the final efficacy and safety after reduction of ribavirin in groups A and B. RESULTS: A sustained virological response (SVR) was 29.6% (8/27) in group A and 10% (1/10) in group B, respectively.",15580403_7,-1,-1,2,6372,-1
6381,azithromycin-induced,8,9,47,67,"A 14-year-old girl is reported with recurrent, azithromycin-induced, acute interstitial nephritis.",15602202_1,-1,-1,2,6381,-1
6407,time periods,12,14,87,99,"Clinical characteristics, medications, and serum chemistries at baseline and follow-up time periods were compared.",15632880_6,-1,-1,2,6407,-1
6433,experimental group,4,6,15,33,"In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas T concentration was almost twice lower than that in the control group.",15638391_6,-1,-1,2,6433,-1
6436,control group,30,32,158,171,"In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas T concentration was almost twice lower than that in the control group.",15638391_6,-1,-1,2,6436,-1
6439,associated with,15,17,106,121,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,2,6439,-1
6443,protein synthesis,14,16,101,118,"Electron microscopy revealed changes in columnar epithelial cells, concerning organelles, engaged in protein synthesis and secretion.",15638391_8,-1,-1,2,6443,-1
6457,dual-perfusion technique,21,23,123,147,The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual-perfusion technique and with thallium-201 single-photon emission tomography (SPECT).,1564236_3,-1,-1,2,6457,-1
6463,dipyridamole-induced,1,2,7,27,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,2,6463,-1
6468,dipyridamole-induced,24,25,105,125,The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.,1564236_7,-1,-1,2,6468,-1
6472,dipyridamole-induced,12,13,82,102,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,2,6472,-1
6476,quantitate,11,12,72,82,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,2,6476,-1
6485,tardive dyskinesia,10,12,86,104,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,2,6485,-1
6514,balloon catheter,13,15,70,86,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,2,6514,-1
6525,morphine-induced spastic paraparesis,22,25,113,149,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,2,6525,-1
6526,cerebrospinal fluid,5,7,23,42,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,2,6526,-1
6528,group M,15,17,90,97,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,2,6528,-1
6529,group C,22,24,128,135,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,2,6529,-1
6532,morphine-induced spastic paraparesis,10,13,83,119,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,2,6532,-1
6542,antiarrhythmic drug,4,6,35,54,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,2,6542,-1
6564,no significant,9,11,68,82,"Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age, sex, duration of the treatment and starvation variables.",15737522_5,-1,-1,2,6564,-1
6573,quantitative assays,41,43,285,304,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,-1,2,6573,-1
6579,dose-related,26,27,165,177,"Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and stereotypies appears to be at least in part dose-related.",15764424_4,-1,-1,2,6579,-1
6594,routine control,11,13,64,79,The patient was asymptomatic and the aneurysm was detected in a routine control.,15804801_3,-1,-1,2,6594,-1
6597,treated with,4,6,29,41,The patient was successfully treated with a graft stent.,15804801_5,-1,-1,2,6597,-1
6598,graft stent,7,9,44,55,The patient was successfully treated with a graft stent.,15804801_5,-1,-1,2,6598,-1
6613,Drug-induced symptoms,2,4,12,33,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,2,6613,-1
6614,associated with,8,10,64,79,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,2,6614,-1
6626,very-low birth-weight infants,22,25,139,168,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,-1,-1,2,6626,-1
6629,Thirty-three children,0,2,0,21,Thirty-three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment.,15814210_2,-1,-1,2,6629,-1
6640,Kaufman Assessment Battery,21,24,145,171,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,-1,-1,2,6640,-1
6641,Draw-a-Man Test,28,30,191,206,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,-1,-1,2,6641,-1
6646,control group,12,14,76,89,Fine motor skills and gross motor function were significantly better in the control group (p<0.01).,15814210_8,-1,-1,2,6646,-1
6647,Draw-a-Man Test,2,4,7,22,"In the Draw-a-Man Test, the control group showed better results (p<0.001).",15814210_9,-1,-1,2,6647,-1
6648,control group,6,8,28,41,"In the Draw-a-Man Test, the control group showed better results (p<0.001).",15814210_9,-1,-1,2,6648,-1
6650,Kaufman Assessment Battery,14,17,80,106,"There were no differences in development of speech, social development, and the Kaufman Assessment Battery for Children.",15814210_10,-1,-1,2,6650,-1
6654,follow-up studies,2,4,18,35,Further long-term follow-up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development.,15814210_13,-1,-1,2,6654,-1
6668,VPA-associated,9,10,63,77,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,-1,2,6668,-1
6671,Sprague-Dawley rats,17,19,126,145,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,-1,2,6671,-1
6674,liver levels,8,10,56,68,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,2,6674,-1
6678,TBARs,25,26,160,165,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,2,6678,-1
6679,liver 15-F(2t)-IsoP,2,4,11,30,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,2,6679,-1
6681,Liver LPO,0,2,0,9,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,2,6681,-1
6690,beta-oxidation,4,5,20,34,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,-1,-1,2,6690,-1
6711,Pre- and posttransplant,0,3,0,23,Pre- and posttransplant crossmatching was done when possible.,15859940_5,-1,-1,2,6711,-1
6714,National Guard Hospital,13,16,79,102,"Three of these cases were from the 25 transplantations performed at King Fahad National Guard Hospital, while the other 2 transplantations had been performed abroad and were referred to us for follow-up.",15859940_7,-1,-1,2,6714,-1
6725,drug-related,3,4,21,33,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,-1,-1,2,6725,-1
6728,procoagulant status,11,13,71,90,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,-1,-1,2,6728,-1
6732,drug related,10,12,72,84,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,-1,-1,2,6732,-1
6739,non-selective,13,14,76,89,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,2,6739,-1
6743,pregnant rats,11,13,59,72,"METHODS: Drugs were separately, orally once daily dosed to pregnant rats from day 8 to 21 (GD1=plug day).",15863244_4,-1,-1,2,6743,-1
6744,GD1=plug day,19,21,91,103,"METHODS: Drugs were separately, orally once daily dosed to pregnant rats from day 8 to 21 (GD1=plug day).",15863244_4,-1,-1,2,6744,-1
6749,VSD,8,9,56,59,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,2,6749,-1
6761,exposure to,1,3,9,20,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,2,6761,-1
6765,historic control,16,18,100,116,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,2,6765,-1
6767,non-selective,5,6,31,44,CONCLUSION: Both selective and non-selective COX-2 inhibitors were toxic for rats fetuses when administered in the highest dose.,15863244_13,-1,-1,2,6767,-1
6773,hepatitis B,3,5,24,35,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,2,6773,-1
6774,rubella prevention,6,8,40,58,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,2,6774,-1
6776,hepatitis B,9,11,68,79,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,2,6776,-1
6777,rubella prevention,12,14,84,102,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,2,6777,-1
6779,paired mother-infant records,7,10,39,67,METHODS: Data were extracted from 2021 paired mother-infant records for the year 2000 birth cohort in New Hampshire's 25 delivery hospitals.,15867025_2,-1,-1,2,6779,-1
6781,New Hampshire's 25 delivery,17,22,102,129,METHODS: Data were extracted from 2021 paired mother-infant records for the year 2000 birth cohort in New Hampshire's 25 delivery hospitals.,15867025_2,-1,-1,2,6781,-1
6782,hepatitis B,10,12,61,72,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,2,6782,-1
6786,antigen-positive mothers,42,44,249,273,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,2,6786,-1
6789,rubella nonimmune,56,58,357,374,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,2,6789,-1
6791,hepatitis B,6,8,38,49,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,2,6791,-1
6792,Hepatitis B,0,2,0,11,Hepatitis B vaccine birth dose was administered to 76.2% of all infants.,15867025_5,-1,-1,2,6792,-1
6793,hepatitis B,6,8,29,40,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,2,6793,-1
6794,antigen-positive mothers,9,11,49,73,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,2,6794,-1
6795,hepatitis B,13,15,88,99,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,2,6795,-1
6799,rubella nonimmunity,13,15,66,85,Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity (9.5%).,15867025_9,-1,-1,2,6799,-1
6801,study documents,3,5,17,32,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,2,6801,-1
6803,national guidelines,14,16,92,111,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,2,6803,-1
6805,rubella prevention,21,23,142,160,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,2,6805,-1
6832,DNA cleavage,21,23,160,172,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,2,6832,-1
6839,B6D2F1 mice,5,7,19,30,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,-1,-1,2,6839,-1
6845,Nontoxic doses,2,4,9,23,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,2,6845,-1
6872,associated with,3,5,25,40,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,-1,-1,2,6872,-1
6876,illicit drug,3,5,19,31,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,-1,-1,2,6876,-1
6881,Thyroid-stimulating hormone,0,2,0,27,"Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied.",15899738_6,-1,-1,2,6881,-1
6888,animal products,19,21,101,116,"Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products.",15899738_11,-1,-1,2,6888,-1
6894,associated with,10,12,55,70,"In addition, it is important to report adverse effects associated with frequently consumed supplements and herbal products to the Food and Drug Administration and in the literature.",15899738_14,-1,-1,2,6894,-1
6898,t1/2,3,4,15,19,"The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.",1592014_1,-1,-1,2,6898,-1
6902,unanesthetized,19,20,104,118,Two separate equimolar doses (0.2 and 0.4 mumol) of either cocaine or BE were injected ventricularly in unanesthetized juvenile rats.,1592014_4,-1,-1,2,6902,-1
6909,cocaine-injected animals,13,15,91,115,BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.,1592014_9,-1,-1,2,6909,-1
6911,BE-induced,5,6,30,40,"The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.",1592014_10,-1,-1,2,6911,-1
6918,single-intervention study,7,9,33,58,"METHODS: This was a prospective, single-intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28, 2002, and October 31, 2003.",15930398_2,-1,-1,2,6918,-1
6922,1-minute,1,2,3,11,"At 1-minute intervals during the procedural sedation, until the patient regained baseline mental status at the end of the procedure, a word from a standardized list was read aloud, and the patient was asked to immediately repeat the word to the investigator.",15930398_4,-1,-1,2,6922,-1
6924,standardized list,26,28,147,164,"At 1-minute intervals during the procedural sedation, until the patient regained baseline mental status at the end of the procedure, a word from a standardized list was read aloud, and the patient was asked to immediately repeat the word to the investigator.",15930398_4,-1,-1,2,6924,-1
6925,read aloud,29,31,169,179,"At 1-minute intervals during the procedural sedation, until the patient regained baseline mental status at the end of the procedure, a word from a standardized list was read aloud, and the patient was asked to immediately repeat the word to the investigator.",15930398_4,-1,-1,2,6925,-1
6926,patient's,12,14,52,61,The BIS score at the time the word was read and the patient's ability to repeat the word were recorded.,15930398_5,-1,-1,2,6926,-1
6929,procedural sedations,8,10,48,68,No serious adverse events were noted during the procedural sedations.,15930398_8,-1,-1,2,6929,-1
6930,data collection,9,11,41,56,The mean (+/-standard deviation) time of data collection was 16.4 minutes (+/-7.1; range 5 to 34 minutes).,15930398_9,-1,-1,2,6930,-1
6933,procedural sedations,8,10,49,69,The mean lowest BIS score occurring during these procedural sedations was 66.9 (+/-14.4; range 33 to 91).,15930398_11,-1,-1,2,6933,-1
6934,/-14.4,14,15,81,87,The mean lowest BIS score occurring during these procedural sedations was 66.9 (+/-14.4; range 33 to 91).,15930398_11,-1,-1,2,6934,-1
6935,words read,15,17,92,102,The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77.1 (95% CI = 74.3 to 80.0).,15930398_12,-1,-1,2,6935,-1
6936,words read,17,19,93,103,CONCLUSIONS: There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words.,15930398_18,-1,-1,2,6936,-1
6937,associated with,16,18,97,112,"Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde amnesia.",15930398_19,-1,-1,2,6937,-1
6944,mechanism(s),3,5,24,36,"Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.",15957009_2,-1,-1,2,6944,-1
6968,serotonergic memory deficit,19,22,116,143,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,2,6968,-1
6971,antiarrhythmic agent,4,6,27,47,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,-1,-1,2,6971,-1
6983,formalin-induced paw licking,17,20,85,113,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,2,6983,-1
6985,capsaicin-induced,26,27,161,178,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,2,6985,-1
6987,associated by,9,11,50,63,OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.,15985056_1,-1,-1,2,6987,-1
6991,associated with,7,9,60,75,DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups.,15985056_6,-1,-1,2,6991,-1
6996,Naranjo adverse effect reaction probability scale,2,8,10,59,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,-1,-1,2,6996,-1
7001,associated with,9,11,59,74,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,-1,-1,2,7001,-1
7006,cocaine overdose,11,13,82,98,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,2,7006,-1
7007,illicit use of,1,4,4,18,The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.,16005948_1,-1,-1,2,7007,-1
7008,cocaine overdose,12,14,79,95,The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.,16005948_1,-1,-1,2,7008,-1
7009,protein-based technology,1,3,8,32,"Current protein-based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream, inactivating its toxic effects.",16005948_2,-1,-1,2,7009,-1
7014,cocaine overdose,14,16,92,108,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,2,7014,-1
7015,Swiss albino mice,0,3,0,17,Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.,16005948_4,-1,-1,2,7015,-1
7021,cocaine toxicity,3,5,24,40,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,2,7021,-1
7027,therapeutic tool,10,12,60,76,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,2,7027,-1
7028,cocaine overdose,13,15,85,101,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,2,7028,-1
7029,Calcium carbonate toxicity,0,3,0,26,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,-1,-1,2,7029,-1
7030,milk-alkali syndrome,6,8,40,60,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,-1,-1,2,7030,-1
7044,milk-alkali syndrome,20,22,121,141,"In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of milk-alkali syndrome and summarize the cases reported from early 1995 to November 2003.",16006300_8,-1,-1,2,7044,-1
7045,Milk-alkali syndrome,2,4,12,32,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,-1,-1,2,7045,-1
7053,electrocardiograms (,1,3,4,24,The electrocardiograms (ECG) of 99 cocaine-abusing patients were compared with the ECGs of 50 schizophrenic controls.,1601297_1,-1,-1,2,7053,-1
7054,cocaine-abusing patients,7,9,35,59,The electrocardiograms (ECG) of 99 cocaine-abusing patients were compared with the ECGs of 50 schizophrenic controls.,1601297_1,-1,-1,2,7054,-1
7058,Warfarin-induced,0,1,0,16,Warfarin-induced leukocytoclastic vasculitis.,16047871_0,-1,-1,2,7058,-1
7060,associated with,2,4,15,30,Skin reactions associated with oral coumarin-derived anticoagulants are an uncommon occurrence.,16047871_1,-1,-1,2,7060,-1
7062,late-onset,5,6,26,36,We report 4 patients with late-onset LV probably due to warfarin.,16047871_3,-1,-1,2,7062,-1
7067,late-onset,4,5,12,22,LV may be a late-onset adverse reaction associated with warfarin therapy.,16047871_7,-1,-1,2,7067,-1
7069,associated with,7,9,40,55,LV may be a late-onset adverse reaction associated with warfarin therapy.,16047871_7,-1,-1,2,7069,-1
7073,bilateral brainstem,13,15,102,121,A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.,1610717_1,-1,-1,2,7073,-1
7074,WKY,19,20,144,147,A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.,1610717_1,-1,-1,2,7074,-1
7076,chronic administration,36,38,244,266,A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.,1610717_1,-1,-1,2,7076,-1
7077,electrode implant,1,3,4,21,The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations.,1610717_2,-1,-1,2,7077,-1
7082,perturbated,14,15,107,118,"Cocaine generated more abnormal behaviors in the brainstem perturbation group, especially the electrically perturbated subjects.",1610717_4,-1,-1,2,7082,-1
7099,serotonergic cellular elements,9,12,64,94,Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated.,1610717_10,-1,-1,2,7099,-1
7100,rTMS,0,1,0,4,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,-1,-1,2,7100,-1
7107,SMA,14,15,93,96,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,2,7107,-1
7113,Intracavitary chemotherapy,0,2,0,26,Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.,16132524_0,-1,-1,2,7113,-1
7114,paclitaxel/carboplatin liquid crystalline cubic phases,3,8,28,82,Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.,16132524_0,-1,-1,2,7114,-1
7117,spite of surgery,9,12,54,70,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,-1,-1,2,7117,-1
7118,radiation therapy,13,15,75,92,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,-1,-1,2,7118,-1
7123,gel-like matrix,9,11,40,55,"Used as a host for cytotoxic drugs, the gel-like matrix can easily be applied to the walls of a surgical resection cavity.",16132524_3,-1,-1,2,7123,-1
7130,glioblastoma multiforme,10,12,46,69,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,-1,-1,2,7130,-1
7131,re-resection,13,14,80,92,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,-1,-1,2,7131,-1
7132,intracavitary,17,18,109,122,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,-1,-1,2,7132,-1
7139,Intracavitary,0,1,0,13,"Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe, yet the clinical benefit remains to be examined in a clinical phase II study.",16132524_8,-1,-1,2,7139,-1
7140,cubic phases,6,8,59,71,"Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe, yet the clinical benefit remains to be examined in a clinical phase II study.",16132524_8,-1,-1,2,7140,-1
7152,MJ,25,26,157,159,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,2,7152,-1
7155,dose-dependent,9,10,43,57,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,2,7155,-1
7166,i.c.v,2,3,25,30,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,-1,2,7166,-1
7167,thyrotropin secretion,16,18,116,137,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,-1,2,7167,-1
7170,effects of,8,10,36,46,"In the present study, we tested the effects of i.c.v.",16160878_4,-1,-1,2,7170,-1
7176,dose-dependent,18,19,75,89,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7176,-1
7178,hole-board test,28,30,134,149,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7178,-1
7179,dose-dependent,35,36,157,171,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7179,-1
7180,white chamber,44,46,214,227,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7180,-1
7181,central platform,60,62,305,321,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7181,-1
7182,plus-maze test,67,69,343,357,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7182,-1
7183,dose-dependent,75,76,369,383,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,-1,-1,2,7183,-1
7199,apomorphine-induced penile erection,19,22,106,141,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,-1,-1,2,7199,-1
7201,stress-induced plasma,27,29,169,190,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,-1,-1,2,7201,-1
7205,anxiogenic-,21,22,120,131,"Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/mouse induces anxiogenic- and depressant-like effects in mouse.",16160878_9,-1,-1,2,7205,-1
7212,drug states,13,15,76,87,In Group 2 the rats were trained to approach different shelves in different drug states.,1616457_4,-1,-1,2,7212,-1
7224,plasminogen activator inhibitor-1,36,39,225,258,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,2,7224,-1
7226,Thirty-nine postmenopausal,2,4,9,35,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,-1,-1,2,7226,-1
7230,Age-matched controls,0,2,0,20,Age-matched controls (n = 14) were given only calcium.,16167916_3,-1,-1,2,7230,-1
7234,Wilcoxon's test,6,9,43,58,Variations of individuals were assessed by Wilcoxon's test.,16167916_5,-1,-1,2,7234,-1
7237,associated with,8,10,50,65,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,2,7237,-1
7266,unpaired t-tests,43,45,267,283,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,-1,-1,2,7266,-1
7273,unpaired t-tests,53,55,337,353,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,-1,-1,2,7273,-1
7281,associated with,31,33,224,239,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,-1,-1,2,7281,-1
7285,kinase-related pathways,6,8,46,69,Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness.,16192988_0,-1,-1,2,7285,-1
7288,METH-induced,8,9,53,65,This increase in aggressiveness was not secondary to METH-induced hyperactivity.,16192988_3,-1,-1,2,7288,-1
7290,antibody microarrays,5,7,37,57,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,2,7290,-1
7293,kinase-related pathways,15,17,116,139,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,2,7293,-1
7302,statistically significant,8,10,35,60,"In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of METH.",16192988_7,-1,-1,2,7302,-1
7304,kinase-related pathways,7,9,47,70,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,2,7304,-1
7305,prefronto-striatal circuitries,11,13,78,108,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,2,7305,-1
7329,drug withdrawal,5,7,37,52,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,-1,-1,2,7329,-1
7331,acitretin-induced,10,11,44,61,"To our knowledge, this is the first case of acitretin-induced dysphonia.",16274958_3,-1,-1,2,7331,-1
7346,gentamicin ototoxicity,8,10,61,83,Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.,16298782_0,-1,-1,2,7346,-1
7365,high-frequency,7,8,54,68,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,-1,-1,2,7365,-1
7367,12-week,21,22,127,134,"Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study.",16330293_0,-1,-1,2,7367,-1
7368,open-label study,25,27,148,164,"Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study.",16330293_0,-1,-1,2,7368,-1
7373,open-label study,9,11,45,61,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,2,7373,-1
7377,Patients',0,2,0,9,"Patients' mean age was 53.9 years, their mean weight was 193.9 pounds, and they smoked a mean of 25.2 cigarettes per day at baseline.",16330293_9,-1,-1,2,7377,-1
7378,mean age,2,4,10,18,"Patients' mean age was 53.9 years, their mean weight was 193.9 pounds, and they smoked a mean of 25.2 cigarettes per day at baseline.",16330293_9,-1,-1,2,7378,-1
7379,mean weight,9,11,41,52,"Patients' mean age was 53.9 years, their mean weight was 193.9 pounds, and they smoked a mean of 25.2 cigarettes per day at baseline.",16330293_9,-1,-1,2,7379,-1
7385,product use,15,17,80,91,"Stratification of patients by sex, age, extent of concurrent smoking, extent of product use, and severity of adverse events revealed no clinically significant differences between the lozenge and gum.",16330293_13,-1,-1,2,7385,-1
7411,effects of,9,11,40,50,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,-1,-1,2,7411,-1
7415,nociceptive information,25,27,133,156,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,-1,-1,2,7415,-1
7419,gabapentin-induced modulation,15,17,88,117,"Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.",16330766_5,-1,-1,2,7419,-1
7427,stimulus-induced deactivations,45,47,270,300,"We found that (i) gabapentin reduced the activations in the bilateral operculoinsular cortex, independently of the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, only during central sensitization; this effect was more robust than the effect on brain activation.",16330766_7,-1,-1,2,7427,-1
7430,drug-induced effects,2,4,13,33,The observed drug-induced effects were not due to changes in the baseline fMRI signal.,16330766_8,-1,-1,2,7430,-1
7431,antinociceptive effect,8,10,57,79,"These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation, thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present.",16330766_9,-1,-1,2,7431,-1
7450,complex IV,36,38,212,222,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,2,7450,-1
7454,DNA analysis,0,2,0,12,DNA analysis revealed low amounts of a 4.8 kb mtDNA deletion but with no differences in frequency or quantity in the control and experimental groups.,16337777_4,-1,-1,2,7454,-1
7456,experimental groups,23,25,129,148,DNA analysis revealed low amounts of a 4.8 kb mtDNA deletion but with no differences in frequency or quantity in the control and experimental groups.,16337777_4,-1,-1,2,7456,-1
7467,published studies,9,11,75,92,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,-1,-1,2,7467,-1
7472,Effects of,0,2,0,10,Effects of suprofen on the isolated perfused rat kidney.,1636026_0,-1,-1,2,7472,-1
7499,Microinjection,0,1,0,14,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,-1,-1,2,7499,-1
7501,CA1 region,5,7,38,48,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,-1,-1,2,7501,-1
7506,MWM,20,21,133,136,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,-1,2,7506,-1
7507,CA1 region,10,12,68,78,Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus.,16364460_2,-1,-1,2,7507,-1
7521,cannulae,64,65,346,354,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,2,7521,-1
7523,MWM,12,13,63,66,Animals were tested for four consecutive days (4 trial/day) in MWM during which the position of hidden platform was unchanged.,16364460_4,-1,-1,2,7523,-1
7524,hidden platform,18,20,96,111,Animals were tested for four consecutive days (4 trial/day) in MWM during which the position of hidden platform was unchanged.,16364460_4,-1,-1,2,7524,-1
7525,water surface,11,13,54,67,"In the fifth day, the platform was elevated above the water surface in another position to evaluate the function of motor, motivational and visual systems.",16364460_5,-1,-1,2,7525,-1
7529,Ritanserin-treated rats,0,2,0,23,Ritanserin-treated rats (4 microg/0.5 microl/side) showed a significant decrease in the mentioned parameters as compared to DMSO-treated group.,16364460_7,-1,-1,2,7529,-1
7534,microinjection,4,5,23,37,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,-1,-1,2,7534,-1
7536,CA1 region,9,11,61,71,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,-1,-1,2,7536,-1
7545,/- 4 mm Hg,14,18,70,80,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,2,7545,-1
7548,Sham-operated,0,1,0,13,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,2,7548,-1
7549,normotensive controls,4,6,29,50,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,2,7549,-1
7561,/- 2,12,14,80,84,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,-1,2,7561,-1
7562,/-,18,19,107,109,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,-1,2,7562,-1
7563,/- 9 mg/24,24,27,133,143,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,-1,2,7563,-1
7566,/-,19,20,147,149,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,-1,-1,2,7566,-1
7567,/-,24,25,167,169,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,-1,-1,2,7567,-1
7570,/-,14,15,81,83,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,-1,-1,2,7570,-1
7571,mm2,18,19,96,99,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,-1,-1,2,7571,-1
7573,/-,29,30,149,151,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,-1,-1,2,7573,-1
7574,mm2,33,34,164,167,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,-1,-1,2,7574,-1
7575,/-,43,44,216,218,"In addition, glomerular size was higher in the nitrendipine-treated group (14.9 +/- 0.17 10(-3) mm2) but lower in the enalapril-treated group (11.5 +/- 0.15 10(-3) mm2) compared with the hypertensive controls (12.1 +/- 0.17 10(-3) mm2).(ABSTRACT TRUNCATED AT 250 WORDS)",1639466_11,-1,-1,2,7575,-1
7591,cardiac IKr channel proteins,12,16,65,93,Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins.,16403073_4,-1,-1,2,7591,-1
7595,TdP.,21,22,120,124,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,-1,-1,2,7595,-1
7599,PTU-associated,0,1,0,14,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,2,7599,-1
7604,antineutrophil cytoplasmic antibodies,13,16,73,110,"A rare cause, drug-induced vasculitis, may result from the production of antineutrophil cytoplasmic antibodies (ANCAs) in response to a medication.",16418614_2,-1,-1,2,7604,-1
7613,radioablation,6,7,56,69,"Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis, a complication described in prior case reports.",16418614_5,-1,-1,2,7613,-1
7623,Alzheimer's disease,33,36,203,222,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,2,7623,-1
7629,active component,9,11,59,75,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,-1,-1,2,7629,-1
7632,effects of,5,7,28,38,"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.",16428827_4,-1,-1,2,7632,-1
7635,scopolamine-induced impairments,12,14,78,109,"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.",16428827_4,-1,-1,2,7635,-1
7638,body weight,6,8,38,49,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,2,7638,-1
7639,Y-maze test,25,27,153,164,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,2,7639,-1
7640,Y-maze tests,10,12,72,84,Injections of scopolamine into mice resulted in impaired performance on Y-maze tests (a 37% decreases in alternation behavior).,16428827_6,-1,-1,2,7640,-1
7658,King Chulalongkorn Memorial Hospital,22,26,103,139,"MATERIAL AND METHOD: Thirty women (aged 30-77 years) diagnosed as having OAB at the Gynecology Clinic, King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study.",16471092_2,-1,-1,2,7658,-1
7663,/-,2,3,3,5,7 +/- 5. 3 to 6. 7 +/- 2.4 times per day.,16471092_7,-1,-1,2,7663,-1
7664,/-,11,12,20,22,7 +/- 5. 3 to 6. 7 +/- 2.4 times per day.,16471092_7,-1,-1,2,7664,-1
7665,/-,9,10,52,54,The number of nocturia episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.,16471092_8,-1,-1,2,7665,-1
7666,/-,14,15,67,69,The number of nocturia episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.,16471092_8,-1,-1,2,7666,-1
7685,double-blind study,7,9,31,49,"DESIGN: This was a randomized, double-blind study.",16563323_2,-1,-1,2,7685,-1
7686,university hospital,8,10,38,57,SETTING: The study was conducted at a university hospital.,16563323_3,-1,-1,2,7686,-1
7687,randomized double-blinded fashion,8,11,46,79,PATIENTS: Sixty patients were pretreated in a randomized double-blinded fashion with remifentanil 1 microg/kg or placebo.,16563323_4,-1,-1,2,7687,-1
7709,general drug use questionnaire,12,16,85,115,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,7709,-1
7710,Brixton Spatial Anticipation task,18,22,121,154,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,7710,-1
7713,Return (,38,40,234,242,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,7713,-1
7715,Tromso Social Intelligence Scale,49,53,292,324,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,7715,-1
7716,Dysexecutive Questionnaire,55,57,333,359,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,-1,-1,2,7716,-1
7719,drug use,10,12,73,81,The latter two deficits remained significant after controlling for other drug use.,16574712_5,-1,-1,2,7719,-1
7726,5-HT neurotoxic,33,35,214,229,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,2,7726,-1
7733,promoter gene region,32,35,202,222,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,2,7733,-1
7736,effects of,9,11,44,54,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,2,7736,-1
7738,genotyped,33,34,176,185,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,2,7738,-1
7740,ex-MDMA+ users,23,25,100,114,"Fifteen moderate MDMA users (<55 lifetime tablets), 22 heavy MDMA+ users (>55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests.",16574713_5,-1,-1,2,7740,-1
7743,genotyped,7,8,44,53,DNA from peripheral nuclear blood cells was genotyped for 5-HTTLPR using standard polymerase chain reaction methods.,16574713_6,-1,-1,2,7743,-1
7745,standard polymerase chain reaction methods,11,16,73,115,DNA from peripheral nuclear blood cells was genotyped for 5-HTTLPR using standard polymerase chain reaction methods.,16574713_6,-1,-1,2,7745,-1
7756,heavy use,22,24,122,131,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,2,7756,-1
7757,No effect,0,2,0,9,No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.,16574713_12,-1,-1,2,7757,-1
7761,antioxidant status,7,9,50,68,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,2,7761,-1
7763,study dealt,2,4,12,23,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,2,7763,-1
7771,Subcutaneous injection,0,2,0,22,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,2,7771,-1
7773,body weight,7,9,42,53,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,2,7773,-1
7783,antioxidant enzymes,3,5,17,36,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,2,7783,-1
7795,body weight,7,9,45,56,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,2,7795,-1
7798,above-mentioned parameters,27,29,160,186,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,2,7798,-1
7799,normal levels,33,35,204,217,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,2,7799,-1
7804,ISPH-induced,19,20,155,167,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,2,7804,-1
7806,ISPH-induced,14,15,90,102,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,2,7806,-1
7812,differences?Randomised,11,12,92,114,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,2,7812,-1
7821,cardiac prostanoid profiles,10,13,71,98,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,-1,-1,2,7821,-1
7826,total exposure time,14,17,89,108,The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time.,16586083_3,-1,-1,2,7826,-1
7828,substance-specific differences,10,12,88,118,"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.",16586083_4,-1,-1,2,7828,-1
7831,prostaglandin-independent effects,29,31,230,263,"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.",16586083_4,-1,-1,2,7831,-1
7836,Pilocarpine seizures,0,2,0,20,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,-1,-1,2,7836,-1
7843,Sprague-Dawley rats,1,3,5,24,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,-1,-1,2,7843,-1
7844,convulsant,17,18,81,91,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,-1,-1,2,7844,-1
7852,sound-source,5,6,30,42,Mature rats were trained with sound-source location and sound-silence discriminations.,16596970_6,-1,-1,2,7852,-1
7853,sound-silence discriminations,8,10,56,85,Mature rats were trained with sound-source location and sound-silence discriminations.,16596970_6,-1,-1,2,7853,-1
7856,P20,4,5,23,26,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,-1,-1,2,7856,-1
7857,sound-source location,11,13,53,74,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,-1,-1,2,7857,-1
7859,sound-source location,10,12,55,76,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,-1,-1,2,7859,-1
7860,sound-silence discriminations,13,15,80,109,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,-1,-1,2,7860,-1
7862,age-dependent,6,7,36,49,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,2,7862,-1
7869,study groups,5,7,27,39,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,2,7869,-1
7878,enzyme-linked immunosorbent assay,10,13,50,83,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,2,7878,-1
7898,hepatitis C,3,5,23,34,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,-1,2,7898,-1
7914,hepatitis C.,29,31,189,201,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,2,7914,-1
7919,alcohol-related fetal growth impairment,9,13,58,97,This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.,16634859_3,-1,-1,2,7919,-1
7921,pregnant hazardous drinkers,13,16,92,119,METHODS: We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study.,16634859_4,-1,-1,2,7921,-1
7923,associated with,6,8,44,59,"Because intensity of alcohol consumption is associated with poorer fetal outcomes, separate analyses were conducted for the heavy (average of >or=5 drinks per drinking day) alcohol consumers.",16634859_6,-1,-1,2,7923,-1
7926,heavy-exposed,4,5,24,37,"Fetal measures from the heavy-exposed fetuses were also compared with measures from a nondrinking group that was representative of normal, uncomplicated pregnancies from our clinics.",16634859_7,-1,-1,2,7926,-1
7927,nondrinking group,13,15,86,103,"Fetal measures from the heavy-exposed fetuses were also compared with measures from a nondrinking group that was representative of normal, uncomplicated pregnancies from our clinics.",16634859_7,-1,-1,2,7927,-1
7931,pregnant drinkers,6,8,28,45,RESULTS: Nearly half of the pregnant drinkers abstained after learning of their pregnancies.,16634859_9,-1,-1,2,7931,-1
7932,drinking early,4,6,27,41,"When women reportedly quit drinking early in their pregnancies, fetal growth measures were not significantly different from a non-alcohol-exposed group, regardless of prior drinking patterns.",16634859_10,-1,-1,2,7932,-1
7939,quit drinking,28,30,193,206,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,2,7939,-1
7942,heavy drinkers,11,13,81,95,CONCLUSIONS: Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies.,16634859_13,-1,-1,2,7942,-1
7943,self-reported,4,5,25,38,"Although the reliance on self-reported drinking is a limitation in this study, these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects.",16634859_14,-1,-1,2,7943,-1
7953,surgery/radiotherapy,31,32,164,184,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,2,7953,-1
7954,phase I trial,51,54,266,279,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,2,7954,-1
7956,Grade less,0,2,0,10,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,-1,2,7956,-1
7958,response lasting,9,11,58,74,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,-1,-1,2,7958,-1
7966,CYP2D6 activity,13,15,70,85,"The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.",16680561_2,-1,-1,2,7966,-1
7968,genotyped,6,7,37,46,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,2,7968,-1
7971,open-label,17,18,114,124,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,2,7971,-1
7972,crossover study,19,21,126,141,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,2,7972,-1
7978,postdose,10,11,51,59,Blood samples were obtained predose and up to 72 h postdose.,16680561_4,-1,-1,2,7978,-1
7979,treatment arms,6,8,42,56,RESULTS: Fourteen subjects completed both treatment arms.,16680561_5,-1,-1,2,7979,-1
7980,C(max,8,9,44,49,"Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.",16680561_6,-1,-1,2,7980,-1
7983,t (max,1,4,4,10,The t (max) was similar between the regimens.,16680561_8,-1,-1,2,7983,-1
8014,associated with,5,7,33,48,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,-1,2,8014,-1
8036,patient's,9,11,44,53,"7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).",16720068_7,-1,-1,2,8036,-1
8039,NMS-like,16,17,102,110,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,2,8039,-1
8043,patient's,22,24,132,141,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,2,8043,-1
8045,combined treatment,29,31,176,194,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,2,8045,-1
8049,Down-regulation,0,1,0,15,Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.,16725121_0,-1,-1,2,8049,-1
8053,chronic inhibition,9,11,60,78,Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.,16725121_1,-1,-1,2,8053,-1
8056,Co-administration,0,1,0,17,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,-1,-1,2,8056,-1
8060,Co-administration,0,1,0,17,Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.,16725121_6,-1,-1,2,8060,-1
8061,down-regulation,4,5,27,42,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,-1,2,8061,-1
8064,desipramine-induced sensitization,18,20,130,163,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,-1,2,8064,-1
8065,lidocaine convulsions,21,23,167,188,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,-1,2,8065,-1
8066,Na(+) channels,2,5,14,28,Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.,16725121_8,-1,-1,2,8066,-1
8068,desipramine-induced,10,11,63,82,Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.,16725121_8,-1,-1,2,8068,-1
8069,down-regulation,11,12,83,98,Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.,16725121_8,-1,-1,2,8069,-1
8070,up-regulation,5,6,43,56,Repeated administration of cocaine induces up-regulation of hippocampal NET function.,16725121_9,-1,-1,2,8070,-1
8072,Desipramine-induced sensitization,0,2,0,33,Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.,16725121_10,-1,-1,2,8072,-1
8079,newspaper report,10,12,53,69,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,2,8079,-1
8082,Alzheimer's disease,19,22,118,137,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,2,8082,-1
8089,HPLC-mass spectrometry,17,19,98,120,Carbachol concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry.,16740173_6,-1,-1,2,8089,-1
8090,oral administration,4,6,23,42,"RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed.",16740173_7,-1,-1,2,8090,-1
8099,High doses,0,2,0,10,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,-1,-1,2,8099,-1
8108,Serum samples,0,2,0,13,"Serum samples from the first and second days contained 3.6 and 1.9 mg/l carbachol, respectively.",16740173_18,-1,-1,2,8108,-1
8111,media report,7,9,37,49,"CONCLUSION: This case started with a media report in a popular newspaper, initiated by published, peer-reviewed research on herbals, and involved human failure in a case history, medical examination and clinical treatment.",16740173_20,-1,-1,2,8111,-1
8116,analytical method,6,8,23,40,"For the first time, an analytical method for the determination of carbachol in plasma and urine has been developed.",16740173_21,-1,-1,2,8116,-1
8119,therapeutic dose,12,14,88,104,The analysed carbachol concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260.,16740173_22,-1,-1,2,8119,-1
8125,effects of,8,10,49,59,"The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice.",16755009_1,-1,-1,2,8125,-1
8129,ethanolic extract,1,3,4,21,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,-1,-1,2,8129,-1
8142,young mice,27,29,116,126,The extent of memory improvement evoked by DCE was 23% at the dose of 200 mg/kg and 35% at the dose of 400 mg/kg in young mice using elevated plus maze.,16755009_6,-1,-1,2,8142,-1
8145,passive avoidance apparatus,10,13,73,100,"Similarly, significant improvements in memory scores were observed using passive avoidance apparatus and aged mice.",16755009_7,-1,-1,2,8145,-1
8146,aged mice,14,16,105,114,"Similarly, significant improvements in memory scores were observed using passive avoidance apparatus and aged mice.",16755009_7,-1,-1,2,8146,-1
8149,brain acetylcholinesterase activity,15,18,71,106,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.",16755009_9,-1,-1,2,8149,-1
8152,aged mice,26,28,125,134,The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice.,16755009_10,-1,-1,2,8152,-1
8156,anticholinesterase activity,34,36,212,239,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,2,8156,-1
8159,associated to,16,18,95,108,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,-1,-1,2,8159,-1
8163,broad-spectrum antiepileptic drug,7,10,25,58,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,2,8163,-1
8172,Sprague-Dawley rats,17,19,112,131,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,2,8172,-1
8178,SBP,6,7,39,42,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,2,8178,-1
8179,/-,11,12,54,56,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,2,8179,-1
8180,/- 0.6 mmHg,16,19,69,80,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,2,8180,-1
8181,/-,31,32,133,135,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,2,8181,-1
8187,/-,17,18,80,82,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,2,8187,-1
8188,/-,22,23,95,97,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,2,8188,-1
8194,/-,35,36,151,153,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,2,8194,-1
8198,saline-treated rats,12,14,75,94,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,-1,-1,2,8198,-1
8199,/-,17,18,102,104,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,-1,-1,2,8199,-1
8200,/-,23,24,124,126,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,-1,-1,2,8200,-1
8213,consolidation therapy,28,30,142,163,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,-1,-1,2,8213,-1
8218,peroneal nerves,9,11,81,96,Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.,16826348_5,-1,-1,2,8218,-1
8228,methamphetamine-induced,6,7,47,70,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,-1,-1,2,8228,-1
8231,associated with,8,10,74,89,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,-1,-1,2,8231,-1
8232,free radicals,14,16,117,130,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,-1,-1,2,8232,-1
8235,reactive oxygen species,14,17,78,101,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,2,8235,-1
8238,MA-induced,30,31,152,162,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,2,8238,-1
8257,MA-induced,8,9,51,61,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,-1,-1,2,8257,-1
8261,drug-drug interactions,9,11,60,82,Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions.,16858720_0,-1,-1,2,8261,-1
8264,warfarin-drug interactions,18,20,126,152,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,2,8264,-1
8268,warfarin-drug interactions,10,12,78,104,Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.,16858720_2,-1,-1,2,8268,-1
8270,drug interactions,8,10,50,67,The proportion of possibly avoidable cases due to drug interactions was estimated.,16858720_3,-1,-1,2,8270,-1
8272,"1.7/100,000 treatment",5,7,27,48,"This imply an incidence of 1.7/100,000 treatment years.",16858720_5,-1,-1,2,8272,-1
8275,warfarin-drug interaction,1,3,2,27,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,-1,-1,2,8275,-1
8279,warfarin-drug interaction,9,11,42,67,Almost half of the cases was related to a warfarin-drug interaction.,16858720_9,-1,-1,2,8279,-1
8286,apomorphine-induced climbing behavior,17,20,120,157,"The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.",16867021_2,-1,-1,2,8286,-1
8287,amphetamine-induced locomotor activities,21,24,162,202,"The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.",16867021_2,-1,-1,2,8287,-1
8291,i.c.v,7,8,43,48,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,2,8291,-1
8295,dose-dependent,21,22,91,105,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,2,8295,-1
8303,no effect,26,28,131,140,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,2,8303,-1
8314,antipsychotic-like profile,3,5,17,43,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,-1,-1,2,8314,-1
8315,apomorphine-induced climbing,15,17,147,175,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,-1,-1,2,8315,-1
8320,mice.1,12,13,72,78,Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.1.,1687392_0,-1,-1,2,8320,-1
8328,dose-dependent,7,8,45,59,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,-1,-1,2,8328,-1
8370,right leg,7,9,54,63,Deep-tendon reflexes were decreased especially in the right leg.,16904497_12,-1,-1,2,8370,-1
8375,associated with,3,5,26,41,CONCLUSION: Complications associated with epidural steroid injections are rare.,16904497_17,-1,-1,2,8375,-1
8380,population-based study,4,6,14,36,"METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.",16938416_2,-1,-1,2,8380,-1
8396,Hepatitis B,0,2,0,11,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,2,8396,-1
8400,Asian countries,22,24,128,143,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,2,8400,-1
8402,standard medical therapies,22,25,142,168,"Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.",16960342_2,-1,-1,2,8402,-1
8403,decompensated,9,10,46,59,"In this report, we encountered a patient with decompensated HBV-related cirrhosis who exhibited the dramatic improvements after antiviral therapy.",16960342_3,-1,-1,2,8403,-1
8404,HBV-related,10,11,60,71,"In this report, we encountered a patient with decompensated HBV-related cirrhosis who exhibited the dramatic improvements after antiviral therapy.",16960342_3,-1,-1,2,8404,-1
8406,medical treatments,2,4,22,40,"Previous conventional medical treatments were not effective for this patient, thus this patient had been referred to our hospital.",16960342_5,-1,-1,2,8406,-1
8409,drug resistant,5,7,23,37,"During this period, no drug resistant mutant HBV emerged, and the serum HBV-DNA level was continuously suppressed.",16960342_7,-1,-1,2,8409,-1
8414,hepatitis B,3,5,15,26,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,-1,-1,2,8414,-1
8416,HBV-related,7,8,50,61,"The administration of lamivudine to patients with HBV-related cirrhosis, like our present case, should be considered as an initial medical therapeutic option, especially in countries where liver transplantation is not reliably available.",16960342_10,-1,-1,2,8416,-1
8427,pentobarbital-anesthetized dogs,24,26,137,168,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,2,8427,-1
8428,Adrenaline arrhythmia,0,2,0,21,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,2,8428,-1
8429,halothane-anesthetized dogs,17,19,105,132,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,2,8429,-1
8432,/-,15,16,123,125,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,2,8432,-1
8433,/-,20,21,139,141,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,2,8433,-1
8434,/- SD,28,30,181,186,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,2,8434,-1
8435,lower dose,1,3,2,12,"A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.",1700207_7,-1,-1,2,8435,-1
8439,/-,15,16,123,125,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,2,8439,-1
8440,/-,20,21,140,142,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,2,8440,-1
8441,/- SD,28,30,182,187,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,2,8441,-1
8447,ICP,13,14,73,76,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,2,8447,-1
8449,BBB,10,11,65,68,Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .,17019386_3,-1,-1,2,8449,-1
8457,enzyme assay,15,17,94,106,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,-1,-1,2,8457,-1
8462,BBB,21,22,113,116,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,-1,2,8462,-1
8464,plasma-to-blood osmotic gradient,28,31,153,185,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,-1,2,8464,-1
8469,antithrombotic treatment,5,7,34,58,"Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.",17020434_2,-1,-1,2,8469,-1
8475,ACTIVE-W,1,2,4,12,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,2,8475,-1
8476,Atrial Fibrillation Clopidogrel,3,6,14,45,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,2,8476,-1
8491,interfere with,6,8,47,61,Preliminary studies suggest that statins could interfere with the risk of recurrence after electrical cardioversion.,17020434_8,-1,-1,2,8491,-1
8495,Placebo-level,0,1,0,13,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,2,8495,-1
8506,double-blind,12,13,70,82,"METHODS: Data were analyzed from four similarly designed, randomized, double-blind, 3- to 12-week studies.",17042884_2,-1,-1,2,8506,-1
8507,12-week studies,16,18,90,105,"METHODS: Data were analyzed from four similarly designed, randomized, double-blind, 3- to 12-week studies.",17042884_2,-1,-1,2,8507,-1
8510,active controls,31,33,154,169,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,2,8510,-1
8524,EPS-related,5,6,26,37,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,2,8524,-1
8547,associated with,2,4,12,27,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,2,8547,-1
8553,No significant,0,2,0,14,No significant differences were observed between quetiapine and placebo on SAS and BARS scores.,17042884_12,-1,-1,2,8553,-1
8555,BARS scores,12,14,83,94,No significant differences were observed between quetiapine and placebo on SAS and BARS scores.,17042884_12,-1,-1,2,8555,-1
8563,rat.1,9,10,82,87,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,-1,-1,2,8563,-1
8565,associated with,8,10,85,100,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,2,8565,-1
8574,downregulation,25,26,119,133,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,2,8574,-1
8583,non-treated,20,21,97,108,"Dexamethasone (10 microg/kg per day, s.c.) or saline was started after 4 days in Ato-treated and non-treated rats and continued for 11-13 days.",17042910_5,-1,-1,2,8583,-1
8585,SBP,4,5,25,28,Systolic blood pressure (SBP) was measured on alternate days using the tail-cuff method.,17042910_6,-1,-1,2,8585,-1
8586,alternate days,9,11,46,60,Systolic blood pressure (SBP) was measured on alternate days using the tail-cuff method.,17042910_6,-1,-1,2,8586,-1
8587,tail-cuff method,13,15,71,87,Systolic blood pressure (SBP) was measured on alternate days using the tail-cuff method.,17042910_6,-1,-1,2,8587,-1
8589,acetylcholine-induced vasorelaxation,5,7,37,73,Endothelial function was assessed by acetylcholine-induced vasorelaxation and phenylephrine-induced vasoconstriction in aortic segments.,17042910_7,-1,-1,2,8589,-1
8590,phenylephrine-induced vasoconstriction,8,10,78,116,Endothelial function was assessed by acetylcholine-induced vasorelaxation and phenylephrine-induced vasoconstriction in aortic segments.,17042910_7,-1,-1,2,8590,-1
8592,eNOS,1,2,9,13,Vascular eNOS mRNA was assessed by semi-quantitative reverse transcription-polymerase chain reaction.,17042910_8,-1,-1,2,8592,-1
8593,semi-quantitative reverse transcription-polymerase chain reaction,6,11,35,100,Vascular eNOS mRNA was assessed by semi-quantitative reverse transcription-polymerase chain reaction.,17042910_8,-1,-1,2,8593,-1
8599,Days 4,22,24,86,92,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,-1,-1,2,8599,-1
8603,/- 2,13,15,52,56,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,2,8603,-1
8610,mRNA expression,4,6,42,57,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,2,8610,-1
8622,child?A,7,8,50,57,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,2,8622,-1
8629,Valproate-induced chorea,0,2,0,24,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,2,8629,-1
8660,Laboratory measurement,0,2,0,22,Laboratory measurement of pre-procedure serum calcium levels in selected donors may identify cases requiring heightened vigilance.,17111419_11,-1,-1,2,8660,-1
8661,pre-procedure,3,4,26,39,Laboratory measurement of pre-procedure serum calcium levels in selected donors may identify cases requiring heightened vigilance.,17111419_11,-1,-1,2,8661,-1
8669,MCA,5,6,33,36,"Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.",1711760_2,-1,-1,2,8669,-1
8670,control group,2,4,7,20,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,2,8670,-1
8679,"2,3,5-triphenyltetrazolium staining",8,10,48,83,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,2,8679,-1
8683,/-,26,27,133,135,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,2,8683,-1
8684,/-,31,32,152,154,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,2,8684,-1
8687,/-,26,27,134,136,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,-1,-1,2,8687,-1
8688,/-,32,33,147,149,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,-1,-1,2,8688,-1
8705,non-nephrotoxic drug,21,23,132,152,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,-1,-1,2,8705,-1
8717,associated with,4,6,28,43,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,2,8717,-1
8738,immunosuppressive agent,9,11,33,56,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,-1,-1,2,8738,-1
8739,consequence of,9,11,50,64,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,-1,-1,2,8739,-1
8748,renal cell carsinom,50,53,217,236,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,2,8748,-1
8750,/-,9,10,33,35,SRL was started at a mean of 78 +/- 42 (15 to 163) months after transplantation.,17175308_5,-1,-1,2,8750,-1
8751,Mean follow-up,0,2,0,14,Mean follow-up on SRL therapy was 20 +/- 12 (6 to 43) months.,17175308_6,-1,-1,2,8751,-1
8753,/-,8,9,38,40,Mean follow-up on SRL therapy was 20 +/- 12 (6 to 43) months.,17175308_6,-1,-1,2,8753,-1
8760,/-,10,11,60,62,Serum creatinine values did not change significantly: 1.98 +/-,17175308_14,-1,-1,2,8760,-1
8762,/-,8,9,39,41,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,2,8762,-1
8763,Kaposi's sarcoma,5,8,32,48,Five patients displayed CAN and Kaposi's sarcoma.,17175308_17,-1,-1,2,8763,-1
8764,Mean urinary protein,0,3,0,20,Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01).,17175308_18,-1,-1,2,8764,-1
8777,P40,3,4,12,15,"At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).",17194457_3,-1,-1,2,8777,-1
8793,Chronic T,0,2,0,9,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,2,8793,-1
8798,Chronic exposure,0,2,0,16,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,-1,-1,2,8798,-1
8812,ifosfamide renal toxicity,3,6,23,48,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,2,8812,-1
8820,Total cumulative doses,0,3,0,22,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,2,8820,-1
8835,total population,21,23,108,124,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,2,8835,-1
8836,Fanconi's syndrome,30,33,168,186,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,2,8836,-1
8839,beta 2 microglobulinuria,6,9,42,66,The remaining seven patients had isolated beta 2 microglobulinuria.,1720453_9,-1,-1,2,8839,-1
8843,low percentage,1,3,5,19,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,2,8843,-1
8846,Effects of,0,2,0,10,"Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice.",17241657_0,-1,-1,2,8846,-1
8851,effects of,16,18,108,118,"Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice.",17241657_0,-1,-1,2,8851,-1
8852,Earlier studies,0,2,0,15,"Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.",17241657_1,-1,-1,2,8852,-1
8862,Receptor binding studies,0,3,0,24,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,-1,-1,2,8862,-1
8865,display preferential,9,11,62,82,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,-1,-1,2,8865,-1
8878,up-regulation,3,4,26,39,Progressive myopathy with up-regulation of MHC-I associated with statin therapy.,17241784_0,-1,-1,2,8878,-1
8885,up-regulation,8,9,45,58,In all cases there was diffuse or multifocal up-regulation of MHC-I expression even in non-necrotic fibres.,17241784_5,-1,-1,2,8885,-1
8889,immunosuppressive therapy,20,22,140,165,These observations suggest that statins may initiate an immune-mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy.,17241784_7,-1,-1,2,8889,-1
8891,up-regulation,22,23,145,158,The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.,17241784_8,-1,-1,2,8891,-1
8894,Use of chromosome substitution,0,4,0,30,Use of chromosome substitution strains to identify seizure susceptibility loci in mice.,17242861_0,-1,-1,2,8894,-1
8896,inbred mouse strains,4,7,36,56,Seizure susceptibility varies among inbred mouse strains.,17242861_1,-1,-1,2,8896,-1
8897,Chromosome substitution strains,0,3,0,31,"Chromosome substitution strains (CSS), in which a single chromosome from one inbred strain (donor) has been transferred onto a second strain (host) by repeated backcrossing, may be used to identify quantitative trait loci (QTLs) that contribute to seizure susceptibility.",17242861_2,-1,-1,2,8897,-1
8898,inbred strain,14,16,77,90,"Chromosome substitution strains (CSS), in which a single chromosome from one inbred strain (donor) has been transferred onto a second strain (host) by repeated backcrossing, may be used to identify quantitative trait loci (QTLs) that contribute to seizure susceptibility.",17242861_2,-1,-1,2,8898,-1
8900,QTLs,42,43,223,227,"Chromosome substitution strains (CSS), in which a single chromosome from one inbred strain (donor) has been transferred onto a second strain (host) by repeated backcrossing, may be used to identify quantitative trait loci (QTLs) that contribute to seizure susceptibility.",17242861_2,-1,-1,2,8900,-1
8906,localize genes,18,20,71,85,We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine-induced seizures.,17242861_4,-1,-1,2,8906,-1
8909,B6 mice,0,2,0,7,B6 mice were resistant to seizures and slower to reach stages compared to A/J mice.,17242861_7,-1,-1,2,8909,-1
8910,A/J mice,13,15,74,82,B6 mice were resistant to seizures and slower to reach stages compared to A/J mice.,17242861_7,-1,-1,2,8910,-1
8911,Chromosomes 10,3,5,12,26,"The CSS for Chromosomes 10 and 18 progressed to the most severe stages, diverging dramatically from the B6 phenotype.",17242861_8,-1,-1,2,8911,-1
8916,mouse Chromosomes,7,9,52,69,CSS mapping suggests seizure susceptibility loci on mouse Chromosomes 10 and 18.,17242861_10,-1,-1,2,8916,-1
8917,homologous candidate genes,9,12,69,95,This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy.,17242861_11,-1,-1,2,8917,-1
8930,purinoceptor desensitization,4,6,15,43,"In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).",17244258_5,-1,-1,2,8930,-1
8956,isoprenaline-induced relaxations,23,25,136,168,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,-1,-1,2,8956,-1
8959,beta-adrenoceptor-mediated relaxations,2,4,21,59,"While postjunctional beta-adrenoceptor-mediated relaxations are reduced, effects by prejunctional inhibitory muscarinic receptors may be increased.",17244258_12,-1,-1,2,8959,-1
8960,effects by,7,9,73,83,"While postjunctional beta-adrenoceptor-mediated relaxations are reduced, effects by prejunctional inhibitory muscarinic receptors may be increased.",17244258_12,-1,-1,2,8960,-1
8974,targeted deletion,21,23,146,163,"METHODS AND RESULTS: To test whether clonidine elicits pharmacological effects independent of alpha2-adrenoceptors, we have generated mice with a targeted deletion of all 3 alpha2-adrenoceptor subtypes (alpha2ABC-/-).",17261653_3,-1,-1,2,8974,-1
8977,Alpha2ABC-/- mice,0,2,0,17,"Alpha2ABC-/- mice were completely unresponsive to the analgesic and hypnotic effects of clonidine; however, clonidine significantly lowered heart rate in alpha2ABC-/- mice by up to 150 bpm.",17261653_4,-1,-1,2,8977,-1
8980,wild-type,24,25,129,138,Clonidine-induced bradycardia in conscious alpha2ABC-/- mice was 32.3% (10 microg/kg) and 26.6% (100 microg/kg) of the effect in wild-type mice.,17261653_5,-1,-1,2,8980,-1
8984,wild-type,17,18,129,138,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,-1,-1,2,8984,-1
8986,HCN4 channels,27,29,188,201,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,-1,-1,2,8986,-1
8987,transfected,30,31,205,216,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,-1,-1,2,8987,-1
8988,HEK293 cells,31,33,217,229,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,-1,-1,2,8988,-1
8989,consequence of,2,4,5,19,"As a consequence of blocking I(f), clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild-type and alpha2ABC-knockout mice.",17261653_8,-1,-1,2,8989,-1
8992,wild-type,27,28,167,176,"As a consequence of blocking I(f), clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild-type and alpha2ABC-knockout mice.",17261653_8,-1,-1,2,8992,-1
8995,gene-targeted mice,16,18,117,135,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,-1,-1,2,8995,-1
8996,in vivo,18,20,136,143,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,-1,-1,2,8996,-1
9007,medical personnel,5,7,29,46,"Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.",17263743_3,-1,-1,2,9007,-1
9008,patient's,9,11,52,61,"Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.",17263743_3,-1,-1,2,9008,-1
9026,anti-hypertensive medications,9,11,85,114,"Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema was suspected, and anti-hypertensive medications were discontinued.",17285209_8,-1,-1,2,9026,-1
9040,Carbamazepine-induced,0,1,0,21,Carbamazepine-induced cardiac dysfunction.,1728915_0,-1,-1,2,9040,-1
9053,associated with,19,21,161,176,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,2,9053,-1
9060,anticancer chemotherapeutic agent,4,7,28,61,Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.,1732369_1,-1,-1,2,9060,-1
9067,healthy control subjects,35,38,255,279,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,-1,2,9067,-1
9069,experimental group,4,6,32,50,Echocardiographic data from the experimental group of 21 patients (mean age 16 +/- 5 years) treated from 1.6 to 14.3 years (median 5.3) before this study with 27 to 532 mg/m2 of doxorubicin (mean 196) were compared with echocardiographic data from 12 normal age-matched control subjects.,1732369_3,-1,-1,2,9069,-1
9070,/- 5 years,14,17,80,90,Echocardiographic data from the experimental group of 21 patients (mean age 16 +/- 5 years) treated from 1.6 to 14.3 years (median 5.3) before this study with 27 to 532 mg/m2 of doxorubicin (mean 196) were compared with echocardiographic data from 12 normal age-matched control subjects.,1732369_3,-1,-1,2,9070,-1
9078,control subjects,10,12,62,78,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,-1,-1,2,9078,-1
9086,/-,15,16,109,111,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,2,9086,-1
9087,/-,21,22,132,134,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,2,9087,-1
9088,control subjects,25,27,146,162,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,2,9088,-1
9092,/-,20,21,150,152,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,2,9092,-1
9093,/-,26,27,173,175,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,2,9093,-1
9094,control subjects,30,32,187,203,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,2,9094,-1
9098,dose-dependently,23,24,160,176,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,-1,-1,2,9098,-1
9099,adriamycin cardiomyopathy,25,27,180,205,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,-1,-1,2,9099,-1
9107,treated 3,18,20,122,131,Myocardial accumulation of [125I]MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less.,1732442_5,-1,-1,2,9107,-1
9116,dose-dependent,11,12,69,83,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,-1,-1,2,9116,-1
9120,MIBG scintigraphy,24,26,168,185,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,-1,2,9120,-1
9122,newborns?OBJECTIVE,20,21,141,159,Influence of smoking on developing cochlea. Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns?OBJECTIVE: Maternal tobacco smoking has negative effects on fetal growth.,17343925_0,-1,-1,2,9122,-1
9124,associated with,20,22,129,144,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,-1,-1,2,9124,-1
9130,control group,15,17,89,102,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,2,9130,-1
9131,non-smokers,27,28,148,159,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,2,9131,-1
9132,Exposure to,0,2,0,11,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,2,9132,-1
9133,exposed neonates,3,5,12,28,"RESULTS: In exposed neonates, TEOAEs mean response (across frequency) and mean amplitude at 4000Hz was significantly lower than in non-exposed neonates.",17343925_6,-1,-1,2,9133,-1
9134,TEOAEs mean response,6,9,30,50,"RESULTS: In exposed neonates, TEOAEs mean response (across frequency) and mean amplitude at 4000Hz was significantly lower than in non-exposed neonates.",17343925_6,-1,-1,2,9134,-1
9135,mean amplitude,14,16,74,88,"RESULTS: In exposed neonates, TEOAEs mean response (across frequency) and mean amplitude at 4000Hz was significantly lower than in non-exposed neonates.",17343925_6,-1,-1,2,9135,-1
9136,non-exposed neonates,23,25,131,151,"RESULTS: In exposed neonates, TEOAEs mean response (across frequency) and mean amplitude at 4000Hz was significantly lower than in non-exposed neonates.",17343925_6,-1,-1,2,9136,-1
9137,no significant,7,9,57,71,Comparisons between exposed newborns' subgroups revealed no significant differences.,17343925_7,-1,-1,2,9137,-1
9139,statistically significant,12,14,63,88,"However, by comparing each subgroup to control group, we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups.",17343925_8,-1,-1,2,9139,-1
9141,TEOAEs responses,1,3,5,21,Mean TEOAEs responses of highly exposed newborns were also significantly lower in comparison to our control group.,17343925_9,-1,-1,2,9141,-1
9142,control group,15,17,100,113,Mean TEOAEs responses of highly exposed newborns were also significantly lower in comparison to our control group.,17343925_9,-1,-1,2,9142,-1
9143,In utero,2,4,12,20,"CONCLUSION: In utero, exposure to tobacco smoking seems to have a small impact on outer hair cells.",17343925_10,-1,-1,2,9143,-1
9144,exposure to,5,7,22,33,"CONCLUSION: In utero, exposure to tobacco smoking seems to have a small impact on outer hair cells.",17343925_10,-1,-1,2,9144,-1
9154,illicit drug use,19,22,117,133,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,2,9154,-1
9158,cross-sectional study interview,4,7,17,48,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,2,9158,-1
9168,associated with,5,7,28,43,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,-1,-1,2,9168,-1
9169,QT interval,8,10,51,62,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,-1,-1,2,9169,-1
9176,QTc interval,8,10,52,64,None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).,17344330_12,-1,-1,2,9176,-1
9177,associated with,7,9,34,49,A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.,17344330_13,-1,-1,2,9177,-1
9178,associated with,4,6,26,41,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,2,9178,-1
9179,QT prolongation,6,8,42,57,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,2,9179,-1
9180,Simvastatin-induced,0,1,0,19,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,2,9180,-1
9190,associated with,11,13,59,74,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,2,9190,-1
9192,associated with,6,8,55,70,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,2,9192,-1
9206,chemical exposures,13,15,80,98,"In addition to genetic influences, recent studies suggest that prenatal drug or chemical exposures are risk factors for autism.",17400887_2,-1,-1,2,9206,-1
9213,effects of,3,5,15,25,We studied the effects of terbutaline on microglial activation in different brain regions and behavioral outcomes in developing rats.,17400887_4,-1,-1,2,9213,-1
9218,PN,14,15,72,74,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,2,9218,-1
9219,PN,20,21,86,88,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,2,9219,-1
9220,PN,34,35,143,145,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,2,9220,-1
9235,aversive stimuli,21,23,129,145,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,2,9235,-1
9236,open field,28,30,171,181,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,2,9236,-1
9237,acoustic startle response test,36,40,201,231,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,2,9237,-1
9251,up-regulation,13,14,106,119,Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats.,17437408_0,-1,-1,2,9251,-1
9253,multidrug resistance protein 2,3,7,13,43,PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB).,17437408_1,-1,-1,2,9253,-1
9255,drug efflux transporter,12,15,56,79,PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB).,17437408_1,-1,-1,2,9255,-1
9261,BBB,46,47,274,277,PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB).,17437408_1,-1,-1,2,9261,-1
9263,transport-deficient (TR(-)),5,10,22,49,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9263,-1
9264,Wistar rat mutant,10,13,50,67,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9264,-1
9266,tissue concentrations,29,31,154,175,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9266,-1
9269,transport-competent,42,43,251,270,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,-1,-1,2,9269,-1
9276,BBB,32,33,170,173,"By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs (AEDs), we recently reported that phenytoin is a substrate for MRP2 in the BBB.",17437408_3,-1,-1,2,9276,-1
9277,genetically deficient,8,10,41,62,"However, one drawback of such studies in genetically deficient rats is the fact that compensatory changes with upregulation of other transporters can occur.",17437408_4,-1,-1,2,9277,-1
9278,upregulation,18,19,111,123,"However, one drawback of such studies in genetically deficient rats is the fact that compensatory changes with upregulation of other transporters can occur.",17437408_4,-1,-1,2,9278,-1
9282,drug efflux transporter,16,19,80,103,"This prompted us to study the brain expression of P-glycoprotein (Pgp), a major drug efflux transporter in many tissues, including the BBB, in TR(-) rats compared with nonmutant (wild-type) Wistar rats.",17437408_5,-1,-1,2,9282,-1
9285,nonmutant,33,34,168,177,"This prompted us to study the brain expression of P-glycoprotein (Pgp), a major drug efflux transporter in many tissues, including the BBB, in TR(-) rats compared with nonmutant (wild-type) Wistar rats.",17437408_5,-1,-1,2,9285,-1
9292,Wistar rats,19,21,93,104,"METHODS: The expression of MRP2 and Pgp in brain and liver sections of TR(-) rats and normal Wistar rats was determined with immunohistochemistry, by using a novel, highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219, respectively.",17437408_6,-1,-1,2,9292,-1
9302,up-regulation,6,7,35,48,TR(-) rats exhibited a significant up-regulation of Pgp in brain capillary endothelial cells compared with wild-type controls.,17437408_8,-1,-1,2,9302,-1
9313,wild-type,14,15,97,106,A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.,17437408_10,-1,-1,2,9313,-1
9314,Wistar rats,15,17,107,118,A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.,17437408_10,-1,-1,2,9314,-1
9315,systemic administration,2,4,17,40,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,-1,-1,2,9315,-1
9320,BBB,33,34,214,217,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,-1,-1,2,9320,-1
9330,overexpression,17,18,95,109,"Furthermore, our data suggest that TR(-) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain, without the need of inducing seizures or other Pgp-enhancing events for this purpose.",17437408_14,-1,-1,2,9330,-1
9333,Pgp-enhancing events,39,41,208,228,"Furthermore, our data suggest that TR(-) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain, without the need of inducing seizures or other Pgp-enhancing events for this purpose.",17437408_14,-1,-1,2,9333,-1
9335,rats.1,8,9,66,72,Role of xanthine oxidase in dexamethasone-induced hypertension in rats.1.,17439425_0,-1,-1,2,9335,-1
9337,associated with,9,11,58,73,Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.,17439425_1,-1,-1,2,9337,-1
9338,nitric oxide-redox imbalance,11,14,74,102,Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.,17439425_1,-1,-1,2,9338,-1
9343,Sprague-Dawley rats,4,6,15,34,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,2,9343,-1
9344,treatment groups,11,13,67,83,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,2,9344,-1
9349,SBP,6,7,29,32,4. Systolic blood pressures (SBP) and bodyweights were recorded each alternate day.,17439425_4,-1,-1,2,9349,-1
9351,Thymus weight,0,2,0,13,"Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.",17439425_5,-1,-1,2,9351,-1
9352,glucocorticoid activity,8,10,38,61,"Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.",17439425_5,-1,-1,2,9352,-1
9353,XO,16,17,89,91,"Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.",17439425_5,-1,-1,2,9353,-1
9359,/-,7,8,43,45,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,2,9359,-1
9361,/-,26,27,106,108,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,2,9361,-1
9370,posterior sub-Tenon's space,11,15,91,118,Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space.,17466854_0,-1,-1,2,9370,-1
9373,posterior sub-Tenon's space,20,24,141,168,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,-1,-1,2,9373,-1
9374,St. Luke's Hospital,2,6,9,28,"SETTING: St. Luke's Hospital, Gwardamangia, Malta.",17466854_2,-1,-1,2,9374,-1
9375,Gwardamangia,7,8,30,42,"SETTING: St. Luke's Hospital, Gwardamangia, Malta.",17466854_2,-1,-1,2,9375,-1
9376,double-blind,3,4,11,23,METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain lignocaine.,17466854_3,-1,-1,2,9376,-1
9379,sub-Tenon's,16,18,133,144,METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain lignocaine.,17466854_3,-1,-1,2,9379,-1
9382,Group A,7,9,29,36,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,2,9382,-1
9385,posterior sub-Tenon's space,29,33,134,161,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,2,9385,-1
9386,Group B,34,36,166,173,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,2,9386,-1
9388,chi-square test,1,3,2,17,A chi-square test was used to assess the statistical significance of results.,17466854_6,-1,-1,2,9388,-1
9390,Group A,5,7,26,33,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,-1,-1,2,9390,-1
9392,Group B,20,22,107,114,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,-1,-1,2,9392,-1
9394,posterior sub-Tenon's space,10,14,76,103,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,-1,-1,2,9394,-1
9397,self-limiting,4,5,25,38,All adverse effects were self-limiting.,17466854_9,-1,-1,2,9397,-1
9399,dopaminergic,6,7,48,60,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,2,9399,-1
9400,substantia,10,11,76,86,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,2,9400,-1
9402,iron overload,6,8,51,64,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,2,9402,-1
9404,substantia nigra,14,16,101,117,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,2,9404,-1
9405,fast cyclic voltammetry,26,29,153,176,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,2,9405,-1
9406,chromatography-electrochemical detection,46,48,276,316,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,2,9406,-1
9410,TH-immunoreactive,19,20,127,144,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,2,9410,-1
9412,chronic overload group,7,10,41,63,Even more dramatic changes were found in chronic overload group.,17490790_5,-1,-1,2,9412,-1
9416,dopaminergic,9,10,53,65,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,2,9416,-1
9418,prepulse inhibition,3,5,25,44,Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats.,17490864_0,-1,-1,2,9418,-1
9429,non-deprived groups,7,9,58,77,"Amphetamine treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups.",17490864_4,-1,-1,2,9429,-1
9436,effects of,2,4,12,22,"The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation, or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus.",17490864_8,-1,-1,2,9436,-1
9438,nucleus accumbens,28,30,205,222,"The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation, or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus.",17490864_8,-1,-1,2,9438,-1
9440,non-invasive,4,5,20,32,Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.,17491223_0,-1,-1,2,9440,-1
9446,dP/dtejc,15,16,85,93,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,-1,2,9446,-1
9451,single-photon emission computed tomography,41,45,260,302,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,-1,2,9451,-1
9452,study group,3,5,13,24,METHODS: The study group comprised 40 patients undergoing Sestamibi-SPECT/dobutamine stress test.,17491223_3,-1,-1,2,9452,-1
9453,Sestamibi-SPECT/dobutamine stress test,9,12,58,96,METHODS: The study group comprised 40 patients undergoing Sestamibi-SPECT/dobutamine stress test.,17491223_3,-1,-1,2,9453,-1
9458,dP/dtejc,3,4,16,24,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,-1,-1,2,9458,-1
9460,non-ischemic group,18,20,110,128,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,-1,-1,2,9460,-1
9461,dP/dtejc,0,1,0,8,"dP/dtejc outcome was combined with the ECG results, giving an ECG-enhanced value, and compared to ECG alone.",17491223_7,-1,-1,2,9461,-1
9462,ECG-enhanced,11,12,62,74,"dP/dtejc outcome was combined with the ECG results, giving an ECG-enhanced value, and compared to ECG alone.",17491223_7,-1,-1,2,9462,-1
9466,cost-savings,24,25,133,145,"CONCLUSIONS: If ECG alone is used for specificity, the combination with dP/dtejc improved the sensitivity of the test and could be a cost-savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia, especially in patients unable to exercise.",17491223_9,-1,-1,2,9466,-1
9476,associated with,22,24,157,172,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,-1,-1,2,9476,-1
9477,cocaine-induced increase,24,26,173,197,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,-1,-1,2,9477,-1
9478,rate-pressure product,27,29,201,222,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,-1,-1,2,9478,-1
9481,cocaine-induced vasoconstriction,16,18,89,121,"With regard to spasm, the clinical findings are largely circumstantial, and the locus of cocaine-induced vasoconstriction remains speculative.",1749407_4,-1,-1,2,9481,-1
9486,consistent with,5,7,43,58,"Diffuse intramural vasoconstriction is not consistent with reports of segmental, discrete infarction.",1749407_6,-1,-1,2,9486,-1
9489,cocaine-induced vasoconstriction,3,5,15,47,The finding of cocaine-induced vasoconstriction in segments of (noninnervated) human umbilical artery suggests that the presence or absence of intact innervation is not sufficient to explain the discrepant data involving the possibility of alpha-mediated effects.,1749407_8,-1,-1,2,9489,-1
9491,alpha-mediated effects,35,37,240,262,The finding of cocaine-induced vasoconstriction in segments of (noninnervated) human umbilical artery suggests that the presence or absence of intact innervation is not sufficient to explain the discrepant data involving the possibility of alpha-mediated effects.,1749407_8,-1,-1,2,9491,-1
9507,L-DOPA-induced,10,11,60,74,Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.,17532790_0,-1,-1,2,9507,-1
9512,striatal samples,15,17,84,100,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,2,9512,-1
9515,two-dimensional difference gel electrophoresis,34,38,224,270,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,2,9515,-1
9519,atmospheric pressure matrix-assisted laser desorption/ionization,25,30,191,255,"Among the 2000 spots compared for statistical difference, 67 spots were significantly changed in abundance and identified using matrix-assisted laser desorption/ionization time-of-flight MS, atmospheric pressure matrix-assisted laser desorption/ionization and HPLC coupled tandem MS (LC/MS/MS).",17532790_5,-1,-1,2,9519,-1
9527,Complementary techniques,0,2,0,24,Complementary techniques such as western immunoblotting and immunohistochemistry were performed to investigate the validity of the data obtained using the proteomic approach.,17532790_7,-1,-1,2,9527,-1
9529,proteomic approach,20,22,155,173,Complementary techniques such as western immunoblotting and immunohistochemistry were performed to investigate the validity of the data obtained using the proteomic approach.,17532790_7,-1,-1,2,9529,-1
9532,randomized double-blind trial,12,15,65,94,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,-1,-1,2,9532,-1
9541,double-blind,13,14,69,81,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,-1,-1,2,9541,-1
9552,postdose,5,6,26,34,The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L) over baseline.,17562951_4,-1,-1,2,9552,-1
9553,SCr,6,7,35,38,The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L) over baseline.,17562951_4,-1,-1,2,9553,-1
9555,postdose,4,5,26,34,"Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr.",17562951_5,-1,-1,2,9555,-1
9559,peak change,30,32,145,156,"Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr.",17562951_5,-1,-1,2,9559,-1
9564,SCr,18,19,104,107,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,2,9564,-1
9570,SCr,5,6,27,30,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,2,9570,-1
9573,SCr,39,40,165,168,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,2,9573,-1
9574,post-SCr,1,2,5,13,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,-1,-1,2,9574,-1
9582,PB-related,16,17,81,91,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,2,9582,-1
9594,non-specific,34,35,213,225,"At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.",17574447_3,-1,-1,2,9594,-1
9601,PB-related,15,16,94,104,"For this reason, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic chronic hepatic enzyme dysfunction.",17574447_6,-1,-1,2,9601,-1
9624,in vitro,9,11,69,77,We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.,17600377_4,-1,-1,2,9624,-1
9625,SH-SY5Y cells,12,14,84,97,We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.,17600377_4,-1,-1,2,9625,-1
9631,cytochrome c release,16,19,117,137,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,2,9631,-1
9632,caspase 3,21,23,143,152,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,2,9632,-1
9636,Alzheimer's disease,22,25,142,161,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,2,9636,-1
9642,methamphetamine-induced,10,11,61,84,Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.,17608141_1,-1,-1,2,9642,-1
9645,inflammatory factor,14,16,83,102,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,-1,-1,2,9645,-1
9646,methamphetamine-induced,21,22,132,155,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,-1,-1,2,9646,-1
9647,nigrostriatal,22,23,156,169,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,-1,-1,2,9647,-1
9648,dopamine neurotoxicity,23,25,170,192,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,-1,-1,2,9648,-1
9654,dose-dependent,14,15,146,160,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,-1,-1,2,9654,-1
9665,nigrostriatal,16,17,146,159,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,-1,-1,2,9665,-1
9666,dopamine neurotoxicity,17,19,160,182,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,-1,-1,2,9666,-1
9667,associated with,2,4,18,33,Acute myocarditis associated with clozapine.,17612891_0,-1,-1,2,9667,-1
9668,associated with,7,9,39,54,"OBJECTIVE: A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors.",17612891_1,-1,-1,2,9668,-1
9673,associated with,8,10,68,83,CONCLUSIONS: Myocarditis is an increasingly recognized complication associated with the use of clozapine.,17612891_7,-1,-1,2,9673,-1
9676,paramedical staff,24,26,151,168,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,-1,-1,2,9676,-1
9694,patient's,6,8,33,42,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,-1,-1,2,9694,-1
9695,human immunodeficiency virus medications,8,12,43,83,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,-1,-1,2,9695,-1
9697,patient's,4,6,20,29,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,-1,-1,2,9697,-1
9709,rosuvastatin carry,17,19,105,123,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,2,9709,-1
9715,oral anticoagulant,6,8,33,51,Warfarin is the most widely used oral anticoagulant and is indicated for many clinical conditions.,17639754_1,-1,-1,2,9715,-1
9735,associated with,8,10,70,85,Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.,17682013_2,-1,-1,2,9735,-1
9738,single reports,8,10,48,62,METHODS: We reviewed the medical literature for single reports and case series of patients presenting with stroke-like episodes while receiving systemic or intrathecal chemotherapy.,17682013_3,-1,-1,2,9738,-1
9746,intrathecal,15,16,102,113,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,-1,-1,2,9746,-1
9759,ADC,14,15,84,87,Complete resolution of symptoms within 1-4 days was accompanied by normalisation of ADC abnormalities.,17682013_9,-1,-1,2,9759,-1
9763,exposure to,9,11,84,95,CONCLUSIONS: Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed.,17682013_11,-1,-1,2,9763,-1
9766,DWI,0,1,0,3,DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.,17682013_12,-1,-1,2,9766,-1
9769,exposure to,1,3,9,20,Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.,17702969_0,-1,-1,2,9769,-1
9787,/-,15,16,101,103,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,-1,-1,2,9787,-1
9788,control animals,20,22,120,135,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,-1,-1,2,9788,-1
9790,/-,36,37,203,205,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,-1,-1,2,9790,-1
9793,serotonin-induced contraction,24,26,123,152,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,2,9793,-1
9794,exposure to,3,5,15,26,"After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).",17702969_10,-1,-1,2,9794,-1
9800,Disulfiram-induced transient optic,0,3,0,34,Disulfiram-induced transient optic and peripheral neuropathy: a case report.,17786501_0,-1,-1,2,9800,-1
9805,case report,5,7,25,36,MATERIALS AND METHODS: A case report.,17786501_2,-1,-1,2,9805,-1
9817,associated with,1,3,10,25,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,9817,-1
9818,lamivudine-resistance,3,4,26,47,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,9818,-1
9819,hepatitis B,8,10,66,77,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,9819,-1
9820,HBV,12,13,85,88,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,9820,-1
9821,co-infection,20,21,129,141,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,9821,-1
9823,HBV,27,28,186,189,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,2,9823,-1
9837,co-infected,23,24,152,163,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,-1,-1,2,9837,-1
9847,Abbott Laboratories,20,22,109,128,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,-1,-1,2,9847,-1
9848,North Chicago,23,25,130,143,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,-1,-1,2,9848,-1
9856,HBV,0,1,0,3,"HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany).",17854040_6,-1,-1,2,9856,-1
9862,mono-infected,9,10,58,71,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,-1,-1,2,9862,-1
9865,co-infected,19,20,122,133,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,-1,-1,2,9865,-1
9866,HBV lamivudine-resistant strains,13,16,67,99,"To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.",17854040_8,-1,-1,2,9866,-1
9869,HBV,1,2,4,7,"The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and <200 to 4.40 x 10(3) copies/ml, respectively.",17854040_9,-1,-1,2,9869,-1
9871,mono-infected,5,6,24,37,"The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and <200 to 4.40 x 10(3) copies/ml, respectively.",17854040_9,-1,-1,2,9871,-1
9872,co-infected,7,8,42,53,"The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and <200 to 4.40 x 10(3) copies/ml, respectively.",17854040_9,-1,-1,2,9872,-1
9873,antiviral mutations,8,10,48,67,"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.",17854040_10,-1,-1,2,9873,-1
9877,South Africa,36,38,244,256,"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.",17854040_10,-1,-1,2,9877,-1
9885,associated with,8,10,53,68,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,2,9885,-1
9886,chronic neuroleptic therapy,10,13,69,96,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,2,9886,-1
9898,male mice,12,14,103,112,We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.,17879945_3,-1,-1,2,9898,-1
9911,Cell extracts,19,21,103,116,"Cells were then treated with 30 ng/ml ritonavir or vehicle in the presence of aggregated LDL for 24 h. Cell extracts were harvested, and lipid or total RNA was isolated.",17879945_8,-1,-1,2,9911,-1
9912,total RNA,27,29,146,155,"Cells were then treated with 30 ng/ml ritonavir or vehicle in the presence of aggregated LDL for 24 h. Cell extracts were harvested, and lipid or total RNA was isolated.",17879945_8,-1,-1,2,9912,-1
9918,transcription factor,14,16,97,117,"Additionally, ritonavir treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.",17879945_11,-1,-1,2,9918,-1
9926,protein expression,14,16,75,93,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,2,9926,-1
9929,exposure to,4,6,29,40,Acute hepatitis attack after exposure to telithromycin.,17919553_0,-1,-1,2,9929,-1
9937,Marmara University Hospital Emergency Department,21,26,99,147,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,2,9937,-1
9941,reference range,13,15,78,93,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,-1,-1,2,9941,-1
9953,Naranjo adverse drug reaction probability scale,8,14,29,76,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,2,9953,-1
9956,associated with,11,13,62,77,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,-1,-1,2,9956,-1
9964,intravitreal implant,27,29,159,179,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,2,9964,-1
9965,multicenter,6,7,27,38,"DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.",17923537_2,-1,-1,2,9965,-1
9966,double-masked,8,9,40,53,"DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.",17923537_2,-1,-1,2,9966,-1
9970,3-year,4,5,20,26,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,2,9970,-1
9971,implanted eyes,10,12,47,61,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,2,9971,-1
9974,IOP-lowering,13,14,81,93,"Topical IOP-lowering medication was administered in 74.8% of implanted eyes, and IOP-lowering surgeries, most of which were trabeculectomies (76.2%), were performed on 36.6% of implanted eyes.",17923537_4,-1,-1,2,9974,-1
9975,trabeculectomies,20,21,124,140,"Topical IOP-lowering medication was administered in 74.8% of implanted eyes, and IOP-lowering surgeries, most of which were trabeculectomies (76.2%), were performed on 36.6% of implanted eyes.",17923537_4,-1,-1,2,9975,-1
9981,IOP-lowering surgery,13,15,49,69,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,2,9981,-1
9985,injection duration,12,14,59,77,AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.,17931375_1,-1,-1,2,9985,-1
9987,subcutaneous injection,12,14,82,104,"BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.",17931375_2,-1,-1,2,9987,-1
9988,injection duration,26,28,170,188,"BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.",17931375_2,-1,-1,2,9988,-1
9989,quasi-experimental research,9,11,51,78,"DESIGN: This study was designed as within-subject, quasi-experimental research.",17931375_3,-1,-1,2,9989,-1
9992,Injections areas,0,2,0,16,Injections areas were assessed for the presence of bruising at 48 and 72 hours after each injection.,17931375_6,-1,-1,2,9992,-1
9996,chi-square test,4,6,25,40,"Data were analysed using chi-square test, Mann-Whitney U, Wilcoxon signed ranks tests and correlation.",17931375_9,-1,-1,2,9996,-1
9998,Wilcoxon signed ranks tests,10,14,58,85,"Data were analysed using chi-square test, Mann-Whitney U, Wilcoxon signed ranks tests and correlation.",17931375_9,-1,-1,2,9998,-1
9999,seconds duration,15,17,80,96,RESULTS: The percentage of bruising occurrence was 64% with the injection of 10 seconds duration and 42% in the 30-second injection.,17931375_10,-1,-1,2,9999,-1
10001,injection duration,6,8,36,54,CONCLUSIONS: It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.,17931375_13,-1,-1,2,10001,-1
10002,subcutaneous administration,17,19,104,131,CONCLUSIONS: It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.,17931375_13,-1,-1,2,10002,-1
10004,Myocardial Fas,0,2,0,14,Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy.,17943461_0,-1,-1,2,10004,-1
10007,HIV-infected,12,13,71,83,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,2,10007,-1
10013,Fas-dependent cell-death pathway,20,23,134,166,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,2,10013,-1
10016,transgenic,35,36,238,248,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,2,10016,-1
10018,non-transgenic (NTg) mice,48,53,304,329,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,2,10018,-1
10030,dose-dependent,16,17,101,115,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,2,10030,-1
10031,associated with,3,5,19,34,"These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.",17943461_7,-1,-1,2,10031,-1
10037,HIV-positive,14,15,78,90,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,-1,2,10037,-1
10047,double-blind study,26,28,214,232,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,2,10047,-1
10054,gastroprotective agents,2,4,7,30,Use of gastroprotective agents and low-dose aspirin was allowed.,17965424_2,-1,-1,2,10054,-1
10057,patient discontinuations,11,13,71,95,The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).,17965424_3,-1,-1,2,10057,-1
10058,AEs,22,23,151,154,The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).,17965424_3,-1,-1,2,10058,-1
10067,patient-years,22,23,133,146,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,2,10067,-1
10070,AEs,8,9,78,81,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,2,10070,-1
10077,discontinuing treatment,11,13,74,97,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,2,10077,-1
10080,renovascular AEs,2,4,22,38,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,-1,2,10080,-1
10088,albino rats,20,22,147,158,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,2,10088,-1
10093,novelty-suppressed feeding latency behaviour,18,22,119,163,"The tests included open-field exploratory behaviour, elevated plus maze and elevated zero maze, social interaction and novelty-suppressed feeding latency behaviour.",17975693_2,-1,-1,2,10093,-1
10096,norfloxacin-treated rats,8,10,54,78,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,-1,-1,2,10096,-1
10105,associated with,12,14,78,93,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,-1,-1,2,10105,-1
10132,target-controlled infusions,22,24,154,181,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,-1,-1,2,10132,-1
10134,double-blind,5,6,27,39,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,2,10134,-1
10135,placebo-controlled trial,7,9,41,65,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,2,10135,-1
10136,effect-site,14,15,97,108,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,2,10136,-1
10141,R2,32,33,166,168,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,2,10141,-1
10145,Remifentanil-related complications,0,2,0,34,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,-1,-1,2,10145,-1
10171,/- standard deviation,6,9,24,45,164 patients (mean age +/- standard deviation [SD] 81.6 +/- 6.8 years) were admitted.,18020536_3,-1,-1,2,10171,-1
10172,/-,14,15,57,59,164 patients (mean age +/- standard deviation [SD] 81.6 +/- 6.8 years) were admitted.,18020536_3,-1,-1,2,10172,-1
10174,non-users,15,16,68,77,"had used BZDs/RDs before admission, and the remainder (n = 86) were non-users.",18020536_5,-1,-1,2,10174,-1
10176,Mini-Mental State Examination (,6,10,38,69,Cognitive ability was assessed by the Mini-Mental State Examination (MMSE).,18020536_6,-1,-1,2,10176,-1
10178,MMSE sum points,6,9,26,41,Patients scoring > or =20 MMSE sum points were interviewed (n = 79) and questioned regarding symptoms and functional abilities during the week prior to admission.,18020536_7,-1,-1,2,10178,-1
10189,/-,5,6,19,21,RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31).,18020536_11,-1,-1,2,10189,-1
10191,/- 7 years,14,17,55,65,RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31).,18020536_11,-1,-1,2,10191,-1
10193,associated with,6,8,33,48,"Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia.",18020536_13,-1,-1,2,10193,-1
10195,confounders,6,7,40,51,"After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE.",18020536_14,-1,-1,2,10195,-1
10201,associated with,6,8,29,44,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,2,10201,-1
10204,associated with,6,8,29,44,Use of BZDs/RDs tended to be associated with a reduced ability to walk and shorter night-time sleep during the week prior to admission.,18020536_16,-1,-1,2,10204,-1
10219,Co.,0,1,0,3,"Co., Ansan, Korea) in a suicide attempt.",18023325_4,-1,-1,2,10219,-1
10228,thyroarytenoid muscle,3,5,28,49,Laryngeal electromyography (thyroarytenoid muscle) showed ample denervation potentials.,18023325_9,-1,-1,2,10228,-1
10242,treated with,13,15,93,105,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,2,10242,-1
10260,dose-dependently,6,7,31,47,"RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.",18083142_4,-1,-1,2,10260,-1
10267,/- mice,8,10,52,59,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,-1,-1,2,10267,-1
10272,cocaine-induced anxiety-like behavior,18,21,146,183,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,-1,-1,2,10272,-1
10274,wild-type,26,27,199,208,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,-1,-1,2,10274,-1
10275,C57BL6/J mice,27,29,209,222,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,-1,-1,2,10275,-1
10278,no effect,43,45,305,314,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,-1,-1,2,10278,-1
10284,meta-analysis,9,10,66,79,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,-1,-1,2,10284,-1
10287,effects of,7,9,40,50,We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non-cardiac surgery.,18086064_1,-1,-1,2,10287,-1
10291,randomised peri-operative studies,4,7,25,58,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,-1,-1,2,10291,-1
10295,PubMed,1,2,2,8,A PubMed Central and EMBASE search was conducted up to July 2007.,18086064_3,-1,-1,2,10295,-1
10297,reference lists,1,3,4,19,The reference lists of identified papers were examined for further trials.,18086064_4,-1,-1,2,10297,-1
10298,meta-analysis,10,11,51,64,"Of 425 studies identified, 20 were included in the meta-analysis (840 patients).",18086064_5,-1,-1,2,10298,-1
10304,randomised placebo-controlled trial,1,4,2,37,A randomised placebo-controlled trial of dexmedetomidine is warranted.,18086064_9,-1,-1,2,10304,-1
10307,associated with,4,6,35,50,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,2,10307,-1
10314,5-week gestation,7,9,33,49,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,2,10314,-1
10322,second trimester,27,29,137,153,"At the time of admission, the patient was at high risk of radiation injury to the fetus, so a coronary angiogram was postponed until the second trimester.",18161408_8,-1,-1,2,10322,-1
10324,case documenting,9,11,50,66,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,2,10324,-1
10333,central prolactin actions,1,4,9,34,"Although central prolactin actions are thought to contribute to this, the mechanisms are poorly understood.",18162529_2,-1,-1,2,10333,-1
10337,estrogen-induced,20,21,154,170,We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.,18162529_3,-1,-1,2,10337,-1
10342,ovariectomized rats,17,19,117,136,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,-1,-1,2,10342,-1
10344,steroid-induced,8,9,44,59,Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.,18162529_5,-1,-1,2,10344,-1
10345,GnRH,15,16,90,94,Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.,18162529_5,-1,-1,2,10345,-1
10349,prolactin's signaling pathway,19,23,109,138,Estradiol is known to influence expression of the long form of prolactin receptors (PRL-R) and components of prolactin's signaling pathway.,18162529_6,-1,-1,2,10349,-1
10353,cytokine signaling,8,10,44,62,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,-1,-1,2,10353,-1
10356,prolactin signaling,22,24,114,133,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,-1,-1,2,10356,-1
10368,GnRH,4,5,21,25,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,-1,-1,2,10368,-1
10371,steroid-dependent,14,15,90,107,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,-1,-1,2,10371,-1
10372,estradiol-dependent,5,6,31,50,They also provide evidence for estradiol-dependent and brain region-specific regulation of PRL-R expression and signaling responses by prolactin.,18162529_13,-1,-1,2,10372,-1
10387,16-week multicenter,4,6,13,32,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,2,10387,-1
10388,double-blind trial,7,9,34,52,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,2,10388,-1
10396,associated with,25,27,115,130,Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal.,18182964_8,-1,-1,2,10396,-1
10398,childhood ADHD,16,18,95,109,"CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.",18182964_10,-1,-1,2,10398,-1
10402,quality of life,20,23,160,175,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,-1,-1,2,10402,-1
10403,therapeutic regimens,5,7,35,55,"However, combinations of different therapeutic regimens require consideration of potential adverse reactions.",18186898_1,-1,-1,2,10403,-1
10406,Wilson's disease,12,15,81,97,We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease.,18186898_2,-1,-1,2,10406,-1
10423,phase III,5,7,26,35,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,2,10423,-1
10424,multicenter,10,11,46,57,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,2,10424,-1
10425,double-blind,16,17,84,96,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,2,10425,-1
10439,Phase III,5,7,27,36,"METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.",18201582_2,-1,-1,2,10439,-1
10440,multicenter,10,11,47,58,"METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.",18201582_2,-1,-1,2,10440,-1
10441,double-blind study,16,18,85,103,"METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.",18201582_2,-1,-1,2,10441,-1
10442,treated with,2,4,14,26,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,-1,-1,2,10442,-1
10451,clinical systolic BP,7,10,46,66,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,2,10451,-1
10452,diastolic BP,11,13,74,86,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,2,10452,-1
10459,T+A group,36,38,164,173,"RESULTS: A total of 210 patients were enrolled in the study; 203 patients (143 men, 60 women) completed the study while 7 were lost to follow-up (4 patients in the T+A group and 3 in the A group) and considered with-drawn.",18201582_6,-1,-1,2,10459,-1
10460,A group,42,44,187,194,"RESULTS: A total of 210 patients were enrolled in the study; 203 patients (143 men, 60 women) completed the study while 7 were lost to follow-up (4 patients in the T+A group and 3 in the A group) and considered with-drawn.",18201582_6,-1,-1,2,10460,-1
10461,with-drawn,47,48,211,221,"RESULTS: A total of 210 patients were enrolled in the study; 203 patients (143 men, 60 women) completed the study while 7 were lost to follow-up (4 patients in the T+A group and 3 in the A group) and considered with-drawn.",18201582_6,-1,-1,2,10461,-1
10462,statistically significant,4,6,14,39,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,2,10462,-1
10471,treatment groups,12,14,81,97,"The prevalences of adverse events were not significantly different between the 2 treatment groups (T+A, 16.0% [17/106]; A, 15.4% [16/104]).",18201582_9,-1,-1,2,10471,-1
10476,statistical significance,59,61,256,280,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,-1,-1,2,10476,-1
10477,FDC,12,13,73,76,"CONCLUSIONS: Among these Indian patients with stage II hypertension, the FDC of T+A was found to be significantly more effective, with regard to BP reductions, than A, and both treatments were well tolerated.",18201582_12,-1,-1,2,10477,-1
10481,antigen assay,5,7,29,42,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,-1,-1,2,10481,-1
10482,optical density,4,6,25,40,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,-1,-1,2,10482,-1
10486,optical density,35,37,184,199,"PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.",18208574_2,-1,-1,2,10486,-1
10490,/-,18,19,84,86,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,2,10490,-1
10492,/-,39,40,183,185,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,2,10492,-1
10494,/-,55,56,267,269,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,2,10494,-1
10497,percent inhibition,8,10,54,72,None of these groups showed significant difference in percent inhibition.,18208574_8,-1,-1,2,10497,-1
10500,associated with,5,7,25,40,"CONCLUSION: Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated-HIT; percent inhibition, however, was not predictive.",18208574_11,-1,-1,2,10500,-1
10502,single-agent activity,3,5,24,45,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,2,10502,-1
10506,immunomodulatory agent,26,28,174,196,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,2,10506,-1
10512,inflammatory cytokines,18,20,113,135,"Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammatory cytokines.",18217897_1,-1,-1,2,10512,-1
10516,confidence interval,27,29,140,159,"Of 24 evaluable patients, two achieved a complete remission and one achieved a partial remission for an overall response rate of 12.5% (95% confidence interval: 2.6-32.4%).",18217897_4,-1,-1,2,10516,-1
10536,gonadally intact,16,18,95,111,"To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.",18221780_3,-1,-1,2,10536,-1
10546,dose-and time-dependent manner,21,24,142,172,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,2,10546,-1
10547,pretreatment,4,5,21,33,"Across the doses and pretreatment times examined, enhancement was not observed in females.",18221780_6,-1,-1,2,10547,-1
10555,associated with,3,5,25,40,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,-1,-1,2,10555,-1
10561,trihexyphenidyl-induced,32,33,228,251,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,-1,-1,2,10561,-1
10567,double blind,5,7,23,35,"This was a randomized, double blind, placebo-controlled, three-way, crossover experimental design.",18239197_3,-1,-1,2,10567,-1
10568,placebo-controlled,8,9,37,55,"This was a randomized, double blind, placebo-controlled, three-way, crossover experimental design.",18239197_3,-1,-1,2,10568,-1
10572,Lader's,2,4,9,16,"Bond and Lader's visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline, 1, 2.5, and 5 hours postdrug administration.",18239197_5,-1,-1,2,10572,-1
10573,visual analog scales,4,7,17,37,"Bond and Lader's visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline, 1, 2.5, and 5 hours postdrug administration.",18239197_5,-1,-1,2,10573,-1
10576,postdrug administration,33,35,182,205,"Bond and Lader's visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline, 1, 2.5, and 5 hours postdrug administration.",18239197_5,-1,-1,2,10576,-1
10585,Buschke Selective Reminding Test,27,31,183,215,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,2,10585,-1
10587,visual analog scales,9,12,54,74,"However, no significant effects were found with other visual analog scales reflecting subjective sedation and clear-headedness.",18239197_8,-1,-1,2,10587,-1
10591,associated with,9,11,55,70,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,-1,-1,2,10591,-1
10594,sirolimus-based immunosuppression,6,8,43,76,Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.,18261172_0,-1,-1,2,10594,-1
10600,associated with,18,20,101,116,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,2,10600,-1
10604,associated with,8,10,57,72,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,-1,-1,2,10604,-1
10612,postswitch,22,23,102,112,"Before the switch, 11.5% of patients had high-grade proteinuria (>1.0 g/day); this increased to 22.9% postswitch (p = 0.006).",18261172_7,-1,-1,2,10612,-1
10633,subcutaneously injected,3,5,15,38,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,-1,-1,2,10633,-1
10635,intraperitoneally,29,30,133,150,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,-1,-1,2,10635,-1
10640,platform quadrant,17,19,112,129,The results showed that rats treated with Morphine/Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency.,18308784_6,-1,-1,2,10640,-1
10642,in vivo,7,9,65,72,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,-1,-1,2,10642,-1
10644,long-term potentiation (LTP,17,21,115,142,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,-1,-1,2,10644,-1
10660,SAR,0,1,0,3,"SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.",18329269_2,-1,-1,2,10660,-1
10661,K(i,10,11,55,58,"SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.",18329269_2,-1,-1,2,10661,-1
10665,nicotine-induced,12,13,73,89,Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.,1833784_0,-1,-1,2,10665,-1
10666,exposure of,6,8,46,57,Previous studies have suggested that repeated exposure of rats to the drug or to the experimental environment is necessary to observe nicotine-induced locomotor stimulation.,1833784_1,-1,-1,2,10666,-1
10667,experimental environment,15,17,85,109,Previous studies have suggested that repeated exposure of rats to the drug or to the experimental environment is necessary to observe nicotine-induced locomotor stimulation.,1833784_1,-1,-1,2,10667,-1
10668,experimental environment,10,12,52,76,In the present study the role of habituation to the experimental environment on the stimulant effect of nicotine in rats was examined.,1833784_2,-1,-1,2,10668,-1
10669,effects of,18,20,130,140,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,-1,-1,2,10669,-1
10673,photocell cages,10,12,70,85,Locomotor activity was assessed in male Sprague-Dawley rats tested in photocell cages.,1833784_4,-1,-1,2,10673,-1
10675,test environment,19,21,109,125,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,-1,-1,2,10675,-1
10676,test environment,38,40,214,230,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,-1,-1,2,10676,-1
10691,no effect,17,19,116,125,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,2,10691,-1
10692,test environment,16,18,112,128,The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment.,1833784_9,-1,-1,2,10692,-1
10696,associated with,4,6,31,46,Central retinal vein occlusion associated with clomiphene-induced ovulation.,18343374_0,-1,-1,2,10696,-1
10697,clomiphene-induced,6,7,47,65,Central retinal vein occlusion associated with clomiphene-induced ovulation.,18343374_0,-1,-1,2,10697,-1
10699,associated with,11,13,62,77,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,2,10699,-1
10700,Case study,2,4,8,18,DESIGN: Case study.,18343374_2,-1,-1,2,10700,-1
10701,academic hospital,6,8,36,53,SETTING: Ophthalmology clinic of an academic hospital.,18343374_3,-1,-1,2,10701,-1
10709,CONCLUSION(S,0,1,0,12,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,2,10709,-1
10719,double-blind,36,37,211,223,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,2,10719,-1
10726,FEV1,2,3,12,16,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,-1,-1,2,10726,-1
10733,amikacin nephrotoxicity,3,5,17,40,An evaluation of amikacin nephrotoxicity in the hematology/oncology population.,18356633_0,-1,-1,2,10733,-1
10743,open-label trial,15,17,118,134,"To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.",18356633_3,-1,-1,2,10743,-1
10744,university-affiliated medical center,21,24,154,190,"To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.",18356633_3,-1,-1,2,10744,-1
10755,conventional group,4,6,20,38,"Six patients in the conventional group had a positive culture, compared with none in the extended-interval group (P = 0.002).",18356633_7,-1,-1,2,10755,-1
10757,extended-interval group,16,18,89,112,"Six patients in the conventional group had a positive culture, compared with none in the extended-interval group (P = 0.002).",18356633_7,-1,-1,2,10757,-1
10763,MRI.OBJECTIVE,9,10,61,74,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,2,10763,-1
10768,associated with,12,14,73,88,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,-1,-1,2,10768,-1
10776,METHODS/MATERIALS,0,1,0,17,"METHODS/MATERIALS: As part of the ongoing Quality Assurance process, data on all sedations are reviewed monthly and protocols modified as needed.",18363626_4,-1,-1,2,10776,-1
10786,associated with,4,6,38,53,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,-1,-1,2,10786,-1
10788,age-adjusted normal range,24,27,151,176,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,-1,-1,2,10788,-1
10791,MRI studies,11,13,83,94,CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.,18363626_9,-1,-1,2,10791,-1
10794,associated with,7,9,42,57,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,-1,-1,2,10794,-1
10801,associated with,1,3,15,30,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,-1,-1,2,10801,-1
10815,ADR,3,4,17,20,METHODS: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years.,18405372_3,-1,-1,2,10815,-1
10828,Caribbean descent,9,11,50,67,Five patients were of Black British of African or Caribbean descent.,18405372_11,-1,-1,2,10828,-1
10836,associated with,4,6,35,50,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,-1,-1,2,10836,-1
10838,under-appreciated,10,11,79,96,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,-1,-1,2,10838,-1
10839,Methamphetamine-induced,0,1,0,23,Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.,18410508_0,-1,-1,2,10839,-1
10842,fractalkine receptor signaling,9,12,84,114,Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.,18410508_0,-1,-1,2,10842,-1
10848,MPTP-induced neurodegeneration,21,23,117,147,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,2,10848,-1
10853,METH-induced,32,33,176,188,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,2,10853,-1
10866,wild-type controls,28,30,160,178,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,2,10866,-1
10867,effects of,1,3,4,14,The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.,18410508_7,-1,-1,2,10867,-1
10869,knockout mice,6,8,30,43,The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.,18410508_7,-1,-1,2,10869,-1
10870,gender-dependent,10,11,53,69,The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.,18410508_7,-1,-1,2,10870,-1
10871,Striatal,0,1,0,8,Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation.,18410508_8,-1,-1,2,10871,-1
10876,METH neurotoxicity,11,13,71,89,We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.,18410508_10,-1,-1,2,10876,-1
10878,striatal-resident,5,6,29,46,"Furthermore, it appears that striatal-resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration.",18410508_11,-1,-1,2,10878,-1
10881,Nicotine-induced nystagmus,0,2,0,26,Nicotine-induced nystagmus correlates with midpontine activation.,18417364_0,-1,-1,2,10881,-1
10884,nicotine-induced nystagmus,3,5,22,48,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,2,10884,-1
10895,NIN-induced,0,1,0,11,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,-1,-1,2,10895,-1
10897,dorsomedial,9,10,70,81,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,-1,-1,2,10897,-1
10899,tegmenti pontis,16,18,125,140,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,-1,-1,2,10899,-1
10905,anticonvulsant activity,7,9,43,66,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,2,10905,-1
10926,pilocarpine-evoked,20,21,96,114,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,2,10926,-1
10937,pilocarpine-induced,12,13,67,86,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,2,10937,-1
10945,secondary to,15,17,90,102,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,2,10945,-1
10952,back-diffusion,13,14,61,75,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,2,10952,-1
10960,Wistar rats,1,3,5,16,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,2,10960,-1
10963,Control rats,0,2,0,12,Control rats received corn oil only.,18442015_5,-1,-1,2,10963,-1
10980,hepatitis B,5,7,33,44,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,-1,2,10980,-1
10981,hepatitis-B surface antigen,10,13,67,94,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,-1,2,10981,-1
10984,Hepatitis B,0,2,0,11,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,2,10984,-1
10985,HBV,4,5,19,22,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,2,10985,-1
10994,historical control group,27,30,178,202,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,2,10994,-1
10998,historical controls,1,3,4,23,The historical controls consisted of 50 consecutive patients who underwent CT without prophylactic lamivudine.,18464113_7,-1,-1,2,10998,-1
10999,control group,2,4,7,20,"Of our control group (n= 50), 21 patients (42%) were established hepatitis.",18464113_10,-1,-1,2,10999,-1
11001,control group,18,20,114,127,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,-1,-1,2,11001,-1
11002,HBV,11,12,89,92,Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.,18464113_14,-1,-1,2,11002,-1
11004,immunosuppressive therapy,22,24,164,189,Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.,18464113_14,-1,-1,2,11004,-1
11009,Vasoactive intestinal polypeptide,0,3,0,33,Vasoactive intestinal polypeptide (VIP) is an immunomodulatory neuropeptide distributed in micturition pathways.,18483878_1,-1,-1,2,11009,-1
11025,CYP-induced,32,33,181,192,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,-1,-1,2,11025,-1
11037,enzyme-linked immunoassays,6,8,45,71,Several regulated genes were validated using enzyme-linked immunoassays including IL-1beta and CXCL1.,18483878_7,-1,-1,2,11037,-1
11057,beta-2 receptor pharmacodynamics,6,9,52,84,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,-1,-1,2,11057,-1
11058,cardioselective,4,5,22,37,The metabolism of the cardioselective beta-blocker metoprolol is under genetic control of the debrisoquine/sparteine type.,1848636_1,-1,-1,2,11058,-1
11067,drug effect,1,3,4,15,The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.,1848636_4,-1,-1,2,11067,-1
11068,terbutaline-induced hypokalemia,10,12,60,91,The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.,1848636_4,-1,-1,2,11068,-1
11072,quantitated,16,17,123,134,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,-1,-1,2,11072,-1
11073,IC50,24,25,162,166,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,-1,-1,2,11073,-1
11074,half-maximum receptor,33,35,234,255,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,-1,-1,2,11074,-1
11093,recipient--case report,14,18,115,137,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,-1,-1,2,11093,-1
11095,immunosuppressive agent,8,10,34,57,TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics.,18503483_1,-1,-1,2,11095,-1
11110,vasoactive agents,6,8,39,56,The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery: findings in six cases.,18513945_0,-1,-1,2,11110,-1
11113,uterotonic,5,6,28,38,"Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension, particularly when given as a bolus.",18513945_1,-1,-1,2,11113,-1
11122,Oxytocin-induced,0,1,0,16,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,-1,-1,2,11122,-1
11130,real time,29,31,177,186,"Pulse power analysis (also called ""pulse contour analysis"") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.",18513945_5,-1,-1,2,11130,-1
11134,cesarean delivery,9,11,51,68,Pulse power analysis was conducted in six cases of cesarean delivery performed under neuraxial anesthesia.,18513945_6,-1,-1,2,11134,-1
11141,cesarean delivery,15,17,99,116,Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia.,18513945_8,-1,-1,2,11141,-1
11144,antithrombin,3,4,22,34,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,-1,-1,2,11144,-1
11145,puromycin aminonucleoside nephrosis,5,8,38,73,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,-1,-1,2,11145,-1
11146,effects of,3,5,20,30,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,2,11146,-1
11147,antithrombin,5,6,31,43,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,2,11147,-1
11148,plasma inhibitor,8,10,47,63,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,2,11148,-1
11153,Antithrombin,0,1,0,12,Antithrombin (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).,18541230_2,-1,-1,2,11153,-1
11157,aminonucleoside-induced hematological abnormalities,6,9,53,104,Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.,18541230_3,-1,-1,2,11157,-1
11162,proteinaceous casts,8,10,67,86,"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.",18541230_5,-1,-1,2,11162,-1
11164,control rats,19,21,136,148,"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.",18541230_5,-1,-1,2,11164,-1
11168,aminonucleoside-induced apoptosis,8,10,66,99,"In addition, antithrombin treatment markedly suppressed puromycin aminonucleoside-induced apoptosis of renal tubular epithelial cells.",18541230_6,-1,-1,2,11168,-1
11171,aminonucleoside-induced,3,4,23,46,"Furthermore, puromycin aminonucleoside-induced increases in renal cytokine content were also decreased.",18541230_7,-1,-1,2,11171,-1
11172,renal cytokine,6,8,60,74,"Furthermore, puromycin aminonucleoside-induced increases in renal cytokine content were also decreased.",18541230_7,-1,-1,2,11172,-1
11181,double-blind study,3,5,14,32,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,2,11181,-1
11191,sevoflurane-sparing effect,9,11,61,87,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,-1,-1,2,11191,-1
11195,detrimental supplement,30,32,208,230,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,-1,-1,2,11195,-1
11200,treated with,9,11,60,72,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,-1,-1,2,11200,-1
11202,treatment modifications,2,4,17,40,Course following treatment modifications.,18560792_1,-1,-1,2,11202,-1
11207,drug withdrawal,18,20,107,122,"However, the incidence and severity of these abnormalities vary from study to study and their course after drug withdrawal has not been systematically assessed.",18560792_3,-1,-1,2,11207,-1
11209,drug withdrawal,17,19,118,133,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,-1,-1,2,11209,-1
11210,case-control study,21,23,139,157,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,-1,-1,2,11210,-1
11216,median interval,6,8,41,56,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,-1,-1,2,11216,-1
11218,sex-matched,4,5,23,34,Controls were age- and sex-matched non-PD patients referred to the cardiology department.,18560792_8,-1,-1,2,11218,-1
11223,n=2.4+/-0.7,6,7,31,42,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,2,11223,-1
11248,platelet factor 4/heparin-reactive,8,11,55,89,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,2,11248,-1
11258,preoperatively,6,7,37,51,"RESULTS: The average platelet counts preoperatively, and on POD 7, 14, and 21 were 65, 88, 149, and 169 x 10(9)/L, respectively.",18589141_9,-1,-1,2,11258,-1
11259,antibody-negative,18,19,104,121,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,-1,2,11259,-1
11263,antibody-positive,4,5,22,39,"The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.",18589141_13,-1,-1,2,11263,-1
11264,preoperatively,9,10,58,72,"The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.",18589141_13,-1,-1,2,11264,-1
11275,treatment strategy,29,31,162,180,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,2,11275,-1
11283,Sprague-Dawley rat,5,7,43,61,"Neonatal cardiomyocytes were isolated from Sprague-Dawley rat hearts and randomly divided into controls, an adriamycin-treated group, and a 3MA plus adriamycin-treated group.",18619688_4,-1,-1,2,11283,-1
11292,in vivo,23,25,134,141,"We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+-K+ ATPase activity in vivo.",18619688_5,-1,-1,2,11292,-1
11298,associated gene,9,11,53,68,"In addition, we analyzed the expression of autophagy associated gene, beclin 1 using RT-PCR and Western blotting in an animal model.",18619688_7,-1,-1,2,11298,-1
11309,downregulated,13,14,87,100,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,-1,-1,2,11309,-1
11311,adriamycin-induced failing heart,20,23,131,163,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,-1,-1,2,11311,-1
11319,gene deletion,8,10,80,93,Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.,18627295_0,-1,-1,2,11319,-1
11321,Clinical use,0,2,0,12,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,2,11321,-1
11327,DOX cardiomyopathy,17,19,88,106,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,-1,2,11327,-1
11329,knockout mice,23,25,123,136,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,-1,2,11329,-1
11335,associated with,2,4,9,24,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,-1,-1,2,11335,-1
11340,mRNA levels,2,4,13,24,"Furthermore, mRNA levels of the proinflammatory cytokine interleukin 6 were increased in the cardiac tissue.",18627295_5,-1,-1,2,11340,-1
11346,associated with,18,20,95,110,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,2,11346,-1
11352,DOX cardiomyopathy,8,10,50,68,These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.,18627295_7,-1,-1,2,11352,-1
11355,DOX cardiomyopathy,16,18,114,132,These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.,18627295_8,-1,-1,2,11355,-1
11365,consequence of,9,11,51,65,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,-1,2,11365,-1
11374,penicillin-induced epileptiform activity,5,8,38,78,Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.,18657397_0,-1,-1,2,11374,-1
11377,penicillin-induced epileptiform activity,13,16,73,113,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,-1,-1,2,11377,-1
11380,Wistar rats,1,3,5,16,Male Wistar rats were anesthetized with i.p. urethane and connected to an electrocorticogram setup.,18657397_3,-1,-1,2,11380,-1
11388,penicillin-induced epileptiform activity,7,10,38,78,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,-1,-1,2,11388,-1
11389,conventional methods,16,18,117,137,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,-1,-1,2,11389,-1
11397,gamma-2 bands,16,18,86,99,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,2,11397,-1
11403,simple analysis method,15,18,94,116,Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies.,18657397_8,-1,-1,2,11403,-1
11417,doxorubicin-induced,9,10,53,72,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,2,11417,-1
11422,posttherapy,19,20,121,132,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,-1,-1,2,11422,-1
11427,cardiac fatty-acid oxidation,13,16,107,135,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,2,11427,-1
11428,upregulated,21,22,156,167,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,2,11428,-1
11429,JAK/STAT3 pathway,22,24,168,185,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,2,11429,-1
11432,male Sprague-Dawley rats,26,29,136,160,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,2,11432,-1
11433,doxorubicin-induced,38,39,188,207,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,2,11433,-1
11442,normal diet-fed,18,20,129,144,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,2,11442,-1
11450,cardiac fatty-acid oxidation,50,53,286,314,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,2,11450,-1
11451,nmol/min/g heart,61,63,372,388,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,2,11451,-1
11452,mitochondrial,71,72,411,424,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,2,11452,-1
11454,cardiac erythropoietin,1,3,10,32,Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.,18674790_8,-1,-1,2,11454,-1
11456,downregulated,7,8,61,74,Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.,18674790_8,-1,-1,2,11456,-1
11458,JAK/STAT3 pathway,10,12,96,113,Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.,18674790_8,-1,-1,2,11458,-1
11459,HFD-induced,3,4,15,26,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,2,11459,-1
11464,downregulating,24,25,200,214,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,2,11464,-1
11465,JAK/STAT3 pathway,26,28,219,236,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,2,11465,-1
11467,dopamine-mediated behaviors,4,6,36,63,Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.,18703024_0,-1,-1,2,11467,-1
11472,receptor binding,22,24,125,141,The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to schizophrenia.,18703024_2,-1,-1,2,11472,-1
11478,MK-801-induced locomotion,6,8,47,72,No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.,18703024_5,-1,-1,2,11478,-1
11519,eighth nerve,19,21,129,141,The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve.,18726058_15,-1,-1,2,11519,-1
11567,urinary protein,4,6,20,35,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,2,11567,-1
11569,urinary protein,29,31,165,180,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,2,11569,-1
11572,LDL apheresis,17,19,110,123,"After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis.",18754075_3,-1,-1,2,11572,-1
11590,gene-targeted mice lacking,15,18,76,102,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).",18768591_4,-1,-1,2,11590,-1
11593,wild-type littermates,25,27,130,151,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).",18768591_4,-1,-1,2,11593,-1
11601,protein expression,16,18,107,125,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,-1,-1,2,11601,-1
11602,sgk1(+/+) mice,19,22,129,143,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,-1,-1,2,11602,-1
11603,lower values,5,7,46,58,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,2,11603,-1
11604,sgk1(+/+) mice,8,11,62,76,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,2,11604,-1
11608,associated with,34,36,158,173,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,2,11608,-1
11612,/-,54,55,263,265,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,2,11612,-1
11613,/-,60,61,280,282,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,2,11613,-1
11615,significantly faster,11,13,77,97,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,2,11615,-1
11617,sgk1(+/+) mice,19,22,124,138,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,2,11617,-1
11619,sgk1(+/+) mice,40,43,224,238,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,2,11619,-1
11620,gene-targeted mice lacking,3,6,15,41,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,2,11620,-1
11625,associated with,5,7,47,62,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,-1,-1,2,11625,-1
11634,supportive interventions,3,5,28,52,"Despite pharmacological and supportive interventions, laboratory parameters worsened and the patient died 17 hours after admission.",18791946_5,-1,-1,2,11634,-1
11644,early phases,17,19,128,140,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,-1,-1,2,11644,-1
11669,myofilaments,5,6,29,41,"Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.",18808529_7,-1,-1,2,11669,-1
11688,neuroprotective,7,8,47,62,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,-1,2,11688,-1
11698,dorsal root ganglion,23,26,145,165,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,-1,-1,2,11698,-1
11728,anti-oxidant,7,8,55,67,"Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.",18809400_7,-1,-1,2,11728,-1
11745,beagle dogs,16,18,101,112,"Using this rationale, the 8-aminoquinoline WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment.",18821488_2,-1,-1,2,11745,-1
11746,rhesus monkey,23,25,133,146,"Using this rationale, the 8-aminoquinoline WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment.",18821488_2,-1,-1,2,11746,-1
11756,methemoglobinemia,11,12,68,85,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,2,11756,-1
11757,beagle dogs,13,15,89,100,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,2,11757,-1
11758,MHb,24,25,162,165,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,2,11758,-1
11759,rhesus monkey,33,35,187,200,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,2,11759,-1
11760,postinjection,9,10,73,86,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,2,11760,-1
11763,orally-treated,19,20,116,130,"Histopathology analyses in the 2 animals that died revealed liver and kidney toxicity, with greater severity in the orally-treated animal.",18821488_8,-1,-1,2,11763,-1
11764,drug-induced,8,9,59,71,CONCLUSIONS: These data demonstrate direct and/or indirect drug-induced toxicity.,18821488_9,-1,-1,2,11764,-1
11769,associated with,8,10,54,69,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,-1,-1,2,11769,-1
11772,Associated with,5,7,30,45,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,-1,-1,2,11772,-1
11779,uninterrupted usage,6,8,60,79,Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.,188339_5,-1,-1,2,11779,-1
11785,placebo-controlled,2,3,5,23,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,2,11785,-1
11786,single-blinded,4,5,25,39,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,2,11786,-1
11787,crossover study,6,8,41,56,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,2,11787,-1
11794,real stimuli,29,31,149,161,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,-1,-1,2,11794,-1
11795,treatment series,54,56,276,292,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,-1,-1,2,11795,-1
11797,no significant,9,11,60,74,Direct comparison between sham and real rTMS effects showed no significant difference in clinician-assessed dyskinesia severity.,18951540_3,-1,-1,2,11797,-1
11798,real rTMS,15,17,110,119,"However, comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo.",18951540_4,-1,-1,2,11798,-1
11801,patient diaries,3,5,14,29,"Similarly, in patient diaries, although both treatments caused reduction in subjective dyskinesia scores during the days of intervention, the effect was sustained for 3 days after the intervention for the real rTMS only.",18951540_6,-1,-1,2,11801,-1
11808,rTMS,16,17,130,134,The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.,18951540_8,-1,-1,2,11808,-1
11815,dose rate,9,11,39,48,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,-1,-1,2,11815,-1
11823,recommended dose,1,3,4,20,"The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.",1899352_8,-1,-1,2,11823,-1
11825,total dose,8,10,47,57,"The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.",1899352_8,-1,-1,2,11825,-1
11830,infusate,25,26,145,153,"The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.",1899352_10,-1,-1,2,11830,-1
11831,infusion schedule,2,4,15,32,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,-1,-1,2,11831,-1
11835,clinical usage,18,20,136,150,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,-1,-1,2,11835,-1
11837,comparative trial,11,13,62,79,"Clinical activity was demonstrated in a single patient, but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained.",1899352_12,-1,-1,2,11837,-1
11839,infusion schedule,20,22,128,145,"Clinical activity was demonstrated in a single patient, but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained.",1899352_12,-1,-1,2,11839,-1
11843,admitted frequent,5,7,22,39,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,2,11843,-1
11844,Emergency Department (,13,16,71,93,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,2,11844,-1
11847,minimally invasive method,21,24,109,134,"The management options in the ED, as exemplified by four individual case reports, in particular the use of a minimally invasive method of intracorporal epinephrine instillation, are discussed.",18996674_3,-1,-1,2,11847,-1
11858,Prophylactic use,0,2,0,16,Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.,19037603_0,-1,-1,2,11858,-1
11862,hepatitis B,20,22,138,149,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,2,11862,-1
11866,hepatitis B,4,6,22,33,"Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records.",19037603_3,-1,-1,2,11866,-1
11870,immunosuppressive therapy,10,12,49,74,Lamivudine therapy was started 3-7 days prior to immunosuppressive therapy in all patients.,19037603_5,-1,-1,2,11870,-1
11879,Prophylactic administration,0,2,0,27,"Prophylactic administration of lamivudine in patients who required immunosuppressive therapy seems to be safe, well tolerated and effective in preventing HBV reactivation.",19037603_13,-1,-1,2,11879,-1
11880,immunosuppressive therapy,8,10,67,92,"Prophylactic administration of lamivudine in patients who required immunosuppressive therapy seems to be safe, well tolerated and effective in preventing HBV reactivation.",19037603_13,-1,-1,2,11880,-1
11886,effects of,9,11,56,66,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,2,11886,-1
11893,membrane bound,33,35,191,205,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,2,11893,-1
11896,albino rats,2,4,11,22,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,2,11896,-1
11931,fruit juices,14,16,87,99,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,-1,-1,2,11931,-1
11934,intraperitoneal,3,4,21,36,Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.,19105845_0,-1,-1,2,11934,-1
11936,controlled release,6,8,35,53,"This is important, since different controlled release formulations of bupropion release the active drug at different rates.",19105845_2,-1,-1,2,11936,-1
11942,Swiss albino mice,37,40,215,232,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,-1,-1,2,11942,-1
11944,intraperitoneal,28,29,141,156,"A total of 69 mice, approximately 7 weeks of age, and weighing 21.0 to 29.1 g were randomly assigned to bupropion HCl 120 mg/kg treatment by intraperitoneal (IP) administration in 7 groups (9 to 10 animals per group).",19105845_4,-1,-1,2,11944,-1
11946,surgically implanted,6,8,36,56,"Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min.",19105845_5,-1,-1,2,11946,-1
11951,group 1,32,34,165,172,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,-1,-1,2,11951,-1
11953,infusion time,5,7,43,56,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,2,11953,-1
11954,odds ratio,14,16,86,96,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,2,11954,-1
11956,associated with,31,33,173,188,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,2,11956,-1
11958,infusion time,3,5,20,33,Further increase in infusion time resulted in further reduction in the odds of convulsions to 99.8% reduction at 240 min.,19105845_9,-1,-1,2,11958,-1
11964,associated with,8,10,72,87,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,2,11964,-1
11967,EVTAC trial,23,25,176,187,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,2,11967,-1
11971,GVHD,14,15,110,114,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,2,11971,-1
11986,acute grade II-IV GVHD,7,11,30,52,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,2,11986,-1
11987,chronic extensive GVHD,23,26,102,124,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,2,11987,-1
11998,phase III clinical trial,8,12,58,82,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,2,11998,-1
12007,comprehensive approach,14,16,74,96,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,2,12007,-1
12009,generalized estimating equation method,1,5,4,42,The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within-subject correlation due to repeated measurements at frequencies.,19139001_3,-1,-1,2,12009,-1
12014,confidence interval,29,31,161,180,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,2,12014,-1
12017,Dose intensity,0,2,0,14,Dose intensity did not add information to models.,19139001_6,-1,-1,2,12017,-1
12021,treatment arms,34,36,176,190,Follow-up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1.08 dB (-0.81 to 2.96 dB; P = 0.26) between treatment arms.,19139001_8,-1,-1,2,12021,-1
12027,confidence interval,17,19,86,105,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,-1,2,12027,-1
12037,analgesic-induced changes,27,29,157,182,"Renal structure and concentrating ability were examined after a recovery period of up to 18 weeks, when no analgesics were given, to investigate whether the analgesic-induced changes were reversible.",1919871_2,-1,-1,2,12037,-1
12043,early stages,2,4,11,23,"During the early stages of analgesic treatment, the changes in urinary concentrating ability were reversible, but after prolonged analgesic treatment, maximum urinary concentrating ability failed to recover.",1919871_5,-1,-1,2,12043,-1
12064,normal range less,20,23,112,129,"Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.",19203554_3,-1,-1,2,12064,-1
12065,myeloperoxidase-ANCA,28,29,143,163,"Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.",19203554_3,-1,-1,2,12065,-1
12074,PR3-ANCA titer,34,36,207,221,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,2,12074,-1
12075,cells/microl,46,47,274,286,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,2,12075,-1
12082,Dahl salt-sensitive,8,10,86,105,Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.,19211690_0,-1,-1,2,12082,-1
12084,BP,3,4,16,18,Blood pressure (BP) is more salt sensitive in men than in premenopausal women.,19211690_1,-1,-1,2,12084,-1
12085,Dahl salt-sensitive rats,1,4,3,27,"In Dahl salt-sensitive rats (DS), high-salt (HS) diet increases BP more in males than females.",19211690_2,-1,-1,2,12085,-1
12088,systemic renin-angiotensin system,4,7,19,52,"In contrast to the systemic renin-angiotensin system, which is suppressed in response to HS in male DS, intrarenal angiotensinogen expression is increased, and intrarenal levels of ANG II are not suppressed.",19211690_3,-1,-1,2,12088,-1
12091,intrarenal,26,27,160,170,"In contrast to the systemic renin-angiotensin system, which is suppressed in response to HS in male DS, intrarenal angiotensinogen expression is increased, and intrarenal levels of ANG II are not suppressed.",19211690_3,-1,-1,2,12091,-1
12094,HS-induced,15,16,78,88,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,-1,-1,2,12094,-1
12096,intrarenal,18,19,105,115,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,-1,-1,2,12096,-1
12103,HS diet,0,2,0,7,"HS diet for 4 wk increased renal cortical angiotensinogen mRNA and protein only in male DS, which was prevented by castration.",19211690_6,-1,-1,2,12103,-1
12105,no effect,5,7,29,38,Ovariectomy of female DS had no effect on intrarenal angiotensinogen expression on either diet.,19211690_7,-1,-1,2,12105,-1
12112,BP,7,8,56,58,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,-1,-1,2,12112,-1
12115,associated with,17,19,116,131,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,-1,-1,2,12115,-1
12125,double-blind pilot study,5,8,27,51,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,2,12125,-1
12130,/-,9,10,42,44,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,-1,-1,2,12130,-1
12133,/-,34,35,153,155,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,-1,-1,2,12133,-1
12135,Yahr stage,45,47,206,216,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,-1,-1,2,12135,-1
12138,globus pallidus interna,7,10,37,60,Six patients were operated on in the globus pallidus interna (GPi) and four in the subthalamic nucleus (STN).,19234905_4,-1,-1,2,12138,-1
12140,subthalamic nucleus,17,19,83,102,Six patients were operated on in the globus pallidus interna (GPi) and four in the subthalamic nucleus (STN).,19234905_4,-1,-1,2,12140,-1
12145,Hoehn_Yahr score,17,19,94,110,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,2,12145,-1
12146,Schwab England,20,22,115,129,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,2,12146,-1
12147,daily living (ADL) score,24,30,144,168,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,2,12147,-1
12148,on'-,32,33,173,177,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,2,12148,-1
12149,off'-drug,35,36,183,192,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,2,12149,-1
12152,daily intake,2,4,20,32,Levodopa equivalent daily intake was significantly reduced in the STN group.,19234905_7,-1,-1,2,12152,-1
12167,medical treatment,25,27,154,171,The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.,19234905_11,-1,-1,2,12167,-1
12169,sensory-discriminative components,4,6,29,62,Explicit episodic memory for sensory-discriminative components of capsaicin-induced pain: immediate and delayed ratings.,19269743_0,-1,-1,2,12169,-1
12172,intradermal injections,13,15,81,103,"In order to address long-term pain memory, nine healthy male volunteers received intradermal injections of three doses of capsaicin (0.05, 1 and 20 microg, separated by 15 min breaks), each given three times in a balanced design across three sessions at one week intervals.",19269743_3,-1,-1,2,12172,-1
12174,computerized visual analogue scale,6,10,34,68,"Pain rating was performed using a computerized visual analogue scale (0-100) digitized at 1/s, either immediately online or one hour or one day after injection.",19269743_4,-1,-1,2,12174,-1
12175,dose-dependent,5,6,39,53,Capsaicin injection reliably induced a dose-dependent flare (p<0.001) without any difference within or across sessions.,19269743_6,-1,-1,2,12175,-1
12176,first-time,21,22,133,143,"Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.",19269743_8,-1,-1,2,12176,-1
12177,first-time,10,11,60,70,Correlation with rating recall after one week was best when first-time ratings were requested as late as one day after injection (R(2)=0.79) indicating that both rating retrievals utilized similar memory traces.,19269743_10,-1,-1,2,12177,-1
12178,R(2)=0.79,22,23,130,139,Correlation with rating recall after one week was best when first-time ratings were requested as late as one day after injection (R(2)=0.79) indicating that both rating retrievals utilized similar memory traces.,19269743_10,-1,-1,2,12178,-1
12182,DSMM XI study,0,3,0,13,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,-1,-1,2,12182,-1
12183,dose definition,4,6,15,30,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,-1,-1,2,12183,-1
12193,younger patients,26,28,193,209,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,2,12193,-1
12195,treated with,3,5,21,33,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,2,12195,-1
12199,maximum tolerated dose,1,4,4,26,The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2).,19274460_3,-1,-1,2,12199,-1
12213,captopril overdose,7,9,35,53,"We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.",1928887_3,-1,-1,2,12213,-1
12214,treated with,13,15,83,95,"To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.",1928887_4,-1,-1,2,12214,-1
12215,microplate method,6,8,41,58,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,-1,-1,2,12215,-1
12222,high-dose,35,36,215,224,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,-1,-1,2,12222,-1
12228,limit of detection,29,32,169,187,"We also demonstrated that OSCS can be identified in heparin products using a simple, inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately 0.1%, well below the NOEL.",19289093_5,-1,-1,2,12228,-1
12235,HIV-infected,11,12,66,78,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,2,12235,-1
12239,HIV-infected,9,10,56,68,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,2,12239,-1
12243,patient 1,1,3,8,17,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,-1,-1,2,12243,-1
12266,periapical segments,9,11,77,96,Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.,19300240_7,-1,-1,2,12266,-1
12270,medical therapy,5,7,32,47,The patient was stabilized with medical therapy.,19300240_9,-1,-1,2,12270,-1
12294,streptozotocin-induced,92,93,482,504,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,2,12294,-1
12295,mechanical stimuli,10,12,62,80,METHODS: The changes in pain thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto.,19300402_2,-1,-1,2,12295,-1
12302,Pretreatment,0,1,0,12,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,2,12302,-1
12321,pronociceptive activity,9,11,78,101,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,-1,-1,2,12321,-1
12323,hyperalgesia bradykinin,17,19,148,171,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,-1,-1,2,12323,-1
12331,French Pharmacovigilance database,16,19,86,119,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,2,12331,-1
12335,systematic study,10,12,57,73,Some case reports are published in the literature but no systematic study from a sample of patients has been published.,19308880_2,-1,-1,2,12335,-1
12337,French Pharmacovigilance database,4,7,19,52,"METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.",19308880_4,-1,-1,2,12337,-1
12351,human prothrombin complex concentrate,14,18,83,120,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,2,12351,-1
12353,CD-1 mice,1,3,5,14,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,-1,-1,2,12353,-1
12355,International Normalized Ratio,24,27,93,123,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,-1,-1,2,12355,-1
12356,intravenous administration,6,8,25,51,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,-1,-1,2,12356,-1
12359,stereotactic injection,3,5,10,32,"Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum.",19319147_6,-1,-1,2,12359,-1
12361,Forty-five minutes,0,2,0,18,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,2,12361,-1
12364,photometric hemoglobin assay,13,16,94,122,"Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay.",19319147_8,-1,-1,2,12364,-1
12373,acute treatment,10,12,63,78,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,-1,-1,2,12373,-1
12378,diffusion-weighted,12,13,110,128,Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,19346865_0,-1,-1,2,12378,-1
12387,retrospectively evaluated,7,9,44,69,"Findings of initial and follow-up MRIs were retrospectively evaluated by 2 neuroradiologists by consensus, to analyze the presence of abnormal signal intensities, their locations, and signal changes on follow-up images.",19346865_6,-1,-1,2,12387,-1
12392,T2-weighted image,15,17,83,100,"RESULTS: Initial MRIs showed abnormal high signal intensities on DWI and FLAIR (or T2-weighted image) at the dentate nucleus (8/8), inferior colliculus (6/8), corpus callosum (2/8), pons (2/8), medulla (1/8), and bilateral cerebral white matter (1/8).",19346865_7,-1,-1,2,12392,-1
12393,dentate nucleus,20,22,109,124,"RESULTS: Initial MRIs showed abnormal high signal intensities on DWI and FLAIR (or T2-weighted image) at the dentate nucleus (8/8), inferior colliculus (6/8), corpus callosum (2/8), pons (2/8), medulla (1/8), and bilateral cerebral white matter (1/8).",19346865_7,-1,-1,2,12393,-1
12406,inferior colliculus,6,8,28,47,"All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.",19346865_9,-1,-1,2,12406,-1
12409,dentate nucleus,19,21,148,163,"CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.",19346865_10,-1,-1,2,12409,-1
12414,immunosuppressive agent,6,8,36,59,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,-1,-1,2,12414,-1
12420,associated with,9,11,75,90,We have encountered several patients who developed substantial proteinuria associated with sirolimus use.,19356053_3,-1,-1,2,12420,-1
12425,Washington Hospital Center,17,20,112,138,METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.,19356053_5,-1,-1,2,12425,-1
12427,immunosuppressant regimen,32,34,201,226,METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.,19356053_5,-1,-1,2,12427,-1
12428,urine samples,12,14,72,85,"In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.",19356053_6,-1,-1,2,12428,-1
12429,turbidometric measurement,15,17,89,114,"In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.",19356053_6,-1,-1,2,12429,-1
12432,proteinuria/day,30,31,182,197,"In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.",19356053_6,-1,-1,2,12432,-1
12435,post-transplantation,15,16,96,116,RESULTS: Twenty-eight patients (24%) developed increased proteinuria from baseline during their post-transplantation course.,19356053_8,-1,-1,2,12435,-1
12453,non-associative,32,33,195,210,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,2,12453,-1
12456,test day,10,12,72,80,"Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle/scopolamine group was significantly lower than that of the vehicle/vehicle group, but this phenomenon was reversed when s-limonene or s-perillyl alcohol were administered before the injection of scopolamine.",19356307_3,-1,-1,2,12456,-1
12462,acetylcholinesterase activity,13,15,85,114,"Simultaneously, we found that these two lemon essential oil components could inhibit acetylcholinesterase activity in vitro using the Ellman method.",19356307_4,-1,-1,2,12462,-1
12465,Long term hormone therapy,0,4,0,25,Long term hormone therapy for perimenopausal and postmenopausal women.,19370593_0,-1,-1,2,12465,-1
12471,HT,8,9,46,48,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,-1,2,12471,-1
12475,Trials Register of the,12,16,71,93,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,2,12475,-1
12478,Cochrane Central Register of Controlled Trials,23,29,147,193,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,2,12478,-1
12479,EMBASE,32,33,204,210,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,2,12479,-1
12480,Biological Abstracts,34,36,212,232,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,2,12480,-1
12481,non-indexed journals,2,4,14,34,Also relevant non-indexed journals and conference abstracts.,19370593_5,-1,-1,2,12481,-1
12483,Randomised double-blind trials,3,6,20,50,"SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women.",19370593_6,-1,-1,2,12483,-1
12486,HT,0,1,0,2,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,2,12486,-1
12489,Nineteen trials,3,5,14,29,"MAIN RESULTS: Nineteen trials involving 41,904 women were included.",19370593_9,-1,-1,2,12489,-1
12490,HT,7,8,49,51,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,-1,2,12490,-1
12514,younger women,13,15,76,89,"However, this study was not powered to detect differences between groups of younger women.",19370593_17,-1,-1,2,12514,-1
12515,AUTHORS' CONCLUSIONS,0,3,0,20,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,2,12515,-1
12525,distracted away,15,17,100,115,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,-1,2,12525,-1
12526,painful pinprick stimulus,19,22,125,150,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,-1,2,12526,-1
12531,control condition,22,24,145,162,"Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.",19387625_4,-1,-1,2,12531,-1
12532,attentional modulation,10,12,69,91,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,-1,-1,2,12532,-1
12548,Isoproterenol-treated rats,0,2,0,26,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,2,12548,-1
12560,respiratory control ratio,9,12,78,103,"In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.",19445921_7,-1,-1,2,12560,-1
12562,isoproterenol-treated rats,17,19,130,156,"In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.",19445921_7,-1,-1,2,12562,-1
12564,isoproterenol-induced,13,14,85,106,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,-1,-1,2,12564,-1
12573,antioxidant activity,11,13,68,88,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,2,12573,-1
12582,PAC neurotoxicity,30,32,198,215,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,2,12582,-1
12584,PAC-induced,13,14,88,99,"This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.",19473225_2,-1,-1,2,12584,-1
12586,placebo-controlled,20,21,139,157,"This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.",19473225_2,-1,-1,2,12586,-1
12596,group G.,27,29,179,187,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,-1,2,12596,-1
12617,associated with,3,5,22,37,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,2,12617,-1
12620,CHC,14,15,102,105,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,2,12620,-1
12634,drug use,25,27,182,190,"Using functional imaging and a face-learning task, we investigated neural correlates of encoding and recalling face-name associations in 20 recreational drug users whose predominant drug use was ecstasy and 20 controls.",19631624_3,-1,-1,2,12634,-1
12636,L.,28,29,165,167,"To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested cannabis users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.",19631624_4,-1,-1,2,12636,-1
12638,parahippocampal,6,7,33,48,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,-1,2,12638,-1
12646,Ecstasy-specific hypoactivity,0,2,0,29,Ecstasy-specific hypoactivity was evident in the right dorsal anterior cingulated cortex (ACC) and left posterior cingulated cortex.,19631624_9,-1,-1,2,12646,-1
12651,left parahippocampal gyrus,17,20,102,128,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,-1,-1,2,12651,-1
12653,left caudate,27,29,163,175,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,-1,-1,2,12653,-1
12654,ecstasy-related deficits,3,5,25,49,"These results elucidated ecstasy-related deficits, only some of which might be attributed to cannabis use.",19631624_11,-1,-1,2,12654,-1
12655,ecstasy-specific effects,1,3,6,30,These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.,19631624_12,-1,-1,2,12655,-1
12667,Vancomycin nephrotoxicity,0,2,0,25,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,-1,-1,2,12667,-1
12671,Disulfiram-like syndrome,0,2,0,24,Disulfiram-like syndrome after hydrogen cyanamide professional skin exposure: two case reports in France.,19657887_0,-1,-1,2,12671,-1
12675,plant growth regulator,4,7,24,46,Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees.,19657887_1,-1,-1,2,12675,-1
12679,acetaldehyde syndrome,19,21,129,150,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,2,12679,-1
12680,disulfiram-like syndrome,12,14,57,81,The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide.,19657887_3,-1,-1,2,12680,-1
12681,occupational exposure to,15,18,92,116,The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide.,19657887_3,-1,-1,2,12681,-1
12686,contact with,10,12,69,81,The second case occurred in a 55-year-old farmer following cutaneous contact with Dormex.,19657887_7,-1,-1,2,12686,-1
12688,disulfiram-like syndrome,7,9,40,64,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,-1,2,12688,-1
12700,rechallenge,18,19,102,113,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,2,12700,-1
12705,tardive dystonia,1,3,18,34,Sulpiride-induced tardive dystonia.,1967484_0,-1,-1,2,12705,-1
12710,tardive dyskinesia,12,14,88,106,"Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.",1967484_2,-1,-1,2,12710,-1
12713,tardive dystonia,9,11,60,76,We could not find any previous reports of sulpiride-induced tardive dystonia.,1967484_4,-1,-1,2,12713,-1
12720,mPGES-1 +/+ mice,12,16,60,76,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,-1,-1,2,12720,-1
12722,associated with,2,4,9,24,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,-1,-1,2,12722,-1
12723,protein expression,7,9,48,66,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,-1,-1,2,12723,-1
12736,dowregulation,4,5,17,30,"In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.",19692487_11,-1,-1,2,12736,-1
12762,general anaesthesia,43,45,293,312,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,-1,-1,2,12762,-1
12764,/-,7,8,41,43,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,2,12764,-1
12766,/-,20,21,102,104,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,2,12766,-1
12768,/- 4 per,27,30,140,148,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,2,12768,-1
12773,/-,20,21,107,109,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,-1,-1,2,12773,-1
12781,associated with,1,3,9,24,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,-1,-1,2,12781,-1
12786,drug-drug interactions,23,25,145,167,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,-1,-1,2,12786,-1
12790,case report,6,8,36,47,The main search terms utilized were case report and levofloxacin.,19707748_3,-1,-1,2,12790,-1
12802,non-narcotic analgesic,7,9,19,41,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,2,12802,-1
12803,antiinflammatory drug,10,12,46,67,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,2,12803,-1
12811,molecular weights,22,24,139,156,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,2,12811,-1
12812,ester bonding,6,8,40,53,IR spectral data confirmed formation of ester bonding in the conjugates.,19719056_4,-1,-1,2,12812,-1
12813,UV-spectrophotometric analysis,5,7,36,66,Etodolac contents were evaluated by UV-spectrophotometric analysis.,19719056_5,-1,-1,2,12813,-1
12815,Mark-Howink-Sakurada equation,10,12,71,100,The molecular weights were determined by measuring viscosity using the Mark-Howink-Sakurada equation.,19719056_6,-1,-1,2,12815,-1
12818,first-order,33,34,145,156,"At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.",19719056_8,-1,-1,2,12818,-1
12833,effects of,7,9,40,50,"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.",19721134_1,-1,-1,2,12833,-1
12835,aconitine-induced,19,20,118,135,"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.",19721134_1,-1,-1,2,12835,-1
12844,guinea pigs,35,37,237,248,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,2,12844,-1
12845,[Ca(2+)](i,0,1,0,10,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,-1,-1,2,12845,-1
12848,myocytes,12,13,77,85,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,-1,-1,2,12848,-1
12851,effects of,17,19,160,170,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,-1,-1,2,12851,-1
12853,guinea pig,12,14,90,100,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,2,12853,-1
12856,cardiac M(3)-mAChR.,23,25,160,179,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,2,12856,-1
12861,healthy middle-aged,10,12,84,103,Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.,19729346_0,-1,-1,2,12861,-1
12865,Seventy-one participants,0,2,0,24,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,-1,-1,2,12865,-1
12866,medication condition,11,13,75,95,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,-1,-1,2,12866,-1
12869,postdose,9,10,64,72,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,2,12869,-1
12872,postdose,35,36,199,207,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,2,12872,-1
12875,postdose,19,20,114,122,"Significant declines in simple and sustained attention, working memory, and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose.",19729346_4,-1,-1,2,12875,-1
12876,age groups,25,27,153,163,"Significant declines in simple and sustained attention, working memory, and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose.",19729346_4,-1,-1,2,12876,-1
12877,postdose,37,38,214,222,"Significant declines in simple and sustained attention, working memory, and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose.",19729346_4,-1,-1,2,12877,-1
12879,age-interaction effects,11,13,63,86,"For almost all cognitive measures, there were no medication by age-interaction effects, which indicates that the 2 age groups exhibited similar responses to the medication challenge.",19729346_5,-1,-1,2,12879,-1
12880,age groups,19,21,115,125,"For almost all cognitive measures, there were no medication by age-interaction effects, which indicates that the 2 age groups exhibited similar responses to the medication challenge.",19729346_5,-1,-1,2,12880,-1
12886,middle-aged adults,35,37,227,245,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,-1,-1,2,12886,-1
12890,older adults,25,27,166,178,"PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults.",19729346_7,-1,-1,2,12890,-1
12892,older adults,10,12,67,79,"Therefore, clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults.",19729346_8,-1,-1,2,12892,-1
12893,older adults,17,19,105,117,"Therefore, clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults.",19729346_8,-1,-1,2,12893,-1
12895,younger adults,27,29,159,173,"Therefore, clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults.",19729346_8,-1,-1,2,12895,-1
12897,antipsychotic-like profile,10,12,80,106,The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,19759529_0,-1,-1,2,12897,-1
12904,glutamatergic system,29,31,189,209,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,2,12904,-1
12913,antipsychotic-like properties,7,9,48,77,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,2,12913,-1
12915,drug challenge,23,25,161,175,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,2,12915,-1
12934,dopaminergic,25,26,175,187,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,-1,-1,2,12934,-1
12938,reserpine-induced neurobehavioral,6,8,36,69,Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats.,19761039_0,-1,-1,2,12938,-1
12963,pilocarpine status epilepticus,8,11,64,94,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,2,12963,-1
12966,mechanism of action,8,11,46,65,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,2,12966,-1
12968,reactive oxygen species,4,7,20,43,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,-1,-1,2,12968,-1
12971,sub-regions,22,23,139,150,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,-1,-1,2,12971,-1
12986,pyramidal cells,16,18,117,132,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,-1,2,12986,-1
12987,interneurons,19,20,137,149,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,-1,2,12987,-1
12988,Low-dose,0,1,0,8,Low-dose PDTC treatment almost completely protected from lesions in the piriform cortex.,19767176_7,-1,-1,2,12988,-1
13025,Twenty-three hours,0,2,0,18,"Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF).",19843802_1,-1,-1,2,13025,-1
13029,CVVHDF,21,22,169,175,"Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF).",19843802_1,-1,-1,2,13029,-1
13034,effects of,2,4,9,19,"When the effects of IV drugs are inadequate in patients receiving CVVHDF, interference with adjacent catheters resulting in elimination of the drug by CVVHDF should be suspected.",19843802_6,-1,-1,2,13034,-1
13040,cross-sectional study,5,7,19,40,METHOD: This was a cross-sectional study of 85 patients from a lithium clinic who received different dose schedules.,1987816_2,-1,-1,2,13040,-1
13041,dose schedules,17,19,101,115,METHOD: This was a cross-sectional study of 85 patients from a lithium clinic who received different dose schedules.,1987816_2,-1,-1,2,13041,-1
13043,urine volume,15,17,95,107,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,-1,-1,2,13043,-1
13045,Multiple daily,2,4,9,23,RESULTS: Multiple daily doses of lithium were associated with higher urine volumes.,1987816_4,-1,-1,2,13045,-1
13046,associated with,8,10,46,61,RESULTS: Multiple daily doses of lithium were associated with higher urine volumes.,1987816_4,-1,-1,2,13046,-1
13047,dosing schedule,1,3,4,19,"The dosing schedule, duration of lithium treatment, and daily dose of lithium did not affect maximum osmolality or creatinine clearance.",1987816_5,-1,-1,2,13047,-1
13060,Population-based,7,8,35,51,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,2,13060,-1
13062,case-control study,11,13,64,82,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,2,13062,-1
13067,Odds ratios,4,6,22,33,MAIN OUTCOME MEASURE: Odds ratios (ORs) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders.,19884587_4,-1,-1,2,13067,-1
13070,confounders,22,23,142,153,MAIN OUTCOME MEASURE: Odds ratios (ORs) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders.,19884587_4,-1,-1,2,13070,-1
13075,AOR,32,33,145,148,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13075,-1
13076,AOR,50,51,200,203,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13076,-1
13078,AOR,66,67,246,249,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13078,-1
13080,AOR,83,84,304,307,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13080,-1
13082,AOR,100,101,359,362,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,2,13082,-1
13086,AOR,8,9,69,72,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,2,13086,-1
13088,AOR,26,27,132,135,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,2,13088,-1
13090,AOR,43,44,184,187,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,2,13090,-1
13093,AOR,63,64,246,249,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,2,13093,-1
13105,hepatitis B,15,17,106,117,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,2,13105,-1
13108,hepatitis B,5,7,30,41,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,2,13108,-1
13110,associated with,21,23,116,131,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,2,13110,-1
13111,vaccine escape,23,25,132,146,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,2,13111,-1
13115,immune escape mutants,7,10,48,69,Recent data suggest a preferential selection of immune escape mutants in distinct peripheral blood leukocyte compartments of infected individuals.,19889778_2,-1,-1,2,13115,-1
13121,antiviral drug susceptibility,28,31,174,203,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,2,13121,-1
13122,treatment-associated mutants,33,35,214,242,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,2,13122,-1
13124,HBV,1,2,22,25,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,2,13124,-1
13129,HBeAg-positive,20,21,125,139,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,2,13129,-1
13130,HBeAg-negative,23,24,147,161,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,2,13130,-1
13142,LAM-resistant,17,18,102,115,"Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.",19889778_6,-1,-1,2,13142,-1
13153,in vitro,24,26,172,180,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,2,13153,-1
13154,immune escape variants,7,10,49,71,"These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex HBV mutants, supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns.",19889778_9,-1,-1,2,13154,-1
13155,drug susceptibility,14,16,95,114,"These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex HBV mutants, supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns.",19889778_9,-1,-1,2,13155,-1
13168,time interval,21,23,117,130,"The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.",19893084_2,-1,-1,2,13168,-1
13173,gentamicin-treated animals,8,10,54,80,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,-1,-1,2,13173,-1
13178,gentamicin-treated animals,14,16,90,116,The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).,19893084_5,-1,-1,2,13178,-1
13179,/-,19,20,124,126,The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).,19893084_5,-1,-1,2,13179,-1
13180,/-,25,26,143,145,The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).,19893084_5,-1,-1,2,13180,-1
13183,control values,11,13,73,87,Vitamin C administration induced slowdown of pressure change back to the control values.,19893084_6,-1,-1,2,13183,-1
13188,gentamicin-treated animals,31,33,209,235,"The pressure dynamic properties, quantitatively defined by comparative pressure dynamic and total pressure dynamic, confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals and beneficial effects of vitamin C administration.",19893084_7,-1,-1,2,13188,-1
13209,blood concentration,6,8,42,61,"In patients receiving tacrolimus therapy, blood concentration should be carefully controlled and extreme attention paid to cardiac involvement.",19917396_9,-1,-1,2,13209,-1
13216,onset of,12,14,68,76,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,-1,-1,2,13216,-1
13220,PA training,1,3,4,15,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,2,13220,-1
13221,suspended platform,14,16,68,86,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,2,13221,-1
13222,Plexiglas tube,18,20,94,108,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,2,13222,-1
13223,automatically delivered,24,26,127,150,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,2,13223,-1
13224,testing trial,8,10,41,54,Latencies were recorded 48 h later for a testing trial.,19923525_5,-1,-1,2,13224,-1
13234,/-,11,12,64,66,RESULTS: All groups exhibited similar training latencies (17.0 +/- 4.6 s).,19923525_8,-1,-1,2,13234,-1
13236,/- 156,15,17,91,97,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,2,13236,-1
13240,/-,36,37,176,178,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,2,13240,-1
13241,/-,42,43,190,192,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,2,13241,-1
13242,/-,49,50,208,210,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,2,13242,-1
13243,Kruskal-Wallis 1-way analysis of,1,5,2,34,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,2,13243,-1
13244,treatment groups,13,15,91,107,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,2,13244,-1
13249,/-,41,42,176,178,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,2,13249,-1
13250,/-,49,50,202,204,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,2,13250,-1
13251,/-,58,59,234,236,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,2,13251,-1
13252,/-,66,67,260,262,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,2,13252,-1
13256,/-,14,15,82,84,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,2,13256,-1
13257,/-,21,22,104,106,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,2,13257,-1
13260,/-,6,7,29,31,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,2,13260,-1
13261,/-,14,15,55,57,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,2,13261,-1
13263,/-,27,28,104,106,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,2,13263,-1
13264,/-,35,36,130,132,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,2,13264,-1
13280,Zollinger-Ellison syndrome,21,23,114,140,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,2,13280,-1
13284,breath 2,10,12,59,67,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,2,13284,-1
13303,effects of,1,3,4,14,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,2,13303,-1
13306,allosteric activator,14,16,97,117,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,2,13306,-1
13311,apomorphine-induced rotations,8,10,33,62,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,-1,-1,2,13311,-1
13318,receptor-dependent,13,14,85,103,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,-1,-1,2,13318,-1
13327,associated with,12,14,92,107,Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity.,19940105_9,-1,-1,2,13327,-1
13352,Rho/ROCK pathway,6,8,23,39,"On the other hand, the Rho/ROCK pathway has an important role in the pathogenesis of coronary artery spasm.",19944333_11,-1,-1,2,13352,-1
13355,Rho/ROCK pathway,9,11,45,61,Our report may show an adverse effect on the Rho/ROCK pathway by sorafenib use.,19944333_12,-1,-1,2,13355,-1
13358,drug delivery system,10,13,50,70,A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood-brain barrier (BBB) and/or to improve the brain localization of a bioactive compound.,19944736_0,-1,-1,2,13358,-1
13359,BBB.The,19,20,106,113,A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood-brain barrier (BBB) and/or to improve the brain localization of a bioactive compound.,19944736_0,-1,-1,2,13359,-1
13362,drug delivery system,47,50,258,278,A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood-brain barrier (BBB) and/or to improve the brain localization of a bioactive compound.,19944736_0,-1,-1,2,13362,-1
13379,i.p.,29,31,188,192,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,-1,-1,2,13379,-1
13388,CA1 field,12,14,93,102,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,-1,-1,2,13388,-1
13393,tacrine-lithium model,18,20,122,143,"In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.",19944736_8,-1,-1,2,13393,-1
13394,drug delivery system,36,39,228,248,"In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.",19944736_8,-1,-1,2,13394,-1
13396,in vivo,47,49,278,285,"In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.",19944736_8,-1,-1,2,13396,-1
13400,S(c)O(2,13,14,83,90,We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.,19957053_2,-1,-1,2,13400,-1
13409,/-,10,11,58,60,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,2,13409,-1
13410,/- 13 mmHg,15,18,71,81,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,2,13410,-1
13411,/- SD,25,27,100,105,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,2,13411,-1
13412,/-,9,10,25,27,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,2,13412,-1
13413,/-,15,16,38,40,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,2,13413,-1
13414,S(c)O(2),21,23,58,66,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,2,13414,-1
13415,no change,30,32,92,101,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,2,13415,-1
13416,/-,37,38,114,116,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,2,13416,-1
13417,/-,42,43,129,131,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,2,13417,-1
13418,/-,14,15,70,72,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,2,13418,-1
13420,/-,33,34,123,125,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,2,13420,-1
13421,/-,38,39,138,140,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,2,13421,-1
13422,S(c)O(2,47,48,171,178,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,2,13422,-1
13423,S(c)O(2,17,18,116,123,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,-1,-1,2,13423,-1
13437,in-depth chart review,3,6,12,33,METHODS: An in-depth chart review was undertaken in all 24 patients who developed perioperative seizures.,19996135_4,-1,-1,2,13437,-1
13456,DTIs,6,7,40,44,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,2,13456,-1
13457,HITT,30,31,189,193,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,2,13457,-1
13464,fresh-frozen,17,18,91,103,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,2,13464,-1
13465,cryoprecipitate,23,24,124,139,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,2,13465,-1
13466,recombinant Factor VIIa,34,37,183,206,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,2,13466,-1
13474,t(1/2,29,30,157,162,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,-1,-1,2,13474,-1
13475,published elimination t(1/2,38,41,194,221,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,-1,-1,2,13475,-1
13502,intravenous administration,5,7,41,67,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,-1,-1,2,13502,-1
13517,C57BL/6 mice,12,14,57,69,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,2,13517,-1
13518,LP-BM5 murine leukaemia,15,18,75,98,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,2,13518,-1
13520,AZT-induced,26,27,129,140,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,2,13520,-1
13521,erythropoietic precursors,38,40,197,222,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,2,13521,-1
13525,LP-BM5 MuLV disease,6,9,27,46,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,2,13525,-1
13526,drinking water,14,16,71,85,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,2,13526,-1
13527,dose-dependent,9,10,42,56,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,2,13527,-1
13533,untreated mice,26,28,145,159,"Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected, untreated mice.",2004015_6,-1,-1,2,13533,-1
13542,AZT-induced,0,1,0,11,AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.,2004015_12,-1,-1,2,13542,-1
13553,double-blind,7,8,37,49,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,-1,-1,2,13553,-1
13560,bispectral index,9,11,76,92,"Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation.",20042557_3,-1,-1,2,13560,-1
13562,Third Edition Revised,15,18,105,126,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,-1,-1,2,13562,-1
13563,light sedation group,10,13,72,92,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,2,13563,-1
13564,deep sedation group,27,30,128,147,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,2,13564,-1
13565,treated with,47,49,237,249,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,2,13565,-1
13566,/- SD,3,5,10,15,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,2,13566,-1
13568,deep sedation group,22,25,116,135,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,2,13568,-1
13573,effects of,1,3,4,14,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,-1,-1,2,13573,-1
13576,double-blind placebo-controlled,19,21,122,153,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,-1,-1,2,13576,-1
13577,randomized study,22,24,158,174,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,-1,-1,2,13577,-1
13580,side-effect,38,39,205,216,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,2,13580,-1
13581,randomized sample,5,7,26,43,PATIENTS AND METHODS: The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI.,20067456_2,-1,-1,2,13581,-1
13589,Arizona Sexual Experience Scale,28,32,168,199,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,2,13589,-1
13590,ASEX,33,34,201,205,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,2,13590,-1
13598,total IIEF score,10,13,61,77,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,-1,-1,2,13598,-1
13600,Total ASEX scores,0,3,0,17,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,-1,-1,2,13600,-1
13604,ASEX,1,2,4,8,The ASEX score and CGI-SF score were correlated (P= 0.003).,20067456_10,-1,-1,2,13604,-1
13611,bone marrow,11,13,89,100,Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy.,20080419_0,-1,-1,2,13611,-1
13615,BMCs,0,1,0,4,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,2,13615,-1
13618,transgenic mice,9,11,51,66,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,2,13618,-1
13621,short term,24,26,147,157,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,-1,2,13621,-1
13627,hippocampal,1,2,3,14,"At hippocampal Schaeffer collateral-CA1 synapses, long-term potentiation was preserved in BMC-transplanted rats compared to epileptic controls.",20080419_7,-1,-1,2,13627,-1
13630,donor-derived GFP(+) cells,1,5,4,30,The donor-derived GFP(+) cells were rarely found in the brains of transplanted epileptic rats.,20080419_8,-1,-1,2,13630,-1
13637,cocaine-dependent participants,3,5,15,45,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,2,13637,-1
13639,double-blind randomized trial,35,38,180,209,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,2,13639,-1
13644,associated with,7,9,49,64,RESULTS: Progressive abstinence from cocaine was associated with worsening of all measured polysomnographic sleep outcomes.,20080983_6,-1,-1,2,13644,-1
13649,cocaine-dependent participants,15,17,105,135,"Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.",20080983_7,-1,-1,2,13649,-1
13651,abstinence week,7,9,44,59,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,-1,-1,2,13651,-1
13652,associated with,11,13,68,83,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,-1,-1,2,13652,-1
13658,cocaine-dependent,14,15,75,92,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,-1,-1,2,13658,-1
13661,cocaine-dependent,25,26,164,181,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,-1,-1,2,13661,-1
13663,associated with,2,4,14,29,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,-1,-1,2,13663,-1
13673,semi-invasive tool,5,7,21,39,BACKGROUND: TEE is a semi-invasive tool broadly used and its utilization associated to sedatives drugs might to affect the procedure safety.,20084309_1,-1,-1,2,13673,-1
13676,associated to,8,10,44,57,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,2,13676,-1
13683,associated to,12,14,71,84,METHOD: prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation.,20084309_3,-1,-1,2,13683,-1
13686,Uni-,0,1,0,4,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,2,13686,-1
13691,mean doses,1,3,4,14,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,2,13691,-1
13706,intracoronary administration,3,5,17,45,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,-1,-1,2,13706,-1
13714,control group,29,31,192,205,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,2,13714,-1
13720,control group,2,4,7,20,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,-1,2,13720,-1
13728,intracoronary injection,11,13,65,88,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,-1,-1,2,13728,-1
13755,patient's,3,5,13,22,"SUMMARY: The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of ""meth mouth."" Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.",20098969_8,-1,-1,2,13755,-1
13760,implant-supported,35,36,212,229,"SUMMARY: The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of ""meth mouth."" Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.",20098969_8,-1,-1,2,13760,-1
13773,primary transcription factor,3,6,12,40,Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.,20103708_2,-1,-1,2,13773,-1
13784,Nrf2(-/-) mice,31,34,222,236,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,-1,-1,2,13784,-1
13800,Nrf2-mediated,13,14,73,86,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,-1,-1,2,13800,-1
13808,overexpression,4,5,27,41,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,-1,-1,2,13808,-1
13812,dose-dependent,15,16,100,114,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,-1,-1,2,13812,-1
13828,gentamicin toxicity,14,16,68,87,Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.,20164825_2,-1,-1,2,13828,-1
13831,reactive oxygen species,8,11,57,80,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,2,13831,-1
13833,cytochrome c release,16,19,111,131,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,2,13833,-1
13837,antioxidant systems,20,22,140,159,"This was accompanied by a lower activity of N-acetyl-beta-D-glucosaminidase, together with a decrease of lipid peroxidation and increase of antioxidant systems.",20164825_5,-1,-1,2,13837,-1
13843,respiratory components,6,8,44,66,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,-1,-1,2,13843,-1
13847,reactive oxygen species,9,12,45,68,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,2,13847,-1
13848,electron transfer chain,14,17,78,101,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,2,13848,-1
13850,gentamicin nephrotoxicity,12,14,74,99,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,2,13850,-1
13871,baseline values,23,25,95,110,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,2,13871,-1
13879,study population,38,40,191,207,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,2,13879,-1
13881,group A,18,20,73,80,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,-1,2,13881,-1
13896,Antituberculosis therapy,0,2,0,24,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,2,13896,-1
13901,South Asia,15,17,109,119,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,2,13901,-1
13902,Prospective studies,0,2,0,19,Prospective studies on ATT-ALF are lacking.,20196116_2,-1,-1,2,13902,-1
13918,hepatitis E,2,4,14,25,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,2,13918,-1
13945,/-,6,7,35,37,Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.,2021202_4,-1,-1,2,13945,-1
13948,/-,24,25,145,147,Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.,2021202_4,-1,-1,2,13948,-1
13957,normotension,22,23,170,182,We conclude that renal compensatory mechanisms are preserved during isoflurane-induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed.,2021202_8,-1,-1,2,13957,-1
13958,HYPREN-trial,5,6,27,39,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,-1,-1,2,13958,-1
13964,multicenter,10,11,54,65,"To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.",2024540_2,-1,-1,2,13964,-1
13965,prazosin-controlled trial,14,16,79,104,"To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.",2024540_2,-1,-1,2,13965,-1
13966,Trial medication,0,2,0,16,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,-1,-1,2,13966,-1
13967,New York Heart Association (NYHA) functional class II,5,15,35,88,Subjects were 1210 inpatients with New York Heart Association (NYHA) functional class II and III.,2024540_4,-1,-1,2,13967,-1
13969,prenatally exposed,5,7,34,52,Brainstem dysgenesis in an infant prenatally exposed to cocaine.,20304337_0,-1,-1,2,13969,-1
13973,cocaine-addicted mother,17,19,111,134,"We report on an infant with multiple cranial-nerve involvement attributable to brainstem dysgenesis, born to a cocaine-addicted mother.",20304337_3,-1,-1,2,13973,-1
13977,risperidone-induced,14,15,73,92,OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.,20331935_1,-1,-1,2,13977,-1
13980,BMD,22,23,148,151,OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.,20331935_1,-1,-1,2,13980,-1
13994,areal BMD,15,17,109,118,"Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography, and areal BMD of the lumbar spine was estimated using dual-energy x-ray absorptiometry.",20331935_5,-1,-1,2,13994,-1
13996,dual-energy x-ray absorptiometry,24,27,159,191,"Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography, and areal BMD of the lumbar spine was estimated using dual-energy x-ray absorptiometry.",20331935_5,-1,-1,2,13996,-1
14006,z scores,12,14,71,79,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,-1,-1,2,14006,-1
14008,associated with,19,21,112,127,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,-1,-1,2,14008,-1
14010,covariates,3,4,25,35,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,2,14010,-1
14011,associated with,19,21,120,135,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,2,14011,-1
14016,non-Hispanic white,11,13,70,88,These findings became more marked when the analysis was restricted to non-Hispanic white patients.,20331935_11,-1,-1,2,14016,-1
14025,Fear-potentiated startle,0,2,0,24,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,2,14025,-1
14029,non-specific,20,21,114,126,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,2,14029,-1
14030,fear-potentiated startle,4,6,17,41,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,2,14030,-1
14033,effects of,5,7,35,45,The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms.,20394767_4,-1,-1,2,14033,-1
14037,Wistar rats,3,5,14,25,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,2,14037,-1
14048,startle amplitude,5,7,42,59,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,2,14048,-1
14052,associated with,2,4,23,38,Rosaceiform dermatitis associated with topical tacrolimus treatment.,20466178_0,-1,-1,2,14052,-1
14059,Continuous topical use of,0,4,0,25,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,-1,-1,2,14059,-1
14077,front-line protocol,27,29,141,160,"During a 9-year period, we retrospectively collected 27 neurological events (11%) in as many patients, from 253 children enrolled in the ALL front-line protocol.",20470218_5,-1,-1,2,14077,-1
14080,high-dose,29,30,135,144,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,2,14080,-1
14081,methotrexate toxicity,30,32,145,166,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,2,14081,-1
14082,antidiuretic hormone secretion,41,44,202,232,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,2,14082,-1
14088,cocaine toxicity,6,8,45,61,Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.,20477932_1,-1,-1,2,14088,-1
14095,NFkappaB activity,1,3,10,27,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,2,14095,-1
14102,NFkappaB activity,0,2,0,17,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,2,14102,-1
14108,NFkappaB activity,15,17,117,134,Memory retrieval of experiences acquired prior to cocaine administration was impaired and negatively correlated with NFkappaB activity in the frontal cortex.,20477932_5,-1,-1,2,14108,-1
14112,nitrosative stress,12,14,80,98,These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine.,20477932_7,-1,-1,2,14112,-1
14117,cisplatin nephrotoxicity,5,7,41,65,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,-1,-1,2,14117,-1
14121,i.p.,18,20,113,117,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,2,14121,-1
14145,cisplatin-induced overexpression,9,11,84,116,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,2,14145,-1
14153,therapeutic option,9,11,58,76,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,2,14153,-1
14167,placebo- and haloperidol-controlled trial,7,11,38,79,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.,20520283_0,-1,-1,2,14167,-1
14172,double-blind 6-week trial,2,5,5,30,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,2,14172,-1
14173,fixed-dose treatment,15,17,96,116,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,2,14173,-1
14179,MMRM,57,58,302,306,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,2,14179,-1
14200,AEs,18,19,117,120,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,-1,-1,2,14200,-1
14202,Salvage therapy,0,2,0,15,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,2,14202,-1
14214,prophylactic intrathecal chemotherapy,24,27,100,137,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,2,14214,-1
14215,salvage therapy,30,32,150,165,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,2,14215,-1
14219,Grade 2,10,12,63,70,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,2,14219,-1
14223,consistent with,20,22,134,149,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,2,14223,-1
14232,dopaminergic,15,16,99,111,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,2,14232,-1
14238,drug effects,25,27,194,206,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,-1,-1,2,14238,-1
14240,genetically engineered,6,8,27,49,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,2,14240,-1
14241,METH neurotoxicity,15,17,86,104,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,2,14241,-1
14243,genetically engineered,7,9,38,60,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,2,14243,-1
14249,Adriamycin-mediated antitumor activity,3,6,23,61,Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.,2054792_1,-1,-1,2,14249,-1
14251,F344 rat model,18,21,140,154,Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.,2054792_1,-1,-1,2,14251,-1
14256,Adriamycin-mediated antitumor activity,13,16,66,104,Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.,2054792_4,-1,-1,2,14256,-1
14262,Adriamycin-mediated antitumor effect,7,10,45,81,"Thus, while whole body hyperthermia enhances Adriamycin-mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.",2054792_7,-1,-1,2,14262,-1
14265,triggered by,3,5,42,54,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,-1,-1,2,14265,-1
14276,comprehensive review,10,12,60,80,"This article summarizes all the cases published, creating a comprehensive review of the current knowledge and approach to SIAT.",20552622_8,-1,-1,2,14276,-1
14293,streptozotocin-induced,17,18,105,127,The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.1.,2055425_0,-1,-1,2,14293,-1
14294,mellitus.1,19,20,137,147,The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.1.,2055425_0,-1,-1,2,14294,-1
14295,effects of,1,3,4,14,The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin-diabetic rats were investigated.,2055425_1,-1,-1,2,14295,-1
14300,streptozotocin-diabetic rats,15,17,85,113,The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin-diabetic rats were investigated.,2055425_1,-1,-1,2,14300,-1
14303,average volume,27,29,150,164,"2. Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment.",2055425_2,-1,-1,2,14303,-1
14312,average volume,27,29,153,167,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,-1,-1,2,14312,-1
14318,effects of,5,7,27,37,The data indicate that the effects of streptozotocin-induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment.,2055425_9,-1,-1,2,14318,-1
14321,Glutamatergic neurotransmission,0,2,0,31,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,-1,-1,2,14321,-1
14323,inferior colliculus,8,10,66,85,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,-1,-1,2,14323,-1
14324,inferior colliculus (,1,4,4,25,"The inferior colliculus (IC) is primarily involved in the processing of auditory information, but it is distinguished from other auditory nuclei in the brainstem by its connections with structures of the motor system.",20558148_1,-1,-1,2,14324,-1
14331,intracollicular,6,7,56,71,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,2,14331,-1
14332,microinjections,7,8,72,87,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,2,14332,-1
14341,intracollicular,4,5,24,39,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,2,14341,-1
14346,horizontal bar,32,34,214,228,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,2,14346,-1
14347,intracollicular,2,3,13,28,"Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.",20558148_7,-1,-1,2,14347,-1
14348,microinjection,3,4,29,43,"Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.",20558148_7,-1,-1,2,14348,-1
14350,glutamate-mediated mechanisms,4,6,28,57,These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.,20558148_8,-1,-1,2,14350,-1
14355,puromycin aminonucleoside nephrosis,16,19,109,144,"Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.",20588063_0,-1,-1,2,14355,-1
14356,BACKGROUND/AIMS,0,1,0,15,BACKGROUND/AIMS: It is still unclear what happens in the glomerulus when proteinuria starts.,20588063_1,-1,-1,2,14356,-1
14357,puromycin aminonucleoside nephrosis,1,4,6,41,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,2,14357,-1
14359,podocyte-associated molecules,23,25,149,178,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,2,14359,-1
14365,immune stainings,3,5,15,31,"METHODS: Using immune stainings, semiquantitative measurement was performed under the electron microscope.",20588063_3,-1,-1,2,14365,-1
14388,drug-induced symptom provocation,15,18,98,130,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,2,14388,-1
14391,OCD-like behaviors,7,9,50,68,None of these current models demonstrate multiple OCD-like behaviors.,20619828_2,-1,-1,2,14391,-1
14400,consistent with,10,12,66,81,CONCLUSIONS: This is the first demonstration of multiple symptoms consistent with an OCD-like profile in animals.,20619828_6,-1,-1,2,14400,-1
14401,OCD-like profile,13,15,85,101,CONCLUSIONS: This is the first demonstration of multiple symptoms consistent with an OCD-like profile in animals.,20619828_6,-1,-1,2,14401,-1
14407,therapeutic strategies,27,29,181,203,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,2,14407,-1
14414,TAA,16,17,87,90,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,2,14414,-1
14416,CaCl(2))-induced arterial injury,22,25,113,145,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,2,14416,-1
14417,disintegrin,33,34,185,196,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,2,14417,-1
14419,matrix metalloproteinases,40,42,227,252,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,2,14419,-1
14422,TAA,53,54,303,306,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,2,14422,-1
14424,Sprague-Dawley rats,6,8,32,51,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,2,14424,-1
14431,NaCl-treated aortic segments,15,18,90,118,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,2,14431,-1
14434,semi-quantitatively analyzed,5,7,29,57,MMP-TIMP and ADAM mRNAs were semi-quantitatively analyzed and protein expressions were determined by immunohistochemistry.,20621845_4,-1,-1,2,14434,-1
14457,TAA,6,7,37,40,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,2,14457,-1
14466,electroconvulsive therapy,8,10,61,86,Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.,20633755_0,-1,-1,2,14466,-1
14469,enzyme gets,9,11,78,89,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,-1,-1,2,14469,-1
14471,electroconvulsive therapy,14,16,81,106,"Here, we present a similar incident in a severely depressed patient who received electroconvulsive therapy (ECT).",20633755_2,-1,-1,2,14471,-1
14478,CHF,21,22,137,140,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,2,14478,-1
14481,treated with,3,5,17,29,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,2,14481,-1
14485,follow up,19,21,124,133,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,-1,-1,2,14485,-1
14492,CHF,22,23,148,151,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,-1,-1,2,14492,-1
14498,antiepileptic drugs,1,3,4,23,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,-1,-1,2,14498,-1
14501,chronic use,15,17,106,117,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,-1,-1,2,14501,-1
14538,associated with,24,26,175,190,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,-1,-1,2,14538,-1
14539,Effects of,0,2,0,10,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,2,14539,-1
14543,streptozocin-induced model,11,13,63,89,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,2,14543,-1
14544,Alzheimer's disease,15,18,102,121,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,2,14544,-1
14547,active components,14,16,83,100,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,2,14547,-1
14551,Alzheimer's disease,11,14,56,75,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,2,14551,-1
14552,intracerebroventricular,16,17,87,110,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,2,14552,-1
14554,Wistar rats,4,6,20,31,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,2,14554,-1
14559,Alzheimer's disease,1,4,3,22,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,-1,-1,2,14559,-1
14565,pre-surgery,23,24,93,104,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,2,14565,-1
14570,Y-maze task,20,22,130,141,"However, the learning and memory performance was assessed using passive avoidance paradigm, and for spatial cognition evaluation, Y-maze task was used.",20683499_7,-1,-1,2,14570,-1
14585,Alzheimer's disease,36,39,226,245,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,2,14585,-1
14586,anemia?BACKGROUND/AIMS,11,12,77,99,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,2,14586,-1
14587,angiogenesis inhibitors,25,27,175,198,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,2,14587,-1
14592,vascular endothelial growth factor,8,12,58,92,"Serum hemoglobin, haptoglobin and angiogenesis markers of vascular endothelial growth factor and angiopoetin-2 were investigated before and after therapy.",20698227_3,-1,-1,2,14592,-1
14593,angiopoetin-2,13,14,97,110,"Serum hemoglobin, haptoglobin and angiogenesis markers of vascular endothelial growth factor and angiopoetin-2 were investigated before and after therapy.",20698227_3,-1,-1,2,14593,-1
14595,Hemoglobin levels,0,2,0,17,Hemoglobin levels also decreased but insignificantly by treatment.,20698227_5,-1,-1,2,14595,-1
14596,serum levels,6,8,33,45,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,2,14596,-1
14598,associated with,6,8,42,57,Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution.,2070391_1,-1,-1,2,14598,-1
14605,/-,20,21,116,118,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,-1,2,14605,-1
14606,/-,25,26,132,134,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,-1,2,14606,-1
14607,associated with,5,7,29,44,Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.,20705401_0,-1,-1,2,14607,-1
14608,Japanese population,11,13,84,103,Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.,20705401_0,-1,-1,2,14608,-1
14614,d-amphetamine-induced,23,24,144,165,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,-1,-1,2,14614,-1
14616,prepulse inhibition,5,7,27,46,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,-1,-1,2,14616,-1
14632,case-control samples,25,27,139,159,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,-1,-1,2,14632,-1
14633,Japanese population,38,40,222,241,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,-1,-1,2,14633,-1
14634,control subjects,6,8,23,39,The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients.,20705401_8,-1,-1,2,14634,-1
14636,associated with,4,6,23,38,RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.,20705401_9,-1,-1,2,14636,-1
14637,allele/genotype-wise analysis,11,13,78,107,RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.,20705401_9,-1,-1,2,14637,-1
14639,haplotype-wise analysis,2,4,7,30,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,-1,-1,2,14639,-1
14648,Japanese population,16,18,100,119,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,-1,-1,2,14648,-1
14650,effects of,9,11,46,56,The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.,2071257_1,-1,-1,2,14650,-1
14655,pretreatment,6,7,26,38,"They were given a ten day pretreatment with either L-alpha-GFC or placebo, p.o., and on the eleventh day either scopolamine or placebo, i.m.",2071257_3,-1,-1,2,14655,-1
14689,glutamatergic dysfunction,18,20,114,139,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,-1,-1,2,14689,-1
14690,placebo-controlled,4,5,22,40,"In a counterbalanced, placebo-controlled, double-blind study design, healthy subjects were administered a continuous subanesthetic S-ketamine infusion while differences in BOLD responses measured with fMRI were detected.",20727411_4,-1,-1,2,14690,-1
14691,double-blind study design,6,9,42,67,"In a counterbalanced, placebo-controlled, double-blind study design, healthy subjects were administered a continuous subanesthetic S-ketamine infusion while differences in BOLD responses measured with fMRI were detected.",20727411_4,-1,-1,2,14691,-1
14697,Ketamine-induced psychopathological,0,2,0,35,Ketamine-induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS).,20727411_6,-1,-1,2,14697,-1
14698,Post-hoc,0,1,0,8,"Post-hoc t-tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency, while the phonological domain remained unaffected.",20727411_8,-1,-1,2,14698,-1
14699,t-tests,1,2,9,16,"Post-hoc t-tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency, while the phonological domain remained unaffected.",20727411_8,-1,-1,2,14699,-1
14718,Danish national referral centre,17,21,115,146,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,-1,-1,2,14718,-1
14721,post-discharge,8,9,53,67,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,-1,-1,2,14721,-1
14727,mortality rate ratio,25,28,166,186,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,-1,-1,2,14727,-1
14740,bench-to-bedside,11,12,79,95,Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.,20880751_0,-1,-1,2,14740,-1
14743,pulsatile stimulation,6,8,51,72,"Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear.",20880751_3,-1,-1,2,14743,-1
14747,post-receptor molecular mechanisms,24,27,153,187,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,2,14747,-1
14750,research focus,9,11,61,75,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,-1,-1,2,14750,-1
14752,postsynaptic mechanisms,18,20,123,146,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,-1,-1,2,14752,-1
14757,Effects of,0,2,0,10,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,-1,-1,2,14757,-1
14761,globus pallidus,3,5,15,30,OBJECTIVE: The globus pallidus plays a critical role in movement regulation.,20882060_1,-1,-1,2,14761,-1
14762,globus pallidus,6,8,41,56,"Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum, and systemic administration of a neurotensin analog could produce antiparkinsonian effects.",20882060_2,-1,-1,2,14762,-1
14763,neurotensinergic innervation,9,11,66,94,"Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum, and systemic administration of a neurotensin analog could produce antiparkinsonian effects.",20882060_2,-1,-1,2,14763,-1
14767,effects of,7,9,43,53,The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.,20882060_3,-1,-1,2,14767,-1
14784,Carmofur-induced,0,1,0,16,Carmofur-induced organic mental disorders.,2096243_0,-1,-1,2,14784,-1
14791,DSM-III-R.,27,28,176,186,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,2,14791,-1
14810,scale-up syntheses,2,4,14,32,"Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.",20973483_2,-1,-1,2,14810,-1
14819,reserpine-induced akinesia,59,61,298,324,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,2,14819,-1
14823,drug-induced rotation,70,72,373,394,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,2,14823,-1
14824,MPTP-treated non-human primate model,74,78,400,436,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,2,14824,-1
14825,Butyrylcholinesterase gene mutations,0,3,0,36,Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.,21029050_0,-1,-1,2,14825,-1
14827,electroconvulsive therapy,4,6,32,57,BACKGROUND: patients undergoing electroconvulsive therapy (ECT) often receive succinylcholine as part of the anesthetic procedure.,21029050_1,-1,-1,2,14827,-1
14834,A-variants,28,29,155,165,"The duration of action may be prolonged in patients with genetic variants of the butyrylcholinesterase enzyme (BChE), the most common being the K- and the A-variants.",21029050_2,-1,-1,2,14834,-1
14840,BChE activity,3,5,18,31,"We determined the BChE activity and the BCHE genotype using molecular genetic methods, the duration of apnea, time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used.",21029050_5,-1,-1,2,14840,-1
14841,BCHE genotype,7,9,40,53,"We determined the BChE activity and the BCHE genotype using molecular genetic methods, the duration of apnea, time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used.",21029050_5,-1,-1,2,14841,-1
14845,published data,7,9,40,54,The duration of apnea was compared with published data on normal subjects.,21029050_6,-1,-1,2,14845,-1
14846,normal subjects,10,12,58,73,The duration of apnea was compared with published data on normal subjects.,21029050_6,-1,-1,2,14846,-1
14848,K-variant,15,16,68,77,"RESULTS: in 11 patients, mutations were found in the BCHE gene, the K-variant being the most frequent.",21029050_7,-1,-1,2,14848,-1
14852,duration of action,9,12,51,69,"CONCLUSION: eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE, indicating that this is the possible reason for a prolonged period of apnea.",21029050_11,-1,-1,2,14852,-1
14855,Effects of,0,2,0,10,Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats.,21294084_0,-1,-1,2,14855,-1
14862,group-1,1,2,3,10,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,2,14862,-1
14864,group-2,12,13,53,60,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,2,14864,-1
14870,control group,2,4,7,20,In the control group hippocampal DBS was on following 8  l saline injection intracortically.,21294084_5,-1,-1,2,14870,-1
14871,hippocampal,4,5,21,32,In the control group hippocampal DBS was on following 8  l saline injection intracortically.,21294084_5,-1,-1,2,14871,-1
14875,frequency hippocampal,3,5,14,35,RESULTS: High frequency hippocampal DBS suppressed the acute penicillin-induced cortical epileptic activity independent from stimulus intensity.,21294084_7,-1,-1,2,14875,-1
14876,control group,2,4,7,20,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,-1,2,14876,-1
14879,5V stimulation,18,20,119,133,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,-1,2,14879,-1
14891,Melbourne Veterinary Specialist Centre,15,19,75,113,DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.,21418164_1,-1,-1,2,14891,-1
14905,CCNU-associated,2,3,13,28,"CONCLUSIONS: CCNU-associated toxicity in dogs is common, but is usually not life threatening.",21418164_8,-1,-1,2,14905,-1
14937,Maximum tolerated dose,0,3,0,22,"Maximum tolerated dose in good-risk patients was 70 mg/m2, and in poor-risk patients, 60 mg/m2.",2224762_5,-1,-1,2,14937,-1
14942,Granulocyte nadir,0,2,0,17,"Granulocyte nadir was on day 14 (range, 4-22).",2224762_7,-1,-1,2,14942,-1
14950,/-,19,20,97,99,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,2,14950,-1
14951,T beta 1/2,23,26,114,124,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,2,14951,-1
14952,/-,29,30,134,136,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,2,14952,-1
14953,T 1/2 gamma,34,37,154,165,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,2,14953,-1
14954,/-,40,41,175,177,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,2,14954,-1
14955,area under the curve,1,5,4,24,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,-1,-1,2,14955,-1
14956,/-,8,9,34,36,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,-1,-1,2,14956,-1
14958,/-,22,23,90,92,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,-1,-1,2,14958,-1
14959,l/m2,24,25,97,101,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,-1,-1,2,14959,-1
14966,starting dose,2,4,16,29,The recommended starting dose for Phase II trials is 60 mg/m2 IV bolus every 3 weeks.,2224762_15,-1,-1,2,14966,-1
14967,Phase II trials,5,8,34,49,The recommended starting dose for Phase II trials is 60 mg/m2 IV bolus every 3 weeks.,2224762_15,-1,-1,2,14967,-1
14971,18-month,2,3,10,18,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,-1,-1,2,14971,-1
14979,tritan-type dyschromatopsy,11,13,65,91,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,2,14979,-1
14983,high-frequency,8,9,49,63,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,2,14983,-1
14996,azidothymidine-induced marrow suppression,2,5,29,70,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,2,14996,-1
15000,in vitro,14,16,86,94,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,2,15000,-1
15002,antihuman immunodeficiency virus,29,32,211,243,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,2,15002,-1
15003,associated with,5,7,35,50,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,2,15003,-1
15007,in vivo,21,23,131,138,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,2,15007,-1
15008,Urd catabolism,3,5,20,34,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,2,15008,-1
15009,in vivo,7,9,40,47,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,2,15009,-1
15010,dose-dependent,18,19,96,110,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,2,15010,-1
15012,drinking water,15,17,83,97,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,2,15012,-1
15018,AZT-induced marrow,13,15,80,98,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,2,15018,-1
15023,HIV-induced,27,28,140,151,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,2,15023,-1
15025,MT4 cells,31,33,173,182,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,2,15025,-1
15033,double-blind trial,2,4,12,30,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,-1,-1,2,15033,-1
15035,Duchenne dystrophy,7,9,46,64,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,-1,-1,2,15035,-1
15037,Duchenne dystrophy,15,17,87,105,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,2,15037,-1
15038,12-month controlled trial,3,6,15,40,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,2,15038,-1
15041,Duchenne dystrophy,20,22,117,135,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,2,15041,-1
15055,GH secretion,5,7,26,38,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,-1,-1,2,15055,-1
15064,Duchenne dystrophy,9,11,55,73,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,-1,-1,2,15064,-1
15067,step-through type,13,15,86,103,Facilitation of memory retrieval by pre-test morphine and its state dependency in the step-through type passive avoidance learning test in mice.,2273650_0,-1,-1,2,15067,-1
15069,test trial,15,17,100,110,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,-1,-1,2,15069,-1
15070,pre-test,18,19,112,120,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,-1,-1,2,15070,-1
15073,training trial,36,38,231,245,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,-1,-1,2,15073,-1
15081,unanesthetized,1,2,3,17,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,-1,-1,2,15081,-1
15091,clonidine-suppressible binding,41,43,206,236,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,-1,-1,2,15091,-1
15093,effects of,9,11,68,78,These findings indicate that in spontaneously hypertensive rats the effects of central alpha-adrenoceptor stimulation involve activation of opiate receptors.,227508_5,-1,-1,2,15093,-1
15094,central alpha-adrenoceptor stimulation,11,14,79,117,These findings indicate that in spontaneously hypertensive rats the effects of central alpha-adrenoceptor stimulation involve activation of opiate receptors.,227508_5,-1,-1,2,15094,-1
15096,receptor site,12,14,66,79,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,-1,-1,2,15096,-1
15113,Older subjects,0,2,0,14,Older subjects tended to display more side effects.,230316_10,-1,-1,2,15113,-1
15116,Prazosin-induced,0,1,0,16,Prazosin-induced stress incontinence.,2304736_0,-1,-1,2,15116,-1
15177,hot plate,17,19,81,90,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,2,15177,-1
15214,associated with,4,6,28,43,The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months.,2334179_7,-1,-1,2,15214,-1
15236,antifibrinolytic treatment,8,10,51,77,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,2,15236,-1
15237,associated with,14,16,101,116,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,-1,-1,2,15237,-1
15239,antifibrinolytic agent,1,3,5,27,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,-1,-1,2,15239,-1
15255,Effects of,0,2,0,10,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,2,15255,-1
15264,effects of,1,3,4,14,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,2,15264,-1
15266,acid-base,11,12,85,94,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,2,15266,-1
15273,partial pressures,23,25,136,153,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,2,15273,-1
15278,PC02,13,14,75,79,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,2,15278,-1
15280,control level,46,48,240,253,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,2,15280,-1
15286,Dipyridamole-thallium-201 imaging,0,2,0,33,Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.,2348231_1,-1,-1,2,15286,-1
15291,dipyridamole-thallium-201 imaging,18,20,151,184,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,-1,-1,2,15291,-1
15299,dipyridamole-induced,7,8,59,79,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,-1,-1,2,15299,-1
15317,intravenous administration,8,10,62,88,"Although generally consisted safe when given intramuscularly, intravenous administration is known to cause respiratory and cardiovascular depression.",2375138_2,-1,-1,2,15317,-1
15319,associated with,12,14,85,100,This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.,2375138_3,-1,-1,2,15319,-1
15323,repetitive stimulation,6,8,25,47,"While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting postsynaptic neuromuscular blockade.",2385256_4,-1,-1,2,15323,-1
15335,5-week,2,3,10,16,"Groups of 5-week old male Fischer-344 rats were fed for 7-25 months semipurified choline-devoid or choline-supplemented diets, containing or not 0.06% phenobarbital.",2396046_2,-1,-1,2,15335,-1
15353,projection descending,30,32,202,223,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,-1,-1,2,15353,-1
15355,midline cells,11,13,69,82,"The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla, coinciding with the raphe magnus.",2422478_2,-1,-1,2,15355,-1
15360,intraspinal injection,2,4,9,30,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,-1,-1,2,15360,-1
15363,"5,7-DHT lesion",2,4,9,23,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,2,15363,-1
15367,associated with,34,36,193,208,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,2,15367,-1
15373,projection restricted,56,58,350,371,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",2422478_6,-1,-1,2,15373,-1
15374,side-effects,3,4,19,31,"On two paradoxical side-effects of prednisolone in rats, ribosomal RNA biosyntheses, and a mechanism of action.",2425813_0,-1,-1,2,15374,-1
15384,tissue-specific,11,12,55,70,It is suggested that the drug acted in a selective and tissue-specific manner to enhance ribosomal RNA synthesis in the liver and depress such synthesis in the muscle.,2425813_3,-1,-1,2,15384,-1
15388,two-stage coronary ligation-,1,4,6,34,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,-1,2,15388,-1
15389,adrenaline-induced canine,8,10,52,77,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,-1,2,15389,-1
15396,/-,31,32,203,205,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,2,15396,-1
15397,/-,43,44,234,236,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,2,15397,-1
15398,/-,55,56,265,267,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,2,15398,-1
15399,/- SDM,83,85,360,366,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,2,15399,-1
15413,PTZ-induced,36,37,230,241,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,2,15413,-1
15417,intraperitoneal,21,22,109,124,"In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.",2440413_2,-1,-1,2,15417,-1
15434,In vitro,0,2,0,8,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,-1,-1,2,15434,-1
15437,3H-TBOB binding,12,14,76,91,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,-1,-1,2,15437,-1
15438,IC50,20,21,119,123,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,-1,-1,2,15438,-1
15439,MPA,0,1,0,3,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,2,15439,-1
15440,BCC,2,3,5,8,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,2,15440,-1
15447,seizure-inducing agents,29,31,170,193,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,2,15447,-1
15457,interferon titers,14,16,93,110,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,2,15457,-1
15466,prospective study,9,11,68,85,Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.,2466960_0,-1,-1,2,15466,-1
15469,associated with,9,11,63,78,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,2,15469,-1
15474,/- 4 hours,6,9,32,42,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,2,15474,-1
15476,/- 9 hours,16,19,73,83,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,2,15476,-1
15486,/-,12,13,66,68,The incidence of ischemic episodes per patient per hour was 0.05 +/-,2466960_6,-1,-1,2,15486,-1
15488,/-,8,9,36,38,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,2,15488,-1
15490,/-,28,29,122,124,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,2,15490,-1
15492,/-,40,41,177,179,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,2,15492,-1
15495,chemotherapy course,17,19,79,98,"There were two cases of sudden death, both of which occurred at the end of the chemotherapy course.",2466960_9,-1,-1,2,15495,-1
15497,associated with,6,8,34,49,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,2,15497,-1
15502,hazardous?Treatment,5,6,28,47,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,2,15502,-1
15503,general practitioners,12,14,84,105,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,2,15503,-1
15519,C57BL/6,11,12,63,70,"These were the albino Sprague-Dawley ICR and BALB/C, the black C57BL/6 and the brown CDF-I mouse strains.",2484011_2,-1,-1,2,15519,-1
15520,CDF-I mouse strains,15,18,85,104,"These were the albino Sprague-Dawley ICR and BALB/C, the black C57BL/6 and the brown CDF-I mouse strains.",2484011_2,-1,-1,2,15520,-1
15524,amantadine depressed,4,6,20,40,The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.,2484011_4,-1,-1,2,15524,-1
15526,BALB/C,15,16,98,104,The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.,2484011_4,-1,-1,2,15526,-1
15528,BALB/C,16,17,123,129,Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive.,2484011_5,-1,-1,2,15528,-1
15530,ICR mice,16,18,104,112,"The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment.",2484011_6,-1,-1,2,15530,-1
15531,drug-free period,22,24,134,150,"The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment.",2484011_6,-1,-1,2,15531,-1
15533,Readministration,0,1,0,16,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,-1,-1,2,15533,-1
15535,drug-free overnight period,6,9,40,66,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,-1,-1,2,15535,-1
15545,BALB/C,14,15,103,109,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,-1,-1,2,15545,-1
15546,strain-dependent,4,5,22,38,The results suggest a strain-dependent effect of amantadine on motility and indicate a differential response to the acute and multiple dose regimens used.,2484011_10,-1,-1,2,15546,-1
15549,BALB/C,1,2,4,10,The BALB/C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine.,2484011_11,-1,-1,2,15549,-1
15554,mouse strain,9,11,59,71,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,2,15554,-1
15561,urotoxicity,5,6,43,54,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,-1,-1,2,15561,-1
15577,site?Twenty,11,12,67,78,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,-1,2,15577,-1
15580,double blind study,36,39,222,240,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,-1,2,15580,-1
15586,consistent with,3,5,12,27,This is not consistent with a CNS origin of migraine attack.,2515254_5,-1,-1,2,15586,-1
15596,zidovudine-related side effects,8,11,43,74,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,-1,-1,2,15596,-1
15599,zidovudine-related side effects,31,34,198,229,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,-1,-1,2,15599,-1
15600,multicenter,38,39,246,257,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,-1,-1,2,15600,-1
15601,dose-range finding study,42,45,272,296,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,-1,-1,2,15601,-1
15602,study group,1,3,4,15,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,2,15602,-1
15603,HIV-positive,6,7,32,44,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,2,15603,-1
15604,groups II B,11,14,73,84,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,2,15604,-1
15605,Centers for Disease Control (CDC),21,28,109,142,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,2,15605,-1
15607,3-week,2,3,12,18,"Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.",2528969_2,-1,-1,2,15607,-1
15618,3-week intervals,7,9,54,70,Clinical and laboratory evaluations were performed at 3-week intervals.,2528969_4,-1,-1,2,15618,-1
15620,reappearing briefly,5,7,35,54,"These were generally self-limited, reappearing briefly at each dose increment.",2528969_6,-1,-1,2,15620,-1
15621,dose increment,9,11,63,77,"These were generally self-limited, reappearing briefly at each dose increment.",2528969_6,-1,-1,2,15621,-1
15624,dose-independent fashion,21,23,115,139,"A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase.",2528969_9,-1,-1,2,15624,-1
15626,reticulocyte count,3,5,16,34,The decrease in reticulocyte count was dose related between 600 and 900 mg/day with no further change when the dose was escalated to 1200 mg/day.,2528969_10,-1,-1,2,15626,-1
15635,double screenings,4,6,25,42,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,2,15635,-1
15636,pregnant women,7,9,46,60,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,2,15636,-1
15638,hepatitis B,18,20,116,127,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,2,15638,-1
15640,hepatitis B,26,28,156,167,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,2,15640,-1
15642,treated with,3,5,18,30,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,2,15642,-1
15657,fluoxetine-induced symptoms,2,4,12,39,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,2,15657,-1
15666,akathisia,5,6,44,53,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,2,15666,-1
15681,hindpaw,42,43,357,364,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,2,15681,-1
15683,dose-dependent,15,16,87,101,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,-1,-1,2,15683,-1
15687,co-injection,15,16,110,122,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,-1,-1,2,15687,-1
15693,peripheral terminals,10,12,56,76,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,-1,-1,2,15693,-1
15694,primary afferents,13,15,80,97,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,-1,-1,2,15694,-1
15699,enzyme inhibition,3,5,21,38,Effect of converting enzyme inhibition on the course of adriamycin-induced nephropathy.,2559236_0,-1,-1,2,15699,-1
15702,Munich-Wistar rats,14,16,78,96,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,-1,-1,2,15702,-1
15703,adriamycin nephrosis,18,20,114,134,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,-1,-1,2,15703,-1
15707,plasma albumin,24,26,134,148,"Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.",2559236_2,-1,-1,2,15707,-1
15708,Groups 1,0,2,0,8,Groups 1 and 3 remained untreated while groups 2 and 4 received enalapril.,2559236_3,-1,-1,2,15708,-1
15709,Groups 1,0,2,0,8,Groups 1 and 2 underwent micropuncture studies after 10 days.,2559236_4,-1,-1,2,15709,-1
15712,/- 2,13,15,85,89,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,15712,-1
15713,/- 3 mm Hg,18,22,99,109,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,15713,-1
15714,group 2,23,25,111,118,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,15714,-1
15716,/- 1,40,42,183,187,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,15716,-1
15717,/- 2,45,47,196,200,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,15717,-1
15718,/-,61,62,261,263,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,15718,-1
15719,/-,66,67,276,278,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,15719,-1
15722,/-,75,76,304,306,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,15722,-1
15723,/-,80,81,322,324,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,2,15723,-1
15724,Groups 3,0,2,0,8,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,-1,-1,2,15724,-1
15726,adriamycin nephrosis,24,26,122,142,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,-1,-1,2,15726,-1
15728,group 4,10,12,83,90,Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4.,2559236_7,-1,-1,2,15728,-1
15729,Untreated group 3,0,3,0,17,"Untreated group 3 rats exhibited a progressive reduction in GFR (0.35 +/- 0.08 ml/min at 4 months, 0.27 +/- 0.07 ml/min at 6 months).",2559236_8,-1,-1,2,15729,-1
15731,/-,13,14,71,73,"Untreated group 3 rats exhibited a progressive reduction in GFR (0.35 +/- 0.08 ml/min at 4 months, 0.27 +/- 0.07 ml/min at 6 months).",2559236_8,-1,-1,2,15731,-1
15732,/-,22,23,105,107,"Untreated group 3 rats exhibited a progressive reduction in GFR (0.35 +/- 0.08 ml/min at 4 months, 0.27 +/- 0.07 ml/min at 6 months).",2559236_8,-1,-1,2,15732,-1
15735,/-,16,17,83,85,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,-1,-1,2,15735,-1
15736,/-,25,26,117,119,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,-1,-1,2,15736,-1
15745,associated with,10,12,62,77,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,-1,-1,2,15745,-1
15747,mechanism(s),26,28,171,183,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,-1,-1,2,15747,-1
15758,locus coeruleus,21,23,139,154,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,-1,-1,2,15758,-1
15761,Microinjection,0,1,0,14,"Microinjection of fentanyl (2.5 micrograms/50 nl) directly into this pontine nucleus, on the other hand, elicited discernible electromyographic excitation.",2564649_5,-1,-1,2,15761,-1
15765,coerulospinal noradrenergic fibers,14,17,85,119,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,-1,-1,2,15765,-1
15766,spinal motoneurons,19,21,127,145,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,-1,-1,2,15766,-1
15770,highly-selective,1,2,4,20,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,2,15770,-1
15781,intraperitoneally,8,9,30,47,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,2,15781,-1
15799,treatment group,14,16,82,97,ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline.,2569282_8,-1,-1,2,15799,-1
15803,dose-dependent,10,11,69,83,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,2,15803,-1
15806,control animals,19,21,119,134,The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate.,2569282_10,-1,-1,2,15806,-1
15811,onset of,20,22,121,129,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,2,15811,-1
15835,no effect,5,7,34,43,"Given three times fluvoxamine had no effect on the immobilization time in the ""behavioral despair"" test in rats.",2576810_5,-1,-1,2,15835,-1
15836,immobilization time,9,11,51,70,"Given three times fluvoxamine had no effect on the immobilization time in the ""behavioral despair"" test in rats.",2576810_5,-1,-1,2,15836,-1
15841,hypomethylation,8,9,44,59,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,2,15841,-1
15853,2-week selection,19,21,129,145,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,-1,-1,2,15853,-1
15855,necrogenic dose,31,33,219,234,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,-1,-1,2,15855,-1
15871,gamma-GT positive,27,29,149,166,"In the absence of the carcinogen, 5-AzC given after a two thirds partial hepatectomy, when its incorporation should be maximum, failed to induce any gamma-GT positive foci.",2578334_5,-1,-1,2,15871,-1
15876,platelet-activating factor antagonist,5,8,32,69,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,2,15876,-1
15878,bupivacaine-induced cardiovascular impairments,13,16,84,130,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,2,15878,-1
15883,Intravenous injection,0,2,0,21,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,-1,-1,2,15883,-1
15893,MBP,26,27,123,126,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,-1,-1,2,15893,-1
15894,bupivacaine-induced ECG alterations,4,7,22,57,A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.,2594614_6,-1,-1,2,15894,-1
15902,consistent with,2,4,6,21,"Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.",2594614_8,-1,-1,2,15902,-1
15904,bupivacaine-induced cardiovascular alterations,16,19,82,128,"Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.",2594614_8,-1,-1,2,15904,-1
15909,analgesic agent,15,17,86,101,"Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent.",2598570_1,-1,-1,2,15909,-1
15912,United States,23,25,144,157,"Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported.",2598570_2,-1,-1,2,15912,-1
15913,case-control study,9,11,49,67,"To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen-exposed control subjects who did not have the syndrome.",2598570_3,-1,-1,2,15913,-1
15915,suprofen-exposed control subjects,31,34,182,215,"To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen-exposed control subjects who did not have the syndrome.",2598570_3,-1,-1,2,15915,-1
15917,odds ratio,9,11,42,52,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,15917,-1
15918,confidence interval,16,18,63,82,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,15918,-1
15919,odds ratio,31,33,129,139,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,15919,-1
15920,confidence interval,38,40,150,169,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,15920,-1
15922,odds ratio,52,54,218,228,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,15922,-1
15923,confidence interval,59,61,239,258,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,15923,-1
15925,odds ratio,85,87,347,357,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,15925,-1
15926,confidence interval,92,94,368,387,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,2,15926,-1
15935,consistent with,3,5,19,34,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,-1,-1,2,15935,-1
15942,non-hypertensive,9,10,71,87,Eighty-nine new referral hypertensive out-patients and 46 new referral non-hypertensive chronically physically ill out-patients completed a mood rating scale at regular intervals for one year.,26094_1,-1,-1,2,15942,-1
15943,out-patients,13,14,115,127,Eighty-nine new referral hypertensive out-patients and 46 new referral non-hypertensive chronically physically ill out-patients completed a mood rating scale at regular intervals for one year.,26094_1,-1,-1,2,15943,-1
15945,regular intervals,20,22,161,178,Eighty-nine new referral hypertensive out-patients and 46 new referral non-hypertensive chronically physically ill out-patients completed a mood rating scale at regular intervals for one year.,26094_1,-1,-1,2,15945,-1
15947,associated with,3,5,25,40,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,-1,2,15947,-1
15952,non-steroidal anti-inflammatory derivative,10,13,57,99,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,2,15952,-1
15963,plasma levels,4,6,14,27,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,-1,-1,2,15963,-1
15970,enzyme blockade,13,15,86,101,Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.,2632720_5,-1,-1,2,15970,-1
15971,Effects of,0,2,0,10,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,2,15971,-1
15992,associated with,1,3,7,22,Stroke associated with cocaine use.,2673163_0,-1,-1,2,15992,-1
15993,/- SD,8,10,35,40,Among these 47 patients the mean (+/- SD) age was 32.5 +/- 12.1 years; 76% (34/45) were men.,2673163_2,-1,-1,2,15993,-1
15994,/-,15,16,56,58,Among these 47 patients the mean (+/- SD) age was 32.5 +/- 12.1 years; 76% (34/45) were men.,2673163_2,-1,-1,2,15994,-1
16001,young adults,27,29,150,162,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,2,16001,-1
16008,anesthetic protocol,7,9,43,62,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,-1,2,16008,-1
16009,drug-induced reductions,11,13,75,98,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,-1,2,16009,-1
16014,associated with,3,5,27,42,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,2,16014,-1
16018,associated with,4,6,33,48,Labetalol administration was not associated with any of these findings.,2696505_4,-1,-1,2,16018,-1
16021,gentamicin nephrotoxicity,5,7,46,71,Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.,2709684_0,-1,-1,2,16021,-1
16025,gentamicin nephrotoxicity,3,5,20,45,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,2,16025,-1
16026,non-diabetic,8,9,61,73,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,2,16026,-1
16029,Unanesthetized,0,1,0,14,"Unanesthetized adult female, Sprague-Dawley rats were divided in four groups and studied for 15 days.",2709684_4,-1,-1,2,16029,-1
16032,Group II,16,18,55,63,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,2,16032,-1
16033,Group III,24,26,82,91,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,2,16033,-1
16034,Group IV,31,33,115,123,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,2,16034,-1
16037,/-,14,15,61,63,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,2,16037,-1
16040,CCr,32,33,153,156,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,2,16040,-1
16041,/-,35,36,162,164,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,2,16041,-1
16044,Group II,1,3,3,11,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,2,16044,-1
16048,/-,29,30,128,130,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,2,16048,-1
16051,/-,40,41,184,186,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,2,16051,-1
16055,/-,28,29,125,127,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,-1,2,16055,-1
16058,/-,38,39,177,179,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,-1,2,16058,-1
16074,cross-tolerant,8,9,55,69,"Rats, tolerant to ketamine-dominant combinations, were cross-tolerant to both drugs, while those tolerant to morphine-dominant combinations were cross-tolerant to morphine but showed either no cross-tolerance or an augmented response to ketamine.",2716967_8,-1,-1,2,16074,-1
16076,cross-tolerant,20,21,145,159,"Rats, tolerant to ketamine-dominant combinations, were cross-tolerant to both drugs, while those tolerant to morphine-dominant combinations were cross-tolerant to morphine but showed either no cross-tolerance or an augmented response to ketamine.",2716967_8,-1,-1,2,16076,-1
16077,cross-tolerance,27,28,193,208,"Rats, tolerant to ketamine-dominant combinations, were cross-tolerant to both drugs, while those tolerant to morphine-dominant combinations were cross-tolerant to morphine but showed either no cross-tolerance or an augmented response to ketamine.",2716967_8,-1,-1,2,16077,-1
16079,cross-tolerance,26,27,169,184,"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.",2716967_9,-1,-1,2,16079,-1
16080,widely-different,29,30,191,207,"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.",2716967_9,-1,-1,2,16080,-1
16092,/-,20,21,116,118,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,2,16092,-1
16096,/-,43,44,210,212,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,2,16096,-1
16101,cold pressor test,13,16,87,104,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,2,16101,-1
16104,R units,37,39,221,228,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,2,16104,-1
16108,/-,32,33,197,199,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,-1,-1,2,16108,-1
16110,/-,41,42,238,240,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,-1,-1,2,16110,-1
16111,R units,43,45,245,252,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,-1,-1,2,16111,-1
16113,/-,50,51,280,282,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,-1,-1,2,16113,-1
16114,dose-response relation,7,9,27,49,A shift to the left in the dose-response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment.,2722224_7,-1,-1,2,16114,-1
16117,associated with,9,11,58,73,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,2,16117,-1
16119,volume).(ABSTRACT TRUNCATED,21,23,137,164,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,2,16119,-1
16127,effects of,1,3,4,14,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,2,16127,-1
16140,i.p.,1,3,9,13,Repeated i.p.,2790457_5,-1,-1,2,16140,-1
16147,treatment regimens,21,23,153,171,"The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.",2790457_8,-1,-1,2,16147,-1
16150,amphotericin B nephrotoxicity,4,7,33,62,Sodium status influences chronic amphotericin B nephrotoxicity in rats.,2802551_0,-1,-1,2,16150,-1
16156,salt-depleted,1,2,3,16,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,-1,-1,2,16156,-1
16181,secondary to,7,9,57,69,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,-1,-1,2,16181,-1
16184,white woman,13,15,91,102,The clinical and radiographic features of cerebral deep venous thrombosis in a 21-year-old white woman are presented.,2819587_1,-1,-1,2,16184,-1
16194,vein of Galen,17,20,103,116,"The magnetic resonance image (MRI) showed increased signal intensity from the internal cerebral veins, vein of Galen, and straight sinus.",2819587_4,-1,-1,2,16194,-1
16199,terbutaline-induced hypokalemia,7,9,57,88,"The time course and concentration-effect relationship of terbutaline-induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.",2826064_1,-1,-1,2,16199,-1
16209,plasma samples,8,10,55,69,"In the 7-hour period after terbutaline administration, plasma samples were taken for determination of plasma potassium levels and drug concentrations.",2826064_4,-1,-1,2,16209,-1
16228,NE-mediated,14,15,96,107,The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.,2840807_2,-1,-1,2,16228,-1
16229,cerebellar Purkinje cells,17,20,122,147,The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.,2840807_2,-1,-1,2,16229,-1
16230,ceruleo-cerebellar pathway,25,27,176,202,The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.,2840807_2,-1,-1,2,16230,-1
16233,Purkinje cell,40,42,188,201,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,2,16233,-1
16234,ceruleo-cerebellar pathway,48,50,239,265,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,2,16234,-1
16235,Purkinje cell synapses,58,61,312,334,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,2,16235,-1
16241,Purkinje cell,108,110,626,639,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,2,16241,-1
16246,nonselective,6,7,26,38,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,-1,-1,2,16246,-1
16250,plasma esterases,4,6,28,44,Flestolol is metabolized by plasma esterases and has an elimination half-life of approximately 6.5 minutes.,2870085_2,-1,-1,2,16250,-1
16256,blood concentrations,1,3,10,30,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,-1,-1,2,16256,-1
16257,blood concentrations,13,15,107,127,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,-1,-1,2,16257,-1
16259,beta-adrenergic blockade,18,20,145,169,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,-1,-1,2,16259,-1
16261,dose-dependent,3,4,21,35,Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.,2870085_6,-1,-1,2,16261,-1
16267,flestolol-induced effects reverse rapidly,7,11,38,79,"In contrast with other beta blockers, flestolol-induced effects reverse rapidly (within 30 minutes) following discontinuation because of its short half-life.",2870085_8,-1,-1,2,16267,-1
16275,well-tolerated,9,10,44,58,"It is concluded that flestolol is a potent, well-tolerated, ultra-short-acting beta-adrenergic blocking agent.",2870085_11,-1,-1,2,16275,-1
16279,stimulus-induced,1,2,9,25,Enhanced stimulus-induced neurotransmitter overflow in epinephrine-induced hypertensive rats is not mediated by prejunctional beta-adrenoceptor activation.,2886572_0,-1,-1,2,16279,-1
16282,stimulus-induced,20,21,104,120,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,-1,-1,2,16282,-1
16283,neurotransmitter overflow,26,28,139,164,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,-1,-1,2,16283,-1
16287,stimulus-induced overflow,4,6,31,56,Renal catecholamine stores and stimulus-induced overflow in the vehicle-treated group consisted of norepinephrine only.,2886572_2,-1,-1,2,16287,-1
16290,molar basis,9,11,54,65,Total tissue catecholamine content of the kidney on a molar basis was unchanged.,2886572_4,-1,-1,2,16290,-1
16291,Stimulus-induced fractional overflow,0,3,0,36,Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney.,2886572_5,-1,-1,2,16291,-1
16292,epinephrine-treated kidneys,7,9,66,93,Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney.,2886572_5,-1,-1,2,16292,-1
16293,fractional overflow,3,5,19,38,This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade.,2886572_6,-1,-1,2,16293,-1
16296,no effect,2,4,16,25,Propranolol had no effect on stimulus-induced overflow in either group.,2886572_7,-1,-1,2,16296,-1
16298,stimulus-induced overflow,2,4,23,48,Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the epinephrine-treated group.,2886572_8,-1,-1,2,16298,-1
16307,estrogen-induced,8,9,70,86,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,-1,-1,2,16307,-1
16310,effects of,3,5,15,25,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,2,16310,-1
16317,estrogen-induced,21,22,152,168,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,2,16317,-1
16321,serum prolactin levels,5,8,23,45,"One h after treatment, serum prolactin levels decreased markedly.",2887062_2,-1,-1,2,16321,-1
16325,Golgi cisternae,16,18,125,140,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,-1,-1,2,16325,-1
16329,secretory granules,8,10,58,76,"Morphometric analysis revealed that the volume density of secretory granules increased, while the volume density of cytoplasmic microtubules decreased.",2887062_4,-1,-1,2,16329,-1
16331,serum prolactin levels,5,8,36,58,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,-1,-1,2,16331,-1
16332,early phase,10,12,66,77,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,-1,-1,2,16332,-1
16335,cytoplasmic microtubules,28,30,185,209,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,-1,-1,2,16335,-1
16340,Golgi cisternae,18,20,124,139,"The prolactinoma cells at this time were well granulated, with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae.",2887062_7,-1,-1,2,16340,-1
16344,Golgi cisternae,13,15,113,128,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,-1,-1,2,16344,-1
16359,No agent,0,2,0,8,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,2,16359,-1
16365,no effect,21,23,126,135,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,2,16365,-1
16368,Pretreatment,0,1,0,12,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,2,16368,-1
16370,anesthetic action,10,12,73,90,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,2,16370,-1
16379,effects of,1,3,4,14,The effects of diazepam on cardiovascular function were assessed in conscious rats.,2894433_1,-1,-1,2,16379,-1
16381,Intravenous administration,0,2,0,26,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,-1,-1,2,16381,-1
16383,dose-dependent,13,14,65,79,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,-1,-1,2,16383,-1
16387,Intravenous pretreatment,0,2,0,24,"Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.",2894433_4,-1,-1,2,16387,-1
16388,no change,10,12,69,78,"Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.",2894433_4,-1,-1,2,16388,-1
16389,adrenaline-induced pressor effect,14,17,86,119,"Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.",2894433_4,-1,-1,2,16389,-1
16390,pretreatment,12,13,94,106,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,-1,2,16390,-1
16393,agent blocks,23,25,158,170,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,-1,2,16393,-1
16394,chloride channels,25,27,171,188,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,-1,2,16394,-1
16396,benzodiazepine-GABA-chloride channel macromolecular complex,34,38,229,288,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,-1,2,16396,-1
16397,benzodiazepine-GABA-chloride channel,8,10,49,85,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,-1,-1,2,16397,-1
16403,Sulfasalazine-induced lupus erythematosus,0,3,0,41,Sulfasalazine-induced lupus erythematosus.,2894766_0,-1,-1,2,16403,-1
16412,sulfasalazine-induced lupus,7,9,37,64,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,2,16412,-1
16418,sulfasalazine-induced lupus syndrome,18,21,115,151,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,2,16418,-1
16425,normal-sodium diet,4,6,24,42,Six patients received a normal-sodium diet and four a low-sodium (17 mmol/day) diet.,28952_3,-1,-1,2,16425,-1
16427,bromide space,6,8,34,47,"The electrolyte balances, weight, bromide space, plasma renin activity, and aldosterone secretion rate were measured.",28952_5,-1,-1,2,16427,-1
16428,proportionally larger,9,11,51,72,"In both groups a potassium deficit developed, with proportionally larger losses from the extracellular than from the intracellular compartment.",28952_6,-1,-1,2,16428,-1
16436,anxiolytic drug,2,4,10,25,"The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.",2907585_1,-1,-1,2,16436,-1
16443,muscarinic side effects,6,9,50,73,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,2,16443,-1
16453,min-1,16,17,89,94,Both groups receiving 10 micrograms kg-1 showed increases in heart rate of up to 30 beat min-1 (95% confidence limits 28-32 beat min-1).,2917114_3,-1,-1,2,16453,-1
16454,confidence limits,20,22,100,117,Both groups receiving 10 micrograms kg-1 showed increases in heart rate of up to 30 beat min-1 (95% confidence limits 28-32 beat min-1).,2917114_3,-1,-1,2,16454,-1
16455,min-1,26,27,129,134,Both groups receiving 10 micrograms kg-1 showed increases in heart rate of up to 30 beat min-1 (95% confidence limits 28-32 beat min-1).,2917114_3,-1,-1,2,16455,-1
16469,effects of,8,10,41,51,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,2,16469,-1
16477,maximal electroshock,25,27,144,164,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,2,16477,-1
16495,sympathoadrenal activity,2,4,14,38,Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.,2951327_0,-1,-1,2,16495,-1
16503,/- 1,29,31,139,143,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,2,16503,-1
16504,/- 1,45,47,178,182,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,2,16504,-1
16505,/-,57,58,210,212,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,2,16505,-1
16507,atrial natriuretic factor,19,22,106,131,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,2,16507,-1
16508,/-,28,29,152,154,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,2,16508,-1
16510,/-,46,47,228,230,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,2,16510,-1
16511,/-,61,62,280,282,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,2,16511,-1
16514,/-,27,28,138,140,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,2,16514,-1
16516,factor.(ABSTRACT,54,55,243,259,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,2,16516,-1
16555,isoniazid neuropathy,6,8,47,67,Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.,3015327_0,-1,-1,2,16555,-1
16559,quotient fibre diameter/axon diameter,7,11,33,70,"Scatter diagrams of the g ratio (quotient fibre diameter/axon diameter) define regenerating fibres as a distinct population, distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre.",3015327_2,-1,-1,2,16559,-1
16565,corticotropin-releasing factor secretion,3,6,29,69,Inhibition of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation by delayed glucocorticoid feedback.,3015567_0,-1,-1,2,16565,-1
16567,glucocorticoid feedback,12,14,121,144,Inhibition of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation by delayed glucocorticoid feedback.,3015567_0,-1,-1,2,16567,-1
16573,urethane-anesthetized rats,17,19,99,125,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,-1,-1,2,16573,-1
16574,pharmacological blockade,20,22,131,155,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,-1,-1,2,16574,-1
16578,feedback dose,41,43,287,300,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,-1,-1,2,16578,-1
16587,cataleptogenic,12,13,70,84,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,2,16587,-1
16593,locus coeruleus,39,41,240,255,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,2,16593,-1
16597,locus coeruleus,20,22,119,134,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,2,16597,-1
16600,control rats,35,37,205,217,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,2,16600,-1
16601,cataleptogenic,5,6,21,35,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,2,16601,-1
16606,locus coeruleus,33,35,195,210,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,2,16606,-1
16609,Multicenter,0,1,0,11,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,2,16609,-1
16610,double-blind,2,3,13,25,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,2,16610,-1
16612,parallel-groups efficacy,6,8,42,66,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,2,16612,-1
16622,double-blind,29,30,187,199,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,2,16622,-1
16623,multiple-dose,31,32,201,214,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,2,16623,-1
16624,parallel-groups study,33,35,216,237,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,2,16624,-1
16625,fifty-five subjects,2,4,12,31,One hundred fifty-five subjects participated.,3057041_2,-1,-1,2,16625,-1
16628,aeroallergens,30,31,155,168,"Subjects ranged in age from 18 to 60 years of age and had at least a 2-year history of spring allergic rhinitis, confirmed by positive skin test to spring aeroallergens.",3057041_3,-1,-1,2,16628,-1
16634,4-week,17,18,114,120,Daily subject symptom cards were completed during a screening period to assess pretreatment symptoms and during a 4-week treatment period while subjects received study medications.,3057041_5,-1,-1,2,16634,-1
16644,statistically greater,18,20,104,125,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,2,16644,-1
16650,treatment groups,10,12,49,65,There were no serious side effects in any of the treatment groups.,3057041_12,-1,-1,2,16650,-1
16660,pre-treatment,17,18,105,118,His renal function remained impaired but stable during 2 years' treatment with captopril but returned to pre-treatment levels soon after cessation of the drug.,3070035_2,-1,-1,2,16660,-1
16666,best-known members,6,8,37,55,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,-1,-1,2,16666,-1
16667,hypolipidaemic agents,12,14,72,93,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,-1,-1,2,16667,-1
16687,well-tolerated agents,7,9,50,71,Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol.,3076126_13,-1,-1,2,16687,-1
16688,therapeutic approach,15,17,88,108,"As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences.",3076126_14,-1,-1,2,16688,-1
16690,remission inducing,3,5,16,34,Toxicity due to remission inducing drugs in rheumatoid arthritis.,3084782_0,-1,-1,2,16690,-1
16703,healthy controls,2,4,12,28,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,2,16703,-1
16704,DR5,6,7,37,40,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,2,16704,-1
16706,substantia nigra,5,7,54,70,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,2,16706,-1
16707,nigrostriatal system,12,14,109,129,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,2,16707,-1
16710,amphetamine-induced rotational behavior,26,29,149,188,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,2,16710,-1
16712,degeneration-induced,7,8,51,71,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,2,16712,-1
16713,lesion-induced,15,16,101,115,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,2,16713,-1
16715,spared cells,25,27,171,183,"A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.",3088349_5,-1,-1,2,16715,-1
16718,lesion volume,13,15,76,89,"However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.",3088349_6,-1,-1,2,16718,-1
16720,amphetamine-induced rotation,25,27,141,169,"However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.",3088349_6,-1,-1,2,16720,-1
16721,observation session,35,37,221,240,"However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.",3088349_6,-1,-1,2,16721,-1
16724,associated with,2,4,18,33,Hepatic reactions associated with ketoconazole in the United Kingdom.,3101906_0,-1,-1,2,16724,-1
16728,United Kingdom,5,7,35,49,Ketoconazole was introduced in the United Kingdom in 1981.,3101906_1,-1,-1,2,16728,-1
16730,associated with,16,18,105,120,"By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug, including five deaths.",3101906_2,-1,-1,2,16730,-1
16732,onset of,7,9,45,53,The average duration of treatment before the onset of jaundice was 61 days.,3101906_6,-1,-1,2,16732,-1
16738,associated with,7,9,36,51,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,-1,-1,2,16738,-1
16742,long term,14,16,101,110,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,-1,-1,2,16742,-1
16745,Drug-induced,0,1,0,12,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,-1,-1,2,16745,-1
16754,consistent with,18,20,106,121,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,-1,2,16754,-1
16763,associated with,12,14,97,112,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,2,16763,-1
16783,Systemic pretreatment,0,2,0,21,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,2,16783,-1
16789,animal's,7,9,55,63,"Following placement of subcutaneous electrodes in each animal's left gastrocnemius muscle, rigidity was assessed by analyzing root-mean-square electromyographic activity.",3115150_2,-1,-1,2,16789,-1
16791,root-mean-square,18,19,126,142,"Following placement of subcutaneous electrodes in each animal's left gastrocnemius muscle, rigidity was assessed by analyzing root-mean-square electromyographic activity.",3115150_2,-1,-1,2,16791,-1
16807,serotonergic pathways,28,30,180,201,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,-1,-1,2,16807,-1
16810,diazepam-induced sedative effects,2,5,14,47,Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block.,3120485_0,-1,-1,2,16810,-1
16813,double-blind,1,2,2,14,A double-blind placebo-controlled investigation of efficacy and safety.,3120485_1,-1,-1,2,16813,-1
16815,diazepam-induced effects,19,21,89,113,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,2,16815,-1
16820,diazepam-induced effects,2,4,14,38,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,-1,-1,2,16820,-1
16822,double-blind placebo-controlled trial,13,16,90,127,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,-1,-1,2,16822,-1
16833,injection site,8,10,41,55,There was no evidence of reaction at the injection site.,3120485_8,-1,-1,2,16833,-1
16834,associated with,1,3,7,22,Chorea associated with oral contraception.,3123611_0,-1,-1,2,16834,-1
16844,central venous (,5,8,23,39,"Ten rats had arterial, central venous (CVP), and subdural cannulae inserted under halothane anesthesia.",3125768_2,-1,-1,2,16844,-1
16849,/- 1 mmHg,13,16,76,85,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,2,16849,-1
16853,/-,21,22,117,119,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,-1,-1,2,16853,-1
16855,/-,29,30,145,147,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,-1,-1,2,16855,-1
16882,dose-dependent,23,24,87,101,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,2,16882,-1
16883,BHA-induced,31,32,145,156,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,2,16883,-1
16888,co-carcinogen,8,9,43,56,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,2,16888,-1
16889,BHA forestomach carcinogenesis,11,14,64,94,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,2,16889,-1
16896,prospective study,4,6,20,37,We have initiated a prospective study to obtain some more data on these subjects.,3137399_2,-1,-1,2,16896,-1
16899,chest X-rays,9,11,61,73,"All patients were studied by repeated physical examinations, chest X-rays, electro- and echocardiography and radionuclide left ventricular ejection fraction (EF) determinations.",3137399_4,-1,-1,2,16899,-1
16901,radionuclide left ventricular ejection fraction,16,21,109,156,"All patients were studied by repeated physical examinations, chest X-rays, electro- and echocardiography and radionuclide left ventricular ejection fraction (EF) determinations.",3137399_4,-1,-1,2,16901,-1
16902,EF,22,23,158,160,"All patients were studied by repeated physical examinations, chest X-rays, electro- and echocardiography and radionuclide left ventricular ejection fraction (EF) determinations.",3137399_4,-1,-1,2,16902,-1
16908,cold pressor test,13,16,70,87,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,-1,-1,2,16908,-1
16910,MMC-related,16,17,86,97,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,-1,2,16910,-1
16915,risk group,13,15,58,68,The incidence is likely to be less than 10% even for this risk group.,3137399_11,-1,-1,2,16915,-1
16918,relatively-safe antihypertensive drug,5,8,30,67,Verapamil is an effective and relatively-safe antihypertensive drug.,3173179_1,-1,-1,2,16918,-1
16923,coincided with,8,10,48,62,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,-1,-1,2,16923,-1
16924,verapamil-related increase,5,7,35,61,Possible mechanisms that involve a verapamil-related increase in platelet and/or vascular alpha 2-adrenoreceptor affinity for catecholamines are discussed.,3173179_4,-1,-1,2,16924,-1
16925,vascular alpha 2-adrenoreceptor,10,13,81,112,Possible mechanisms that involve a verapamil-related increase in platelet and/or vascular alpha 2-adrenoreceptor affinity for catecholamines are discussed.,3173179_4,-1,-1,2,16925,-1
16935,associated with,3,5,28,43,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,2,16935,-1
16938,chemotherapeutic agent,4,6,30,52,Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.,3183120_1,-1,-1,2,16938,-1
16953,ECG recordings,12,14,83,97,Before treatment all patients had a cardiac evaluation and during treatment serial ECG recordings were performed.,3187073_5,-1,-1,2,16953,-1
16954,pre-treatment,2,3,7,20,"In the pre-treatment evaluation, signs of cardiovascular disease were found in 33 patients (43%).",3187073_6,-1,-1,2,16954,-1
16956,entire group,12,14,55,67,"The mean age of these patients was the same as for the entire group, 64 years.",3187073_8,-1,-1,2,16956,-1
16959,pre-treatment,20,21,125,138,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,-1,-1,2,16959,-1
16971,27-year old,5,7,26,37,"Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs.",3192036_2,-1,-1,2,16971,-1
16972,high-risk group,14,16,72,87,"Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs.",3192036_2,-1,-1,2,16972,-1
16974,Berkowitz score,19,21,103,118,"Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs.",3192036_2,-1,-1,2,16974,-1
16989,secondary to,42,44,233,245,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,-1,2,16989,-1
16995,agressive,18,19,117,126,Close observation of the response status both clinically and with beta-hCG values may indicate whether and when more agressive combination chemotherapy should be started.(ABSTRACT TRUNCATED AT 250 WORDS),3192036_10,-1,-1,2,16995,-1
16996,started.(ABSTRACT TRUNCATED,23,25,162,189,Close observation of the response status both clinically and with beta-hCG values may indicate whether and when more agressive combination chemotherapy should be started.(ABSTRACT TRUNCATED AT 250 WORDS),3192036_10,-1,-1,2,16996,-1
16997,Receptor mechanisms,0,2,0,19,Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.,3220106_0,-1,-1,2,16997,-1
16999,chronic nicotine-treated rats,7,10,67,96,Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.,3220106_0,-1,-1,2,16999,-1
17011,associated with,23,25,145,160,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,-1,-1,2,17011,-1
17030,QS/QT,17,18,106,111,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,-1,-1,2,17030,-1
17040,QS/QT,36,37,205,210,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,2,17040,-1
17041,cm H2O,1,3,4,10,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,2,17041,-1
17047,QS/QT,25,26,173,178,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,2,17047,-1
17054,cm H2O,1,3,5,11,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,-1,-1,2,17054,-1
17057,above-mentioned variables,13,15,71,96,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,-1,-1,2,17057,-1
17058,cm H2O,3,5,12,18,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,-1,-1,2,17058,-1
17062,QS/QT,15,16,79,84,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,-1,-1,2,17062,-1
17066,QS/QT,25,26,147,152,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,-1,-1,2,17066,-1
17070,cm H2O,21,23,124,130,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,2,17070,-1
17071,QS/QT,27,28,150,155,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,2,17071,-1
17079,St. Anthony's fire,0,4,0,18,"St. Anthony's fire, then and now: a case report and historical review.",3300918_0,-1,-1,2,17079,-1
17091,immunosuppressive protocol,10,12,70,96,Cardiac transplantation: improved quality of survival with a modified immunosuppressive protocol.,3311455_0,-1,-1,2,17091,-1
17093,immunosuppressive protocols,8,10,47,74,The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients.,3311455_1,-1,-1,2,17093,-1
17095,group I,1,3,3,10,"In group I, cyclosporine was given before the procedure at a loading dose of 17.5 mg/kg and then continued after the procedure to keep a whole blood level about 1000 ng/ml.",3311455_2,-1,-1,2,17095,-1
17098,group II,1,3,3,11,"In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week.",3311455_3,-1,-1,2,17098,-1
17100,Group II,0,2,0,8,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,-1,-1,2,17100,-1
17105,Group II,0,2,0,8,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,-1,-1,2,17105,-1
17113,immunosuppressive regimen,19,21,125,150,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,-1,-1,2,17113,-1
17132,/-,7,8,37,39,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,2,17132,-1
17133,HEM group,13,15,57,66,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,2,17133,-1
17134,/-,20,21,87,89,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,2,17134,-1
17138,/-,20,21,93,95,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,2,17138,-1
17139,/-,25,26,110,112,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,2,17139,-1
17150,effects of,22,24,158,168,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,2,17150,-1
17156,carbamazepine neurotoxicity,1,3,18,45,Verapamil-induced carbamazepine neurotoxicity.,3371379_0,-1,-1,2,17156,-1
17157,carbamazepine neurotoxicity,5,7,27,54,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,-1,-1,2,17157,-1
17163,12-week controlled study,2,5,5,29,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,2,17163,-1
17172,tardive dyskinesia,10,12,68,86,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,2,17172,-1
17191,pair-matched,24,25,173,185,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,2,17191,-1
17207,phenylethylbarbiturate-induced,1,2,10,40,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,2,17207,-1
17217,associated with,25,27,166,181,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,2,17217,-1
17238,Dapsone-associated Heinz body,0,3,0,29,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,-1,-1,2,17238,-1
17247,Heinz body formation,10,13,51,71,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,2,17247,-1
17249,GSH,18,19,104,107,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,2,17249,-1
17253,AE,2,3,13,15,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,2,17253,-1
17254,Heinz body formation,13,16,83,103,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,2,17254,-1
17255,GSH,18,19,109,112,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,2,17255,-1
17264,United States,8,10,46,59,"Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an infection is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E.",3425586_7,-1,-1,2,17264,-1
17269,CB,13,14,117,119,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,2,17269,-1
17271,tight-binding inhibitor,22,24,177,200,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,2,17271,-1
17276,exposure of,3,5,20,31,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,-1,-1,2,17276,-1
17281,high-pressure liquid chromatography,33,36,185,220,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,-1,-1,2,17281,-1
17294,drug precipitation,9,11,43,61,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,-1,-1,2,17294,-1
17298,clinical trial,9,11,42,56,"In an attempt to overcome this problem, a clinical trial of CB 3717 administered with alkaline diuresis is under way.",3431591_7,-1,-1,2,17298,-1
17312,needle-stick,4,5,23,35,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,2,17312,-1
17313,hepatitis B,9,11,62,73,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,2,17313,-1
17314,Veterans Administration Cooperative Study,4,8,20,61,Final report of the Veterans Administration Cooperative Study.,343678_1,-1,-1,2,17314,-1
17319,double-blind trial,20,22,98,116,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,2,17319,-1
17320,needle-stick,33,34,190,202,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,2,17320,-1
17321,exposure to,34,36,203,214,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,2,17321,-1
17322,hepatitis B,36,38,215,226,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,2,17322,-1
17343,antianginal drug therapy,3,6,24,48,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,-1,-1,2,17343,-1
17357,debrisoquine/sparteine type,37,39,179,206,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,-1,-1,2,17357,-1
17368,coadministration,3,4,14,30,"Moreover, the coadministration of these frequently used drugs is expected to be especially harmful in this subgroup of patients.",3437726_10,-1,-1,2,17368,-1
17385,double-blind trial,7,9,38,56,Clinical experiences in an open and a double-blind trial.,347884_0,-1,-1,2,17385,-1
17393,single dose,27,29,111,122,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,2,17393,-1
17401,double blind study,2,5,7,25,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,-1,2,17401,-1
17403,Certain clues,0,2,0,13,"Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol.",347884_9,-1,-1,2,17403,-1
17409,troleandomycin-induced,3,4,28,50,Prolonged cholestasis after troleandomycin-induced acute hepatitis.,3496378_0,-1,-1,2,17409,-1
17417,troleandomycin-induced,8,9,68,90,This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.,3496378_5,-1,-1,2,17417,-1
17438,normal serum ferritin values,19,23,124,152,Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction.,3503576_12,-1,-1,2,17438,-1
17443,treatment regimens,2,4,8,26,The two treatment regimens were equally efficacious.,3535719_2,-1,-1,2,17443,-1
17449,piperacillin-treated patients,24,26,107,136,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,2,17449,-1
17452,piperacillin-treated patients,12,14,77,106,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,-1,-1,2,17452,-1
17454,piperacillin-treated patients,27,29,191,220,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,-1,-1,2,17454,-1
17456,piperacillin-treated patients,40,42,241,270,The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin- vs tobramycin and piperacillin-treated patients (18 of 78 vs 67 of 115).,3535719_6,-1,-1,2,17456,-1
17459,Intravenous administration,0,2,0,26,Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.,354896_1,-1,-1,2,17459,-1
17477,associated with,1,3,13,28,Hyperkalemia associated with sulindac therapy.,3560096_0,-1,-1,2,17477,-1
17480,renal prostacyclin synthesis,19,22,116,144,"Several recent studies have stressed the renal sparing features of sulindac, owing to its lack of interference with renal prostacyclin synthesis.",3560096_2,-1,-1,2,17480,-1
17482,associated with,11,13,72,87,These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified.,3560096_6,-1,-1,2,17482,-1
17483,Case report,0,2,0,11,Case report.,3564823_1,-1,-1,2,17483,-1
17489,intracerebral infusions,9,11,49,72,"Calcitonin receptors are found in the brain, and intracerebral infusions of calcitonin can produce behavioral effects.",3615541_1,-1,-1,2,17489,-1
17492,food intake,7,9,48,59,Among these behavioral effects are decreases in food intake and decreases in amphetamine-induced locomotor activity.,3615541_2,-1,-1,2,17492,-1
17493,amphetamine-induced locomotor activity,12,15,77,115,Among these behavioral effects are decreases in food intake and decreases in amphetamine-induced locomotor activity.,3615541_2,-1,-1,2,17493,-1
17501,nucleus accumbens,17,19,114,131,"The areas where calcitonin is most effective in decreasing locomotor activity are located in the hypothalamus and nucleus accumbens, suggesting that these areas are the major sites of action of calcitonin in inhibiting amphetamine-induced locomotor activity.",3615541_5,-1,-1,2,17501,-1
17502,amphetamine-induced locomotor activity,34,37,219,257,"The areas where calcitonin is most effective in decreasing locomotor activity are located in the hypothalamus and nucleus accumbens, suggesting that these areas are the major sites of action of calcitonin in inhibiting amphetamine-induced locomotor activity.",3615541_5,-1,-1,2,17502,-1
17516,beagle dogs,14,16,96,107,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,-1,-1,2,17516,-1
17517,dose-dependent,18,19,117,131,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,-1,-1,2,17517,-1
17524,/- 5,31,33,202,206,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,2,17524,-1
17526,/-,48,49,269,271,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,2,17526,-1
17543,HCBD,26,27,173,177,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,2,17543,-1
17557,molecular weight,15,17,101,117,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,2,17557,-1
17559,molecular weights,23,25,136,153,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,2,17559,-1
17570,molecular weight pattern,10,13,60,84,It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage.,3653576_8,-1,-1,2,17570,-1
17575,Children's Hospital,7,10,43,62,"Twenty-six cases of Reye syndrome from The Children's Hospital, Camperdown, Australia, occurring between 1973 and 1982 were reviewed.",3670965_1,-1,-1,2,17575,-1
17587,United States,22,24,114,127,The mortality for these Reye syndrome cases in Australia was 45% as compared with a 32% case-fatality rate in the United States.,3670965_6,-1,-1,2,17587,-1
17595,subarachnoid haemorrhage,11,13,54,78,Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.,3676049_2,-1,-1,2,17595,-1
17601,/-,29,30,152,154,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,2,17601,-1
17603,/-,37,38,184,186,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,2,17603,-1
17606,/-,46,47,221,223,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,2,17606,-1
17607,/- SEM,52,54,239,245,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,2,17607,-1
17609,/-,30,31,158,160,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,2,17609,-1
17611,/-,12,13,59,61,"This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged.",3676049_5,-1,-1,2,17611,-1
17627,Triazolam-induced brief episodes,0,3,0,32,Triazolam-induced brief episodes of secondary mania in a depressed patient.,3693336_0,-1,-1,2,17627,-1
17633,Kearns-Sayre syndrome,6,8,41,62,Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome.,3703509_0,-1,-1,2,17633,-1
17634,long-standing Kearns-Sayre syndrome,13,16,79,114,This paper presents the clinical and metabolic findings in two young boys with long-standing Kearns-Sayre syndrome.,3703509_1,-1,-1,2,17634,-1
17635,short exposure,1,3,10,24,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,2,17635,-1
17641,Kearns-Sayre syndrome,15,17,107,128,We believe these two cases represent a newly described and catastrophic metabolic-endocrine failure in the Kearns-Sayre syndrome.,3703509_6,-1,-1,2,17641,-1
17642,cyclosporine nephrotoxicity,1,3,13,40,Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.,3708922_0,-1,-1,2,17642,-1
17655,toxic doses,2,4,14,25,"Gentamicin at toxic doses, however, increased CSA nephrotoxicity.",3708922_4,-1,-1,2,17655,-1
17660,mipafox-induced,7,8,59,74,The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.,3714122_0,-1,-1,2,17660,-1
17668,post-exposure,14,15,80,93,"Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of Mipafox (ip, 1-15 mg/kg).",3714122_2,-1,-1,2,17668,-1
17672,post-exposure,23,24,138,151,These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14-21 days post-exposure.,3714122_3,-1,-1,2,17672,-1
17673,NTE activity,14,16,70,82,Those dosages (greater than or equal to 10 mg/kg) that inhibited mean NTE activity in the spinal cord greater than or equal to 73% and brain greater than or equal to 67% of control values produced severe (greater than or equal to 3) cervical cord pathology in 85% of the rats.,3714122_4,-1,-1,2,17673,-1
17675,control values,37,39,173,187,Those dosages (greater than or equal to 10 mg/kg) that inhibited mean NTE activity in the spinal cord greater than or equal to 73% and brain greater than or equal to 67% of control values produced severe (greater than or equal to 3) cervical cord pathology in 85% of the rats.,3714122_4,-1,-1,2,17675,-1
17678,NTE,18,19,85,88,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,2,17678,-1
17679,spinal cord less,21,24,101,117,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,2,17679,-1
17680,brain less,31,33,143,153,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,2,17680,-1
17691,cisplatin-induced impaired,27,29,185,211,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,2,17691,-1
17713,chlorthalidone phase,6,8,37,57,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,2,17713,-1
17714,associated with,9,11,62,77,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,2,17714,-1
17734,Transketolase abnormality,0,2,0,25,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,3762968_0,-1,-1,2,17734,-1
17735,thiamine-dependent enzyme,3,5,13,38,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,2,17735,-1
17738,transketolase abnormality,33,35,211,236,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,2,17738,-1
17741,postalcoholic Wernicke-Korsakoff syndrome,50,53,307,348,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,2,17741,-1
17743,above-mentioned patient,4,6,18,41,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,2,17743,-1
17744,transketolase,21,22,133,146,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,2,17744,-1
17746,postalcoholic Wernicke-Korsakoff syndrome,6,9,40,81,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,-1,-1,2,17746,-1
17747,transketolase abnormality,21,23,171,196,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,-1,-1,2,17747,-1
17749,treated with,5,7,36,48,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,-1,-1,2,17749,-1
17757,Post-operative,0,1,0,14,Post-operative rigidity after fentanyl administration.,3780697_0,-1,-1,2,17757,-1
17759,post-operative,13,14,88,102,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,-1,-1,2,17759,-1
17764,Wistar rats,0,2,0,11,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,2,17764,-1
17779,stereotyped (S),14,18,78,93,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,2,17779,-1
17782,AS/KS group,32,34,172,183,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,2,17782,-1
17785,dopaminergic,37,38,197,209,"In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.",3780846_6,-1,-1,2,17785,-1
17789,dopaminergic,29,30,153,165,"The results suggest that rigidity, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.",3780846_9,-1,-1,2,17789,-1
17793,DA-innervated,30,31,179,192,The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS/KS group might be due to rapid shifts in the predominance of various DA-innervated structures.,3780846_11,-1,-1,2,17793,-1
17808,three-week history of right,17,21,125,152,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,2,17808,-1
17826,cold preparations,27,29,168,185,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,2,17826,-1
17849,treated with,11,13,87,99,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,-1,2,17849,-1
17852,intrathecal dosing,37,39,268,286,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,-1,2,17852,-1
17859,steady-state,50,51,268,280,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,-1,-1,2,17859,-1
17885,associated with,6,8,41,56,A prospective study of adverse reactions associated with vancomycin therapy.,3934126_0,-1,-1,2,17885,-1
17887,16-month period,18,20,114,129,A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16-month period.,3934126_1,-1,-1,2,17887,-1
17903,associated with,11,13,56,71,"In 42 of these patients, data were examined for factors associated with clinical outcome.",3950060_2,-1,-1,2,17903,-1
17913,peak levels,37,39,205,216,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,-1,-1,2,17913,-1
17914,mean area,44,46,238,247,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,-1,-1,2,17914,-1
17915,serum concentration-time curve,48,51,258,288,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,-1,-1,2,17915,-1
17919,IF,76,77,398,400,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,-1,-1,2,17919,-1
17921,[Cmax]/MIC,87,88,444,454,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,-1,-1,2,17921,-1
17924,one-compartment model,10,12,82,103,Model-dependent pharmacokinetic parameters were calculated by computer based on a one-compartment model.,3950060_4,-1,-1,2,17924,-1
17928,Bayes' theorem,6,9,27,41,"Based on this model and on Bayes' theorem, the predictive accuracy of identifying ""nephrotoxic"" patients increased from 0.17 to 0.39.",3950060_7,-1,-1,2,17928,-1
17934,Cmax/MIC),20,22,84,93,"When examined individually, mean IF, MIC, total dose, mean daily dose, and ln (mean Cmax/MIC) correlated significantly (P less than .05) with cure.",3950060_8,-1,-1,2,17934,-1
17940,statistical model,29,31,154,171,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,2,17940,-1
17942,Bayes',2,4,9,15,"Based on Bayes' theorem and the first model, the predictive accuracy of identifying patients not cured increased from 0.19 to 0.83.",3950060_10,-1,-1,2,17942,-1
17953,Prinzmetal's angina,9,12,72,91,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,2,17953,-1
17958,5-FU cardiotoxicity,30,32,171,190,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,2,17958,-1
17959,Dose-related,0,1,0,12,Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.,3961813_0,-1,-1,2,17959,-1
17976,distal levels,7,9,52,65,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,2,17976,-1
17996,LW,1,2,13,15,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,-1,2,17996,-1
17998,average interval,21,23,124,140,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,-1,-1,2,17998,-1
18009,treatment regimens,11,13,82,100,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,-1,-1,2,18009,-1
18015,immunosuppressive drugs,6,8,32,55,"There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped.",3970039_3,-1,-1,2,18015,-1
18018,maximal effects,9,11,45,60,"Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it.",3970039_5,-1,-1,2,18018,-1
18027,treated with,11,13,80,92,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,-1,-1,2,18027,-1
18035,QTC interval,4,6,27,39,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,2,18035,-1
18037,QT interval,12,14,84,95,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,2,18037,-1
18052,Anticoagulant-induced femoral nerve palsy,0,4,0,41,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,2,18052,-1
18065,sinoatrial block,1,3,19,35,Amiodarone-induced sinoatrial block.,4008111_0,-1,-1,2,18065,-1
18067,Wolff-Parkinson-White syndrome,17,19,119,149,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,2,18067,-1
18071,treated with,3,5,19,31,"An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the ""subtherapeutic"" range.",4027862_1,-1,-1,2,18071,-1
18078,drug therapy,17,19,121,133,Further studies of specifically elderly patients are now required to establish safer and more appropriate guidelines for drug therapy.,4027862_4,-1,-1,2,18078,-1
18080,anesthetic-induced damage,3,5,16,41,Repair of local anesthetic-induced damage.,4038130_1,-1,-1,2,18080,-1
18081,Local anesthetics,0,2,0,17,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,2,18081,-1
18093,exposure to,17,19,96,107,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,2,18093,-1
18097,anesthetic-induced damage,24,26,144,169,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,-1,-1,2,18097,-1
18099,Gentamicin nephropathy,0,2,0,22,Gentamicin nephropathy in a neonate.,4069770_0,-1,-1,2,18099,-1
18112,cor pulmonale,21,23,116,129,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,2,18112,-1
18114,drug withdrawal,6,8,46,61,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,-1,-1,2,18114,-1
18115,re-exposure,10,11,69,80,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,-1,-1,2,18115,-1
18121,interfere with,4,6,44,58,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,-1,-1,2,18121,-1
18127,Leeds strain,6,8,33,45,Groups of male and female inbred Leeds strain rats were fed diets containing either 0.5% or 1.0% paracetamol by weight for up to 18 months.,4090988_2,-1,-1,2,18127,-1
18137,paracetamol-treated rats,7,9,27,51,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,2,18137,-1
18144,hepatocarcinogens,28,29,191,208,An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens.,4090988_9,-1,-1,2,18144,-1
18158,episode of,20,22,130,140,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,-1,-1,2,18158,-1
18160,re-exposure,29,30,170,181,"In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.",424937_9,-1,-1,2,18160,-1
18165,Very rarely,0,2,0,11,"Very rarely, the toxic neurological manifestations of this drug are of cerebral origin.",430165_3,-1,-1,2,18165,-1
18171,dose-response study,1,3,2,21,A dose-response study.,435349_1,-1,-1,2,18171,-1
18177,tetanic stimulation,12,14,76,95,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,2,18177,-1
18179,bolus dose,0,2,0,10,bolus dose.,435349_5,-1,-1,2,18179,-1
18181,tetanus suppression,9,11,57,76,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,2,18181,-1
18186,levodopa-induced,2,3,12,28,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,-1,2,18186,-1
18190,levodopa-induced,12,13,88,104,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,2,18190,-1
18191,peak dose,13,15,105,114,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,2,18191,-1
18193,end-of-dose akinesia,12,14,86,106,"However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.",458486_2,-1,-1,2,18193,-1
18195,no effect,2,4,13,22,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,-1,2,18195,-1
18196,levodopa-induced,5,6,26,42,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,-1,2,18196,-1
18198,overstimulation,13,14,89,104,These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.,458486_4,-1,-1,2,18198,-1
18201,regular intervals,6,8,39,56,Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.,4812392_4,-1,-1,2,18201,-1
18205,associated with,5,7,42,57,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,2,18205,-1
18217,lactic acid,18,20,111,122,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,2,18217,-1
18220,associated with,4,6,26,41,Angiosarcoma of the liver associated with diethylstilbestrol.,567256_0,-1,-1,2,18220,-1
18224,associated with,11,13,88,103,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,-1,-1,2,18224,-1
18242,gas-liquid chromatography,8,10,52,77,"Plasma concentrations of the drug were estimated by gas-liquid chromatography, in a smaller number of the subjects.",6103707_4,-1,-1,2,18242,-1
18244,effects of,1,3,4,14,The effects of i.m. administration were apparent earlier and sometimes lasted longer than those following oral administration.,6103707_6,-1,-1,2,18244,-1
18261,ouabain arrhythmia,11,13,91,109,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,2,18261,-1
18270,Medical Research Council Working Party,2,7,10,48,Report of Medical Research Council Working Party on Mild to Moderate Hypertension.,6115999_1,-1,-1,2,18270,-1
18271,Medical Research Council treatment trial,3,8,20,60,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,-1,-1,2,18271,-1
18272,treatment groups,18,20,121,137,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,-1,-1,2,18272,-1
18275,patient-years,2,3,7,20,"23 582 patient-years of observation have been completed so far, 10 684 on active drugs and 12 898 on placebos.",6115999_4,-1,-1,2,18275,-1
18282,associated with,21,23,132,147,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,2,18282,-1
18284,Raynaud's,27,29,178,187,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,2,18284,-1
18294,muscimol-induced,7,8,55,71,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,-1,-1,2,18294,-1
18304,dose-dependent,15,16,71,85,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,2,18304,-1
18317,verapamil--report,7,10,63,80,Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases.,6127992_0,-1,-1,2,18317,-1
18320,combined therapy,15,17,115,131,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,2,18320,-1
18339,Crohn's disease,8,11,38,53,"In the twin pregnancy, the mother had Crohn's disease.",6133211_3,-1,-1,2,18339,-1
18340,Potter-type IIa,10,12,37,52,"The first twin, a female, had a left Potter-type IIa polycystic kidney and a rudimentary left uterine cornu.",6133211_4,-1,-1,2,18340,-1
18342,Potter's facies,11,14,46,61,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,2,18342,-1
18345,equinovarus,25,26,122,133,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,2,18345,-1
18351,short-,19,20,142,148,The H2-histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.,6150641_1,-1,-1,2,18351,-1
18354,Zollinger-Ellison syndrome,3,5,22,48,"Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.",6150641_2,-1,-1,2,18354,-1
18362,high doses,2,4,15,25,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,2,18362,-1
18364,associated with,49,51,261,276,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,-1,-1,2,18364,-1
18368,antiandrogen,18,19,92,104,"Both are safe at high doses, but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine.",6150641_9,-1,-1,2,18368,-1
18375,surgically ablated,8,10,58,76,Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.,6153967_5,-1,-1,2,18375,-1
18381,associated with,5,7,45,60,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,-1,2,18381,-1
18382,antineoplastic chemotherapy,7,9,61,88,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,-1,2,18382,-1
18391,forme,16,17,110,115,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,-1,2,18391,-1
18402,cisplatin nephrotoxicity,30,32,178,202,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,2,18402,-1
18409,body weight,24,26,153,164,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,2,18409,-1
18413,Ventricular RNA,0,2,0,15,Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a maximal level following 8 days of therapy.,6203632_4,-1,-1,2,18413,-1
18414,half time,1,3,4,13,The half time for RNA accumulation was 2.0 days.,6203632_5,-1,-1,2,18414,-1
18418,steady-state,23,24,118,130,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,-1,-1,2,18418,-1
18421,experimental animals,11,13,83,103,Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy.,6203632_8,-1,-1,2,18421,-1
18429,I. Report,8,10,68,77,International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.,6209318_0,-1,-1,2,18429,-1
18432,double-blind placebo trial,17,20,112,138,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,-1,-1,2,18432,-1
18443,statistically significant,26,28,111,136,There were more deaths in the mexiletine group (7.6%) than in the placebo group (4.8%); the difference was not statistically significant.,6209318_6,-1,-1,2,18443,-1
18454,elastosis perforans serpiginosa,4,7,26,57,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,2,18454,-1
18456,Wilson's disease,20,23,122,138,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,2,18456,-1
18463,double-blind study,18,20,112,130,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,-1,-1,2,18463,-1
18464,timolol-treated patients,1,3,4,28,The timolol-treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group.,6229975_3,-1,-1,2,18464,-1
18468,timolol-related,1,2,4,19,The timolol-related increase in heart size was observed only in patients with normal and borderline heart size.,6229975_5,-1,-1,2,18468,-1
18477,patients',10,12,62,71,The powders had been obtained from pharmacists unknown to the patients' medical practitioners.,625456_2,-1,-1,2,18477,-1
18478,medical practitioners,12,14,72,93,The powders had been obtained from pharmacists unknown to the patients' medical practitioners.,625456_2,-1,-1,2,18478,-1
18480,Vitamin D3 toxicity,0,3,0,19,Vitamin D3 toxicity in dairy cows.,6286738_0,-1,-1,2,18480,-1
18482,parenteral doses,1,3,6,22,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,2,18482,-1
18491,pregnant Jersey cows,42,45,243,263,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,2,18491,-1
18494,control cows,24,26,132,144,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,-1,-1,2,18494,-1
18499,control cows,24,26,118,130,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,-1,2,18499,-1
18501,vitamin D3 toxicity,2,5,9,28,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,2,18501,-1
18502,nonlactating,9,10,50,62,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,2,18502,-1
18504,vitamin D3 toxicity,22,25,139,158,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,2,18504,-1
18506,pregnant Jersey cows,9,12,49,69,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,2,18506,-1
18521,Guillain-Barr,0,1,0,13,"Guillain-Barr   syndrome was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy.",6287825_4,-1,-1,2,18521,-1
18530,Doxorubicin cardiomyopathy,0,2,0,26,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,2,18530,-1
18531,Wilms tumor,6,8,55,66,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,2,18531,-1
18534,anthracycline cardiomyopathy,11,13,68,96,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,2,18534,-1
18536,Wilms tumor,14,16,79,90,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,-1,-1,2,18536,-1
18538,sharply restricted,7,9,45,63,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,-1,-1,2,18538,-1
18539,Wilms tumor,12,14,81,92,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,-1,-1,2,18539,-1
18541,Effects of,0,2,0,10,Effects of calcitonin on rat extrapyramidal motor system: behavioral and biochemical data.,6293644_0,-1,-1,2,18541,-1
18543,effects of,1,3,4,14,The effects of i.v.c.,6293644_1,-1,-1,2,18543,-1
18544,i.v.c,3,4,15,20,The effects of i.v.c.,6293644_1,-1,-1,2,18544,-1
18549,GAD activity,8,10,61,73,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,2,18549,-1
18551,GAD activity,20,22,130,142,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,2,18551,-1
18554,GABAergic pathway,15,17,89,106,The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.,6293644_5,-1,-1,2,18554,-1
18555,DA-related,19,20,121,131,The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.,6293644_5,-1,-1,2,18555,-1
18557,caffeine toxicity,2,4,13,30,Reduction in caffeine toxicity by acetaminophen.,6308277_0,-1,-1,2,18557,-1
18561,DBA/2J,2,3,11,17,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,-1,-1,2,18561,-1
18564,maximal electroshock,20,22,99,119,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,-1,-1,2,18564,-1
18565,convulsant,27,28,142,152,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,-1,-1,2,18565,-1
18566,Anticonvulsant Screening Project,38,41,211,243,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,-1,-1,2,18566,-1
18573,lethal dose,6,8,48,59,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,-1,-1,2,18573,-1
18579,high-affinity binding,17,19,135,156,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,2,18579,-1
18585,drug action,2,4,16,27,Modification of drug action by hyperammonemia.,6323692_0,-1,-1,2,18585,-1
18590,morphine-treated mice,17,19,91,112,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,2,18590,-1
18594,no effect,37,39,230,239,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,2,18594,-1
18596,altering drug action,6,9,35,55,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,-1,2,18596,-1
18597,drug metabolism,16,18,99,114,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,-1,2,18597,-1
18598,drug responses,20,22,127,141,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,-1,-1,2,18598,-1
18604,KCl-induced,24,25,153,164,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,2,18604,-1
18607,calcium-independent,12,13,72,91,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,2,18607,-1
18609,ammonia blocks,4,6,29,43,These results suggested that ammonia blocks calcium channels.,6323692_5,-1,-1,2,18609,-1
18613,diazepam-induced,15,16,87,103,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,2,18613,-1
18615,amphetamine-induced motor activity,20,23,144,178,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,2,18615,-1
18619,effects of,14,16,97,107,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,-1,2,18619,-1
18620,central nervous system depressants,16,20,108,142,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,-1,2,18620,-1
18629,ventralis intermedius,49,51,308,329,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,-1,-1,2,18629,-1
18631,double-blind study,1,3,2,20,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,2,18631,-1
18634,double-blind,3,4,12,24,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,-1,-1,2,18634,-1
18635,parallel treatment study,4,7,25,49,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,-1,-1,2,18635,-1
18646,associated with,10,12,64,79,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,-1,-1,2,18646,-1
18657,double-blind,57,58,288,300,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,2,18657,-1
18661,tapped faster,1,3,9,22,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,-1,-1,2,18661,-1
18666,ifosfamide-induced,2,3,13,31,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,2,18666,-1
18679,4-week cycle,59,61,331,343,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,2,18679,-1
18687,polychemotherapy,7,8,37,53,A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures (raised fluid intake and forced diuresis).,6402369_5,-1,-1,2,18687,-1
18712,ceroid,12,13,65,71,The child in whom the seizures persisted was later found to have ceroid lipofuscinosis.,6415512_3,-1,-1,2,18712,-1
18716,effects of,14,16,82,92,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,2,18716,-1
18726,latency-to-onset,14,15,82,98,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,2,18726,-1
18733,mechanism(s),9,11,51,63,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,-1,-1,2,18733,-1
18741,standardized loading dose,1,4,2,27,"A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.",6436733_2,-1,-1,2,18741,-1
18747,VPA-induced,2,3,13,24,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,2,18747,-1
18754,SHR,13,14,89,92,The possibility of reproducing the same renal abnormality with captopril was examined in SHR.,6454943_2,-1,-1,2,18754,-1
18756,SHR,16,17,106,109,Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.,6454943_3,-1,-1,2,18756,-1
18758,SHR,18,19,136,139,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,-1,-1,2,18758,-1
18763,SHR,19,20,130,133,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,-1,-1,2,18763,-1
18770,control group,1,3,2,15,A control group was included for comparison with the lower dose range of glycopyrrolate and atropine.,6466532_4,-1,-1,2,18770,-1
18772,control group,11,13,51,64,"A frequency of bradycardia of 50% was noted in the control group, but this was not significantly different from the frequency with the active drugs.",6466532_5,-1,-1,2,18772,-1
18784,trazodone's effect,12,15,67,85,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,-1,2,18784,-1
18794,Small-,0,1,0,6,Small- and medium-sized hepatic veins were blocked by thrombosis.,6503301_4,-1,-1,2,18794,-1
18796,Published cases,0,2,0,15,Published cases from the literature are reviewed and pertinent features discussed.,6503301_6,-1,-1,2,18796,-1
18813,lithium-induced,23,24,174,189,"Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.",6518066_4,-1,-1,2,18813,-1
18815,Effects of,0,2,0,10,Effects of training on the extent of experimental myocardial infarction in aging rats.,6534871_0,-1,-1,2,18815,-1
18817,effects of,1,3,4,14,"The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.",6534871_1,-1,-1,2,18817,-1
18819,albino rats,15,17,110,121,"The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.",6534871_1,-1,-1,2,18819,-1
18824,associated with,7,9,46,61,These changes in the serum transaminases were associated with corresponding depletions in the cardiac GOT and GPT.,6534871_5,-1,-1,2,18824,-1
18827,interfere with,6,8,25,39,"However, age was seen to interfere with the responses exhibited by the young and old rats.",6534871_6,-1,-1,2,18827,-1
18830,adriamycin toxicity,6,8,37,56,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,-1,-1,2,18830,-1
18835,chronic treatment,25,27,115,132,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,2,18835,-1
18840,chronic low-dose-ADR-associated lethality,8,11,56,97,PEG 400 impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality.,6538499_2,-1,-1,2,18840,-1
18842,ADR-induced,8,9,67,78,Light microscopic analysis showed a significant protection against ADR-induced cardiac morphological alterations.,6538499_3,-1,-1,2,18842,-1
18845,L1210 leukemia,10,12,62,76,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,2,18845,-1
18847,Effects of,0,2,0,10,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,2,18847,-1
18851,ketamine-induced catatonia,15,17,97,123,"The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.",6540303_1,-1,-1,2,18851,-1
18859,pinealectomized chick,32,34,183,204,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,-1,-1,2,18859,-1
18862,young chick,26,28,151,162,This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.,6540303_6,-1,-1,2,18862,-1
18869,heparin-dependent platelet membrane,8,11,55,90,Immunologic testing has demonstrated the presence of a heparin-dependent platelet membrane antibody.,6615052_4,-1,-1,2,18869,-1
18875,patient's,23,25,134,143,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,-1,-1,2,18875,-1
18876,platelet anti-aggregating agents,7,10,45,77,"Management consists of cessation of heparin, platelet anti-aggregating agents, and alternate forms of anticoagulation when indicated.",6615052_8,-1,-1,2,18876,-1
18895,quaternary antiarrhythmic agent,17,20,114,145,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,2,18895,-1
18897,ouabain-induced ventricular tachycardias,27,30,190,230,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,2,18897,-1
18899,bioavailability,4,5,34,49,Both anti-arrhythmic efficacy and bioavailability were compared to oral drug.,6634932_1,-1,-1,2,18899,-1
18906,alternate form,36,38,198,212,"The area under the plasma concentration time curve at 90 min was 4-12 times greater than for oral drug, suggesting the existence of an absorption-limiting process in the intestine, and providing an alternate form of administration for quaternary drugs.",6634932_3,-1,-1,2,18906,-1
18912,antiarrhythmic drugs,36,38,183,203,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,2,18912,-1
18918,/- standard deviation,32,35,182,203,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,2,18918,-1
18919,/-,37,38,210,212,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,2,18919,-1
18920,antiarrhythmic drug,29,31,169,188,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,-1,-1,2,18920,-1
18927,VF refractory,13,15,87,100,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,2,18927,-1
18928,antiarrhythmic drugs,17,19,117,137,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,2,18928,-1
18935,intravesically,8,9,42,56,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,2,18935,-1
18938,afterwards monthly,16,18,94,112,"Instillation was repeated twice during the first week, then weekly during the first month and afterwards monthly for 1 year.",6640832_3,-1,-1,2,18938,-1
18947,D-penicillamine-induced angiopathy,0,2,0,34,D-penicillamine-induced angiopathy in rats.,6666578_0,-1,-1,2,18947,-1
18951,Sprague-Dawley rats,1,3,5,24,Male Sprague-Dawley rats were treated with D-penicillamine (D-pen) 500 mg/kg/day for 10 or 42 days.,6666578_2,-1,-1,2,18951,-1
18955,light-,7,8,46,52,Changes in aortic morphology were examined by light- and transmission-electron microscopy (TEM).,6666578_4,-1,-1,2,18955,-1
18956,transmission-electron microscopy,9,11,57,89,Changes in aortic morphology were examined by light- and transmission-electron microscopy (TEM).,6666578_4,-1,-1,2,18956,-1
18960,i.,25,26,144,146,"In addition, the endothelial permeability and the penetration through the aortic wall of albumin were studied 10 minutes, 24 and 48 hours after i. v. injection of human serum 131I-albumin (131I-HSA).",6666578_5,-1,-1,2,18960,-1
18961,v. injection,26,28,147,159,"In addition, the endothelial permeability and the penetration through the aortic wall of albumin were studied 10 minutes, 24 and 48 hours after i. v. injection of human serum 131I-albumin (131I-HSA).",6666578_5,-1,-1,2,18961,-1
18967,consistent with,12,14,79,94,"TEM revealed extensive elastolysis in the arterial wall of D-pen-treated rats, consistent with an inhibitory effect on crosslink formation.",6666578_6,-1,-1,2,18967,-1
18968,crosslink formation,18,20,119,138,"TEM revealed extensive elastolysis in the arterial wall of D-pen-treated rats, consistent with an inhibitory effect on crosslink formation.",6666578_6,-1,-1,2,18968,-1
18974,aorta/serum-ratio,1,2,4,21,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,-1,-1,2,18974,-1
18984,aorta/serum-ratio,16,17,111,128,"The endothelial ultrastructure was unaffected by D-pen, and no differences in aortic 131I-HSA radioactivity or aorta/serum-ratio were recorded between experimental and control groups 10 minutes after tracer injection, indicating that the permeability of the endothelial barrier to albumin remained unaffected by D-pen treatment.",6666578_9,-1,-1,2,18984,-1
18985,control groups,22,24,168,182,"The endothelial ultrastructure was unaffected by D-pen, and no differences in aortic 131I-HSA radioactivity or aorta/serum-ratio were recorded between experimental and control groups 10 minutes after tracer injection, indicating that the permeability of the endothelial barrier to albumin remained unaffected by D-pen treatment.",6666578_9,-1,-1,2,18985,-1
18996,year-old,18,19,97,105,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,2,18996,-1
19000,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced,4,5,21,74,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,-1,-1,2,19000,-1
19004,co-administration,1,2,4,21,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,2,19004,-1
19015,FANFT-induced cell proliferation,0,3,0,32,FANFT-induced cell proliferation in the bladder was significantly suppressed by aspirin co-administration after 4 weeks but not after 12 weeks.,6692345_3,-1,-1,2,19015,-1
19018,FANFT-induced,15,16,70,83,"In the forestomach, and also in the liver, aspirin did not affect the FANFT-induced increase in labeling index.",6692345_4,-1,-1,2,19018,-1
19020,consistent with,4,6,24,39,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,2,19020,-1
19022,FANFT carcinogenesis,16,18,124,144,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,2,19022,-1
19026,associated with,41,43,264,279,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,2,19026,-1
19028,chronic ingestion,13,15,59,76,"Also, there appears to be an adaptation by the rats to the chronic ingestion of aspirin.",6692345_6,-1,-1,2,19028,-1
19030,associated with,2,4,20,35,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,2,19030,-1
19036,Subarachnoid,0,1,0,12,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,-1,-1,2,19036,-1
19058,tardive dyskinesia,3,5,10,28,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,-1,-1,2,19058,-1
19063,tardive dyskinesia,7,9,48,66,Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug.,6727060_4,-1,-1,2,19063,-1
19066,effects of,3,5,16,26,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,-1,-1,2,19066,-1
19072,urinary measurements,8,10,59,79,"Scanning electron microscopy of the glomerular endothelia, urinary measurements of sodium, potassium, endogenous lysozyme, N-acetyl-beta-D-glucosaminidase (NAG) as well as clearance and accumulation experiments after i.v.",6728084_2,-1,-1,2,19072,-1
19077,treatment group,16,18,98,113,administration of egg-white lysozyme and measurements of inulin clearance (GFR) were done in each treatment group.,6728084_3,-1,-1,2,19077,-1
19086,no effect,6,8,52,61,administration of egg-white lysozyme netilmicin had no effect.,6728084_8,-1,-1,2,19086,-1
19089,nephrotoxicants,6,7,33,48,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,-1,-1,2,19089,-1
19100,rechallenge,1,2,2,13,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,2,19100,-1
19105,Intra-arterial,0,1,0,14,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,2,19105,-1
19110,intra-arterial administration,12,14,89,118,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,2,19110,-1
19111,intravenous administration,20,22,163,189,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,2,19111,-1
19122,radiation therapy,18,20,114,131,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,-1,-1,2,19122,-1
19124,chemotherapy response,8,10,43,64,"In the nine responders, median duration of chemotherapy response from the time of operation was 25 weeks (range 12 to more than 91 weeks).",6747681_5,-1,-1,2,19124,-1
19125,18-month,24,25,107,115,"The median duration of survival in the 12 patients was 54 weeks (range 21 to more than 156 weeks), with an 18-month survival rate of 42%.",6747681_6,-1,-1,2,19125,-1
19128,irradiation therapy,13,15,84,103,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,2,19128,-1
19129,intra-arterial,24,25,149,163,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,2,19129,-1
19137,nonhuman primates.10 monkeys,8,11,63,91,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,-1,-1,2,19137,-1
19148,autonomic neuropathy?The,8,10,65,89,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,-1,2,19148,-1
19164,lithium carbonate toxicity,4,7,34,60,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,2,19164,-1
19178,Effects of,0,2,0,10,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,2,19178,-1
19184,exposed to,52,54,303,313,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,2,19184,-1
19186,scopolamine-induced,77,78,436,455,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,2,19186,-1
19195,subconvulsant electroshock,194,196,1148,1174,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,2,19195,-1
19201,therapeutic window',10,13,62,81,The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown.,6817363_4,-1,-1,2,19201,-1
19217,concentration-blood pressure effect curve,19,23,153,194,Intrarenal compared with intravenous infusion of noradrenaline caused higher plasma noradrenaline concentrations and a shift of the plasma noradrenaline concentration-blood pressure effect curve towards lower plasma noradrenaline levels.,6861444_3,-1,-1,2,19217,-1
19221,chronic treatment,9,11,53,70,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,2,19221,-1
19222,implanted subcutaneously,21,23,110,134,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,2,19222,-1
19225,single-cell preparations,27,29,153,177,"Over a range of 1-150 days of DES treatment, pairs of control and DES-treated rats were sacrificed, and their pituitaries dissociated enzymatically into single-cell preparations.",6888657_2,-1,-1,2,19225,-1
19231,immunocytochemical,27,28,176,194,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,2,19231,-1
19240,control values,20,22,124,138,Total cell yields from DES-treated pituitaries increased from 1.3 times control yields at 8 days of treatment to 58.9 times control values by day 150.,6888657_4,-1,-1,2,19240,-1
19242,control levels,9,11,55,69,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,2,19242,-1
19244,in vitro,15,17,87,95,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,2,19244,-1
19245,PRL-positive,9,10,52,64,"Beyond 8 days of DES exposure, the immunochemically PRL-positive proportion of cells increased to over 50% of the total population.",6888657_6,-1,-1,2,19245,-1
19246,total population,20,22,114,130,"Beyond 8 days of DES exposure, the immunochemically PRL-positive proportion of cells increased to over 50% of the total population.",6888657_6,-1,-1,2,19246,-1
19250,separation protocols,21,23,122,142,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,2,19250,-1
19251,ovariectomized animals,10,12,63,85,All these effects of DES were more pronounced among previously ovariectomized animals.,6888657_8,-1,-1,2,19251,-1
19263,Calcium chloride depressed,0,3,0,26,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,2,19263,-1
19277,atropine-like action,13,15,75,95,These results further support the view that calcium ions in excess have an atropine-like action also in the central nervous system.,6892185_6,-1,-1,2,19277,-1
19280,antihypertensive treatment programs,9,12,61,96,Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.,6942642_1,-1,-1,2,19280,-1
19285,control period,5,7,23,37,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,2,19285,-1
19286,/-,10,11,47,49,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,2,19286,-1
19289,/-,27,28,106,108,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,2,19289,-1
19290,/-,32,33,119,121,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,2,19290,-1
19291,/-,37,38,132,134,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,2,19291,-1
19292,/-,43,44,149,151,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,2,19292,-1
19294,Corresponding figures,0,2,0,21,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,2,19294,-1
19296,/-,14,15,64,66,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,2,19296,-1
19297,/-,19,20,78,80,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,2,19297,-1
19298,/-,24,25,92,94,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,2,19298,-1
19299,/-,30,31,110,112,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,2,19299,-1
19303,/-,6,7,29,31,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,2,19303,-1
19304,beats/min,9,10,41,50,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,2,19304,-1
19306,dynamic exercise 0.6 +,17,21,81,103,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,2,19306,-1
19307,/-,26,27,120,122,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,2,19307,-1
19308,Corresponding figures,0,2,0,21,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,2,19308,-1
19310,/-,11,12,65,67,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,2,19310,-1
19311,/-,16,17,78,80,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,2,19311,-1
19316,lysosomal enzymes acid,4,7,22,44,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,-1,-1,2,19316,-1
19324,paracetamol overdose,26,28,160,180,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,2,19324,-1
19326,serum acid protease activity,5,9,32,60,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,-1,-1,2,19326,-1
19327,prothrombin time,10,12,65,81,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,-1,-1,2,19327,-1
19332,serum samples,14,16,75,88,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,-1,-1,2,19332,-1
19333,high-pressure liquid chromatography,30,33,170,205,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,-1,-1,2,19333,-1
19337,/-,14,15,77,79,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,-1,-1,2,19337,-1
19373,time-course study,11,13,66,83,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,-1,-1,2,19373,-1
19386,LDL density class,19,22,87,104,Plasma apolipoprotein A-I was found not only in HDL (1.063-1.210 g/ml) but also in the LDL density class (1.025-1.050 g/ml).,7066357_9,-1,-1,2,19386,-1
19392,plasma lipoproteins,7,9,66,85,These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL.,7066357_11,-1,-1,2,19392,-1
19394,HDL metabolism,26,28,133,147,It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism.,7066357_12,-1,-1,2,19394,-1
19407,associated with,7,9,45,60,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,2,19407,-1
19408,National Registry of Drug-Induced Ocular Side Effects,17,24,121,174,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,2,19408,-1
19409,Oregon Health Sciences University,25,29,176,209,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,2,19409,-1
19425,in utero,16,18,98,106,Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.,7088431_1,-1,-1,2,19425,-1
19447,prophylactic antiparkinsonians,15,17,89,119,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,2,19447,-1
19449,CD50,3,4,19,23,Median convulsant (CD50) and median lethal (LD50) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic-induced convulsions.,7189975_1,-1,-1,2,19449,-1
19450,median lethal,6,8,29,42,Median convulsant (CD50) and median lethal (LD50) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic-induced convulsions.,7189975_1,-1,-1,2,19450,-1
19453,CD50,1,2,4,8,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,-1,-1,2,19453,-1
19454,LD50,3,4,13,17,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,-1,-1,2,19454,-1
19465,convulsant,4,5,23,33,The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated.,7189975_6,-1,-1,2,19465,-1
19471,effects of,1,3,4,14,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,2,19471,-1
19478,quipazine-induced head twitches,27,30,166,197,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,2,19478,-1
19485,total volume,9,11,39,51,The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated.,7199841_2,-1,-1,2,19485,-1
19503,Procainamide-induced,0,1,0,20,Procainamide-induced polymorphous ventricular tachycardia.,7234705_0,-1,-1,2,19503,-1
19505,procainamide-induced,3,4,15,35,Seven cases of procainamide-induced polymorphous ventricular tachycardia are presented.,7234705_1,-1,-1,2,19505,-1
19516,treated with,10,12,59,71,"In four patients, the arrhythmia was rapidly diagnosed and treated with disappearance of further episodes of the arrhythmia.",7234705_5,-1,-1,2,19516,-1
19525,Phenobarbitone-induced enlargement,0,2,0,34,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,2,19525,-1
19533,phenobarbitone-induced,84,85,476,498,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,2,19533,-1
19534,cytochrome P450/CCl4 toxic state,8,12,38,70,At this point it was assumed that the cytochrome P450/CCl4 toxic state was both maximal and stable.,7248170_2,-1,-1,2,19534,-1
19544,in vitro,7,9,60,68,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,-1,-1,2,19544,-1
19546,Triamterene nephrolithiasis,0,2,0,27,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,-1,2,19546,-1
19548,triamterene nephrolithiasis,3,5,10,37,A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.,7265370_1,-1,-1,2,19548,-1
19552,triamterene nephrolithiasis,2,4,18,45,Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.,7265370_3,-1,-1,2,19552,-1
19556,busulfan cystitis,7,9,53,70,The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.,7269015_3,-1,-1,2,19556,-1
19563,doxorubicin cardiomyopathy,5,7,52,78,Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.,7282516_0,-1,-1,2,19563,-1
19566,dose-effect,23,24,128,139,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,2,19566,-1
19580,DXR-CM,1,2,3,9,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,-1,-1,2,19580,-1
19585,critical dose,23,25,136,149,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,-1,-1,2,19585,-1
19588,desipramine toxicity,4,6,35,55,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,-1,-1,2,19588,-1
19590,desipramine toxicity,10,12,63,83,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,-1,-1,2,19590,-1
19592,R-R interval,14,16,95,107,"Unusual features of the arrhythmia are repetitive group beating, progressive shortening of the R-R interval, progressive widening of the QRS complex with eventual failure of intraventricular conduction, and changes in direction of the QRS axis.",7292072_2,-1,-1,2,19592,-1
19593,QRS complex,21,23,137,148,"Unusual features of the arrhythmia are repetitive group beating, progressive shortening of the R-R interval, progressive widening of the QRS complex with eventual failure of intraventricular conduction, and changes in direction of the QRS axis.",7292072_2,-1,-1,2,19593,-1
19595,QRS axis,36,38,235,243,"Unusual features of the arrhythmia are repetitive group beating, progressive shortening of the R-R interval, progressive widening of the QRS complex with eventual failure of intraventricular conduction, and changes in direction of the QRS axis.",7292072_2,-1,-1,2,19595,-1
19608,medical therapy,22,24,153,168,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,2,19608,-1
19615,Control rats,0,2,0,12,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,-1,-1,2,19615,-1
19620,control animals,5,7,28,43,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,2,19620,-1
19622,saralasin-treated animals,20,22,122,147,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,2,19622,-1
19625,control animals,9,11,56,71,"Following discontinuation of SNP, blood pressure in the control animals rebounded to 94 torr, as compared with 78 torr in the saralasin-treated rats.",7352670_6,-1,-1,2,19625,-1
19628,post-SNP rebound of,20,23,127,146,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,-1,-1,2,19628,-1
19634,longterm,12,13,71,79,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,2,19634,-1
19638,control group,6,8,30,43,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,2,19638,-1
19643,control groups,10,12,60,74,"A subjective assessment of sexual behavior in the study and control groups was carried out, using parameters such as sexual desire, sexual excitement, and frequency of sexual relations.",7416947_4,-1,-1,2,19643,-1
19654,study group,31,33,179,190,"Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire, sexual excitement phase (erection), and frequency of sexual relations in the study group.",7416947_8,-1,-1,2,19654,-1
19666,tobramycin-treated patients,9,11,24,51,Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.,7420681_6,-1,-1,2,19666,-1
19678,adriamycin cardiotoxicity,3,5,25,50,Metabolic involvement in adriamycin cardiotoxicity.,7423039_0,-1,-1,2,19678,-1
19688,adenylate energy charge,15,18,92,115,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,-1,-1,2,19688,-1
19691,adriamycin-treated cells,26,28,176,200,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,-1,-1,2,19691,-1
19692,adenylate energy charge,1,4,4,27,"The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged.",7423039_4,-1,-1,2,19692,-1
19694,mole fraction,14,16,97,110,"The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged.",7423039_4,-1,-1,2,19694,-1
19696,adriamycin-treated cells,2,4,7,31,"In the adriamycin-treated cells, the addition of adenosine increased the adenylate charge and, concomitant with this inrcease, the cells' functional integrity, in terms of percentage of beating cells and rate of contractions, was maintained.",7423039_7,-1,-1,2,19696,-1
19697,adenylate charge,11,13,73,89,"In the adriamycin-treated cells, the addition of adenosine increased the adenylate charge and, concomitant with this inrcease, the cells' functional integrity, in terms of percentage of beating cells and rate of contractions, was maintained.",7423039_7,-1,-1,2,19697,-1
19705,No evidence,0,2,0,11,No evidence was found for any reduction of glomerular filtration during lithium treatment.,7437994_5,-1,-1,2,19705,-1
19708,pre-lithium values,16,18,93,111,Low clearance values found in several patients could be accounted for by their age and their pre-lithium values.,7437994_6,-1,-1,2,19708,-1
19715,preweaning,11,12,73,83,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,2,19715,-1
19716,doxorubicin cardiotoxicity,3,5,11,37,"Late, late doxorubicin cardiotoxicity.",7449470_0,-1,-1,2,19716,-1
19724,lithium-induced diabetes-insipidus-like syndrome,3,6,19,67,Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.,7453952_0,-1,-1,2,19724,-1
19736,diabetes-insipidus-like,10,11,63,86,"In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.",7453952_6,-1,-1,2,19736,-1
19742,associated with,2,4,29,44,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,-1,-1,2,19742,-1
19753,cross-reactivity,12,13,76,92,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,2,19753,-1
19760,out-patients,19,20,121,133,METHODS: Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department (in- or out-patients) from 1986 to 1992.,7504976_2,-1,-1,2,19760,-1
19770,pre-therapeutic,21,22,133,148,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,2,19770,-1
19773,effects of,1,3,12,22,Interactive effects of variations in [Na]o and [Ca]o on rat atrial spontaneous frequency.,7516729_0,-1,-1,2,19773,-1
19777,effects of,1,3,4,14,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,2,19777,-1
19784,/- 4,12,14,63,67,Basal frequency (BF) evaluated by surface electrogram was 223 +/- 4 beats/min.,7516729_2,-1,-1,2,19784,-1
19785,beats/min,14,15,68,77,Basal frequency (BF) evaluated by surface electrogram was 223 +/- 4 beats/min.,7516729_2,-1,-1,2,19785,-1
19786,/-,5,6,20,22,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,2,19786,-1
19787,LNa,15,16,54,57,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,2,19787,-1
19788,/-,20,21,64,66,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,2,19788,-1
19790,LNa+LCa,36,37,135,142,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,2,19790,-1
19791,/-,41,42,152,154,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,2,19791,-1
19792,LNa+HCa,57,58,218,225,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,2,19792,-1
19797,/-,41,42,171,173,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,2,19797,-1
19799,BF-dependent,5,6,39,51,All negative chronotropic effects were BF-dependent.,7516729_6,-1,-1,2,19799,-1
19800,Dose-dependent,0,1,0,14,"Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.",7516729_7,-1,-1,2,19800,-1
19810,LNa+HCa,45,46,216,223,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,2,19810,-1
19815,LNa+HCa,19,20,103,110,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,-1,-1,2,19815,-1
19817,HCa,23,24,119,122,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,-1,-1,2,19817,-1
19819,/-,47,48,241,243,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,-1,-1,2,19819,-1
19822,LCa.(ABSTRACT TRUNCATED,16,18,95,118,Also the enhancement of verapamil effects on atrial beating was more pronounced at LNa than at LCa.(ABSTRACT TRUNCATED AT 250 WORDS),7516729_10,-1,-1,2,19822,-1
19834,juxtaglomerular apparatus,48,50,258,283,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,2,19834,-1
19835,Wistar rats,52,54,292,303,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,2,19835,-1
19838,FK506 toxicity,6,8,36,50,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,2,19838,-1
19841,intracytoplasmic receptors,8,10,50,76,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,2,19841,-1
19850,immunophilin-drug-calcineurin complexes,3,5,18,57,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,2,19850,-1
19871,treated with,2,4,13,25,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,-1,-1,2,19871,-1
19877,parenteral challenges,7,9,41,62,"Clinical examinations and skin, oral and parenteral challenges with different corticosteroids and ELISA tests were performed.",7582165_4,-1,-1,2,19877,-1
19878,ELISA tests,13,15,98,109,"Clinical examinations and skin, oral and parenteral challenges with different corticosteroids and ELISA tests were performed.",7582165_4,-1,-1,2,19878,-1
19882,single-blind,1,2,2,14,"A single-blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug, and negative with its excipients.",7582165_6,-1,-1,2,19882,-1
19883,parenteral challenge,2,4,15,35,"A single-blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug, and negative with its excipients.",7582165_6,-1,-1,2,19883,-1
19886,parenteral challenges,6,8,29,50,We also carried out oral and parenteral challenges with other corticosteroids and found intolerance to some of them.,7582165_7,-1,-1,2,19886,-1
19913,intraplatelet cAMP,18,20,123,141,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,-1,2,19913,-1
19919,Intraplatelet,0,1,0,13,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,-1,-1,2,19919,-1
19920,/-,11,12,78,80,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,-1,-1,2,19920,-1
19921,initial value,25,27,144,157,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,-1,-1,2,19921,-1
19922,/-,30,31,165,167,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,-1,-1,2,19922,-1
19923,time intervals,8,10,67,81,The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted.,7596955_9,-1,-1,2,19923,-1
19928,combined administration,24,26,135,158,"In conclusion, the combined administration of BPT/CLZ is safe at doses used in the study, though the beneficial clinical effect of the combined administration has yet to be elucidated.",7596955_10,-1,-1,2,19928,-1
19929,associated with,6,8,38,53,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,-1,2,19929,-1
19942,intraperitonealinjection,13,14,64,88,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,2,19942,-1
19943,gastric intubation,10,12,55,73,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,-1,-1,2,19943,-1
19946,brain ammonia,25,27,154,167,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,2,19946,-1
19949,brain ammonia,7,9,33,46,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,2,19949,-1
19966,Seventy-five human immunodeficiency virus,0,4,0,41,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,2,19966,-1
19967,CD4+,7,9,71,75,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,2,19967,-1
19969,group I,26,28,158,165,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,2,19969,-1
19973,group II,54,56,282,290,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,2,19973,-1
19974,group I,24,26,104,111,"Finally, 15 patients were excluded from the study (noncompliance 14, death 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis.",7628595_3,-1,-1,2,19974,-1
19975,group II,29,31,122,130,"Finally, 15 patients were excluded from the study (noncompliance 14, death 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis.",7628595_3,-1,-1,2,19975,-1
19976,No significant,0,2,0,14,No significant differences between groups were found at enrollment.,7628595_4,-1,-1,2,19976,-1
19978,group II,13,15,77,85,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,2,19978,-1
19987,ZDV-induced,17,18,107,118,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,2,19987,-1
19991,cross-react,8,9,61,72,Halogenated anesthetics form liver adducts and antigens that cross-react with halothane-induced antibodies.,7647582_0,-1,-1,2,19991,-1
19992,halothane-induced antibodies,10,12,78,106,Halogenated anesthetics form liver adducts and antigens that cross-react with halothane-induced antibodies.,7647582_0,-1,-1,2,19992,-1
19997,Halothane hepatitis,0,2,0,19,Halothane hepatitis appears to involve an aberrant immune response.,7647582_2,-1,-1,2,19997,-1
20001,halothane hepatitis,16,18,112,131,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,2,20001,-1
20002,cross-reactivity,6,7,38,54,This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.,7647582_4,-1,-1,2,20002,-1
20006,halothane-induced antibodies,10,12,76,104,"The subcellular and lobular production of hepatic neoantigens recognized by halothane-induced antibodies following enflurane and isoflurane, and the biochemical nature of these neoantigens was investigated in two animal models.",7647582_5,-1,-1,2,20006,-1
20015,guinea pigs,18,20,110,121,"In the same liver, biochemical analysis detected fluorinated liver adducts that were up to 20-fold greater in guinea pigs than in rats.",7647582_7,-1,-1,2,20015,-1
20018,ocular instillation,4,6,36,55,Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.,7650771_0,-1,-1,2,20018,-1
20022,ophthalmic drops,13,15,87,103,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,2,20022,-1
20027,eye drops,18,20,140,149,Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops.,7650771_2,-1,-1,2,20027,-1
20044,cytotoxic therapy,18,20,124,141,"Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.",7707116_2,-1,-1,2,20044,-1
20046,maximal-tolerated dosage,9,11,49,73,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,-1,-1,2,20046,-1
20056,MTD,3,4,13,16,RESULTS: The MTD of cis-RA was 160 mg/m2/d.,7707116_7,-1,-1,2,20056,-1
20063,/-,5,6,21,23,Serum levels of 7.4 +/- 3.0 mumol/L (peak) and 4.0 +/- 2.8 mumol/L (trough) at the MTD were maintained during 14 days of therapy.,7707116_11,-1,-1,2,20063,-1
20064,/-,14,15,52,54,Serum levels of 7.4 +/- 3.0 mumol/L (peak) and 4.0 +/- 2.8 mumol/L (trough) at the MTD were maintained during 14 days of therapy.,7707116_11,-1,-1,2,20064,-1
20065,MTD,22,23,83,86,Serum levels of 7.4 +/- 3.0 mumol/L (peak) and 4.0 +/- 2.8 mumol/L (trough) at the MTD were maintained during 14 days of therapy.,7707116_11,-1,-1,2,20065,-1
20066,DLT,1,2,4,7,The DLT correlated with serum levels > or = 10 mumol/L. CONCLUSION: The MTD of cis-RA given on this intermittent schedule was 160 mg/m2/d.,7707116_12,-1,-1,2,20066,-1
20067,serum levels,4,6,24,36,The DLT correlated with serum levels > or = 10 mumol/L. CONCLUSION: The MTD of cis-RA given on this intermittent schedule was 160 mg/m2/d.,7707116_12,-1,-1,2,20067,-1
20068,MTD,14,15,72,75,The DLT correlated with serum levels > or = 10 mumol/L. CONCLUSION: The MTD of cis-RA given on this intermittent schedule was 160 mg/m2/d.,7707116_12,-1,-1,2,20068,-1
20070,intermittent schedule,20,22,100,121,The DLT correlated with serum levels > or = 10 mumol/L. CONCLUSION: The MTD of cis-RA given on this intermittent schedule was 160 mg/m2/d.,7707116_12,-1,-1,2,20070,-1
20072,in vitro,8,10,57,65,Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose.,7707116_13,-1,-1,2,20072,-1
20081,femoral vein four times,8,12,56,79,"Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.",7710775_2,-1,-1,2,20081,-1
20087,zero time,10,12,63,72,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,2,20087,-1
20097,microliters/min,53,54,347,362,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,-1,2,20097,-1
20108,control animals,23,25,97,112,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,-1,-1,2,20108,-1
20114,post-injection,2,3,7,21,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,-1,-1,2,20114,-1
20122,DXNP killed less,10,13,66,82,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,-1,-1,2,20122,-1
20144,intra-arterial,3,4,14,28,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,2,20144,-1
20148,intra-arterial,27,28,165,179,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,2,20148,-1
20169,seventy-eight-year-old,1,2,2,24,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,-1,-1,2,20169,-1
20186,Forty-five hospitalized elderly,2,5,9,40,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,2,20186,-1
20189,Group A,33,35,204,211,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,2,20189,-1
20193,Group B,47,49,273,280,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,2,20193,-1
20202,Group B,48,50,219,226,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,2,20202,-1
20204,Group A,16,18,68,75,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,2,20204,-1
20205,Group B,25,27,96,103,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,2,20205,-1
20207,A. Response,30,32,131,142,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,2,20207,-1
20219,DSM-III criteria,10,12,51,67,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,-1,-1,2,20219,-1
20222,placebo subjects,2,4,14,30,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,2,20222,-1
20228,drop-out rate,4,6,18,31,"Despite this, the drop-out rate was low.",7802851_10,-1,-1,2,20228,-1
20229,side-effects,4,5,31,43,CONCLUSIONS: Alprazolam caused side-effects and adverse effects during treatment but many patients were willing to accept these.,7802851_11,-1,-1,2,20229,-1
20237,over-the-counter antitussives,22,24,137,166,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,2,20237,-1
20238,Bornstein 1968,3,5,17,31,Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.,7803371_2,-1,-1,2,20238,-1
20245,Isbell,51,52,280,286,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,2,20245,-1
20246,Fraser,53,54,291,297,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,2,20246,-1
20248,McCarthy 1971,61,63,323,336,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,2,20248,-1
20254,Effects of,0,2,0,10,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,-1,-1,2,20254,-1
20259,effects of,1,3,4,14,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,2,20259,-1
20262,effects of,3,5,16,26,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,2,20262,-1
20272,mean+/-SE,8,9,62,71,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,2,20272,-1
20277,consistent with,22,24,145,160,The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility.,783197_7,-1,-1,2,20277,-1
20278,No significant,0,2,0,14,No significant change in these parameters occurred in the control patients.,783197_8,-1,-1,2,20278,-1
20279,control patients,9,11,58,74,No significant change in these parameters occurred in the control patients.,783197_8,-1,-1,2,20279,-1
20284,control patients,31,33,201,217,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,-1,-1,2,20284,-1
20289,associated with,5,7,26,41,"Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption.",783197_11,-1,-1,2,20289,-1
20293,associated with,3,5,41,56,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,-1,-1,2,20293,-1
20301,report documents,1,3,5,21,This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.,7834920_5,-1,-1,2,20301,-1
20310,donor eyes,7,9,40,50,"METHODS: The anterior segments of human donor eyes from regional eye banks were placed in a constant flow, variable pressure perfusion culture system.",7843916_3,-1,-1,2,20310,-1
20322,/-,28,29,163,165,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,-1,-1,2,20322,-1
20334,dexamethasone-induced morphologic changes,17,20,130,171,"The dexamethasone-treated nonresponder eyes appeared to be morphologically similar to the untreated eyes, although several subtle dexamethasone-induced morphologic changes were evident.",7843916_11,-1,-1,2,20334,-1
20336,dexamethasone-treated eyes,23,25,152,178,"CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.",7843916_12,-1,-1,2,20336,-1
20341,steroid glaucoma,16,18,95,111,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,2,20341,-1
20342,high-dose,5,6,29,38,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,-1,-1,2,20342,-1
20345,treated with,4,6,22,34,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,2,20345,-1
20364,5-fluorouracil neurotoxicity,3,5,20,48,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,2,20364,-1
20365,Krebs cycle blockade,10,13,65,85,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,2,20365,-1
20382,associated with,2,4,21,36,Auditory disturbance associated with interscalene brachial plexus block.,7880714_0,-1,-1,2,20382,-1
20383,interscalene brachial plexus block,4,8,37,71,Auditory disturbance associated with interscalene brachial plexus block.,7880714_0,-1,-1,2,20383,-1
20403,treated with,2,4,10,22,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,2,20403,-1
20411,lipid extracts,12,14,74,88,Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances.,7881871_6,-1,-1,2,20411,-1
20417,associated with,5,7,35,50,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,2,20417,-1
20425,Hounsfield units,25,27,150,166,"In the remaining 12 patients, localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units (values of < 100 HU predict cholesterol rich, dissolvable stones).",7890216_4,-1,-1,2,20425,-1
20429,supersaturated bile,4,6,21,40,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,-1,-1,2,20429,-1
20441,CD4 cells/mm3.We,21,23,135,151,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,2,20441,-1
20442,double-blind,25,26,164,176,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,2,20442,-1
20448,CD4 cells/mm3,5,7,25,38,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,2,20448,-1
20450,combination therapy,3,5,24,43,"Sixty patients received combination therapy and 58, zidovudine and placebo.",7905523_2,-1,-1,2,20450,-1
20452,steady-state,3,4,18,30,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,2,20452,-1
20453,/-,9,10,51,53,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,2,20453,-1
20456,CD4 cells,4,6,21,30,"The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).",7905523_5,-1,-1,2,20456,-1
20457,CD4 cells,11,13,63,72,"For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively.",7905523_6,-1,-1,2,20457,-1
20462,nondepolarizing,4,5,27,42,Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.,7910951_0,-1,-1,2,20462,-1
20464,nondepolarizing,4,5,21,36,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,2,20464,-1
20476,Repetitive stimulation,0,2,0,22,Repetitive stimulation at 2 Hz showed a decremental response in 2 patients.,7910951_6,-1,-1,2,20476,-1
20486,Erythema multiforme,0,2,0,19,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,2,20486,-1
20488,erythema multiforme,7,9,31,50,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,2,20488,-1
20492,erythema multiforme,4,6,35,54,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,2,20492,-1
20494,treated with,3,5,16,28,The patient was treated with methylprednisolone and gradually improved.,7919560_4,-1,-1,2,20494,-1
20496,Macrophage-migration inhibition (MIF) test,0,6,0,42,Macrophage-migration inhibition (MIF) test with ampicillin was positive.,7919560_5,-1,-1,2,20496,-1
20497,erythema multiforme,6,8,42,61,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,-1,2,20497,-1
20499,MIF test,1,3,9,17,Positive MIF test for ampicillin showed sensitization of the patient's lymphocytes to ampicillin.,7919560_7,-1,-1,2,20499,-1
20500,patient's,9,11,61,70,Positive MIF test for ampicillin showed sensitization of the patient's lymphocytes to ampicillin.,7919560_7,-1,-1,2,20500,-1
20508,drug effect,32,34,182,193,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,2,20508,-1
20509,placebo-controlled conditions,8,10,49,78,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,2,20509,-1
20510,orally 2 hours,11,14,64,78,Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection.,7930386_3,-1,-1,2,20510,-1
20519,control values,30,32,206,220,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,-1,-1,2,20519,-1
20523,time studies,23,25,135,147,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,2,20523,-1
20524,/-,28,29,153,155,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,2,20524,-1
20525,/-,34,35,167,169,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,2,20525,-1
20527,interfere with,50,52,240,254,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,2,20527,-1
20529,REM sleep,3,5,16,25,"The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency, as, for both, mean nocturnal values were similar with and without prior clomipramine ingestion.",7930386_8,-1,-1,2,20529,-1
20548,intravenous administration,3,5,25,51,Angioedema following the intravenous administration of metoprolol.,7988234_0,-1,-1,2,20548,-1
20558,beta-blocking drug exposure,4,7,20,47,She had no previous beta-blocking drug exposure.,7988234_5,-1,-1,2,20558,-1
20561,associated with,4,6,28,43,The morbidity and mortality associated with heparin-induced thrombosis remain high despite numerous empirical therapies.,8012887_1,-1,-1,2,20561,-1
20562,empirical therapies,12,14,100,119,The morbidity and mortality associated with heparin-induced thrombosis remain high despite numerous empirical therapies.,8012887_1,-1,-1,2,20562,-1
20565,reexposure,21,22,156,166,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,-1,-1,2,20565,-1
20568,associated with,2,4,19,34,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,2,20568,-1
20569,saline-induced,7,8,66,80,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,-1,-1,2,20569,-1
20571,saline-induced,11,12,83,97,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,2,20571,-1
20573,midtrimester-induced,3,4,31,51,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,2,20573,-1
20582,skin test antigen,10,13,72,89,Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different.,804391_2,-1,-1,2,20582,-1
20594,Oral administration,0,2,0,19,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,2,20594,-1
20597,intracerebroventricular administration,19,21,120,158,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,2,20597,-1
20598,dose-dependent,37,38,229,243,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,2,20598,-1
20601,dependently,6,7,49,60,"These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively.",8045270_4,-1,-1,2,20601,-1
20604,subthreshold,15,16,81,93,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,2,20604,-1
20619,effects of,11,13,58,68,The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick.,8073369_4,-1,-1,2,20619,-1
20622,dose-dependent,8,9,54,68,Both compounds caused deformations and lethality in a dose-dependent manner.,8073369_6,-1,-1,2,20622,-1
20628,statistically significant,3,5,12,37,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,-1,-1,2,20628,-1
20630,Control chicks,0,2,0,14,"Control chicks were in motion an average of 33.67% of the time, while coniine-treated chicks were only moving 8.95% of a 5-min interval, and no movement was observed for nicotine sulfate treated chicks.",8073369_11,-1,-1,2,20630,-1
20632,coniine-induced arthrogryposis,15,17,89,119,"In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced arthrogryposis.",8073369_12,-1,-1,2,20632,-1
20639,RAST,10,11,55,59,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,2,20639,-1
20640,radioallergosorbent test,12,14,61,85,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,2,20640,-1
20653,RAST,5,6,24,28,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,2,20653,-1
20655,single-blind,11,12,52,64,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,2,20655,-1
20656,placebo-controlled challenge tests,13,16,66,100,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,2,20656,-1
20666,RAST,0,1,0,4,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,2,20666,-1
20668,RAST,6,7,31,35,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,2,20668,-1
20675,AX-allergic,6,7,33,44,We describe the largest group of AX-allergic patients who have tolerated PG reported so far.,8092427_15,-1,-1,2,20675,-1
20678,diagnostic methods,18,20,107,125,Further studies are necessary to determine the exact extent of this problem and to improve the efficacy of diagnostic methods.,8092427_17,-1,-1,2,20678,-1
20682,effects of,7,9,40,50,Our study was designed to determine the effects of combined nitroglycerin and phenylephrine therapy.,809711_2,-1,-1,2,20682,-1
20685,/-,20,21,148,150,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,2,20685,-1
20686,/-,25,26,160,162,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,2,20686,-1
20688,/- 2,8,10,53,57,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,2,20688,-1
20693,Subsequent addition,0,2,0,19,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,2,20693,-1
20694,re-elevate,8,9,61,71,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,2,20694,-1
20695,/- 4 mm Hg,15,19,103,113,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,2,20695,-1
20725,patient's,7,9,47,56,"RESULTS: Hallucinations occurred only when the patient's eyes were closed and, in all but one case, were reported as disturbing or frightening.",8111719_5,-1,-1,2,20725,-1
20727,infusion-time,6,7,30,43,The incidence may be dose and infusion-time related.,8111719_8,-1,-1,2,20727,-1
20740,Effects of,0,2,0,10,Effects of calcium channel blockers on bupivacaine-induced toxicity.,8231633_0,-1,-1,2,20740,-1
20742,bupivacaine-induced,6,7,39,58,Effects of calcium channel blockers on bupivacaine-induced toxicity.,8231633_0,-1,-1,2,20742,-1
20744,bupivacaine-induced acute,15,17,90,115,The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.,8231633_1,-1,-1,2,20744,-1
20747,control group,42,44,207,220,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,2,20747,-1
20752,anesthetic-induced mortality,2,4,10,38,The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers.,8231633_5,-1,-1,2,20752,-1
20766,drug/light interaction,8,10,67,89,The photodistribution of the telangiectasia suggests a significant drug/light interaction.,8251368_5,-1,-1,2,20766,-1
20767,Penicillamine-induced,0,1,0,21,Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.,8267029_0,-1,-1,2,20767,-1
20775,granular IgG,3,5,35,47,"Immunofluorescence revealed scanty granular IgG, IgA and C3 deposits along the capillary walls and mesangium.",8267029_3,-1,-1,2,20775,-1
20776,C3 deposits,8,10,57,68,"Immunofluorescence revealed scanty granular IgG, IgA and C3 deposits along the capillary walls and mesangium.",8267029_3,-1,-1,2,20776,-1
20779,treated with,3,5,16,28,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,-1,-1,2,20779,-1
20788,vigorous treatment,6,8,50,68,The prompt discontinuation of D-penicillamine and vigorous treatment measures could allow for a good prognosis as in this case.,8267029_7,-1,-1,2,20788,-1
20789,treated with,11,13,67,79,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,2,20789,-1
20806,retrospectively sampled,3,5,15,38,All cases were retrospectively sampled from three different hospitals in Copenhagen.,8278214_2,-1,-1,2,20806,-1
20815,treatment proposals,6,8,42,61,The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations.,8278214_6,-1,-1,2,20815,-1
20825,EBF,22,23,116,119,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,2,20825,-1
20827,EBF,28,29,144,147,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,2,20827,-1
20835,mmHg,47,48,260,264,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,2,20835,-1
20839,rate pressure product,8,11,36,57,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,2,20839,-1
20850,/-,31,32,155,157,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,2,20850,-1
20851,/- 9.9 ml/100,5,8,14,27,30 min: 32.3 +/- 9.9 ml/100 g/min (P < 0.05).,8302922_7,-1,-1,2,20851,-1
20852,/-,5,6,12,14,60 min: 30 +/- 7.5 ml/100 g/min (P < 0.05)).,8302922_8,-1,-1,2,20852,-1
20859,Kaposi's sarcoma,4,7,35,51,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,-1,-1,2,20859,-1
20861,non-randomized Phase II,3,6,12,35,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,2,20861,-1
20866,Kaposi's sarcoma,5,8,36,52,Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.,8305357_2,-1,-1,2,20866,-1
20867,target',11,13,59,66,"Changes in size, colour and associated oedema of selected 'target' lesions were measured.",8305357_3,-1,-1,2,20867,-1
20868,Ten subjects,0,2,0,12,Ten subjects were evaluated.,8305357_5,-1,-1,2,20868,-1
20870,Kaposi's sarcoma,2,5,17,33,"Stabilization of Kaposi's sarcoma occurred in the remaining six, maintained until the end of the trial period in four.",8305357_7,-1,-1,2,20870,-1
20874,tolerated agent,13,15,79,94,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,-1,-1,2,20874,-1
20875,Kaposi's sarcoma,19,22,115,131,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,-1,-1,2,20875,-1
20892,A1,12,13,77,79,Tonotopic organization is an essential feature of the primary auditory area (A1) of primate cortex.,8372922_1,-1,-1,2,20892,-1
20893,primate cortex,15,17,84,98,Tonotopic organization is an essential feature of the primary auditory area (A1) of primate cortex.,8372922_1,-1,-1,2,20893,-1
20894,macaque monkeys,3,5,9,24,"In A1 of macaque monkeys, low frequencies are represented rostrolaterally and high frequencies are represented caudomedially.",8372922_2,-1,-1,2,20894,-1
20895,caudomedially,16,17,111,124,"In A1 of macaque monkeys, low frequencies are represented rostrolaterally and high frequencies are represented caudomedially.",8372922_2,-1,-1,2,20895,-1
20900,macaque monkeys,9,11,55,70,"Under anesthesia, the superior temporal gyrus of adult macaque monkeys was exposed, and the tonotopic organization of A1 was mapped using conventional microelectrode recording techniques.",8372922_4,-1,-1,2,20900,-1
20903,tone-burst,10,11,63,73,The actual frequencies deafened were determined by the loss of tone-burst elicited auditory brainstem responses.,8372922_6,-1,-1,2,20903,-1
20907,cytoarchitectural features,1,3,11,37,Postmortem cytoarchitectural features identifying A1 were correlated with the electrophysiologic data.,8372922_8,-1,-1,2,20907,-1
20914,treated with,6,8,43,55,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,2,20914,-1
20917,effects of,33,35,182,192,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,2,20917,-1
20927,long term,8,10,56,65,Neuropathic complaints were not very troublesome on the long term.,8384253_11,-1,-1,2,20927,-1
20929,vincristine neuropathy,15,17,94,116,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,-1,2,20929,-1
20932,intracavernous injections,7,9,53,78,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,2,20932,-1
20935,associated with,8,10,47,62,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,-1,2,20935,-1
20941,intracorporeal medications,46,48,301,327,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,-1,2,20941,-1
20949,intracorporeal injections,10,12,59,84,"From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication, which can be overcome by elevating the pH to a neutral level.",8386779_8,-1,-1,2,20949,-1
20950,antibody-positive,11,12,48,65,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,2,20950,-1
20958,CD4+,4,6,22,26,"Only minor changes in CD4+ lymphocyte subset count were observed in AIDS patients, although a more significant rise occurred in those with earlier stages of disease.",8387218_3,-1,-1,2,20958,-1
20962,CD4+,27,29,138,142,"Of those positive for p24 antigen at the commencement of the study 67% showed a positive response, and this was most likely in those with CD4+ lymphocyte subset counts above 100 mm3.",8387218_4,-1,-1,2,20962,-1
20964,mm3,34,35,178,181,"Of those positive for p24 antigen at the commencement of the study 67% showed a positive response, and this was most likely in those with CD4+ lymphocyte subset counts above 100 mm3.",8387218_4,-1,-1,2,20964,-1
20979,associated with,12,14,77,92,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,2,20979,-1
20981,Special reference,0,2,0,17,"Special reference is made to their clinical presentation, which may be totally asymptomatic.",839274_2,-1,-1,2,20981,-1
20998,molecular weight,14,16,103,119,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,-1,-1,2,20998,-1
21010,molecular weight,13,15,101,117,Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state.,8410052_5,-1,-1,2,21010,-1
21021,dentate gyrus,22,24,138,151,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,-1,-1,2,21021,-1
21023,Sprague-Dawley rats,0,2,0,19,"Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.",8410199_2,-1,-1,2,21023,-1
21029,dentate gyrus,28,30,183,196,"In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.",8410199_3,-1,-1,2,21029,-1
21031,time intervals,40,42,260,274,"In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.",8410199_3,-1,-1,2,21031,-1
21039,putative basket cells,16,19,106,127,The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer.,8410199_5,-1,-1,2,21039,-1
21045,experimental animals,38,40,230,250,Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA-containing neurons in the hilus of both groups of experimental animals.,8410199_6,-1,-1,2,21045,-1
21046,No significant,0,2,0,14,"No significant differences were found in the molecular layer or the granule cell layer, which included labeled neurons along the lower margin of the granule cell layer.",8410199_7,-1,-1,2,21046,-1
21047,molecular layer,7,9,45,60,"No significant differences were found in the molecular layer or the granule cell layer, which included labeled neurons along the lower margin of the granule cell layer.",8410199_7,-1,-1,2,21047,-1
21055,cimetidine-associated mental confusion.15,7,10,54,95,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,-1,2,21055,-1
21056,cimetidine-associated,12,13,105,126,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,-1,2,21056,-1
21058,M.S.,13,14,76,80,"In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes.",84204_1,-1,-1,2,21058,-1
21059,serum concentrations,18,20,103,123,"In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes.",84204_1,-1,-1,2,21059,-1
21061,M.S.,33,34,190,194,"In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes.",84204_1,-1,-1,2,21061,-1
21064,M.S.,3,4,16,20,"The severity of M.S. changes increased as trough-concentrations rose, 5 patients had lumbar puncture.",84204_3,-1,-1,2,21064,-1
21068,serum ratio,4,6,25,36,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,-1,-1,2,21068,-1
21070,M.S.,26,27,175,179,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,-1,-1,2,21070,-1
21081,treated with,18,20,131,143,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,-1,-1,2,21081,-1
21085,/-,40,41,253,255,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,-1,-1,2,21085,-1
21108,control group,7,9,51,64,Seventeen patients without hypotension served as a control group.,8424298_3,-1,-1,2,21108,-1
21113,/-,28,29,107,109,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,-1,2,21113,-1
21115,/-,48,49,189,191,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,-1,2,21115,-1
21116,control group,56,58,227,240,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,-1,-1,2,21116,-1
21119,Wechsler Adult Intelligence Scale,11,15,71,104,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,2,21119,-1
21121,digit symbol,23,25,147,159,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,2,21121,-1
21122,Trail-Making tests A,27,30,162,182,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,2,21122,-1
21123,Zung tests,33,35,190,200,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,2,21123,-1
21125,preoperatively,4,5,25,39,The tests were performed preoperatively and 2 days postoperatively.,8424298_6,-1,-1,2,21125,-1
21130,normotensive anaesthesia,20,22,142,166,The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.,8424298_8,-1,-1,2,21130,-1
21132,associated with,2,4,13,28,Sinus arrest associated with continuous-infusion cimetidine.,8437969_0,-1,-1,2,21132,-1
21133,associated with,10,12,87,102,The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.,8437969_1,-1,-1,2,21133,-1
21141,associated with,9,11,48,63,This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.,8437969_4,-1,-1,2,21141,-1
21150,immunosuppressive therapy,19,21,94,119,"In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.",8441146_3,-1,-1,2,21150,-1
21178,double-blind,16,17,85,97,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,2,21178,-1
21179,diet- and placebo-controlled trial,18,22,99,133,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,2,21179,-1
21181,participating centers,7,9,46,67,SETTING: Ambulatory patients recruited by 362 participating centers throughout the United States.,8480959_3,-1,-1,2,21181,-1
21182,United States,11,13,83,96,SETTING: Ambulatory patients recruited by 362 participating centers throughout the United States.,8480959_3,-1,-1,2,21182,-1
21186,dose-related changes,20,22,86,106,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,2,21186,-1
21188,transaminase elevations,1,3,11,34,Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose.,8480959_8,-1,-1,2,21188,-1
21189,upper limit of normal,8,12,64,85,Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose.,8480959_8,-1,-1,2,21189,-1
21193,associated with,23,25,131,146,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,2,21193,-1
21196,no effect,5,7,46,55,Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin.,8480959_10,-1,-1,2,21196,-1
21203,diuretic ingestion,1,3,14,32,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,2,21203,-1
21204,effects of,25,27,120,130,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,-1,-1,2,21204,-1
21207,associated with,1,3,15,30,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,-1,-1,2,21207,-1
21220,associated with,9,11,68,83,"Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.",8514073_1,-1,-1,2,21220,-1
21229,nonsteroidal anti-inflammatory drug use,2,6,9,48,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,-1,-1,2,21229,-1
21232,no effect,26,28,150,159,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,-1,-1,2,21232,-1
21252,ESRD,33,34,204,208,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,-1,-1,2,21252,-1
21260,peroxisomes,14,15,102,113,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,-1,-1,2,21260,-1
21265,peroxisomes,10,11,58,69,A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes.,85485_4,-1,-1,2,21265,-1
21266,peroxisomes,16,17,105,116,A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes.,85485_4,-1,-1,2,21266,-1
21268,peroxisomes,17,18,103,114,"Within the nodules, foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared.",85485_5,-1,-1,2,21268,-1
21275,European Organization,0,2,0,21,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,2,21275,-1
21286,confidence interval,23,25,99,118,"RESULTS: Six of 30 patients (20%) without prior chemotherapy achieved a partial response (PR) (95% confidence interval [CI], 8% to 39%).",8558192_4,-1,-1,2,21286,-1
21287,weeks',20,22,83,89,"One of 16 patients (6%) with prior chemotherapy had a complete response (CR) of 31 weeks' duration (95% CI, 0% to 30%).",8558192_6,-1,-1,2,21287,-1
21303,salt-sensitivity,7,8,50,66,Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.,8586822_0,-1,-1,2,21303,-1
21309,Male SHR,2,4,9,17,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,2,21309,-1
21312,ganglionic blockade,9,11,42,61,"After 2 weeks, the rats were subjected to ganglionic blockade and 2 days later, an infusion of clonidine.",8586822_3,-1,-1,2,21312,-1
21314,Intravenous infusion,0,2,0,20,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,2,21314,-1
21317,SHR,22,23,146,149,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,2,21317,-1
21354,double-blind trial,4,6,17,35,"In a randomized, double-blind trial, 90 women were allocated to receive one of three treatments prior to induction of anaesthesia with propofol.",8595686_2,-1,-1,2,21354,-1
21356,Group C,2,4,12,19,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,2,21356,-1
21362,infusion pump,22,24,125,138,Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1).,8595686_4,-1,-1,2,21362,-1
21365,/- SD,15,17,75,80,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,2,21365,-1
21366,/- 2.5,28,30,128,134,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,2,21366,-1
21367,/-,36,37,148,150,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,2,21367,-1
21369,/-,46,47,178,180,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,2,21369,-1
21377,/-,11,12,53,55,Recovery room discharge times were similar: C (75.9 +/- 19.4 min); L 73.6 +/- 21.6 min); T (77.1 +/- 18.9 min).,8595686_8,-1,-1,2,21377,-1
21378,/-,19,20,75,77,Recovery room discharge times were similar: C (75.9 +/- 19.4 min); L 73.6 +/- 21.6 min); T (77.1 +/- 18.9 min).,8595686_8,-1,-1,2,21378,-1
21379,/-,28,29,98,100,Recovery room discharge times were similar: C (75.9 +/- 19.4 min); L 73.6 +/- 21.6 min); T (77.1 +/- 18.9 min).,8595686_8,-1,-1,2,21379,-1
21384,associated with,1,3,11,26,Angioedema associated with droperidol administration.,8599504_0,-1,-1,2,21384,-1
21386,Quincke's disease,8,11,49,66,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,2,21386,-1
21397,Cumulative doses,0,2,0,16,Cumulative doses of doxorubicin were 225-550 mg/m2 (median dose 360).,8600333_3,-1,-1,2,21397,-1
21399,median dose,10,12,52,63,Cumulative doses of doxorubicin were 225-550 mg/m2 (median dose 360).,8600333_3,-1,-1,2,21399,-1
21401,signal averaged ECG,15,18,86,105,"The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography.",8600333_4,-1,-1,2,21401,-1
21402,24-hour ambulatory ECG,19,22,107,129,"The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography.",8600333_4,-1,-1,2,21402,-1
21403,radionuclide angiography,25,27,152,176,"The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography.",8600333_4,-1,-1,2,21403,-1
21411,length of follow-up,7,10,54,73,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,2,21411,-1
21416,LVPW index,14,16,83,93,"When adjusted to body surface area, the left ventricular posterior wall thickness (LVPW index) was decreased in all patients.",8600333_8,-1,-1,2,21416,-1
21417,doxorubicin-induced,3,4,17,36,"The incidence of doxorubicin-induced cardiotoxicity is high and increases with follow-up, irrespective of cumulative dose.",8600333_9,-1,-1,2,21417,-1
21426,mm Hg,22,24,109,114,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,2,21426,-1
21430,screening BP,15,17,80,92,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,2,21430,-1
21432,Caffeine-induced changes,0,2,0,24,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,2,21432,-1
21433,diastolic BP,3,5,28,40,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,2,21433,-1
21435,impedance-derived measures,38,40,183,209,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,2,21435,-1
21438,diastolic BP,7,9,46,58,The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96%.,8607407_8,-1,-1,2,21438,-1
21445,time-based sensitization,6,8,35,59,Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.,8617710_0,-1,-1,2,21445,-1
21447,double-blind,1,2,5,17,"This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.",8617710_1,-1,-1,2,21447,-1
21448,placebo-controlled study,5,7,31,55,"This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.",8617710_1,-1,-1,2,21448,-1
21449,effects of,9,11,70,80,"This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.",8617710_1,-1,-1,2,21449,-1
21452,drug administration period,52,55,242,268,"From Days 9 to 25, subjects were randomly assigned to either sertraline (12 subjects) or placebo (12 subjects); the sertraline dose was titrated from 50 to 200 mg/day from Days 9 to 16, and remained at 200 mg/day for the final 10 days of the drug administration period.",8617710_3,-1,-1,2,21452,-1
21454,24-hour period,10,12,66,80,"Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25.",8617710_4,-1,-1,2,21454,-1
21458,treatment groups,22,24,133,149,"When single-dose haloperidol was given again 25 days later, greater impairment with earlier onset was noted in several tests in both treatment groups, suggesting enhancement of this effect.",8617710_6,-1,-1,2,21458,-1
21464,Neuromuscular blocking agents,0,3,0,29,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,-1,-1,2,21464,-1
21476,associated with,10,12,76,91,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,-1,-1,2,21476,-1
21478,year-old,2,3,12,20,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,-1,2,21478,-1
21487,ICA,12,13,78,81,Left carotid angiography found occlusion of the left internal carotid artery (ICA).,8638876_5,-1,-1,2,21487,-1
21507,NSCLC,21,22,133,138,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,2,21507,-1
21512,stage IIIB,20,22,122,132,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,-1,-1,2,21512,-1
21514,stage IV,7,9,26,34,Most patients (72.4%) had stage IV NSCLC.,8643966_6,-1,-1,2,21514,-1
21526,grade 1,2,4,11,18,"Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.",8643966_11,-1,-1,2,21526,-1
21528,grade 3,20,22,105,112,"Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.",8643966_11,-1,-1,2,21528,-1
21529,grade 1,12,14,71,78,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,-1,-1,2,21529,-1
21530,grade 3,21,23,109,116,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,-1,-1,2,21530,-1
21534,24-hour infusion,21,23,127,143,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,-1,-1,2,21534,-1
21547,induction therapy,15,17,103,120,Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy.,8643971_1,-1,-1,2,21547,-1
21579,surgery/radiotherapy,5,6,42,62,Eleven responding patients had subsequent surgery/radiotherapy or radical radiotherapy.,8643971_14,-1,-1,2,21579,-1
21585,first-line regimen,4,6,37,55,Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.,8643971_18,-1,-1,2,21585,-1
21594,maximum tolerated dose,8,11,36,58,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,-1,2,21594,-1
21604,Calvert formula,27,29,137,152,The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.,8643973_2,-1,-1,2,21604,-1
21608,Eastern Cooperative Oncology Group,15,19,79,113,"To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study.",8643973_4,-1,-1,2,21608,-1
21612,No patient,0,2,0,10,No patient had disease progression.,8643973_8,-1,-1,2,21612,-1
21616,1-hour infusion,18,20,117,132,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,-1,-1,2,21616,-1
21619,recommended dose,1,3,4,20,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,-1,-1,2,21619,-1
21635,levodopa-induced ballistic,12,14,82,108,This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.,8649546_4,-1,-1,2,21635,-1
21636,Effects of,0,2,0,10,Effects of acute steroid administration on ventilatory and peripheral muscles in rats.,8665051_0,-1,-1,2,21636,-1
21645,associated with,2,4,9,24,This was associated with a similar loss in body weight.,8665051_4,-1,-1,2,21645,-1
21650,/-,14,15,66,68,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,2,21650,-1
21652,/-,27,28,108,110,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,2,21652,-1
21654,/- 145,43,45,156,162,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,2,21654,-1
21658,force-frequency curve,9,11,55,76,Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).,8665051_9,-1,-1,2,21658,-1
21664,pair-fed (PF) study,3,8,11,30,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,2,21664,-1
21681,ESRD,29,30,188,192,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,2,21681,-1
21687,habitual use,24,26,122,134,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,2,21687,-1
21696,Continuous subcutaneous administration,0,3,0,38,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,-1,-1,2,21696,-1
21702,cytotoxic agent,19,21,125,140,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,-1,-1,2,21702,-1
21704,intravenous route,6,8,39,56,"Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.",8677458_2,-1,-1,2,21704,-1
21705,oral delivery,12,14,83,96,"Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.",8677458_2,-1,-1,2,21705,-1
21706,subcutaneous administration,2,4,15,42,The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access.,8677458_3,-1,-1,2,21706,-1
21709,subcutaneous delivery,3,5,13,34,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,-1,-1,2,21709,-1
21711,associated with,12,14,73,88,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,-1,-1,2,21711,-1
21714,ifosfamide-induced emesis,33,35,204,229,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,-1,-1,2,21714,-1
21734,associated with,5,7,24,39,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,-1,-1,2,21734,-1
21735,intrathecal,8,9,44,55,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,-1,-1,2,21735,-1
21739,sulphate-associated,3,4,21,40,Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.,8690168_0,-1,-1,2,21739,-1
21744,sulphate-associated,1,2,8,27,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,-1,-1,2,21744,-1
21753,computerized image processor,10,13,73,101,Morphometric analysis at the ultrastructural level was performed using a computerized image processor.,8690168_2,-1,-1,2,21753,-1
21755,sulphate specificity,2,4,12,32,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,2,21755,-1
21756,cuprolinic blue staining,6,9,40,64,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,2,21756,-1
21761,no effect,31,33,237,246,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,2,21761,-1
21763,control rats,14,16,58,70,The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane.,8690168_4,-1,-1,2,21763,-1
21764,lamina rara externa,21,24,94,113,The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane.,8690168_4,-1,-1,2,21764,-1
21767,lamina densa,9,11,58,70,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,2,21767,-1
21768,lamina rara interna,12,15,75,94,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,2,21768,-1
21769,lamina rara externa,24,27,145,164,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,2,21769,-1
21771,control rats,39,41,238,250,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,2,21771,-1
21772,control animals,21,23,118,133,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,2,21772,-1
21774,anionic sites,10,12,49,62,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,2,21774,-1
21783,lamina rara interna,19,22,114,133,Number and total anionic site surface in the remaining part of the glomerular basement membrane (lamina densa and lamina rara interna) were not significantly changed.,8690168_8,-1,-1,2,21783,-1
21785,urinary albumin,9,11,67,82,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,-1,-1,2,21785,-1
21788,lamina rara externa,23,26,160,179,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,-1,-1,2,21788,-1
21792,extracerebral decarboxylase inhibition,14,17,68,106,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,-1,-1,2,21792,-1
21794,MAO-inhibited dogs,27,29,150,168,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,-1,-1,2,21794,-1
21796,no effect,17,19,139,148,"In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.",869641_2,-1,-1,2,21796,-1
21814,central alpha-receptor stimulation,9,12,64,98,It is concluded that L-dopa enhances reflex bradycardia through central alpha-receptor stimulation.,869641_8,-1,-1,2,21814,-1
21824,plasma exchange,10,12,59,74,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,2,21824,-1
21830,cross-react,14,15,74,85,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,2,21830,-1
21833,immuno-suppressive drug,23,25,115,138,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,2,21833,-1
21835,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea.,871943_0,-1,-1,2,21835,-1
21837,re-established,4,5,37,51,Adequate spontaneous respiration was re-established in an average period of ten minutes after the injection.,871943_2,-1,-1,2,21837,-1
21842,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.,871943_6,-1,-1,2,21842,-1
21843,sulfation,1,2,10,19,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,-1,-1,2,21843,-1
21851,Control rats,0,2,0,12,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,2,21851,-1
21861,estradiol-treated,1,2,8,25,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,2,21861,-1
21864,consistent with,15,17,112,127,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,2,21864,-1
21869,sulfation,18,19,109,118,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,2,21869,-1
21871,consistent with,3,5,18,33,These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.,873132_6,-1,-1,2,21871,-1
21875,choleretic,10,11,55,65,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,2,21875,-1
21877,choleretic,18,19,95,105,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,2,21877,-1
21895,Wistar rats,47,49,234,245,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,2,21895,-1
21905,statistically significant,11,13,54,79,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,2,21905,-1
21910,statistically significant,9,11,54,79,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,2,21910,-1
21931,free-field activity,8,10,60,79,The interpeduncular nucleus regulates nicotine's effects on free-field activity.,8741744_0,-1,-1,2,21931,-1
21933,interpeduncular nucleus of the,9,13,50,80,Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat.,8741744_1,-1,-1,2,21933,-1
21935,sham-operated controls,2,4,14,36,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,2,21935,-1
21939,interpeduncular nucleus,12,14,95,118,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,-1,-1,2,21939,-1
21940,catecholaminergic A10 region,28,31,183,211,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,-1,-1,2,21940,-1
21943,nicotinic,14,15,109,118,We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain.,8741744_4,-1,-1,2,21943,-1
21947,acetaminophen hepatotoxicity,7,9,44,72,Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.,8742498_0,-1,-1,2,21947,-1
21954,effects of,5,7,35,45,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,2,21954,-1
21957,NMRI mice,24,26,124,133,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,2,21957,-1
21958,AAP hepatitis,27,29,139,152,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,2,21958,-1
21959,serum activities,5,7,34,50,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,-1,-1,2,21959,-1
21965,laboratory diet,16,18,98,113,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,2,21965,-1
21975,end-product,18,19,117,128,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,2,21975,-1
21978,dietary depletion,26,28,161,178,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,2,21978,-1
21979,enzyme's,30,32,186,194,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,2,21979,-1
21984,Lithium-associated cognitive,0,2,0,28,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,2,21984,-1
21988,first-line treatment,5,7,30,50,BACKGROUND: Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder.,8752018_1,-1,-1,2,21988,-1
22008,serotonergic neurotransmission,10,12,57,87,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,2,22008,-1
22021,desipramine toxicity,8,10,58,78,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,2,22021,-1
22027,QRS prolongation,12,14,95,111,"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.",8800187_6,-1,-1,2,22027,-1
22033,QRS prolongation,11,13,57,73,RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.,8800187_9,-1,-1,2,22033,-1
22055,associated with,10,12,74,89,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,-1,-1,2,22055,-1
22063,non-reactive,23,24,139,151,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,2,22063,-1
22070,effects of,4,6,29,39,The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed.,88336_6,-1,-1,2,22070,-1
22075,drug intoxication,13,15,90,107,"It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant hypoxaemia, a favourable outcome may be anticipated.",88336_8,-1,-1,2,22075,-1
22084,reference therapy,18,20,106,123,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,2,22084,-1
22086,double-blind fashion,16,18,113,133,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,2,22086,-1
22095,primary variable,2,4,8,24,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,2,22095,-1
22096,confidence interval,21,23,91,110,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,2,22096,-1
22109,cocaine-induced paranoia,9,11,50,74,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,2,22109,-1
22110,Cocaine-induced paranoia,0,2,0,24,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,2,22110,-1
22112,drug-induced model,8,10,52,70,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,2,22112,-1
22118,denied past,31,33,184,195,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,2,22118,-1
22123,circular polarized head coil,22,26,99,127,"Five females and 6 males, 21-59 years of age, were examined with a 1.5-T whole-body system using a circular polarized head coil.",8864707_2,-1,-1,2,22123,-1
22126,high-resolution 3D,6,8,28,46,"In addition, we performed a high-resolution 3D gradient echo, T1-weighted sequences at a 1-mm slice thickness.",8864707_4,-1,-1,2,22126,-1
22127,T1-weighted sequences,11,13,62,83,"In addition, we performed a high-resolution 3D gradient echo, T1-weighted sequences at a 1-mm slice thickness.",8864707_4,-1,-1,2,22127,-1
22129,patient group,4,6,26,39,Cerebellar volume for the patient group ranged between 67.66 and 131.08 ml (mean 108.9 ml).,8864707_6,-1,-1,2,22129,-1
22130,data sets,5,7,29,38,In addition 3D gradient echo data sets from 10 healthy male and 10 healthy female age-matched volunteers were used to compare cerebellar volumes.,8864707_7,-1,-1,2,22130,-1
22140,venlafaxine-tranylcypromine interaction,3,5,24,63,Serotonin syndrome from venlafaxine-tranylcypromine interaction.,8888541_0,-1,-1,2,22140,-1
22151,120/67,6,7,33,39,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,2,22151,-1
22166,woman taking,14,16,63,75,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,-1,-1,2,22166,-1
22184,treated with,5,7,28,40,Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease.,8911359_4,-1,-1,2,22184,-1
22185,endoscopic resection,7,9,41,61,Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease.,8911359_4,-1,-1,2,22185,-1
22191,chronic administration,5,7,47,69,Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.,8919272_0,-1,-1,2,22191,-1
22196,intragastric,1,2,10,22,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,2,22196,-1
22201,valproate encephalopathy,47,49,247,271,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,2,22201,-1
22211,Golgi apparatus,24,26,141,156,"Organelles of these cells, in particular the mitochondria (increased number and size, distinct degeneration of their matrix and cristae) and Golgi apparatus were altered.",8919272_6,-1,-1,2,22211,-1
22227,antiluminal sides,6,8,41,58,In electron micrographs both luminal and antiluminal sides of the BBB of the cerebellar cortex had similar lesions.,8919272_14,-1,-1,2,22227,-1
22232,valproate encephalopathy,15,17,93,117,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,-1,2,22232,-1
22235,paramedic misjudgment,5,7,21,42,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,2,22235,-1
22254,quantitated,6,7,44,55,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,-1,-1,2,22254,-1
22262,synthesis/release,17,18,114,131,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,-1,-1,2,22262,-1
22273,de novo,17,19,121,128,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,2,22273,-1
22274,purine synthesis,19,21,129,145,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,2,22274,-1
22294,cocaine toxicity,15,17,108,124,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,-1,-1,2,22294,-1
22297,cocaine overdose,27,29,140,156,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,2,22297,-1
22299,medical treatment,25,27,118,135,"They were less likely to have a low body mass index, and more likely to have died in police custody, to have received medical treatment immediately before death, to have survived for a longer period, to have developed hyperthermia, and to have died in summer months.",8988571_4,-1,-1,2,22299,-1
22301,consistent with,5,7,36,51,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,-1,2,22301,-1
22302,dopaminergic,14,15,101,113,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,-1,2,22302,-1
22312,control groups,14,16,84,98,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,2,22312,-1
22319,ototoxic drugs,13,15,92,106,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,-1,-1,2,22319,-1
22332,associated in,5,7,31,44,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,2,22332,-1
22336,twin siblings,9,11,45,58,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,2,22336,-1
22350,choreoathetosis,8,9,50,65,"Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.",9022662_10,-1,-1,2,22350,-1
22351,Forty-eight hours,0,2,0,17,"Forty-eight hours after admission, the children appeared to be at their baseline and were discharged home.",9022662_11,-1,-1,2,22351,-1
22370,myopic excimer laser,2,5,10,30,Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve.,9041081_0,-1,-1,2,22370,-1
22371,keratectomy,6,7,47,58,Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve.,9041081_0,-1,-1,2,22371,-1
22380,L'Aquila University,9,11,44,63,"SETTING: Eye Clinic, S. Salvatore Hospital, L'Aquila University, Italy.",9041081_2,-1,-1,2,22380,-1
22385,preoperatively,3,4,17,31,"Testing was done preoperatively and 3, 6, 12, and 18 months postoperatively.",9041081_4,-1,-1,2,22385,-1
22386,steroid-induced elevated intraocular pressure,11,15,49,94,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,2,22386,-1
22388,No statistically significant,2,5,9,37,RESULTS: No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively.,9041081_7,-1,-1,2,22388,-1
22390,preoperatively,17,18,118,132,RESULTS: No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively.,9041081_7,-1,-1,2,22390,-1
22393,transient steroid-induced IOP,1,4,4,33,The transient steroid-induced IOP rise did not seem to cause functional impairment.,9041081_9,-1,-1,2,22393,-1
22413,control subjects,21,23,156,172,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,2,22413,-1
22420,Serum C3 complement levels,0,4,0,26,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,2,22420,-1
22422,control subjects,12,14,84,100,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,2,22422,-1
22427,complement receptor,27,29,174,193,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,2,22427,-1
22436,CS cytoprotection,8,10,49,66,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,2,22436,-1
22443,galactosamine-induced,48,49,297,318,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,2,22443,-1
22444,CS-mediated,7,8,47,58,"The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.",9067481_3,-1,-1,2,22444,-1
22446,toxic chemical,20,22,129,143,"The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.",9067481_3,-1,-1,2,22446,-1
22447,pretreatment,2,3,7,19,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,2,22447,-1
22454,CS-mediated,1,2,8,19,Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.,9067481_5,-1,-1,2,22454,-1
22460,chemical bioactivation,15,17,84,106,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,2,22460,-1
22461,galactosamine hepatotoxicity,30,32,185,213,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,2,22461,-1
22463,CS-mediated,5,6,29,40,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,2,22463,-1
22479,groups B,2,4,17,25,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,-1,-1,2,22479,-1
22482,groups A,3,5,26,34,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,2,22482,-1
22485,mmHg,19,20,110,114,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,2,22485,-1
22486,arterial ketone body ratio,2,6,22,48,"Measurements included arterial ketone body ratio (AKBR, aceto-acetate/3-hydroxybutyrate) and clinical hepatic function parameters.",9088814_5,-1,-1,2,22486,-1
22495,B.,17,18,103,105,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,-1,2,22495,-1
22496,group C,19,21,109,116,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,-1,2,22496,-1
22498,normotension,58,59,263,275,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,-1,2,22498,-1
22502,PGE1-induced,13,14,73,85,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,-1,2,22502,-1
22506,Wistar albino rats,25,28,172,190,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,2,22506,-1
22509,effects with,22,24,146,158,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,-1,-1,2,22509,-1
22510,Wistar Albino rats,12,15,65,83,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,-1,-1,2,22510,-1
22514,Prolactin levels,0,2,0,16,Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days.,9098464_4,-1,-1,2,22514,-1
22516,Marmara University,2,4,9,27,"SETTING: Marmara University School of Medicine, Department of Histology and Embryology, Zeynep Kamil Women and Children's Hospital.",9098464_5,-1,-1,2,22516,-1
22522,prolactin levels of castrated,3,7,13,42,RESULTS: The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups.,9098464_7,-1,-1,2,22522,-1
22527,noncastrated group,11,13,70,88,"Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.",9098464_8,-1,-1,2,22527,-1
22535,general induce,14,16,94,108,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,2,22535,-1
22537,calcium channel blockers,3,6,17,41,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,-1,-1,2,22537,-1
22550,associated with,4,6,41,56,Postinfarction ventricular septal defect associated with long-term steroid therapy.,9105126_0,-1,-1,2,22550,-1
22572,s.c.)-induced,26,27,169,182,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,-1,2,22572,-1
22574,ED50,34,35,229,233,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,-1,2,22574,-1
22578,ED50,17,18,109,113,"The corresponding epimers with the 3-hydroxy group in the beta-position were also effective but less potent (ED50 values, 33.8-63.5, i.p.).",9121607_3,-1,-1,2,22578,-1
22584,TD50,32,33,241,245,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,2,22584,-1
22586,ED50,38,39,278,282,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,2,22586,-1
22591,dose-dependent,13,14,84,98,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,-1,-1,2,22591,-1
22597,dose-dependent,5,6,27,41,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,2,22597,-1
22599,s.c.)-induced lethality,13,15,68,91,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,2,22599,-1
22600,NMDA seizures,22,24,132,145,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,2,22600,-1
22605,extrahepatic angiotensinogen,2,4,12,40,Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome.,9154656_0,-1,-1,2,22605,-1
22614,slot-blot hybridization technique,20,23,105,138,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,-1,2,22614,-1
22620,half-normal,6,7,39,50,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,2,22620,-1
22627,hepatic levels,23,25,112,126,"Furthermore, the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6, nor did its hepatic levels at days 1, 3, 5, or 7 after PAN injection.",9154656_5,-1,-1,2,22627,-1
22638,dose-related D2 receptor blockade,14,18,102,135,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,-1,-1,2,22638,-1
22672,Treatment strategies,0,2,0,20,Treatment strategies aimed at avoiding retinal toxicity are discussed.,9199746_6,-1,-1,2,22672,-1
22676,akathisia,12,13,81,90,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,2,22676,-1
22679,neuroleptic treatment,23,25,149,170,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,2,22679,-1
22684,effects of,3,5,15,25,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,2,22684,-1
22701,apomorphine-induced stereotypy,10,12,70,100,Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.,9201797_7,-1,-1,2,22701,-1
22708,physostigmine-induced lethality,6,8,35,66,"Finally, carteolol did not inhibit physostigmine-induced lethality in rats.",9201797_9,-1,-1,2,22708,-1
22710,beta-adrenoceptor antagonistic activity,11,14,93,132,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,2,22710,-1
22713,antagonistic activity,36,38,299,320,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,2,22713,-1
22715,associated with,6,8,34,49,Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.,9205462_0,-1,-1,2,22715,-1
22727,DNA elongation,5,7,29,43,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,2,22727,-1
22730,CBA/Ca,0,1,0,6,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,2,22730,-1
22739,bizarre nuclei,24,26,181,195,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,2,22739,-1
22761,reserpinized dogs,28,30,194,211,"Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.",921394_4,-1,-1,2,22761,-1
22764,vascular endothelial growth factor,3,7,19,53,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,-1,-1,2,22764,-1
22765,estrogen-induced,14,15,97,113,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,-1,-1,2,22765,-1
22768,estrogen carcinogenesis,9,11,64,87,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,-1,-1,2,22768,-1
22783,associated with,6,8,40,55,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,-1,-1,2,22783,-1
22788,FVIIIRAg immunohistochemistry,2,4,13,42,"VEGF/VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin (UEA1) binding studies, indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non-endothelial cells.",9214597_7,-1,-1,2,22788,-1
22789,endothelial specific lectin,5,8,47,74,"VEGF/VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin (UEA1) binding studies, indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non-endothelial cells.",9214597_7,-1,-1,2,22789,-1
22800,non-endothelial-derived,3,4,16,39,The function of non-endothelial-derived VEGF is not clear.,9214597_9,-1,-1,2,22800,-1
22805,microblood vessels,20,22,146,164,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,-1,-1,2,22805,-1
22811,lithium-induced,9,10,51,66,"Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.",9226773_2,-1,-1,2,22811,-1
22818,Effects of,0,2,0,10,Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.,9228650_0,-1,-1,2,22818,-1
22827,IC50s,18,19,105,110,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,2,22827,-1
22839,Alzheimer's disease,14,17,76,95,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,2,22839,-1
22846,effects of,20,22,143,153,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,-1,-1,2,22846,-1
22848,effects of,37,39,250,260,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,-1,-1,2,22848,-1
22851,pipe smokers,3,5,20,32,Clinical studies of pipe smokers and people using transdermal nicotine support the idea that toxins other than nicotine are the most important causes of acute cardiovascular events.,9245658_5,-1,-1,2,22851,-1
22856,cigarette exposures,30,32,182,201,"Finally, the dose response for cardiovascular events of nicotine appears to be flat, suggesting that if nicotine is involved, adverse effects might be seen with relatively low-level cigarette exposures.",9245658_6,-1,-1,2,22856,-1
22859,Wolff-Parkinson-White syndrome,15,17,130,160,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,2,22859,-1
22861,WPW syndrome,4,6,18,30,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,2,22861,-1
22863,AVRT,16,17,122,126,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,2,22863,-1
22865,QRS,0,1,0,3,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,-1,-1,2,22865,-1
22897,Acute administration,0,2,0,20,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,2,22897,-1
22906,intermediate duration,7,9,37,58,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,2,22906,-1
22908,therapeutic tools,25,27,145,162,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,2,22908,-1
22918,exposed workers,2,4,9,24,All nine exposed workers were affected to various degrees.,9284778_4,-1,-1,2,22918,-1
22937,associated with,8,10,51,66,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,-1,-1,2,22937,-1
22938,halothane hepatitis,10,12,67,86,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,-1,-1,2,22938,-1
22939,exposure of,3,5,25,36,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,-1,2,22939,-1
22941,exposed population,24,26,135,153,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,-1,2,22941,-1
22943,trifluoroacetyl-altered liver proteins,17,20,102,140,"Although the exact mechanism of hepatotoxicity of these agents is not known, the results suggest that trifluoroacetyl-altered liver proteins are involved.",9284778_13,-1,-1,2,22943,-1
22944,safer alternatives,18,20,97,115,"In view of the potentially widespread use of these compounds, there is an urgent need to develop safer alternatives.",9284778_14,-1,-1,2,22944,-1
22952,non-specific,10,11,49,61,"If the patient develops a liver mass, because of non-specific clinical features and imaging appearances, biopsy may be the only way to achieve a definitive diagnosis.",9293063_3,-1,-1,2,22952,-1
22955,immunoreactivity,1,2,15,31,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,-1,-1,2,22955,-1
22959,granule cells,7,9,37,50,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,-1,2,22959,-1
22967,high-frequency,18,19,126,140,This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices.,9305828_2,-1,-1,2,22967,-1
22968,hippocampal,21,22,156,167,This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices.,9305828_2,-1,-1,2,22968,-1
22974,immunostaining,3,4,36,50,We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.,9305828_4,-1,-1,2,22974,-1
22979,immunoreactivity,4,5,36,52,"PILO-injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells.",9305828_5,-1,-1,2,22979,-1
22980,mossy fibre terminals,10,13,74,95,"PILO-injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells.",9305828_5,-1,-1,2,22980,-1
22985,immunoreactivity,1,2,4,20,"NPY immunoreactivity was also dramatically changed in the entorhinal cortex, amygdala and sensorimotor areas.",9305828_6,-1,-1,2,22985,-1
22989,injected animals,4,6,18,34,"In addition, PILO injected animals exhibited a reduction in the number of NPY-immunoreactive interneurons compared with controls.",9305828_7,-1,-1,2,22989,-1
22993,granule cells,13,15,84,97,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,2,22993,-1
22994,mossy fibres,16,18,102,114,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,2,22994,-1
22996,PILO,30,31,174,178,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,2,22996,-1
23004,drug withdrawal,15,17,99,114,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,-1,-1,2,23004,-1
23005,medical regimens,28,30,161,177,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,-1,-1,2,23005,-1
23006,preoperatively,4,5,27,41,"All patients were examined preoperatively and 39 were examined at six months; 27 of the patients were also examined at one year, and 11 at two years.",9321531_3,-1,-1,2,23006,-1
23007,off-period score,12,14,65,81,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,23007,-1
23009,confidence interval,24,26,133,152,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,23009,-1
23011,off-period score,43,45,230,246,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,23011,-1
23012,confidence interval,56,58,302,321,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,23012,-1
23013,on-period score,65,67,342,357,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,23013,-1
23014,confidence interval,76,78,412,431,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,23014,-1
23015,on-period score,86,88,456,471,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,23015,-1
23016,confidence interval,97,99,524,543,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,-1,-1,2,23016,-1
23031,methylation,7,8,41,52,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,2,23031,-1
23046,cost-effective strategy,12,14,86,109,"Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy.",9334596_0,-1,-1,2,23046,-1
23051,effects of,36,38,248,258,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,-1,-1,2,23051,-1
23052,endocrine therapy,38,40,259,276,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,-1,-1,2,23052,-1
23057,personal cohort,9,11,57,72,"Prolactin results were compared with those of a previous personal cohort of 1,340 patients with erectile dysfunction and systematic prolactin determination.",9334596_5,-1,-1,2,23057,-1
23080,prolactin greater,7,9,53,70,Bromocriptine was definitely effective in cases with prolactin greater than 35 ng./ml.,9334596_19,-1,-1,2,23080,-1
23082,effects of,5,7,33,43,CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.,9334596_22,-1,-1,2,23082,-1
23100,associated with,7,9,49,64,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,2,23100,-1
23110,clinical doses,16,18,107,121,Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses.,9351491_4,-1,-1,2,23110,-1
23127,second-line therapy,11,13,68,87,"For previously treated advanced breast cancer, there is no standard second-line therapy.",9390208_1,-1,-1,2,23127,-1
23128,Combination chemotherapy,0,2,0,24,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,2,23128,-1
23143,Median number,0,2,0,13,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,-1,-1,2,23143,-1
23167,colony-stimulating factors,6,8,55,81,Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.,9401499_7,-1,-1,2,23167,-1
23170,paraventricular,9,10,58,73,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,-1,-1,2,23170,-1
23175,paraventricular,11,12,57,72,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,2,23175,-1
23179,Wistar rats,2,4,9,20,The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.,9406968_2,-1,-1,2,23179,-1
23189,upregulation,22,23,143,155,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,2,23189,-1
23191,gene expression,25,27,163,178,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,2,23191,-1
23193,Li-induced,35,36,209,219,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,2,23193,-1
23198,prostigmine-morphine-induced,12,13,66,94,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,-1,2,23198,-1
23205,Tmax,14,15,101,105,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23205,-1
23208,/-,25,26,142,144,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23208,-1
23209,/-,30,31,161,163,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23209,-1
23212,/-,43,44,208,210,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23212,-1
23213,/-,48,49,226,228,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23213,-1
23214,T1/2,58,59,270,274,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23214,-1
23216,/-,69,70,315,317,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23216,-1
23217,/-,74,75,335,337,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23217,-1
23219,/-,82,83,357,359,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23219,-1
23220,/-,87,88,377,379,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23220,-1
23222,/-,95,96,403,405,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23222,-1
23223,/-,100,101,421,423,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,-1,2,23223,-1
23226,prostigmine-morphine-induced,6,7,55,83,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23226,-1
23227,TmaX,13,14,130,134,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23227,-1
23228,/-,20,21,155,157,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23228,-1
23229,HH,25,26,173,175,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23229,-1
23230,/-,29,30,184,186,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23230,-1
23231,CBD,35,36,206,209,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23231,-1
23232,/-,39,40,218,220,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23232,-1
23233,T1/2,43,44,231,235,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23233,-1
23234,/-,50,51,256,258,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23234,-1
23235,HH,55,56,274,276,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23235,-1
23236,/-,59,60,285,287,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23236,-1
23237,CBD,65,66,307,310,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23237,-1
23238,/-,69,70,319,321,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,2,23238,-1
23242,morphine-induced,16,17,104,120,CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.,9431903_6,-1,-1,2,23242,-1
23246,antiamnesic,2,3,20,31,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,2,23246,-1
23248,PG-9.The,9,10,84,92,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,2,23248,-1
23256,i.c.v,48,49,259,264,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,2,23256,-1
23257,guinea pigs,58,60,298,309,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,2,23257,-1
23258,hot-plate,64,65,324,333,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,-1,-1,2,23258,-1
23264,antinociception,1,2,4,19,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,2,23264,-1
23267,M1-selective,15,16,112,124,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,2,23267,-1
23274,H3 agonist,42,44,347,357,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,2,23274,-1
23276,D2,47,48,389,391,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,2,23276,-1
23290,i.p.,22,24,94,98,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,2,23290,-1
23299,guinea pig atrium,20,23,128,145,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,-1,-1,2,23299,-1
23300,guinea pig,26,28,154,164,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,-1,-1,2,23300,-1
23301,guinea pig,33,35,191,201,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,-1,-1,2,23301,-1
23303,M4/M1 selectivity,44,46,241,258,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,-1,-1,2,23303,-1
23304,antinociception,55,56,307,322,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,-1,-1,2,23304,-1
23305,anti-amnesic effect,58,60,331,350,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,-1,-1,2,23305,-1
23310,rota-rod test,17,19,112,125,"In the antinociceptive and antiamnesic dose range, (+/-)-PG-9 did not impair mouse performance evaluated by the rota-rod test and Animex apparatus.",9495837_6,-1,-1,2,23310,-1
23311,Animex apparatus,20,22,130,146,"In the antinociceptive and antiamnesic dose range, (+/-)-PG-9 did not impair mouse performance evaluated by the rota-rod test and Animex apparatus.",9495837_6,-1,-1,2,23311,-1
23312,penicillamine-induced glomerular disease,2,5,19,59,Immunopathology of penicillamine-induced glomerular disease.,950631_0,-1,-1,2,23312,-1
23325,early-acting complement components,22,25,145,179,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,-1,-1,2,23325,-1
23340,stereotactic space,3,5,15,33,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,-1,-1,2,23340,-1
23351,post-operative,20,21,98,112,"Up until now, the only factor studied has been the effect of the diameter of the spinal needle on post-operative sensorineural hearing loss.",9522143_2,-1,-1,2,23351,-1
23366,intrathecal injection,5,7,43,64,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,-1,-1,2,23366,-1
23373,L3-L4 dermatomes,21,23,122,138,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,2,23373,-1
23377,long follow-up,9,11,62,76,Prospective multicentre studies with a large population and a long follow-up should be performed in order to evaluate the incidence of this unusual side effect.,9522152_4,-1,-1,2,23377,-1
23380,hyperbaric anaesthetic solution,18,21,115,146,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,2,23380,-1
23382,slow injection,26,28,175,189,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,2,23382,-1
23393,prospective double-blind study,5,8,26,56,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,-1,-1,2,23393,-1
23396,duration of action,17,20,124,142,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,-1,-1,2,23396,-1
23398,American Society of Anesthesiologists physical status I,6,13,39,94,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,-1,-1,2,23398,-1
23415,duration of action,17,20,110,128,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,-1,-1,2,23415,-1
23418,associated with,9,11,77,92,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,2,23418,-1
23419,total dose,12,14,97,107,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,2,23419,-1
23421,double blind randomized trial,20,24,136,165,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,2,23421,-1
23426,double-blind,6,7,32,44,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,-1,-1,2,23426,-1
23427,prospective study,8,10,46,63,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,-1,-1,2,23427,-1
23432,group 3,6,8,25,32,MP before and after TDI (group 3).,9523850_6,-1,-1,2,23432,-1
23433,group 2,10,12,48,55,"Fifty-eight percent of group 1 patients, 33% of group 2, and 26% of group 3 had reactions to TDI.",9523850_8,-1,-1,2,23433,-1
23434,group 3,17,19,68,75,"Fifty-eight percent of group 1 patients, 33% of group 2, and 26% of group 3 had reactions to TDI.",9523850_8,-1,-1,2,23434,-1
23436,two-sided Fisher's exact test,5,10,26,55,Data were analyzed by the two-sided Fisher's exact test using 95% confidence intervals with the approximation of Woolf.,9523850_10,-1,-1,2,23436,-1
23437,confidence intervals,13,15,66,86,Data were analyzed by the two-sided Fisher's exact test using 95% confidence intervals with the approximation of Woolf.,9523850_10,-1,-1,2,23437,-1
23456,QT-interval,8,9,40,51,The patient was in near syncope and had QT-interval prolongation.,9545159_4,-1,-1,2,23456,-1
23478,ipsi-,35,36,248,253,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,-1,2,23478,-1
23484,pallidothalamocortical motor loop,39,42,253,286,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,-1,-1,2,23484,-1
23485,Open-label,0,1,0,10,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,-1,-1,2,23485,-1
23490,pre-therapy,4,5,19,30,All patients had a pre-therapy Gram's stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy.,9564988_3,-1,-1,2,23490,-1
23500,pre-therapy,15,16,101,112,Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre-therapy pathogen(s).,9564988_5,-1,-1,2,23500,-1
23501,pathogen(s),16,18,113,124,Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre-therapy pathogen(s).,9564988_5,-1,-1,2,23501,-1
23504,Staphylococcus aureus,13,15,90,111,"RESULTS: The most common pathogens were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis.",9564988_6,-1,-1,2,23504,-1
23506,post-therapy,23,24,93,105,"Of 300 clinically evaluable patients, 175 (58%) were cured and 90 (30%) were improved at the post-therapy evaluation, resulting in a clinical success rate of 88%.",9564988_7,-1,-1,2,23506,-1
23508,clinically failed,6,8,27,44,Thirty-five patients (12%) clinically failed treatment.,9564988_8,-1,-1,2,23508,-1
23513,post-therapy visit,30,32,152,170,Microbiologic eradication rates (presumed plus documented) of the most common pathogens ranged from 93% (M. catarrhalis) to 100% (S. pneumoniae) at the post-therapy visit.,9564988_10,-1,-1,2,23513,-1
23514,post-therapy,13,14,62,74,All but one of the 265 patients who were cured or improved at post-therapy returned for a long-term follow-up visit; 243 (92%) remained well 4 to 6 weeks after therapy; and 21 (8%) had a relapse of symptoms.,9564988_11,-1,-1,2,23514,-1
23515,follow-up visit,18,20,100,115,All but one of the 265 patients who were cured or improved at post-therapy returned for a long-term follow-up visit; 243 (92%) remained well 4 to 6 weeks after therapy; and 21 (8%) had a relapse of symptoms.,9564988_11,-1,-1,2,23515,-1
23523,French case-control study,13,16,87,112,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,-1,2,23523,-1
23528,case-control study,22,24,142,160,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,-1,-1,2,23528,-1
23537,length of,11,13,73,82,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,2,23537,-1
23550,Pelvic radiotherapy,0,2,0,19,Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer.,9579567_10,-1,-1,2,23550,-1
23557,risk-benefit ratio,5,7,30,48,A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.,9579567_13,-1,-1,2,23557,-1
23559,Suxamethonium-induced,0,1,0,21,Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.,9587734_0,-1,-1,2,23559,-1
23574,associated with,13,15,81,96,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,-1,-1,2,23574,-1
23584,intermediate-caudal parts,11,13,66,91,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,-1,-1,2,23584,-1
23591,MMG,18,19,132,135,"Muscle tone was examined using a combined mechanoand electromyographic method, which measured simultaneously the muscle resistance (MMG) of the rat's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity (EMG) of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior.",9630698_2,-1,-1,2,23591,-1
23592,rat's,22,24,144,149,"Muscle tone was examined using a combined mechanoand electromyographic method, which measured simultaneously the muscle resistance (MMG) of the rat's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity (EMG) of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior.",9630698_2,-1,-1,2,23592,-1
23601,rostral region,25,27,149,163,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,2,23601,-1
23607,intermediate-caudal region,12,14,74,100,"5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.",9630698_5,-1,-1,2,23607,-1
23611,rostral part,15,17,87,99,The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug.,9630698_6,-1,-1,2,23611,-1
23624,Wistar rats,28,30,146,157,MATERIALS AND METHODS: Two different schedules of CBDCA administration (10 mg/kg and 15 mg/kg i.p. twice a week for nine times) were evaluated in Wistar rats.,9636837_3,-1,-1,2,23624,-1
23631,dose-dependent,5,6,38,52,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,-1,2,23631,-1
23638,lesser extent,10,12,50,63,"The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.",9636837_7,-1,-1,2,23638,-1
23654,diuretic abuse,26,28,173,187,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,2,23654,-1
23660,up-regulation,7,8,67,80,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,-1,-1,2,23660,-1
23663,down-regulation,33,34,215,230,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,2,23663,-1
23667,alpha1-adrenergic systems,24,26,134,159,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,-1,-1,2,23667,-1
23673,reserpine hypothermia,14,16,65,86,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,2,23673,-1
23681,D3 effects,20,22,162,172,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,2,23681,-1
23691,reuptake inhibition,5,7,30,49,"A question arises whether the reuptake inhibition is of any importance to the adaptive changes induced by repeated antidepressants, suggested to be responsible for the antidepressant activity.",9660111_10,-1,-1,2,23691,-1
23693,Effects of,0,2,0,10,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,-1,-1,2,23693,-1
23704,IBS,29,30,172,175,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,2,23704,-1
23709,week's,28,30,170,176,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,2,23709,-1
23714,cisapride-treated diarrhoea-predominant,1,3,3,42,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23714,-1
23716,/-,13,14,101,103,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23716,-1
23717,/-,18,19,121,123,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23717,-1
23719,pretreatment,32,33,173,185,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23719,-1
23720,/-,36,37,193,195,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23720,-1
23721,/-,50,51,251,253,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23721,-1
23722,/-,55,56,270,272,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23722,-1
23724,pretreatment,68,69,320,332,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23724,-1
23725,/-,72,73,339,341,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23725,-1
23727,/-,86,87,399,401,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23727,-1
23728,/-,91,92,418,420,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23728,-1
23729,cont./min,93,94,425,434,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23729,-1
23731,pretreatment,104,105,474,486,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23731,-1
23732,/- 1.1 cont./min,108,111,493,509,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,2,23732,-1
23736,constipation-predominant,10,11,65,89,No significant differences in jejunal motility were found in the constipation-predominant IBS group.,9669632_6,-1,-1,2,23736,-1
23738,visual analogue scale,6,9,34,55,Symptoms were assessed by using a visual analogue scale before and after treatment.,9669632_7,-1,-1,2,23738,-1
23741,/-,20,21,138,140,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,2,23741,-1
23742,/-,25,26,154,156,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,2,23742,-1
23744,pretreatment,38,39,201,213,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,2,23744,-1
23745,/-,42,43,219,221,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,2,23745,-1
23746,Diarrhoea-predominant IBS,0,2,0,25,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,2,23746,-1
23748,/-,16,17,95,97,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,2,23748,-1
23749,/-,21,22,112,114,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,2,23749,-1
23752,/-,38,39,177,179,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,2,23752,-1
23757,Italian randomised trial,11,14,74,98,Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.,9672273_0,-1,-1,2,23757,-1
23758,hysterectomised,15,16,105,120,Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.,9672273_0,-1,-1,2,23758,-1
23759,chemopreventive agent,6,8,37,58,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,-1,-1,2,23759,-1
23763,hysterectomised,6,7,28,43,Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive.,9672273_3,-1,-1,2,23763,-1
23764,chemopreventive,12,13,68,83,Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive.,9672273_3,-1,-1,2,23764,-1
23765,double-blind placebo-controlled,10,12,40,71,"METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy.",9672273_4,-1,-1,2,23765,-1
23768,trialists,6,7,19,28,"In June, 1997, the trialists and the data-monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study.",9672273_7,-1,-1,2,23768,-1
23769,data-monitoring committee,9,11,37,62,"In June, 1997, the trialists and the data-monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study.",9672273_7,-1,-1,2,23769,-1
23773,intention-to-treat,7,8,46,64,This preliminary interim analysis is based on intention-to-treat.,9672273_10,-1,-1,2,23773,-1
23800,self-dosing,4,5,29,40,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,-1,-1,2,23800,-1
23802,short time intervals,8,11,57,77,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,-1,-1,2,23802,-1
23814,ASA,26,27,157,160,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,2,23814,-1
23817,Dupuytren's contracture,54,57,336,359,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,2,23817,-1
23818,intravenous administration,1,3,6,32,"After intravenous administration of labetalol, metoprolol and midazolam the patient's condition improved, and 15 min later he woke up.",9698967_2,-1,-1,2,23818,-1
23824,patient's,28,30,186,195,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,-1,-1,2,23824,-1
23828,Stevens-Johnson syndromes,6,8,52,77,Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.,9721172_0,-1,-1,2,23828,-1
23830,Stevens-Johnson syndrome,0,2,0,24,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,-1,2,23830,-1
23831,well-recognized,4,5,30,45,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,-1,2,23831,-1
23837,Stevens-Johnson syndrome,18,20,119,143,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,-1,-1,2,23837,-1
23838,associated with,26,28,178,193,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,-1,-1,2,23838,-1
23843,drug-related vanishing bile duct syndrome,4,9,26,67,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,2,23843,-1
23846,Stevens-Johnson syndrome,24,26,161,185,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,2,23846,-1
23849,associated with,6,8,49,64,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,-1,-1,2,23849,-1
23853,associated with,15,17,92,107,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,-1,-1,2,23853,-1
23857,matched controls,8,10,64,80,Thirty-five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months (1992-1994) in Belgium.,9727773_3,-1,-1,2,23857,-1
23858,Exposure to,0,2,0,11,Exposure to appetite-suppressants was assessed on the basis of hospital records and standardized interview.,9727773_4,-1,-1,2,23858,-1
23874,Inappropriate use,0,2,0,17,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,-1,-1,2,23874,-1
23891,associated with,2,4,25,40,Choreoathetoid movements associated with rapid adjustment to methadone.,9754849_0,-1,-1,2,23891,-1
23900,epilepsy)OBJECTIVE,13,14,76,94,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,2,23900,-1
23904,randomised trial,5,7,22,38,"STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.",9758264_1,-1,-1,2,23904,-1
23911,periconception,10,11,63,77,Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.,9758264_4,-1,-1,2,23911,-1
23918,drug-induced lupus,11,13,75,93,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,2,23918,-1
23922,Physiological dose,0,2,0,18,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,2,23922,-1
23927,Working Group,1,3,14,27,Collaborative Working Group on Clinical Trial Evaluations.,9766615_1,-1,-1,2,23927,-1
23959,individual's,30,32,187,199,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,2,23959,-1
23963,case-control study,1,3,5,23,This case-control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California.,9799166_3,-1,-1,2,23963,-1
23965,Southern California,17,19,120,139,This case-control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California.,9799166_3,-1,-1,2,23965,-1
23966,3-year,16,17,81,87,"We attempted to identify all incident strokes in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations.",9799166_4,-1,-1,2,23966,-1
23974,face-to-face interviews,4,6,27,50,We obtained information in face-to-face interviews.,9799166_6,-1,-1,2,23974,-1
23976,confidence interval,21,23,116,135,The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).,9799166_8,-1,-1,2,23976,-1
23977,confounders,5,6,39,50,"After further adjustment for potential confounders, the odds ratio in women who reported using cocaine and/or amphetamine was 7.0 (95% confidence interval = 2.8-17.9).",9799166_9,-1,-1,2,23977,-1
23978,odds ratio,8,10,56,66,"After further adjustment for potential confounders, the odds ratio in women who reported using cocaine and/or amphetamine was 7.0 (95% confidence interval = 2.8-17.9).",9799166_9,-1,-1,2,23978,-1
23979,confidence interval,23,25,135,154,"After further adjustment for potential confounders, the odds ratio in women who reported using cocaine and/or amphetamine was 7.0 (95% confidence interval = 2.8-17.9).",9799166_9,-1,-1,2,23979,-1
23982,placebo-controlled,3,4,14,32,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,2,23982,-1
23984,Alzheimer's disease,14,17,112,131,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,2,23984,-1
23987,Alzheimer's disease,33,36,191,210,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,2,23987,-1
23988,random-assignment,5,6,20,37,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,2,23988,-1
23989,double-blind,7,8,39,51,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,2,23989,-1
23990,placebo-controlled trial,9,11,53,77,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,2,23990,-1
23991,phase A,12,14,79,86,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,2,23991,-1
23995,Alzheimer's disease,45,48,213,232,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,2,23995,-1
23996,double-blind crossover phase,4,7,26,54,"For the subsequent 6-week double-blind crossover phase (phase B), patients taking standard- or low-dose haloperidol were switched to placebo, and patients taking placebo were randomly assigned to standard- or low-dose haloperidol.",9812111_3,-1,-1,2,23996,-1
23997,phase B,8,10,56,63,"For the subsequent 6-week double-blind crossover phase (phase B), patients taking standard- or low-dose haloperidol were switched to placebo, and patients taking placebo were randomly assigned to standard- or low-dose haloperidol.",9812111_3,-1,-1,2,23997,-1
24009,phase A,14,16,75,82,"The advantage of standard dose over low dose was replicated in phase B. In phase A, extrapyramidal signs tended to be greater with the standard dose than in the other two conditions, primarily because of a subgroup (20%) who developed moderate to severe signs.",9812111_6,-1,-1,2,24009,-1
24016,starting dose,1,3,2,15,"A starting dose of 1 mg/day with gradual, upward dose titration is recommended.",9812111_9,-1,-1,2,24016,-1
24019,Alzheimer's disease,15,18,101,120,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,2,24019,-1
24023,follow-up study,1,3,2,17,A follow-up study of cases reported earlier.,982002_1,-1,-1,2,24023,-1
24037,Effects of,0,2,0,10,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,-1,-1,2,24037,-1
24044,radiocalcium uptakes,15,17,79,99,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,-1,-1,2,24044,-1
24047,saline-infused control animals,38,41,247,277,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,-1,-1,2,24047,-1
24048,dried tissue,51,53,323,335,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,-1,-1,2,24048,-1
24049,fat-free dry weight,16,19,98,117,Myocardial concentrations of calcium also increased significantly (12.0 vs. 5.0 mg.per 100 Gm. of fat-free dry weight).,983936_3,-1,-1,2,24049,-1
24053,Mitochondrial radiocalcium,0,2,0,26,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,-1,-1,2,24053,-1
24057,dried fraction,34,36,243,257,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,-1,-1,2,24057,-1
24058,fat-free dry weight,20,23,93,112,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,2,24058,-1
24059,treatment groups,29,31,141,157,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,2,24059,-1
24061,treatment groups,12,14,70,86,Evidence of microscopic damage was graded as less severe in the three treatment groups.,983936_8,-1,-1,2,24061,-1
24075,beagle dogs,26,28,189,200,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,2,24075,-1
24087,pre-treatment,3,4,17,30,"Nine weeks after pre-treatment, dogs were given four courses of either doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg) once every 3 weeks.",9848575_6,-1,-1,2,24087,-1
24108,nonepisode biopsy,13,15,97,114,Thirteen biopsies were performed from stable functioning renal allografts with informed consent (nonepisode biopsy) and the other 13 were from dysfunctional renal allografts with a clinical indication for biopsy (episode biopsy).,9855119_3,-1,-1,2,24108,-1
24117,FK506 nephropathy,55,57,210,227,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,2,24117,-1
24118,FK506 nephropathy,65,67,251,268,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,2,24118,-1
24119,nonepisode biopsies,2,4,7,26,"Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.",9855119_5,-1,-1,2,24119,-1
24130,FK506 nephropathy,10,12,65,82,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,2,24130,-1
24132,statistically higher,21,23,130,150,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,2,24132,-1
24133,minimum-type chronic FK506-nephropathy group,27,31,169,213,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,2,24133,-1
24134,FK506 nephropathy,7,9,50,67,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,2,24134,-1
24140,FK506 nephropathy,27,29,202,219,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,2,24140,-1
24167,double-immunolabeling,7,8,47,68,Alterations in hepatocyte TJs were assessed by double-immunolabeling for 7H6 and ZO-1 using a confocal laser scanning microscope.,9862868_6,-1,-1,2,24167,-1
24170,confocal laser scanning microscope,14,18,94,128,Alterations in hepatocyte TJs were assessed by double-immunolabeling for 7H6 and ZO-1 using a confocal laser scanning microscope.,9862868_6,-1,-1,2,24170,-1
24171,control rats,1,3,3,15,"In control rats, immunostaining for 7H6 and ZO-1 colocalized to outline bile canaliculi in a continuous fashion.",9862868_7,-1,-1,2,24171,-1
24172,immunostaining,4,5,17,31,"In control rats, immunostaining for 7H6 and ZO-1 colocalized to outline bile canaliculi in a continuous fashion.",9862868_7,-1,-1,2,24172,-1
24182,Immunostaining,0,1,0,14,"Immunostaining for 7H6, not ZO-1, decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL.",9862868_9,-1,-1,2,24182,-1
24188,immunostaining,6,7,31,45,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,-1,-1,2,24188,-1
24228,PG-9.The,14,15,110,118,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,2,24228,-1
24229,effects of,15,17,119,129,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,2,24229,-1
24236,training session,22,24,94,110,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,2,24236,-1
24242,i.c.v,15,16,66,71,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,-1,-1,2,24242,-1
24245,Irwin test,17,19,96,106,"At the highest effective doses, PG-9 did not produce any collateral symptoms as revealed by the Irwin test, and it did not modify spontaneous motility and inspection activity, as revealed by the hole-board test.",9869257_3,-1,-1,2,24245,-1
24249,in vitro,11,13,58,66,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,2,24249,-1
24250,dose-dependent,17,18,86,100,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,2,24250,-1
24252,control value,11,13,64,77,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,2,24252,-1
24266,steady-state,17,18,98,110,OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.,9875685_1,-1,-1,2,24266,-1
24273,Peak concentrations,0,2,0,19,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,2,24273,-1
24275,peak concentrations,1,3,5,24,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,2,24275,-1
24279,t1/2,17,18,89,93,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,2,24279,-1
24294,single-dose therapy,2,4,8,27,"Using a single-dose therapy, peak concentration determination is not necessary, only trough samples should be monitored to ensure levels below 2 microg/ml.",9875685_15,-1,-1,2,24294,-1
24295,peak concentration determination,5,8,29,61,"Using a single-dose therapy, peak concentration determination is not necessary, only trough samples should be monitored to ensure levels below 2 microg/ml.",9875685_15,-1,-1,2,24295,-1
24305,GABAergic inhibition,9,11,65,85,These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone.,9915601_5,-1,-1,2,24305,-1
24307,nucleus ambiguus,10,12,62,78,"Such interference could be exerted centrally, possibly at the nucleus ambiguus, or peripherally at the sinus node.",9915601_6,-1,-1,2,24307,-1
24310,rat.-Tacrolimus,7,8,49,64,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,-1,-1,2,24310,-1
24335,mm Hg,13,15,73,78,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,-1,-1,2,24335,-1
24353,gene expression,18,20,138,153,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,2,24353,-1
24356,Earlier observations,0,2,0,20,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,2,24356,-1
24363,Balb-c,34,35,226,232,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,2,24363,-1
24372,steady-state,21,22,130,142,"In parallel, total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady-state level of three RNA transcripts encoded by the COXII, COXIII, and COXIV genes.",9952311_4,-1,-1,2,24372,-1
24376,COXIV genes,35,37,208,219,"In parallel, total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady-state level of three RNA transcripts encoded by the COXII, COXIII, and COXIV genes.",9952311_4,-1,-1,2,24376,-1
24377,comparative studies,14,16,81,100,"Similarly, samples obtained from the liver of the same animals were analyzed for comparative studies.",9952311_5,-1,-1,2,24377,-1
24382,body weight,39,41,229,240,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,2,24382,-1
24387,COXII gene,25,27,132,142,"Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.",9952311_7,-1,-1,2,24387,-1
